[{"ID": "CANIMM/212", "Drug": "AKT inhibitor (TCN-P; ),", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14636", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": "CN1N=C(N)C2=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C3=C2C1=NC=N3", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "CL30", "Dose": "10 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/214", "Drug": "AKT inhibitor (TCN-P; ),", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14636", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": "CN1N=C(N)C2=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C3=C2C1=NC=N3", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "IO33", "Dose": "10 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/215", "Drug": "AKT inhibitor (TCN-P; ),", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14636", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": "CN1N=C(N)C2=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C3=C2C1=NC=N3", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "CL25", "Dose": "10 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/216", "Drug": "AKT inhibitor (TCN-P; ),", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14636", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": "CN1N=C(N)C2=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C3=C2C1=NC=N3", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H157", "Dose": "10 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/217", "Drug": "AKT inhibitor (TCN-P; ),", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14636", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": "CN1N=C(N)C2=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C3=C2C1=NC=N3", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H1975", "Dose": "10 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/976", "Drug": "ONC201, an imipridone compound", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14844", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "73777259", "STR_LINK_(SMILES)": "CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O", "Single/Combination": "Single Drug", "PMID": "28977902", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "H9", "Dose": "1.25, 2.5, 5.0, and 10.0 μM ofONC201 for 48, 72, and 96 hrs", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/977", "Drug": "ONC201, an imipridone compound", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14844", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "73777259", "STR_LINK_(SMILES)": "CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O", "Single/Combination": "Single Drug", "PMID": "28977902", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "Mac2A", "Dose": "1.25, 2.5, 5.0, and 10.0 μM ofONC201 for 48, 72, and 96 hrs", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/980", "Drug": "ONC201, an imipridone compound", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14844", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "73777259", "STR_LINK_(SMILES)": "CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O", "Single/Combination": "Single Drug", "PMID": "28977902", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "MyLa", "Dose": "1.25, 2.5, 5.0, and 10.0 μM ofONC201 for 48, 72, and 96 hrs", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/981", "Drug": "ONC201, an imipridone compound", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14844", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "73777259", "STR_LINK_(SMILES)": "CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O", "Single/Combination": "Single Drug", "PMID": "28977902", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "PB2S", "Dose": "1.25, 2.5, 5.0, and 10.0 μM ofONC201 for 48, 72, and 96 hrs", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/982", "Drug": "ONC201, an imipridone compound", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14844", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "73777259", "STR_LINK_(SMILES)": "CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O", "Single/Combination": "Single Drug", "PMID": "28977902", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "SeAx", "Dose": "1.25, 2.5, 5.0, and 10.0 μM ofONC201 for 48, 72, and 96 hrs", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1495", "Drug": "ONC201, an imipridone compound", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14844", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "73777259", "STR_LINK_(SMILES)": "CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O", "Single/Combination": "Single Drug", "PMID": "28977902", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "HH", "Dose": "1.25, 2.5, 5.0, and 10.0 μM ofONC201 for 48, 72, and 96 hrs", "Technique": "Flow cytometry,western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis,ATF4 protein,TRAIL, BAX, and caspase-mediated cleavage of poly (ADP-Ribose) polymerase (C-PARP)-hall marks of integrated stress response (ISR)", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Apoptosis; PARP cleavage / PARP; BAX", "Immune_System-Function_inhibited/numbers_decreased": "IL-32β Akt,JAK3, pJAK3, STAT3, pSTAT3, and pSTAT1-JAK STAT Pathway,NF-κB pathway", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; NF-κB; AKT; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1496", "Drug": "ONC201, an imipridone compound", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14844", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "73777259", "STR_LINK_(SMILES)": "CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O", "Single/Combination": "Single Drug", "PMID": "28977902", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "Hut78", "Dose": "1.25, 2.5, 5.0, and 10.0 μM ofONC201 for 48, 72, and 96 hrs", "Technique": "Flow cytometry,western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis,ATF4 protein,TRAIL, BAX, and caspase-mediated cleavage of poly (ADP-Ribose) polymerase (C-PARP)-hall marks of integrated stress response (ISR)", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Apoptosis; PARP cleavage / PARP; BAX", "Immune_System-Function_inhibited/numbers_decreased": "IL-32β Akt,JAK3, pJAK3, STAT3, pSTAT3, and pSTAT1-JAK STAT Pathway,NF-κB pathway", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; NF-κB; AKT; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1497", "Drug": "ONC201, an imipridone compound", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14844", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "73777259", "STR_LINK_(SMILES)": "CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O", "Single/Combination": "Single Drug", "PMID": "28977902", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "Primary CD4+ malignant T cells-isolated from the peripheral blood of 5 patients with MF/SS", "Dose": "1.25, 2.5, 5.0, and 10.0 μM ofONC201 for 48, 72, and 96 hrs", "Technique": "Flow cytometry,western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis,ATF4 protein,TRAIL, BAX, and caspase-mediated cleavage of poly (ADP-Ribose) polymerase (C-PARP)-hall marks of integrated stress response (ISR)", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Apoptosis; PARP cleavage / PARP; BAX", "Immune_System-Function_inhibited/numbers_decreased": "IL-32β Akt,JAK3, pJAK3, STAT3, pSTAT3, and pSTAT1-JAK STAT Pathway,NF-κB pathway", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; NF-κB; AKT; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1498", "Drug": "ONC201, an imipridone compound", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB14844", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "73777259", "STR_LINK_(SMILES)": "CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O", "Single/Combination": "Single Drug", "PMID": "28977902", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "MJ", "Dose": "1.25, 2.5, 5.0, and 10.0 μM ofONC201 for 48, 72, and 96 hrs", "Technique": "Flow cytometry,western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis,ATF4 protein,TRAIL, BAX, and caspase-mediated cleavage of poly (ADP-Ribose) polymerase (C-PARP)-hall marks of integrated stress response (ISR)", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Apoptosis; PARP cleavage / PARP; BAX", "Immune_System-Function_inhibited/numbers_decreased": "IL-32β Akt, pSTAT1,NF-κB pathway", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB; AKT", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/947", "Drug": "Cyclophosphamide (CPM)", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug__ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "26156960", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung/Breast", "System": "Immature DCs +supernatants derived from A549 or MCF7 tumour cells", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T cells CD80, CD83 and CD86 on DCs", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; CD83; CD86; CD80/CD86 costimulation; T cells; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/983", "Drug": "Cyclophosphamide (CTX)", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug__ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "21156650", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "naive DC were cocultured with CFSE-labeled MAFO-EG7", "Dose": "CTX derivative MAFO at 10 μmol/L", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8α+ CD11c+ DC IL-1α and IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "CD11c / ITGAX; IL-1 family; IL-6; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/984", "Drug": "Cyclophosphamide (CTX)", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug__ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "21156650", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "MAFO-treated RBL-5 ells", "Dose": "CTX derivative MAFO at 10 μmol/L", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HMGB1", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/985", "Drug": "Cyclophosphamide (CTX)", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug__ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "21156650", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "MAFO-treated B16 cells", "Dose": "CTX derivative MAFO at 10 μmol/L", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HMGB1", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/986", "Drug": "Cyclophosphamide (CTX)", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug__ID": "D07760", "Pubchem_ID": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "21156650", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "MAFO-treated EG7 (MAFO-EG7) cells", "Dose": "CTX derivative MAFO at 10 μmol/L", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "sCRT, HMGB1", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1", "Immune_System-Function_inhibited/numbers_decreased": "CD31", "Controlled_Terms_Function_inhibited_Number_decreased": "CD31 / PECAM-1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/467", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Human TNBC", "System": "MDA-MB-436", "Dose": "10 ng/mL", "Technique": "RT-PCR, flow cytometery", "Controlled_Technique": "CD69 expression, IFN-γ (IFNG) and granzyme B (GZMB), T-BET (Tbx21),TRAIL (TNFSF10) and Fas ligand (FASLG), lymphotactin (XCL1), Phospho-STAT4 levels , increased NK-cell cytotoxicity, higher levels of IFN-γ, TNF-α and granzyme B", "Immune_System-Function_enhanced/numbers_increased": "TRAIL; Granzyme B / GZMB; IFN-γ; TNF-α / TNF; Cytotoxicity / cytolysis; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "AN", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "trabectedin has a direct stimulatory effect on NK cells and can be combined with IL-12 to activate NK cells in the presence of TNBC", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells; IL-12", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/468", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Human TNBC", "System": "MDA-MB-231", "Dose": "10 ng/mL", "Technique": "RT-PCR, flow cytometery", "Controlled_Technique": "CD69 expression, IFN-γ (IFNG) and granzyme B (GZMB), T-BET (Tbx21),TRAIL (TNFSF10) and Fas ligand (FASLG), lymphotactin (XCL1), Phospho-STAT4 levels , increased NK-cell cytotoxicity, higher levels of IFN-γ, TNF-α and granzyme B", "Immune_System-Function_enhanced/numbers_increased": "TRAIL; Granzyme B / GZMB; IFN-γ; TNF-α / TNF; Cytotoxicity / cytolysis; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "AN", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "trabectedin has a direct stimulatory effect on NK cells and can be combined with IL-12 to activate NK cells in the presence of TNBC", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells; IL-12", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/470", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Human TNBC", "System": "MDA-MB-468", "Dose": "10 ng/mL", "Technique": "RT-PCR, flow cytometery", "Controlled_Technique": "CD69 expression, IFN-γ (IFNG) and granzyme B (GZMB), T-BET (Tbx21),TRAIL (TNFSF10) and Fas ligand (FASLG), lymphotactin (XCL1), Phospho-STAT4 levels , increased NK-cell cytotoxicity, higher levels of IFN-γ, TNF-α and granzyme B", "Immune_System-Function_enhanced/numbers_increased": "TRAIL; Granzyme B / GZMB; IFN-γ; TNF-α / TNF; Cytotoxicity / cytolysis; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "AN", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "trabectedin has a direct stimulatory effect on NK cells and can be combined with IL-12 to activate NK cells in the presence of TNBC", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells; IL-12", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1001", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "AMO-CFZ", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1012", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM1S", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1023", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "RPMI-8226", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1034", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM2", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1045", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "RPMI-8226 DOX40", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1056", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "U266 LR7", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1067", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "JJN3", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/945", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "AMO-1", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/956", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "U266", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/967", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "NCI-H929", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/979", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "SKMM1", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/990", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "Single/Combination": "Single Drug", "PMID": "30898137", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "AMO-BZB", "Dose": "0.5 to 2.5 nM", "Technique": "AnnV/7-AAD assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/471", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Human TNBC", "System": "K562", "Dose": "10 ng/mL", "Technique": "Human NK-cell cytotoxicity assay", "Controlled_Technique": "increased NK-cell cytotoxicity", "Immune_System-Function_enhanced/numbers_increased": "Cytotoxicity / cytolysis", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "AN", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "trabectedin has a direct stimulatory effect on NK cells and can be combined with IL-12 to activate NK cells in the presence of TNBC", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells; IL-12", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/709", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Sarcoma", "System": "HT-1080", "Dose": "0.5 nM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/710", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": null, "System": "SW684", "Dose": "0.5 nM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/711", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": null, "System": "402.91", "Dose": "0.5 nM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/712", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": null, "System": "DMR", "Dose": "0.5 nM in vitro; animal dose NR", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/714", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": null, "System": "MES-SA", "Dose": "0.5 nM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/715", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": null, "System": "S018", "Dose": "0.5 nM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/716", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": null, "System": "S006", "Dose": "0.5 nM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/349", "Drug": "Ceritinib", "Drug_category": "Anaplastic lymphoma kinase (ALK) inhibitors", "Drugbank_ID": "DB09063", "Target/s_or_mechanism_of_action": "Ceritinib inhibits Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246), which is an enzyme that in humans is encoded by the ALK gene", "KEGG_Drug__ID": "D10551", "Pubchem_ID": "57379345", "STR_LINK_(SMILES)": "CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1", "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Anaplastic Large Cell Lymphoma (ALCL)", "System": "Karpas 299", "Dose": "Certitinib (0-100nM)", "Technique": "Western BLot and Flow cytometery", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": "pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1510", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MM200", "Dose": "vemurafenib (3 μM)", "Technique": "Western Blot, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 pERK1/2", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/350", "Drug": "Ceritinib", "Drug_category": "Anaplastic lymphoma kinase (ALK) inhibitors", "Drugbank_ID": "DB09063", "Target/s_or_mechanism_of_action": "Ceritinib inhibits Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246), which is an enzyme that in humans is encoded by the ALK gene", "KEGG_Drug__ID": "D10551", "Pubchem_ID": "57379345", "STR_LINK_(SMILES)": "CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1", "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Anaplastic Large Cell Lymphoma (ALCL)", "System": "SUDHL-1", "Dose": "Certitinib (0-100nM)", "Technique": "Western BLot and Flow cytometery", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": "pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/594", "Drug": "Aclacinomycin (Aclarubicin; ACM)+allogeneic NK cells", "Drug_category": "Anthracycline antineoplastic antibiotic", "Drugbank_ID": "DB11617", "Target/s_or_mechanism_of_action": "Topoisomerase II inhibition; DNA interaction", "KEGG_Drug__ID": "D02756", "Pubchem_ID": "451415", "STR_LINK_(SMILES)": "CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O", "Single/Combination": "Combination", "PMID": "40051630", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Immune / leukemia cell model", "System": "KG-1α cell line; in vitro", "Dose": "40 nmol/L ACM; NK-cell effector-to-target ratio 20:1 where applicable; assay-specific incubation", "Technique": "Flow cytometry, apoptosis assays", "Controlled_Technique": "Increased allogeneic NK-cell-mediated AML cytotoxicity; increased perforin and granzyme B; increased immunogenic cell death markers calreticulin (CRT), ATP and HMGB1; increased AML-cell apoptosis", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis; HMGB1; Calreticulin / CRT; Immunogenic cell death; Granzyme B / GZMB; Perforin / PRF1; Cytotoxicity / cytolysis", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/595", "Drug": "Aclacinomycin (Aclarubicin; ACM)+allogeneic NK cells", "Drug_category": "Anthracycline antineoplastic antibiotic", "Drugbank_ID": "DB11617", "Target/s_or_mechanism_of_action": "Topoisomerase II inhibition; DNA interaction", "KEGG_Drug__ID": "D02756", "Pubchem_ID": "451415", "STR_LINK_(SMILES)": "CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O", "Single/Combination": "Combination", "PMID": "40051630", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Immune / leukemia cell model", "System": "HL-60 cell line; in vitro", "Dose": "40 nmol/L ACM; NK-cell effector-to-target ratio 20:1 where applicable; assay-specific incubation", "Technique": "Flow cytometry, apoptosis assays", "Controlled_Technique": "Increased allogeneic NK-cell-mediated AML cytotoxicity; increased perforin and granzyme B; increased immunogenic cell death markers calreticulin (CRT), ATP and HMGB1; increased AML-cell apoptosis", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis; HMGB1; Calreticulin / CRT; Immunogenic cell death; Granzyme B / GZMB; Perforin / PRF1; Cytotoxicity / cytolysis", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/592", "Drug": "Aclacinomycin (Aclarubicin; ACM)", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB11617", "Target/s_or_mechanism_of_action": "Topoisomerase II inhibition; DNA interaction", "KEGG_Drug__ID": "D02756", "Pubchem_ID": "451415", "STR_LINK_(SMILES)": "CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O", "Single/Combination": "Single", "PMID": "40051630", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Immune / leukemia cell model", "System": "KG-1α cell line; in vitro", "Dose": "40 nmol/L (reported experimental concentration; verify against individual assay)", "Technique": "Flow cytometry, apoptosis assays", "Controlled_Technique": "AML cytotoxicity; increased perforin and granzyme B; increased immunogenic cell death markers calreticulin (CRT), ATP and HMGB1; increased AML-cell apoptosis", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis; HMGB1; Calreticulin / CRT; Immunogenic cell death; Granzyme B / GZMB; Perforin / PRF1; Cytotoxicity / cytolysis", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/593", "Drug": "Aclacinomycin (Aclarubicin; ACM)", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB11617", "Target/s_or_mechanism_of_action": "Topoisomerase II inhibition; DNA interaction", "KEGG_Drug__ID": "D02756", "Pubchem_ID": "451415", "STR_LINK_(SMILES)": "CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O", "Single/Combination": "Single", "PMID": "40051630", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Immune / leukemia cell model", "System": "HL-60 cell line; in vitro", "Dose": "40 nmol/L (reported experimental concentration; verify against individual assay)", "Technique": "Flow cytometry, apoptosis assays", "Controlled_Technique": "AML cytotoxicity; increased perforin and granzyme B; increased immunogenic cell death markers calreticulin (CRT), ATP and HMGB1; increased AML-cell apoptosis", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis; HMGB1; Calreticulin / CRT; Immunogenic cell death; Granzyme B / GZMB; Perforin / PRF1; Cytotoxicity / cytolysis", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1075", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MU89", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1076", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "136.2", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1077", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MO", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1079", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MM96L+", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1080", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MUX", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1081", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MM96L−,", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1082", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1083", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "H59-44T", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/809", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Gliomas", "System": "U-87", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/810", "Drug": "Daunorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00694", "Target/s_or_mechanism_of_action": "A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius", "KEGG_Drug__ID": "D07776", "Pubchem_ID": "30323", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "21052994", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Gliomas", "System": "U-118", "Dose": "100 nM daunorubicin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Melan-A/MART-1,HMB-45 on melanomas-antigen expression", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Tumor antigen expression; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "29500278", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-231 +serum from mice treated with doxo", "Dose": null, "Technique": "ALDEFLUOR assay", "Controlled_Technique": "ALDEFLUOR assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "ALDEFLUORbright BC cells-stem cell marker", "Controlled_Terms_Negative_Regulation": "Stemness-associated phenotype"}, {"ID": "CANIMM/1063", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - (Fibrosarcoma)", "System": "MCA205 (fibrosarcoma)", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "translocation of CRT and ERp57 onto tumor cell plasma membrane-ROS marker", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; ERp57 / PDIA3; Reactive oxygen species / ROS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1084", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - (Melanoma)", "System": "B16F10 (melanoma)", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "translocation of CRT and ERp57 onto tumor cell plasma membrane-ROS marker", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; ERp57 / PDIA3; Reactive oxygen species / ROS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/808", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "14617634", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "S-Type Neuroblastoma", "System": "SH-EP1", "Dose": "0.5 μg/ml", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Caspase-3 and caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "caspase-8", "Controlled_Terms_Unaffected": "Caspase-8; Caspase activation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/849", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - (Colon Carcinoma)", "System": "CT26 (colon carcinoma)", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "translocation of CRT and ERp57 onto tumor cell plasma membrane-ROS marker", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; ERp57 / PDIA3; Reactive oxygen species / ROS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1251", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-231", "Dose": "doxorubicin (0.1-1 µM", "Technique": "Flow cytometry + ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1252", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7,", "Dose": "doxorubicin (0.1-1 µM", "Technique": "Flow cytometry + ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1253", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SK-BR-3", "Dose": "doxorubicin (0.1-1 µM", "Technique": "Flow cytometry + ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1259", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "CT26 (colon carcinoma)", "Dose": null, "Technique": "ELISA,immunofluoresence and Cyto-ID labeling in Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and LC3 puncta-autophagy and immunogenic cell death marker", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Autophagy / macroautophagy; HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1274", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "SC1", "Dose": "doxorubicin (1 μM)", "Technique": "ELISA, FACS analysis", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1275", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "tumor-derived SC1 cells", "Dose": "doxorubicin (1 μM)", "Technique": "ELISA, FACS analysis", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/76", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "26689911", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Malignant Mesothelioma (MM)", "System": "H2461", "Dose": "(0–25 μM)", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NLRP3", "Controlled_Terms_Negative_Regulation": "NLRP3 inflammasome"}, {"ID": "CANIMM/154", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "26689911", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Malignant Mesothelioma (MM)", "System": "Hmeso", "Dose": "(0–25 μM)", "Technique": "qRT-PCR, Western blot analysis or ELISA", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-1β, IL-18, FGF2 and HMGB1 NLRP3 inflammasome, capsase-1", "Controlled_Terms_Negative_Regulation": "IL-1 family; IL-18; FGF2; NLRP3 inflammasome; HMGB1"}, {"ID": "CANIMM/155", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "14617634", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "S-Type Neuroblastoma", "System": "SH-EP1", "Dose": "0.5 μg/ml", "Technique": "immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD95/Fas expression on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/156", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "14617634", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "S-Type Neuroblastoma", "System": "SK-N-AS", "Dose": "0.5 μg/ml", "Technique": "immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD95/Fas expression on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/174", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "System": "CT26", "Dose": null, "Technique": "Western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "eIF2α phosphorylation-a marker of reticulum stress/ROS stress", "Controlled_Terms_Function_enhanced_Number_increased": "eIF2α / EIF2S1; Reactive oxygen species / ROS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/339", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "26689911", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Malignant Mesothelioma (MM)", "System": "H2373", "Dose": "(0–25 μM)", "Technique": "Western blot analysis or ELISA", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-1β, IL-18, FGF2 and HMGB1 NLRP3 inflammasome, capsase-1", "Controlled_Terms_Negative_Regulation": "IL-1 family; IL-18; FGF2; NLRP3 inflammasome; HMGB1"}, {"ID": "CANIMM/439", "Drug": "Doxorubicin (Dox)", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "DNA intercalation, inhibits TOP2-mediated repair,generates ROS and DNA damage", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/662", "Drug": "Doxorubicin (Dox)", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "DNA intercalation, inhibits TOP2-mediated repair,generates ROS and DNA damage", "KEGG_Drug__ID": "D03899", "Pubchem_ID": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "melanoma", "System": "B16F10", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1064", "Drug": "Bleomycin", "Drug_category": "Antibiotic", "Drugbank_ID": "DB00290", "Target/s_or_mechanism_of_action": "Acts by induction of DNA strand breaks", "KEGG_Drug__ID": "C06854", "Pubchem_ID": "5360373", "STR_LINK_(SMILES)": "[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - (Fibrosarcoma)", "System": "MCA205 (fibrosarcoma)", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "translocation of CRT and ERp57 onto tumor cell plasma membrane-ROS marker", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; ERp57 / PDIA3; Reactive oxygen species / ROS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1085", "Drug": "Bleomycin", "Drug_category": "Antibiotic", "Drugbank_ID": "DB00290", "Target/s_or_mechanism_of_action": "Acts by induction of DNA strand breaks", "KEGG_Drug__ID": "C06854", "Pubchem_ID": "5360373", "STR_LINK_(SMILES)": "[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - (Melanoma)", "System": "B16F10 (melanoma)", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "translocation of CRT and ERp57 onto tumor cell plasma membrane-ROS marker", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; ERp57 / PDIA3; Reactive oxygen species / ROS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/850", "Drug": "Bleomycin", "Drug_category": "Antibiotic", "Drugbank_ID": "DB00290", "Target/s_or_mechanism_of_action": "Acts by induction of DNA strand breaks", "KEGG_Drug__ID": "C06854", "Pubchem_ID": "5360373", "STR_LINK_(SMILES)": "[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - (Colon Carcinoma)", "System": "CT26 (colon carcinoma)", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "translocation of CRT and ERp57 onto tumor cell plasma membrane-ROS marker", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; ERp57 / PDIA3; Reactive oxygen species / ROS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1258", "Drug": "Bleomycin", "Drug_category": "Antibiotic", "Drugbank_ID": "DB00290", "Target/s_or_mechanism_of_action": "Acts by induction of DNA strand breaks", "KEGG_Drug__ID": "C06854", "Pubchem_ID": "5360373", "STR_LINK_(SMILES)": "[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - (Colon Carcinoma)", "System": "CT26 (colon carcinoma)", "Dose": null, "Technique": "ELISA,immunofluoresence and Cyto-ID labeling in Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and LC3 puncta-autophagy and immunogenic cell death marker", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Autophagy / macroautophagy; HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/175", "Drug": "Bleomycin", "Drug_category": "Antibiotic", "Drugbank_ID": "DB00290", "Target/s_or_mechanism_of_action": "Acts by induction of DNA strand breaks", "KEGG_Drug__ID": "C06854", "Pubchem_ID": "5360373", "STR_LINK_(SMILES)": "[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "System": "CT26", "Dose": null, "Technique": "Western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "eIF2α phosphorylation-a marker of reticulum stress/ROS stress marker", "Controlled_Terms_Function_enhanced_Number_increased": "eIF2α / EIF2S1; Reactive oxygen species / ROS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1477", "Drug": "BRAFi PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "3601R", "Dose": "BRAFi PLX4720 (10μM)", "Technique": "FACS, western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1613", "Drug": "BRAFi PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "8505c", "Dose": "BRAFi PLX4720 10μM", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression and mRNA exxpression phospho ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; ERK / MAPK; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/485", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "MEK1/MEK2 inhibition", "KEGG_Drug__ID": "D10405", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O", "Single/Combination": "Single", "PMID": "42183887", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "MDA-MB-468, human TNBC", "System": "In vitro human TNBC cells", "Dose": null, "Technique": "flow cytometry, Western blot", "Controlled_Technique": "Increased CRT expression", "Immune_System-Function_enhanced/numbers_increased": "Calreticulin / CRT; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1614", "Drug": "BRAFi PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "BCPAP", "Dose": "BRAFi PLX4720 10μM", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression and mRNA exxpression phospho ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; ERK / MAPK; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1615", "Drug": "BRAFi PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "SW1736", "Dose": "BRAFi PLX4720 10μM", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1096", "Drug": "Dabrafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08912", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene.", "KEGG_Drug__ID": "D10064", "Pubchem_ID": "44462760", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1", "Single/Combination": "Single Drug", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "System": "gp10025-33-activated pmel-1 mouse splenocytes", "Dose": "Dabrafenib: L=0.1μM, M=5μM, H=20μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ expressing CD3+ CD8+ cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD3; CD8; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/766", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "UACC903 melanoma cells -cultured with CTL specific for either MART-1 (left) or gp100 (right)", "Dose": "1 μmol/L", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "IFN-γ", "Controlled_Terms_Unaffected": "IFN-γ", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/802", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "HLA-A2+ UACC903 melanoma cells- cultured with CTL specific for MART-1 or gp100 versus control lymphocytes\n (GFP-transduced) at various E:T ratios", "Dose": "(1 μmol/L)", "Technique": "ELISA,intracellular staining for IFN-γ,cytotoxicity assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay; Cellular cytotoxicity/function assay; intracellular staining for IFN-γ", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1338", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "888 MEL", "Dose": "(1 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1339", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "624 MEL", "Dose": "(1 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1340", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL28", "Dose": "(1 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1341", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "UACC903", "Dose": "(1 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1557", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "HLA-A2+ 888 MEL melanoma cells- cultured with CTL specific for MART-1 or gp100 versus control lymphocytes\n (GFP-transduced) at various E:T ratios", "Dose": "(1 μmol/L)", "Technique": "intracellular staining for IFN-γ", "Controlled_Technique": "intracellular staining for IFN-γ", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1592", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "24903021", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "BP", "Dose": "2μM of BRAFi for 0, 48 or 72hrs", "Technique": "Quantitative PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanoma antigens including dopachrome tautomerase (TYRP2, DCT), tyrosinase (TYR), melanoma antigen recognized by T-cells (MLANA), and microphthalmia-associated transcription factor (MITF)", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/355", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "10 μM PLX4720", "Technique": "Flow cytometery, Immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Phospho-ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1508", "Drug": "Trametinib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MM200", "Dose": "trametinib (1 μM)", "Technique": "Western Blot, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 pERK1/2", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/783", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "32912923", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SK28 S", "Dose": "vemurafenib (5 μM)", "Technique": "ELISA and Luminex\n assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "PD-L1\n and PD-L2", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "ICAM1 and CEACAM1", "Controlled_Terms_Function_inhibited_Number_decreased": "ICAM-1 / CD54", "Immune_System_function_unaffected": "B7H6", "Controlled_Terms_Unaffected": "B7-H6 / NCR3LG1; B7 family ligand", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/784", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "32912923", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "M14S", "Dose": "vemurafenib (5 μM)", "Technique": "ELISA and Luminex\n assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "HLA-DR", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/785", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "32912923", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "M14R", "Dose": "vemurafenib (5 μM)", "Technique": "ELISA and Luminex\n assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "MICA, HLA-DR", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR; MICA; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": "ULBP2, B7H6,HLA-E, ICAM1 and CEACAM1", "Controlled_Terms_Function_inhibited_Number_decreased": "ICAM-1 / CD54; ULBP2; B7-H6 / NCR3LG1; B7 family ligand", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1086", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "30221038", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-86c melanoma cells", "Dose": "vemurafenib, 0.5 uM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Annexin V+ cells, IFNy+ CD8+ T cells increased intially upto day 14 with BRAFi treatment IFN-y HLA-class I to PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; CD8; Annexin V; T cells; CD8+ T cells; PD-L1 immune checkpoint pathway; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": "IFNy+ CD8+ T cells reduced after 14 day treatement with BRAFi", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; T cells; CD8+ T cells; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1087", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-103", "Dose": "1 uM Vemurafenib", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MHC", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "UBLP3", "Controlled_Terms_Unaffected": "ULBP3", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1088", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "32330348", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "Vemurafenib (0.5-10 uM)+ IFN-y (0-100 ug/ml)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IFN-y-inducible PD-L1 surface expression STAT1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; STAT1; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1091", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "32330348", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MEL5", "Dose": "Vemurafenib (0.5-10 uM)+ IFN-y (0-100 ug/ml)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IFN-y-inducible PD-L1 surface expression STAT1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; STAT1; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1092", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "32330348", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MEL28", "Dose": "Vemurafenib (0.5-10 uM)+ IFN-y (0-100 ug/ml)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IFN-y-inducible PD-L1 surface expression STAT1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; STAT1; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1095", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "30221038", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "BRAFV600E-positive Ma-Mel-86c melanoma cells", "Dose": "0.5 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "IFNγ release by CD8+ TILs (after 14 d of BRAFi treatment)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; IFN-γ; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1097", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-86f", "Dose": "1 uM Vemurafenib", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "ULBP2/5/6, CD155, MICA, UBLP3 pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "CD155 / PVR; ULBP2; ULBP3; ULBP2/5/6 family; MICA; ERK / MAPK; MICA/MICB", "Immune_System_function_unaffected": "CD112", "Controlled_Terms_Unaffected": "CD112 / Nectin-2 / PVRL2", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1098", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-86c", "Dose": "1 uM Vemurafenib", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "MICA, UBLP3,CD155 pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "CD155 / PVR; ULBP3; MICA; ERK / MAPK; MICA/MICB", "Immune_System_function_unaffected": "CD112", "Controlled_Terms_Unaffected": "CD112 / Nectin-2 / PVRL2", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1099", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-55", "Dose": "1 uM Vemurafenib", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "MICA, CD155 pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "CD155 / PVR; MICA; ERK / MAPK; MICA/MICB", "Immune_System_function_unaffected": "CD112", "Controlled_Terms_Unaffected": "CD112 / Nectin-2 / PVRL2", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1279", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "30221038", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-63 melanoma cells", "Dose": "vemurafenib, 0.5 uM", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cell IFN-y HLA-class I to PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; CD8; T cells; CD8+ T cells; PD-L1 immune checkpoint pathway; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1358", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MM200 cells (BRAFV600E)", "Dose": "vemurafenib (3 μM)", "Technique": "Western blot analysis,Flow cytometry, qPCR analysis", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression activation of ERK", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1506", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "27462428", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "vemurafenib (2 μM) for 48 h", "Technique": "Western Blot, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD271", "Controlled_Terms_Function_enhanced_Number_increased": "CD271 / NGFR", "Immune_System-Function_inhibited/numbers_decreased": "phosphorylated ERK (pERK) and total ERK (ERK)", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1507", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "27462428", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "1205Lu", "Dose": "vemurafenib (2 μM) for 48 h", "Technique": "Western Blot, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD271", "Controlled_Terms_Function_enhanced_Number_increased": "CD271 / NGFR", "Immune_System-Function_inhibited/numbers_decreased": "phosphorylated ERK (pERK) and total ERK (ERK)", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1509", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-CV", "Dose": "vemurafenib (3 μM)", "Technique": "Western Blot, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 pERK1/2", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/506", "Drug": "JQ1", "Drug_category": "Others/combination", "Drugbank_ID": "DB17021", "Target/s_or_mechanism_of_action": "BRD4 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "46907787", "STR_LINK_(SMILES)": "CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C", "Single/Combination": "Single", "PMID": "35517410", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "LoVo", "Dose": "0.1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "HLA-ABC, MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "surface PD-L1", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 / CD274", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1632", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "primary melanoma cell cultures of paired BRAFV600E melanoma biopsy samples from five patients pre- and post-treatment with vemurafenib", "Dose": null, "Technique": "Western blot analysis,qPCR analysis", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression", "Controlled_Terms_Function_enhanced_Number_increased": "Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1634", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-CV", "Dose": "vemurafenib (3 μM)", "Technique": "Western blot analysis,qPCR analysis", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression activation of ERK", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/289", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "IgR3", "Dose": "vemurafenib (3 μM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47", "Controlled_Terms_Function_enhanced_Number_increased": "CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/290", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Sk-Mel-28", "Dose": "vemurafenib (3 μM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47", "Controlled_Terms_Function_enhanced_Number_increased": "CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/292", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "fresh melanoma isolates", "Dose": "vemurafenib (3 μM) for 24 hours", "Technique": "Western blot analysis", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression", "Controlled_Terms_Function_enhanced_Number_increased": "Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/293", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "BRAFV600E (IgR3)", "Dose": "vemurafenib (3 μM)", "Technique": "Western blot analysis", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression", "Controlled_Terms_Function_enhanced_Number_increased": "Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/294", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "BRAFV600E ( Sk-Mel-28)", "Dose": "vemurafenib (3 μM)", "Technique": "Western blot analysis", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression", "Controlled_Terms_Function_enhanced_Number_increased": "Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/356", "Drug": "Vemurafenib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "10 μM Vemurafenib", "Technique": "Flow cytometery, Immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I molecules (HLA-A,B,C), β2\n microblobulin, MHC Class II molecules (HLA-D,R)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-A;", "Immune_System-Function_inhibited/numbers_decreased": "Phospho-ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/417", "Drug": "Vemurafenib (BRAF-I)", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "26851802", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Colo38", "Dose": "BRAF-I vemurafenib", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFNAR1", "Controlled_Terms_Function_enhanced_Number_increased": "IFNAR1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/418", "Drug": "Vemurafenib (BRAF-I)", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "26851802", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "M 21", "Dose": "BRAF-I vemurafenib", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFNAR1, IFNAR2", "Controlled_Terms_Function_enhanced_Number_increased": "IFNAR1; IFNAR2", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/419", "Drug": "Vemurafenib (BRAF-I)", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "26851802", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SK-Mel-37", "Dose": "BRAF-I vemurafenib", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFNAR1, IFNAR2", "Controlled_Terms_Function_enhanced_Number_increased": "IFNAR1; IFNAR2", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1093", "Drug": "Vemurafenib (Vem)", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "23264894", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Tumor-infiltrating lymphocytes (TILs) enriched in CD8+ T cells specific for defined melanoma differentation antigens (MART-1 and gp100), overexpressed (AIM-2) or cancer-testis (TAG) antigens were co-cultured with BRAFV600K- FM88", "Dose": "(between 100 and 250 nM) or which induced an effect close to the maximum (1 to 2 μM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cell recognition", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Antigen-specific recognition", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1094", "Drug": "Vemurafenib (Vem)", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "23264894", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Tumor-infiltrating lymphocytes (TILs) were co-cultured with autologous BRAFV600E mutant melanoma target cell lines", "Dose": "(between 100 and 250 nM) or which induced an effect close to the maximum (1 to 2 μM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor necrosis factor α (TNFα)− and interferon γ (IFNγ)-producing CD8+ TILs. CD107a", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD107a / LAMP1; TNF-α / TNF; IFN-γ; T cells; Degranulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1378", "Drug": "Abemaciclib", "Drug_category": "CDK4 protein kinase inhibitor", "Drugbank_ID": "DB12001", "Target/s_or_mechanism_of_action": "Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells", "KEGG_Drug__ID": "D10688", "Pubchem_ID": "46220502", "STR_LINK_(SMILES)": "CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1", "Single/Combination": "Single Drug", "PMID": "32929370", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "ID8 cells", "Dose": "10 μmol/L\n abemaciclib", "Technique": "mouse\n cytokine array C1000", "Controlled_Technique": "Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "IL9, IL3, CXCL16, CRG-2, TNFSF8, and\n CXCL13", "Controlled_Terms_Function_enhanced_Number_increased": "CXCL13", "Immune_System-Function_inhibited/numbers_decreased": "TCK-1,\n MMP3, and SDF1-α", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL12 / SDF-1; MMP3; TCK-1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1100", "Drug": "NU7441", "Drug_category": "DNA-dependent protein kinase (DNA-PK) Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "11327430", "STR_LINK_(SMILES)": "C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56", "Single/Combination": "Single Drug", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "C8161, a human melanoma cell line which lacks BRAFV600 or NRAS mutations", "Dose": "1 μM NU", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-I", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1102", "Drug": "NU7441", "Drug_category": "DNA-dependent protein kinase (DNA-PK) Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "11327430", "STR_LINK_(SMILES)": "C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56", "Single/Combination": "Single Drug", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "2 μM NU", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-I", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1103", "Drug": "NU7441", "Drug_category": "DNA-dependent protein kinase (DNA-PK) Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "11327430", "STR_LINK_(SMILES)": "C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56", "Single/Combination": "Single Drug", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SK-MEL-30", "Dose": "2 μM NU", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-I", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1499", "Drug": "OKI-005", "Drug_category": "DNA-dependent protein kinase (DNA-PK) Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "OKI-005 inhibits histone-deacetylase, which may lead to enhanced tumor immunogenicity and sensitize tumor cells to immunotherapy", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31235619", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas", "System": "G1XP", "Dose": "250 nM,500 nM, 1 µM", "Technique": "Flow cytometry, western blotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC class I and class II cell cycle arrest, apoptosis and growth inhibition", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; Apoptosis; Cell-cycle arrest;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/295", "Drug": "Sodium Valproate", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-12-510 cells", "Dose": "sodium valproate (250 μM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/296", "Drug": "Sodium Valproate", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-13-198 cells", "Dose": "sodium valproate (250 μM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/297", "Drug": "Sodium Valproate", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-12-542 cells", "Dose": "sodium valproate (250 μM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/298", "Drug": "Sodium Valproate", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-11-1080 cells", "Dose": "sodium valproate (250 μM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/299", "Drug": "Sodium Valproate", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-08-196 cells", "Dose": "sodium valproate (250 μM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/300", "Drug": "Sodium Valproate", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-12-293 cells", "Dose": "sodium valproate (250 μM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/301", "Drug": "Sodium Valproate", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL24", "Dose": "sodium valproate (250 μM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/303", "Drug": "Sodium Valproate", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL28", "Dose": "sodium valproate (250 μM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1008", "Drug": "Valproic acid", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "30387821", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "U266", "Dose": "0-4mM", "Technique": "Cell Counting kit-8 assay,Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity,apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": "NF-κB pathway", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1009", "Drug": "Valproic acid", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "30387821", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "RPMI8226", "Dose": "0-4mM", "Technique": "Cell Counting kit-8 assay,Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity,apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": "NF-κB pathway", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1608", "Drug": "Valproic acid", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "29371976", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "Triple-negative MDA-MB231", "Dose": "1-5 µM", "Technique": "western blot, qReal-Time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in tumor cells.", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1400", "Drug": "ACY-241 (citarinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "53340426", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "T-cells isolated from melanoma patient PBMC samples(activated via αCD3/CD28)", "Dose": "500nM", "Technique": "Luminex", "Controlled_Technique": "Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Th2 cytokine production (e.g. IL-4, IL-5, IL-6,IL-10, IL-13)", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-4; IL-5; IL-6; IL-10", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1013", "Drug": "ACY-241 (citarinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "53340426", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl", "Single/Combination": "Single Drug", "PMID": "29487385", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "U266", "Dose": "(0 μM, 0.5 μM, 1 μM, 2μM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Dendritic cells B7 family proteins (CD80, CD86 ) and MHC Class I (HLA-A2, HLA-ABC) and MHC Class II (HLA-DP/DQ/DR) on Dendritic cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; CD80; CD86; CD80/CD86 costimulation; Dendritic cells;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1016", "Drug": "ACY-241 (citarinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "53340426", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl", "Single/Combination": "Single Drug", "PMID": "29487385", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "myeloma patients’ bone marrow mononuclear cells", "Dose": "(0, 0.5, 1 μM) for 48 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Treg (CD3+CD4+ CD25+FOXP3+), MDSC (HLA-DRLow/- CD11b+CD33+) CD138+ MM cells, PD-L1 expression on CD138+ tumor and Treg cells, PD1 expression on CD3+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-1 / PDCD1; CD3; CD4; CD25 / IL2RA; CD11b / ITGAM; T cells; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1142", "Drug": "ACY-241 (citarinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "53340426", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "T-cells isolated from melanoma patient PBMC samples(activated via αCD3/CD28)", "Dose": "500nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8 + TBET+PD1+ T-cells, a less terminally differentiated phenotype IFNγ and TNF T-BET expression in T cells, T-BET expression in CD8+ and CD4+ T-cells", "Controlled_Terms_Function_enhanced_Number_increased": "PD-1 / PDCD1; CD4; CD8; TNF-α / TNF; IFN-γ; T cells; CD4+ T cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "EOMES+PD1+ T-cells -a phenotype associated with terminal exhaustion GATA3 levels in CD 8, EOMES expression in CD8+ T-cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1; CD8; T cells; CD8+ T cells; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1147", "Drug": "ACY-241 (citarinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "53340426", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "T-cells harvested from melanoma patient PBMC", "Dose": "10nM to 2uM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "FOXP3-expressing Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1148", "Drug": "ACY-241 (citarinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "53340426", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "T-cells from melanoma patient PBMC + co-cultured with CFSE-labeled, irradiated allogeneic PBMC (target cells)", "Dose": "500nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/818", "Drug": "ACY-241 (citarinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "53340426", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl", "Single/Combination": "Single Drug", "PMID": "29487385", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB231", "Dose": "(0 μM, 0.5 μM, 1 μM, 2μM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Dendritic cells B7 family proteins (CD80, CD86 ) and MHC Class I (HLA-A2, HLA-ABC) and MHC Class II (HLA-DP/DQ/DR) on Dendritic cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; CD80; CD86; CD80/CD86 costimulation; Dendritic cells;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/851", "Drug": "ACY-241 (citarinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "53340426", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl", "Single/Combination": "Single Drug", "PMID": "29487385", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "SW480", "Dose": "(0 μM, 0.5 μM, 1 μM, 2μM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Dendritic cells B7 family proteins (CD80, CD86 ) and MHC Class I (HLA-A2, HLA-ABC) and MHC Class II (HLA-DP/DQ/DR) on Dendritic cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; CD80; CD86; CD80/CD86 costimulation; Dendritic cells;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/185", "Drug": "ACY-241 (citarinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "53340426", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl", "Single/Combination": "Single Drug", "PMID": "31652644", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116 cells", "Dose": "0-10 μm", "Technique": "western blot analysis-two critical autophagic biomarkers LC3B-II and p62", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "autophagy- LC3B-II formation and downregulation of p62", "Controlled_Terms_Function_enhanced_Number_increased": "Autophagy / macroautophagy; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ-Induced PD-L1 Expression in CRC Cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; IFN-γ; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/993", "Drug": "Apicidin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Apicidin is a fungal metabolite, as well as a histone deacetylase inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "6918328", "STR_LINK_(SMILES)": "CC[C@H](C)[C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC3=CN(C4=CC=CC=C43)OC)CCCCCC(=O)CC", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "DB cells", "Dose": "3 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-DR expression,HLA-ABC", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-DR; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/113", "Drug": "AR-42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "23715898", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical Cancer", "System": "TC-1 tumor cells-Luciferase-expressing + E7-specific CTLs", "Dose": "0.5 μM AR-42", "Technique": "decrease of luminescence activity and measured with the IVIS Luminescence Imaging System Series 200", "Controlled_Technique": "Bioluminescence/luciferase assay", "Immune_System-Function_enhanced/numbers_increased": "Cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/847", "Drug": "AR-42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "23715898", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical Cancer", "System": "TC-1 tumor + HPV-16 E7-specific CD8+ T cell", "Dose": "2.5 μM AR-42", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Cytotoxicity IFN-γ(IFN-γ-producing CD8+ T cells )", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; IFN-γ; Cytotoxicity / cytolysis; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/848", "Drug": "AR-42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "23715898", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical Cancer", "System": "A15- a TC-1 cell clone", "Dose": "2.5 μM AR-42", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/304", "Drug": "AR42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-12-510 cells", "Dose": "AR42 (600 nM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/305", "Drug": "AR42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-13-198 cells", "Dose": "AR42 (600 nM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/306", "Drug": "AR42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-12-542 cells", "Dose": "AR42 (600 nM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/307", "Drug": "AR42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-11-1080 cells", "Dose": "AR42 (600 nM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/308", "Drug": "AR42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-08-196 cells", "Dose": "AR42 (600 nM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/309", "Drug": "AR42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "TPF-12-293 cells", "Dose": "AR42 (600 nM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/310", "Drug": "AR42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL24", "Dose": "AR42 (600 nM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/311", "Drug": "AR42", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL28", "Dose": "AR42 (600 nM) for 6h", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "class I MHC molecule MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression in", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/917", "Drug": "Benzamide-derived MS-275, Entinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "19759901", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCS used for Nurse like cells (NLCs) generation", "Dose": "Ibrutinib 1μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IL10 CD163, MRC1 (CD206), CCL18, PD-L1 nicotinamide phosphoribosyltransferase (NAMPT), STAT6 phosphorylation", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; CD163; CD206 / MRC1; IL-10; CCL18; STAT6; NAMPT; PD-L1 immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "IL-1, TNFα and IL-2 STAT1 phosphorylation", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; IL-2; TNF-α / TNF; STAT1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/920", "Drug": "Benzamide-derived MS-275, Entinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "19759901", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs selected for CD14+ monocytic population", "Dose": "Ibrutinib 1μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD206, CD11b, Tie2 receptor (TEM)", "Controlled_Terms_Function_enhanced_Number_increased": "CD11b / ITGAM; CD206 / MRC1; Tie2 / TEK", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/680", "Drug": "Chidamide (CS055/HBI-8000)/Tucidinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "22080169", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Human Myeloid Leukemia", "System": "K562 + PBMC from healthy individuals", "Dose": "100 nM", "Technique": "lactate dehydrogenase release assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "immune cell-mediated cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1399", "Drug": "Chidamide (CS055/HBI-8000)/Tucidinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "Su-DHL-6", "Dose": "5 µM Chidamide", "Technique": "Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD20 surface expression in DLBCL cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD20 / MS4A1; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1401", "Drug": "Chidamide (CS055/HBI-8000)/Tucidinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "Su-DHL-8", "Dose": "5 µM Chidamide", "Technique": "Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD20 surface expression in DLBCL cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD20 / MS4A1; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1402", "Drug": "Chidamide (CS055/HBI-8000)/Tucidinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "OCI-Ly7", "Dose": "5 µM Chidamide", "Technique": "Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD20 surface expression in DLBCL cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD20 / MS4A1; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1544", "Drug": "Chidamide (CS055/HBI-8000)/Tucidinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "22080169", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "peripheral WBC from two patients with T-cell lymphoma", "Dose": "32.5 mg (P1) and 30 mg (P2)", "Technique": "microarray geneprofiling studies", "Controlled_Technique": "Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "NK-activating surface receptors-CD16, NKG2D, and KLRG1, cytotoxic enzymes-GZMH, GZMA and Perforin, , FASLG", "Controlled_Terms_Function_enhanced_Number_increased": "CD16 / FcγRIIIa; Fas ligand / FasL / FASLG; NKG2D / KLRK1; KLRG1; Cytotoxicity / cytolysis; Granzyme A / GZMA; Granzyme H / GZMH; Perforin / PRF1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1546", "Drug": "Chidamide (CS055/HBI-8000)/Tucidinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Diffuse Large B Cell Lymphoma (Dlbcl)", "System": "Su-DHL-8", "Dose": "5 µM Chidamide", "Technique": "transcriptome profiling using RNA seq.", "Controlled_Technique": "Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CD20 (MS4A1), human leucocyte antigens (HLA) and integrin (ITGs)-ITGA-3 (CD49c), ITGA-5 (CD49e), ITGB-3 (CD61), ITGMG (CD11b), CD1A, CD3E, CD1D, CD59, LOC102723407 (immunoglobulin heavy variable 4-38-2-like protein) and LOC102724971 (putative V-set and immunoglobulin domain-containing-like protein) genes", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d; CD11b / ITGAM; CD20 / MS4A1; Cell adhesion", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1547", "Drug": "Chidamide (CS055/HBI-8000)/Tucidinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Diffuse Large B Cell Lymphoma (Dlbcl)", "System": "OCI-Ly7", "Dose": "5 µM Chidamide", "Technique": "transcriptome profiling using RNA seq.", "Controlled_Technique": "Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CD20 (MS4A1), human leucocyte antigens (HLA) and integrin (ITGs)-ITGA-3 (CD49c), ITGA-5 (CD49e), ITGB-3 (CD61), ITGMG (CD11b), CD1A, CD3E, CD1D, CD59, LOC102723407 (immunoglobulin heavy variable 4-38-2-like protein) and LOC102724971 (putative V-set and immunoglobulin domain-containing-like protein) genes", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d; CD11b / ITGAM; CD20 / MS4A1; Cell adhesion", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/801", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30969023", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Peripheral T-Cell Lymphoma (PTCL)", "System": "K562 + PD‐1 (+) cells from patient", "Dose": "0.3 μmol/L", "Technique": "CFSE/7‐AAD assay", "Controlled_Technique": "Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "cytotoxicity IFN‐γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/691", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "THP-1 cells + HLA-A0201-restricted PRAME-specific CTLs(Induced in vitro from PBMCs of 2 HLA-A0201+ healthy donors )", "Dose": null, "Technique": "CFSE LABELLING BASED CYTOTOXICITY ASSAY", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "PRAME-specific CTL", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Cancer-testis antigens; PRAME antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1014", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30387821", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "U266", "Dose": "0-8 µM", "Technique": "Cell Counting kit-8 assay,Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity,apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": "NF-κB pathway", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1015", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30387821", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "RPMI8226", "Dose": "0-8 µM", "Technique": "Cell Counting kit-8 assay,Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity,apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": "NF-κB pathway", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/918", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30210693", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs obtained from 14 CLL patients", "Dose": "anti-ILT2 blocking antibody (10 μg/ml", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells CD69 on NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD69; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/919", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30210693", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs obtained from 14 CLL patients", "Dose": "anti-ILT2 blocking antibody (10 μg/ml) and IL-2 (50 U/ml) for 7 days", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells CD69 on NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD69; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1442", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "THP-1", "Dose": "1 µM for 24 h", "Technique": "real-time quantitative RT-PCR,western blot, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME ,Apoptosis, Cell Cycle Arrest, Reduces Colony Forming Ability", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Apoptosis; Cell-cycle arrest; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/22", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "bone marrow mononuclear cells from 6 PRAME+ AML patient", "Dose": "1 µM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; PRAME antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/23", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "Hut78", "Dose": "1 µM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/24", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "Molt-4", "Dose": "1 µM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/26", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "Z138", "Dose": "1 µM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/27", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "Kasumi-1", "Dose": "1 µM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/28", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "NB4", "Dose": "1 µM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/29", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "U937", "Dose": "1 µM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/675", "Drug": "Domatinostat (4SC-202)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Inhibits HDAC1, HDAC2, HDAC3; also inhibits LSD1/REST at μM concentrations; induces G2/M arrest, apoptosis and increases APM/MHC-I expression", "KEGG_Drug__ID": null, "Pubchem_ID": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Single", "PMID": "33002502", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Aggressive neuroendocrine skin cancer", "System": "MKL-2 (MCPyV+)", "Dose": "2.5 μM; 24–48 h", "Technique": "Cell-cycle analysis; apoptosis; RT-qPCR; flow cytometry", "Controlled_Technique": "MHC-I or HLA class I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/557", "Drug": "Depsipeptide (FK228) or Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "18185535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "C57BL/6 mice were immunized by s.c. injection of irradiated IL-12/IL-18 cDNA-transduced B16/F10 cells. Spleen cells were isolated and used as effectors against luc-B16/F10 cells", "Dose": "depsipeptide (5 nM) and recombinant FLAG-tagged FasL (10 ng/ ml ) and multimerized with anti-FLAG M2 antibodies (1 mg/ ml ) for 16 hours.", "Technique": "Luciferase activity (photon counts) n evaluated in the presence of D-luciferin", "Controlled_Technique": "Bioluminescence/luciferase assay", "Immune_System-Function_enhanced/numbers_increased": "cytotoxicity IFNγ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1416", "Drug": "Depsipeptide (FK228) or Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "18185535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16/F10", "Dose": "depsipeptide (10 nM) for 16 hours", "Technique": "RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "major histocompatibility complex (MHC) class I (H2-Db ) and Fas (CD95) death receptor expression in B16/F10 cells gp100/ pmel17 melanoma antigen", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; CD95 / Fas / FAS; Melanoma differentiation antigens; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1417", "Drug": "Depsipeptide (FK228) or Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "18185535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MC (RPM-MC)", "Dose": "depsipeptide (10 nM) for 16 hours", "Technique": "RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC class I gp100/ pmel17 melanoma antigen", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Melanoma differentiation antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1418", "Drug": "Depsipeptide (FK228) or Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "18185535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "BP (MM-BP)", "Dose": "depsipeptide (10 nM) for 16 hours", "Technique": "RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC class I gp100/ pmel17 melanoma antigen", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Melanoma differentiation antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1419", "Drug": "Depsipeptide (FK228) or Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "18185535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "LH (MM-LH)", "Dose": "depsipeptide (10 nM) for 16 hours", "Technique": "RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC class I gp100/ pmel17 melanoma antigen", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Melanoma differentiation antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1420", "Drug": "Depsipeptide (FK228) or Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "18185535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "RU (MM-RU)", "Dose": "depsipeptide (10 nM) for 16 hours", "Technique": "RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC class I gp100/ pmel17 melanoma antigen", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Melanoma differentiation antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/320", "Drug": "Depsipeptide (FK228) or Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "18185535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Luc-B16/F10 cells", "Dose": "1–10 nM", "Technique": "Luciferase activity (photon counts) n evaluated in the presence of D-luciferin, Caspase-Glo 3/7 Assay system (Promega), Western blot", "Controlled_Technique": "Western blot/immunoblot analysis; Apoptosis/cell viability assay; Bioluminescence/luciferase assay; Caspase-Glo3/7 Assay", "Immune_System-Function_enhanced/numbers_increased": "caspase-3/7 activity,cell cycle regulator p21Waf/Cip1-induce apoptosis and cell cycle arrest", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; Cell-cycle arrest; p21 / CDKN1A", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/673", "Drug": "Domatinostat (4SC-202)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Inhibits HDAC1, HDAC2, HDAC3; also inhibits LSD1/REST at μM concentrations; induces G2/M arrest, apoptosis and increases APM/MHC-I expression", "KEGG_Drug__ID": null, "Pubchem_ID": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Single", "PMID": "33002502", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Aggressive neuroendocrine skin cancer", "System": "WaGa (MCPyV+)", "Dose": "2.5 μM; 24 h for scRNA-seq; 2.5 μM; 24–72 h for other assays", "Technique": "scRNA-seq; cell-cycle analysis; apoptosis; RT-qPCR; immunoblot; flow cytometry", "Controlled_Technique": "APM genes increased: large multifunctional protease 2 and 7 (LMP2 and LMP7), transporter associated with antigen processing 1 and 2 (TAP1 and TAP2); HLA-A, β2-Microglobulin and MHC-I surface expression increased", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; HLA-A; TAP1; TAP2; LMP2 / PSMB9; LMP7 / PSMB8; β2-microglobulin / B2M; Antigen presentation; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/674", "Drug": "Domatinostat (4SC-202)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Inhibits HDAC1, HDAC2, HDAC3; also inhibits LSD1/REST at μM concentrations; induces G2/M arrest, apoptosis and increases APM/MHC-I expression", "KEGG_Drug__ID": null, "Pubchem_ID": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Single", "PMID": "33002502", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Aggressive neuroendocrine skin cancer", "System": "MKL-1 (MCPyV+)", "Dose": "2.5 μM; 24–48 h", "Technique": "Cell-cycle analysis; apoptosis; RT-qPCR; immunoblot; flow cytometry", "Controlled_Technique": "MHC-I or HLA class I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1120", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B78H1", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/676", "Drug": "Domatinostat (4SC-202)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Inhibits HDAC1, HDAC2, HDAC3; also inhibits LSD1/REST at μM concentrations; induces G2/M arrest, apoptosis and increases APM/MHC-I expression", "KEGG_Drug__ID": null, "Pubchem_ID": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Single", "PMID": "33002502", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Aggressive neuroendocrine skin cancer", "System": "UM-MCC34 (MCPyV−)", "Dose": "2.5 μM; 24–48 h", "Technique": "Cell-cycle analysis; apoptosis; RT-qPCR; flow cytometry", "Controlled_Technique": "MHC-I or HLA class I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/14", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung - Small Cell Lung Cancer", "System": "H1882 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/247", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "OVCAR-3 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/25", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H441+NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/258", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SK-OV-3+NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/269", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "HEY-T30 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/336", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "DU145 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/347", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "PC-3 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/36", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H460 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/402", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28919994", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "CCH-OS-D +NK cells", "Dose": "2 µM entinostat (≤IC50) for 48 h", "Technique": "calcein release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/731", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28919994", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "LM7 + NK cells", "Dose": "2 µM entinostat (≤IC50) for 48 h", "Technique": "calcein release assay, blocking antibodies", "Controlled_Technique": "Cytotoxicity/release assay; Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1065", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "24203492", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "SaOS2", "Dose": "0.1 μM entinostat", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICA/B on tumor cells, MICA/B and ULBP2-NKG2D-L", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; MICA; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1066", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "24203492", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "LM7", "Dose": "0.1 μM entinostat", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICA/B on tumor cells, MICA/B and ULBP2-NKG2D-L", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; MICA; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1068", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "24203492", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "CCH-OS-T", "Dose": "0.1 μM entinostat", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICA/B on tumor cells, MICA/B and ULBP2-NKG2D-L", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; MICA; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1069", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "24203492", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "CCH-OS-D", "Dose": "0.1 μM entinostat, 0.1-10 μM for cell viablity", "Technique": "Flow cytometry,Vi-cell assay", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICA/B on tumor cells, MICA/B and ULBP2-NKG2D-L inhibits tumor cell growth", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; MICA; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1070", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28919994", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "CCH-OS-D", "Dose": "2 µM entinostat (≤IC50) for 48 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD155,MIC A/B, ULBP1, and ULBP2/5/6-NK cell-activating receptors", "Controlled_Terms_Function_enhanced_Number_increased": "CD155 / PVR; ULBP1; ULBP2; ULBP2/5/6 family; NK cells; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1071", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28919994", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "CCH-OS-O", "Dose": "2 µM entinostat (≤IC50) for 48 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MIC A/B, ULBP1, and ULBP2/5/6-NK cell-activating receptors", "Controlled_Terms_Function_enhanced_Number_increased": "ULBP1; ULBP2; ULBP2/5/6 family; NK cells; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1072", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28919994", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "KRIB", "Dose": "2 µM entinostat (≤IC50) for 48 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MIC A/B, ULBP1, and ULBP2/5/6-NK cell-activating receptors", "Controlled_Terms_Function_enhanced_Number_increased": "ULBP1; ULBP2; ULBP2/5/6 family; NK cells; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/811", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "24203492", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "COL", "Dose": "0.1 μM entinostat, 0.1-10 μM for cell viablity", "Technique": "Flow cytometry,Vi-cell assay", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICA/B on tumor cells, MICA/B and ULBP2-NKG2D-L inhibits tumor cell growth", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; MICA; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/819", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Metastatic Breast Cancer", "System": "PBMCs from seven heavily pretreated metastatic breast cancer patients", "Dose": "entinostat (500 nM) for 72 hours", "Technique": "Flow cytometry.", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells CD3−CD56DIMCD16+ mature NK cells expressing NKG2D, NKp30, and DNAM-1-activation phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "CD3; NKG2D / KLRK1; NKp30 / NCR3; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/949", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28408401", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "Peripheral blood mononuclear cells (PBMCs) from NSCLC patients or dissociated tumors", "Dose": "2.5μm", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD86 on CD14+ monocyte", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Monocytes", "Immune_System-Function_inhibited/numbers_decreased": "CD4+FOXP3+ Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1208", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "24203492", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "System": "HCT-15 cells", "Dose": "entinostat (0, 0.1, 1, and 10 μM).", "Technique": "Flow cytometry,Vi-cell assay,MTT assay", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "MICA/B on tumor cells, MICA/B and ULBP2-NKG2D-L inhibits tumor cell growth", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; MICA; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1248", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "24203492", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "System": "HCT-15 and primary NK cells", "Dose": "1 μM entinostat", "Technique": "calcein release assay, blocking antibodies, Flow cytometry", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay; Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell, degranulation of NK cells that recognize tumor targets by NKG2D-dependent mechanisms", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; NK cells; Degranulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1331", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28498806", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "ID8", "Dose": "2.5-10 μM", "Technique": "quantitative PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "Cd74, H2-Aa, H2-Eb1, and Ciita, MHC II expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; CIITA; CD74; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1449", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28919994", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "LM7", "Dose": "2 µM entinostat (≤IC50) for 48 h", "Technique": "Flow cytometry,RT-PCR analysis,Western blotting", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD155,MIC A/B, ULBP1, and ULBP2/5/6-NK cell-activating receptors", "Controlled_Terms_Function_enhanced_Number_increased": "CD155 / PVR; ULBP1; ULBP2; ULBP2/5/6 family; NK cells; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1539", "Drug": "Entinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "22303460", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "HepG2 cells", "Dose": "0.5 µM entinostat", "Technique": "IP and Western blot, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Immunoprecipitation assay", "Immune_System-Function_enhanced/numbers_increased": "STAT3 acetylation", "Controlled_Terms_Function_enhanced_Number_increased": "STAT3", "Immune_System-Function_inhibited/numbers_decreased": "Foxp3 levels in Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/611", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC1/HDAC3 inhibition; enhances antigen presentation and recognition by TCR-engineered T cells", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "42515717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Human NSCLC; KRASG12D-targeted T-cell model", "System": "SKLU-1-A11 human NSCLC cells + TCRG12D-engineered T cells", "Dose": "1–2.5 µM entinostat", "Technique": "IncuCyte; flow cytometry; 24-h T-cell recognition assay; GFP-based tumor-cell killing assay", "Controlled_Technique": "MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased representing increased tumor immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/612", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC1/HDAC3 inhibition; increases MHC-I and PD-L1", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "42515717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "KRASG12D/p53-mutant murine NSCLC", "System": "KPN1.1 murine NSCLC cells", "Dose": "1–3.5 µM", "Technique": "Flow cytometry, IncuCyte live-cell imaging", "Controlled_Technique": "MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased representing increased tumor immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/614", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC1/HDAC3 inhibition; increases histone acetylation and tumor-cell immune visibility, including MHC-I expression", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "42515717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Human non-small-cell lung cancer", "System": "A549 human NSCLC cells", "Dose": "1–3.5 µM", "Technique": "Flow cytometry, IncuCyte live-cell imaging", "Controlled_Technique": "MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased representing increased tumor immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/615", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC1/HDAC3 inhibition; increases histone acetylation and tumor-cell immune visibility, including MHC-I expression", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "42515717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Human non-small-cell lung cancer", "System": "H460 human NSCLC cells", "Dose": "1–3.5 µM", "Technique": "Flow cytometry, IncuCyte live-cell imaging", "Controlled_Technique": "MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased representing increased tumor immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/616", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC1/HDAC3 inhibition; increases histone acetylation and tumor-cell immune visibility, including MHC-I expression", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "42515717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Human non-small-cell lung cancer", "System": "L4 human NSCLC cell line", "Dose": "1–3.5 µM", "Technique": "Flow cytometry, IncuCyte live-cell imaging", "Controlled_Technique": "MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased representing increased tumor immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1572", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31059004", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "MDA‑MB‑231", "Dose": "entinostat (10‑500 nM) for 3 days", "Technique": "SYBR‑Green qPCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD44, ALDH1 and COX‑2", "Controlled_Terms_Function_enhanced_Number_increased": "CD44; COX-2 / PTGS2", "Immune_System-Function_inhibited/numbers_decreased": "ALKBH5", "Controlled_Terms_Function_inhibited_Number_decreased": "ALKBH5", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1573", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31059004", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "TNBC BT‑549", "Dose": "entinostat (10‑500 nM) for 3 days", "Technique": "SYBR‑Green qPCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "phosphorylation of AKT, ERK, p38, STAT3", "Controlled_Terms_Unaffected": "IL-6/JAK/STAT3 signaling; STAT3; ERK / MAPK; AKT", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1574", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31059004", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "LM2‑4", "Dose": "entinostat (10‑500 nM) for 3 days", "Technique": "SYBR‑Green qPCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1609", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "29371976", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "Triple-negative MDA-MB231", "Dose": "1-3 µM", "Technique": "western blot, qReal-Time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in tumor cells,", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/368", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "MDA-MB-231", "Dose": "(500 nM) for 72 hours", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression,ICAM-1,Fas,DR5", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; CD95 / Fas / FAS; ICAM-1 / CD54; TRAIL-R2 / DR5 / TNFRSF10B; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/370", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "SUM159PT", "Dose": "(500 nM) for 72 hours", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MIC-A/B, PD-L1 expression, ULBP-3,ULBP-2/5/6 ,CD112 ,CD155,ICAM-1,HLA-ABC", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; CD112 / Nectin-2 / PVRL2; CD155 / PVR; ICAM-1 / CD54; ULBP2; ULBP3; ULBP2/5/6 family; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/387", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "H1882", "Dose": "(500 nM) for 72 hours", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression, ULBP-1, ULBP-3, ULBP-2/5/6 ,CD112 ,ICAM-1,Fas,HLA-ABC", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; CD95 / Fas / FAS; CD112 / Nectin-2 / PVRL2; ICAM-1 / CD54; ULBP1; ULBP2; ULBP3; ULBP2/5/6 family; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/390", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H441", "Dose": "(500 nM) for 72 hours", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MIC-A/B, PD-L1 expression,ULBP-3,CD155,DR5", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; CD155 / PVR; ULBP3; TRAIL-R2 / DR5 / TNFRSF10B; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/392", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H460", "Dose": "(500 nM) for 72 hours", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MIC-A/B, PD-L1 expression,ULBP-3,ULBP-2/5/6 ,CD112 , CD155 ,Fas,DR5,HLA-ABC", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; CD95 / Fas / FAS; CD112 / Nectin-2 / PVRL2; CD155 / PVR; ULBP2; ULBP3; ULBP2/5/6 family; TRAIL-R2 / DR5 / TNFRSF10B; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/410", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "HEY-T30", "Dose": "(500 nM) for 72 hours", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MIC-A/B, PD-L1 expression,ULBP-2/5/6 ,CD155 ,ICAM-1,DR5,HLA-ABC", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; CD155 / PVR; ICAM-1 / CD54; ULBP2; ULBP2/5/6 family; TRAIL-R2 / DR5 / TNFRSF10B; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/411", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "PC-3", "Dose": "(500 nM) for 72 hours", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression,ULBP-1,CD112,ICAM-1,Fas,HLA-ABC", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; CD95 / Fas / FAS; CD112 / Nectin-2 / PVRL2; ICAM-1 / CD54; ULBP1; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/415", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "DU145", "Dose": "(500 nM) for 72 hours", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MIC-A/B, PD-L1 expression,ULBP-1,ICAM-1,DR5,HLA-ABC", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; ICAM-1 / CD54; ULBP1; TRAIL-R2 / DR5 / TNFRSF10B; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/445", "Drug": "Entinostat (ENT/MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibitors", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1 and TS/A,", "Dose": "20 mg/kg/day", "Technique": "RT-qPCR, flow cytometry,NanoString analysis", "Controlled_Technique": "MHC-II , MHC-I , CD74 , class II transcriptional activator (CIITA), CD80/CD86-related costimulatory activity, 4-1BB, CD40, ICOSL, PD-L1, CXCL10, CXCL13", "Immune_System-Function_enhanced/numbers_increased": "CD80; CD86; CD80/CD86 costimulation; MHC class I; MHC class II; PD-L1 / CD274; CXCL10 / IP-10; CXCL13; CD40", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/496", "Drug": "Entinostat (ENT/MS-275)+IFN-γ", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibitors", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "combination", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1 and TS/A,", "Dose": "20 mg/kg/day", "Technique": "flow cytometry", "Controlled_Technique": "MHCII, MHC I, CD74,PD-L1 expression, STAT1, PD-L1, and\nCXCL10", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II; PD-L1 / CD274; CXCL10 / IP-10; STAT1; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1017", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "INA-6", "Dose": "0.25 μM or 1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1363", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "4T1", "Dose": "5 μM", "Technique": "RT-PCR, Flow cytometry, propidium iodide staining", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CIITA and CD74, MHCII and CD74, PD-L1 expression , costimulatory molecules, 41BB, CD40, and ICOSL, the inhibitory ligand, PD-L1, and the T-cell chemoattractant, CXCL10 impairs tumor cell proliferation", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class II; CIITA; CD40; ICOS ligand / ICOSL / CD275; 4-1BB / CD137; CD74; CXCL10 / IP-10; Cell proliferation; CD80/CD86 costimulation; T cells; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1364", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "TS/A", "Dose": "5 μM", "Technique": "RT-PCR, Flow cytometry, propidium iodide staining", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CIITA and CD74, MHCII and CD74, PD-L1 expression , costimulatory molecules, 41BB, CD40, and ICOSL, the inhibitory ligand, PD-L1, and the T-cell chemoattractant, CXCL10 impairs tumor cell proliferation", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class II; CIITA; CD40; ICOS ligand / ICOSL / CD275; 4-1BB / CD137; CD74; CXCL10 / IP-10; Cell proliferation; CD80/CD86 costimulation; T cells; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1403", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "NCI-H929", "Dose": "100 nm MS-275", "Technique": "RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CIITA,MHCI", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; CIITA;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1404", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "DB cells", "Dose": "250 nM", "Technique": "Flow cytometry and quantitative RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-DR, CIITA and HLA-DRα,HLA-ABC", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-DR; CIITA", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1407", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS-11", "Dose": "0.25 μM or 1 μM", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligands, MICA/B and ULBP2/5/6,IFN-γR1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICA; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1408", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "0.25 μM or 1 μM", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligands, MICA/B and ULBP2/5/6,IFN-γR1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICA; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1409", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "0.25 μM or 1 μM", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligands, MICA/B and ULBP2/5/6,IFN-γR1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICA; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/51", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 cells", "Dose": "500nM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "T cell attracting chemokine genes - Cxcl10", "Controlled_Terms_Function_enhanced_Number_increased": "CXCL10 / IP-10; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/75", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "SUDHL-6 GCB", "Dose": "25-250 nM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CIITA and HLA-DRα", "Controlled_Terms_Function_enhanced_Number_increased": "HLA-DR; CIITA", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/536", "Drug": "FK228 (Romidepsin)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "HDAC inhibitor; reported to directly inhibit HDAC1, HDAC2, HDAC4 and HDAC6. In this study, FK228 induces ER-stress-associated necroptosis in tumor cells, producing immunogenic cell death and remodeling the tumor immune microenvironment.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "5352062", "STR_LINK_(SMILES)": "C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C", "Single/Combination": "Single", "PMID": "40940553", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": null, "System": "In vitro: MC38 tumor cells", "Dose": "IC50 concentration 43.37 nM", "Technique": "7-AAD staining/flow cytometry, CCK-8 cell viability assay, colony-formation assay, Western blotting, Luminex cytokine/chemokine analysis, ATP-release assay, calreticulin immunofluorescence/flow cytometry", "Controlled_Technique": "FK228 increased acetylation of histones, including H3K9, H3K27, H4K8 and H4K16, consistent with HDAC inhibition. FK228 predominantly induces necroptosis in MC38 cells. FK228 resulted in immunogenic cell death by increasing inflammatory chemokines, including CX3CL1 and CXCL10.", "Immune_System-Function_enhanced/numbers_increased": "Immunogenic cell death; CXCL10 / IP-10", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/537", "Drug": "FK228 (Romidepsin)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "HDAC inhibitor; reported to directly inhibit HDAC1, HDAC2, HDAC4 and HDAC6. In this study, FK228 induces ER-stress-associated necroptosis in tumor cells, producing immunogenic cell death and remodeling the tumor immune microenvironment.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "5352062", "STR_LINK_(SMILES)": "C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C", "Single/Combination": "Single", "PMID": "40940553", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": null, "System": "In vitro: CT26 tumor cells", "Dose": "IC50 concentration CT26 58.61 nM", "Technique": "7-AAD staining/flow cytometry, CCK-8 cell viability assay, colony-formation assay, Western blotting, Luminex cytokine/chemokine analysis, ATP-release assay, calreticulin immunofluorescence/flow cytometry", "Controlled_Technique": "FK228 increased acetylation of histones, including H3K9, H3K27, H4K8 and H4K16, consistent with HDAC inhibition. FK228 predominantly induces necroptosis in MC38 cells. FK228 resulted in immunogenic cell death by increasing inflammatory chemokines, including CX3CL1 and CXCL10.", "Immune_System-Function_enhanced/numbers_increased": "Immunogenic cell death; CXCL10 / IP-10", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/538", "Drug": "FK228 (Romidepsin)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "HDAC inhibitor; reported to directly inhibit HDAC1, HDAC2, HDAC4 and HDAC6. In this study, FK228 induces ER-stress-associated necroptosis in tumor cells, producing immunogenic cell death and remodeling the tumor immune microenvironment.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "5352062", "STR_LINK_(SMILES)": "C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C", "Single/Combination": "Single", "PMID": "40940553", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": null, "System": "In vitro: 4T1 tumor cells", "Dose": "IC50 concentration 4T1 13.49 nM", "Technique": "7-AAD staining/flow cytometry, CCK-8 cell viability assay, colony-formation assay, Western blotting, Luminex cytokine/chemokine analysis, ATP-release assay, calreticulin immunofluorescence/flow cytometry", "Controlled_Technique": "FK228 increased acetylation of histones, including H3K9, H3K27, H4K8 and H4K16, consistent with HDAC inhibition. FK228 predominantly induces necroptosis in MC38 cells. FK228 resulted in immunogenic cell death by increasing inflammatory chemokines, including CX3CL1 and CXCL10.", "Immune_System-Function_enhanced/numbers_increased": "Immunogenic cell death; CXCL10 / IP-10", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/707", "Drug": "FOLFOX (5-FU + leucovorin + oxaliplatin)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "5-FU inhibits nucleotide synthesis; leucovorin enhances 5-FU activity; oxaliplatin causes DNA crosslinks", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "40380807", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "gastric cancer cell line", "System": "AGS", "Dose": "leucovorin: 14 μM; 5-Fu: 200 μM; oxaliplatin: 6 μM) for 48 h", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Increased cell-surface PD-L1 and MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Increased PD-L1 may promote inhibitory immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/708", "Drug": "FOLFOX (5-FU + leucovorin + oxaliplatin)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "5-FU inhibits nucleotide synthesis; leucovorin enhances 5-FU activity; oxaliplatin causes DNA crosslinks", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "40380807", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "gastric cancer cell line", "System": "SNU-1", "Dose": "leucovorin: 14 μM; 5-Fu: 200 μM; oxaliplatin: 6 μM) for 48 h", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Increased cell-surface PD-L1 and MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Increased PD-L1 may promote inhibitory immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1108", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM983A", "Dose": "(10nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1109", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM793", "Dose": "(10nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1110", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B78H1", "Dose": "(10nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1111", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SkMel21", "Dose": "(10nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1113", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM35", "Dose": "(10nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1114", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM1366", "Dose": "(10nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1115", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16F10", "Dose": "(10nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1116", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-624", "Dose": "(10nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1117", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-888", "Dose": "(10nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1138", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "primary human melanomas", "Dose": "10-40nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1, PD-L2 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1228", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16–F10", "Dose": "25-nM", "Technique": "Flow cytometry to evaluate Annexin V and DAPI.", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1229", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM164", "Dose": "25-nM", "Technique": "Flow cytometry to evaluate Annexin V and DAPI.", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/325", "Drug": "LBH589 (Panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26176219", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Wilms Tumor ( Embryonic Kidney Cancer)", "System": "SK-NEP-1", "Dose": "50nM and 100nM for 24 hours", "Technique": "Annexin V, cell cycle, tunnel and Hochest33342 assays,western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay; Cell-cycle analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Bcl-2", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/326", "Drug": "LBH589 (Panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26176219", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Wilms Tumor ( Embryonic Kidney Cancer)", "System": "G401", "Dose": "50nM and 100nM for 24 hours", "Technique": "Annexin V, cell cycle, tunnel and Hochest33342 assays,western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay; Cell-cycle analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Bcl-2", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/643", "Drug": "M344", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits HDACs 1, 2, 3 and 6; inhibits histone H3 deacetylation; increases MHC class I expression on pancreatic cancer cells", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "36126055", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Human pancreatic cancer xenograft", "System": "S2-013", "Dose": "1 μM or 10 μM", "Technique": "Immunoblotting", "Controlled_Technique": "MHC class I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1118", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM983A", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1119", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM793", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1121", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SkMel21", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1122", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM35", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1124", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM1366", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1125", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16F10", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1126", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-624", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1127", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-888", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1139", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "primary human melanomas", "Dose": "0.25-1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1, PD-L2 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1540", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30344659", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Classical Hodgkin'S Lymphoma (CHL)", "System": "L1236", "Dose": "(0, 0.5, 1 or 2 µM) for 24 h", "Technique": "western blotting, Laser confocal microscopy,Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Microscopy; Confocal microscopy", "Immune_System-Function_enhanced/numbers_increased": "cell apoptosis and cell cycle arrest", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell-cycle arrest", "Immune_System-Function_inhibited/numbers_decreased": "Bcl-2 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-2; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 NF-κB", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; NF-κB; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/1541", "Drug": "MGCD0103 (mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30344659", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Classical Hodgkin'S Lymphoma (CHL)", "System": "L428", "Dose": "(0, 0.5, 1 or 2 µM) for 24 h", "Technique": "western blotting, Laser confocal microscopy,Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Microscopy; Confocal microscopy", "Immune_System-Function_enhanced/numbers_increased": "cell apoptosis and cell cycle arrest", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell-cycle arrest", "Immune_System-Function_inhibited/numbers_decreased": "Bcl-2 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-2; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 NF-κB", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; NF-κB; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/52", "Drug": "MGCD0103 (Mocetinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 cells", "Dose": "1μM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "T cell attracting chemokine genes - Cxcl10", "Controlled_Terms_Function_enhanced_Number_increased": "CXCL10 / IP-10; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/272", "Drug": "Mocetinostat (mgcd0103)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "20880107", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Hodgkin Lymphoma", "System": "HD-LM2(of T cell origin)", "Dose": "1 μmol/l", "Technique": "Western blot, Flow cyto metry", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "activated caspases 9 and 3, and induced apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "XIAP", "Controlled_Terms_Function_inhibited_Number_decreased": "XIAP", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/273", "Drug": "Mocetinostat (mgcd0103)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "20880107", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Hodgkin Lymphoma", "System": "L428 (of B cell origin)", "Dose": "1 μmol/l", "Technique": "Western blot, Flow cyto metry", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "activated caspases 9 and 3, and induced apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "XIAP", "Controlled_Terms_Function_inhibited_Number_decreased": "XIAP", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/274", "Drug": "Mocetinostat (mgcd0103)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "20880107", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Hodgkin Lymphoma", "System": "KMH2(of B cell origin)", "Dose": "1 μmol/l", "Technique": "Western blot, Flow cyto metry", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "activated caspases 9 and 3, and induced apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "XIAP", "Controlled_Terms_Function_inhibited_Number_decreased": "XIAP", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/334", "Drug": "Mocetinostat (mgcd0103)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "20880107", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Hodgkin Lymphoma", "System": "HD-LM2(of T cell origin)", "Dose": "MGCD103 (0.5 or 1 μmol/l) for 24 or 48 h", "Technique": "ELISA assay, Western blot", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "TNF-α NFk-B activation", "Controlled_Terms_Negative_Regulation": "TNF-α / TNF; NF-κB; NF-κB activation"}, {"ID": "CANIMM/337", "Drug": "Mocetinostat (mgcd0103)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "20880107", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Hodgkin Lymphoma", "System": "L428 (of B cell origin)", "Dose": "MGCD103 (0.5 or 1 μmol/l) for 24 or 48 h", "Technique": "ELISA assay, Western blot", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "TNF-α NFk-B activation", "Controlled_Terms_Negative_Regulation": "TNF-α / TNF; NF-κB; NF-κB activation"}, {"ID": "CANIMM/540", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "Inhibits MEK1/2 → suppresses MAPK/ERK signaling", "KEGG_Drug__ID": "D10405", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "CN1CCN(CC1)C(=O)C2=C(C=C(C=C2F)F)NC3=C(C=C(C=C3)F)I", "Single/Combination": "Single", "PMID": "34389557", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CT26 murine colorectal carcinoma cells", "System": "CT26 WT cells", "Dose": "1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/338", "Drug": "Mocetinostat (mgcd0103)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11830", "Target/s_or_mechanism_of_action": "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D09641", "Pubchem_ID": "9865515", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "20880107", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Hodgkin Lymphoma", "System": "KMH2(of B cell origin)", "Dose": "MGCD103 (0.5 or 1 μmol/l) for 24 or 48 h", "Technique": "ELISA assay, Western blot", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "TNF-α NFk-B activation", "Controlled_Terms_Negative_Regulation": "TNF-α / TNF; NF-κB; NF-κB activation"}, {"ID": "CANIMM/559", "Drug": "MPT0G612", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Selective HDAC6 inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "31652644", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal carcinoma", "System": "HCT116", "Dose": "10 μM", "Technique": "Western blotting; SRB assay; MTT assay; flow cytometry/PI staining; Annexin V/PI; shRNA-mediated HDAC6 knockdown", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ-induced PD-L1 expression decreased", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 / CD274; Expression / abundance phenotype; IFN-γ", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/560", "Drug": "MPT0G612", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Selective HDAC6 inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "31652644", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal carcinoma", "System": "HT-29", "Dose": "10 μM", "Technique": "Western blotting; SRB assay; MTT assay; flow cytometry/PI staining; Annexin V/PI; shRNA-mediated HDAC6 knockdown", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ-induced PD-L1 expression decreased", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 / CD274; Expression / abundance phenotype; IFN-γ", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1128", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM983A", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1129", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM793", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1130", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B78H1", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1131", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SkMel21", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1132", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM35", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1133", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM1366", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1135", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16F10", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1136", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-624", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1137", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-888", "Dose": "(500nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1140", "Drug": "MS275 (etinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "primary human melanomas", "Dose": "0.25-1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1, PD-L2 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1593", "Drug": "Nexturastat A", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "71462653", "STR_LINK_(SMILES)": "CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM164", "Dose": "2 μM", "Technique": "qRT‐PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanoma antigens gp100, MART1, TYRP1 and TYRP2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1594", "Drug": "Nexturastat A", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "71462653", "STR_LINK_(SMILES)": "CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM793", "Dose": "2 μM", "Technique": "qRT‐PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanoma antigens gp100, MART1, TYRP1 and TYRP2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1595", "Drug": "Nexturastat A", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "71462653", "STR_LINK_(SMILES)": "CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "IPC298", "Dose": "2 μM", "Technique": "qRT‐PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanoma antigens gp100, MART1, TYRP1 and TYRP2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1596", "Drug": "Nexturastat A", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "71462653", "STR_LINK_(SMILES)": "CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL30", "Dose": "2 μM", "Technique": "qRT‐PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanoma antigens gp100, MART1, TYRP1 and TYRP2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/115", "Drug": "Nexturastat A", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "71462653", "STR_LINK_(SMILES)": "CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2", "Single/Combination": "Single Drug", "PMID": "30992475", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "System": "SM1 melanoma cells ( co-cultured with CD3/CD28 activated splenocytes in the presence or absence of IFNγ blocking antibody at 1:1000 and 1:100 dilutions)", "Dose": "0-5 μm", "Technique": "qRT-PCR,ELISA", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 in tumor cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/588", "Drug": "OBP-801", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12279", "Target/s_or_mechanism_of_action": "Potent class-I HDAC inhibitor", "KEGG_Drug__ID": "NR", "Pubchem_ID": "11178958", "STR_LINK_(SMILES)": "CC(C)[C@H]1NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C)C(=O)N2)OC(=O)C[C@@H]1O", "Single/Combination": "Single", "PMID": "39682244", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Clear cell renal cell carcinoma", "System": "RENCA", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "LMP2/PSMB9, MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; LMP2 / PSMB9", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/589", "Drug": "OBP-801", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12279", "Target/s_or_mechanism_of_action": "Potent class-I HDAC inhibitor", "KEGG_Drug__ID": "NR", "Pubchem_ID": "11178958", "STR_LINK_(SMILES)": "CC(C)[C@H]1NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C)C(=O)N2)OC(=O)C[C@@H]1O", "Single/Combination": "Single", "PMID": "39682244", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Clear cell renal cell carcinoma", "System": "786-O", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "LMP2/PSMB9, MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; LMP2 / PSMB9", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/590", "Drug": "OBP-801", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12279", "Target/s_or_mechanism_of_action": "Potent class-I HDAC inhibitor", "KEGG_Drug__ID": "NR", "Pubchem_ID": "11178958", "STR_LINK_(SMILES)": "CC(C)[C@H]1NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C)C(=O)N2)OC(=O)C[C@@H]1O", "Single/Combination": "Single", "PMID": "39682244", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Clear cell renal cell carcinoma", "System": "Caki-1", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "LMP2/PSMB9, MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; LMP2 / PSMB9", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/476", "Drug": "OKI-005", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Cell-active prodrug converted to OKI-006, which inhibits class I HDACs; increases histone acetylation and p21", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "34965958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "TNBC", "System": "CAL-120 human triple-negative breast cancer cell line", "Dose": "0–500 nM for apoptosis", "Technique": "Caspase-3/7 assay", "Controlled_Technique": "7/9 fold increase caspase −3 and −7 activity", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/477", "Drug": "OKI-005", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Cell-active prodrug converted to OKI-006, which inhibits class I HDACs; increases histone acetylation and p21", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "34965958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "TNBC", "System": "MDA-MB-231", "Dose": "0–500 nM for apoptosis", "Technique": "Caspase-3/7 assay", "Controlled_Technique": "7/9 fold increase caspase −3 and −7 activity", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/478", "Drug": "OKI-005", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Cell-active prodrug converted to OKI-006, which inhibits class I HDACs; increases histone acetylation and p21", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "34965958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "TNBC", "System": "HCC1395", "Dose": "0–500 nM for apoptosis", "Technique": "Caspase-3/7 assay", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "caspase −3 and −7 activity", "Immune_System_function_unaffected": "Caspase activation", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/479", "Drug": "OKI-005", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Cell-active prodrug converted to OKI-006, which inhibits class I HDACs; increases histone acetylation and p21", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "34965958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "TNBC", "System": "Hs578T", "Dose": "0–500 nM for apoptosis", "Technique": "Caspase-3/7 assay", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "caspase −3 and −7 activity", "Immune_System_function_unaffected": "Caspase activation", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/534", "Drug": "OKI-005", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "NR", "Target/s_or_mechanism_of_action": "Prodrug converted to OKI-006, active metabolite inhibits HDAC1/2/3", "KEGG_Drug__ID": "NR", "Pubchem_ID": "NR", "STR_LINK_(SMILES)": "CC(C)CC(=O)SCC/C=C/[C@@H]1CC(=O)NCC2=NC(=CS2)C(=O)NC(C)(C)C(=O)N[C@H](C(=O)O1)C(C)C", "Single/Combination": "Single", "PMID": "37744352", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "MC38 cells", "Dose": "1 μM", "Technique": "Flow cytometry; intracellular cytokine staining", "Controlled_Technique": "TNFα-producing T cells", "Immune_System-Function_enhanced/numbers_increased": "T cells; TNF-α / TNF", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2, IFNγ, IL-4 and IL-17 production", "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ; IL-2; IL-4", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/991", "Drug": "OKI-179", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "novel oral Class I histone deacetylase (HDAC) inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31235619", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas", "System": "OCI-Ly3", "Dose": "250 nM.500 nM, 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A, B and C, HLA-DP, DQ and DR", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1288", "Drug": "OKI-179", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "novel oral Class I histone deacetylase (HDAC) inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31235619", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas", "System": "OCI-Ly7", "Dose": "250 nM.500 nM, 1 µM", "Technique": "RNA-Seq, Flow cytometry", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "HLA-A, B and C", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/1538", "Drug": "OKI-179", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "novel oral Class I histone deacetylase (HDAC) inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31235619", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas", "System": "G1XP", "Dose": "250 nM,500 nM, 1 µM", "Technique": "Flow cytometry, western blotting, RNA-Seq", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC class I and class II cell cycle arrest, apoptosis and growth inhibition", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; Apoptosis; Cell-cycle arrest;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/556", "Drug": "OKI-179 (bocodepsin)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB17583", "Target/s_or_mechanism_of_action": "Prodrug of OKI-006; selectively inhibits class-I HDACs (HDAC1/2/3), causing increased histone acetylation and altered gene expression", "KEGG_Drug__ID": "NR", "Pubchem_ID": "118551244", "STR_LINK_(SMILES)": "O=C1C2=CSC(CNC(C[C@H](OC([C@@H](NC(C(C)(N1)C)=O)C(C)C)=O)/C=C/CCSC(=O)[C@H](C(C)C)N)=O)=N2", "Single/Combination": "Single", "PMID": "37744352", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Human phase-I patients with advanced solid tumors; syngeneic MC38 colorectal cancer mouse model", "System": "Human PBMCs / T cells", "Dose": "60–450 mg in patients", "Technique": "Flow cytometry; ex-vivo PBMC analysis", "Controlled_Technique": "TNFα-producing T cells", "Immune_System-Function_enhanced/numbers_increased": "T cells; TNF-α / TNF", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2", "Immune_System-Function_inhibited/numbers_decreased": "IL-2", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/497", "Drug": "Panobinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Pan-HDAC inhibitor", "KEGG_Drug__ID": "D10319", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO", "Single/Combination": "Single", "PMID": "34531855", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical cancer", "System": "HeLa", "Dose": "25, 50, 100 nM; 24 h", "Technique": "flow cytometry", "Controlled_Technique": "CD80, CD86 and CD112 expression increased on tumor cells", "Immune_System-Function_enhanced/numbers_increased": "CD80; CD86; CD112 / Nectin-2 / PVRL2; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/684", "Drug": "Panobinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Pan-HDAC inhibitor", "KEGG_Drug__ID": "D10319", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO", "Single/Combination": "Single", "PMID": "34531855", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin cancer", "System": "A375", "Dose": "25, 50, 100 nM; 24 h", "Technique": "flow cytometry", "Controlled_Technique": "CD80, CD86 and CD112 expression increased on tumor cells", "Immune_System-Function_enhanced/numbers_increased": "CD80; CD86; CD112 / Nectin-2 / PVRL2; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/705", "Drug": "Panobinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Pan-HDAC inhibitor", "KEGG_Drug__ID": "D10319", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO", "Single/Combination": "Single", "PMID": "34531855", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Liver cancer", "System": "HepG2", "Dose": "25, 50, 100 nM; 24 h", "Technique": "flow cytometry", "Controlled_Technique": "CD80, CD86 and CD112 expression increased on tumor cells", "Immune_System-Function_enhanced/numbers_increased": "CD80; CD86; CD112 / Nectin-2 / PVRL2; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/706", "Drug": "Panobinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Pan-HDAC inhibitor", "KEGG_Drug__ID": "D10319", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO", "Single/Combination": "Single", "PMID": "34531855", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Liver cancer", "System": "Huh7", "Dose": "25, 50, 100 nM; 24 h", "Technique": "flow cytometry", "Controlled_Technique": "CD80, CD86 and CD112 expression increased on tumor cells", "Immune_System-Function_enhanced/numbers_increased": "CD80; CD86; CD112 / Nectin-2 / PVRL2; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1010", "Drug": "Panobinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "RPMI8226", "Dose": "25 nM or 100 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligands, MICA/B and ULBP2/5/6", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICA; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1011", "Drug": "Panobinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "INA-6", "Dose": "25 nM or 100 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1406", "Drug": "Panobinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS-11", "Dose": "25 nM or 100 nM", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligands, MICA/B and ULBP2/5/6, IFN-γR1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICA; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1410", "Drug": "Panobinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "25 nM or 100 nM", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligands, MICA/B and ULBP2/5/6,IFN-γR1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICA; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1412", "Drug": "Panobinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "25 nM or 100 nM", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligands, MICA/B and ULBP2/5/6,IFN-γR1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICA; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1610", "Drug": "Panobinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "29371976", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "Triple-negative MDA-MB231", "Dose": "1-10 µM", "Technique": "western blot, qReal-Time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in tumor cells.", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/539", "Drug": "Panobinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "HDAC inhibitors", "KEGG_Drug__ID": "D10319", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO", "Single/Combination": "Single", "PMID": "37744352", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "MC38 cells", "Dose": "10 nM", "Technique": "Flow cytometry; intracellular cytokine staining; Ac-H3K27 analysis", "Controlled_Technique": "TNFα-producing T cells", "Immune_System-Function_enhanced/numbers_increased": "T cells; TNF-α / TNF", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2, IFNγ, IL-4 and IL-17 production", "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ; IL-2; IL-4", "Controlled_Terms_Function_inhibited_Number_decreased": "NR", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "NR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/767", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "23963286", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16 murine melanoma cells (H-2b) + naöve OVA-specific CD4+ T-cells (OT-II) with the presence of cognate OVA-peptide", "Dose": "25nM, 50nM", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-2 and IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1151", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "23963286", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM793", "Dose": "25nM, 50nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I and class II, CD40 and CD86 apoptosis and a G1 cell cycle arrest", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; CD40; CD86; Apoptosis; Cell-cycle arrest;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1152", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "23963286", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM983A", "Dose": "25nM, 50nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I, CD40 and CD86 apoptosis and a G1 cell cycle arrest", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; CD40; CD86; Apoptosis; Cell-cycle arrest;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1153", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "23963286", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16", "Dose": "25nM, 50nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I, MHC class II CD40, CD80 and CD860 (modest upregulation) apoptosis and a G1 cell cycle arrest", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; CD40; CD80; Apoptosis; Cell-cycle arrest; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1365", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "4T1", "Dose": "10 nM", "Technique": "RT-PCR, Flow cytometry, propidium iodide staining", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CIITA and CD74, MHCII and CD74, PD-L1 expression , costimulatory molecules, 41BB, CD40, and ICOSL, the inhibitory ligand, PD-L1, and the T-cell chemoattractant, CXCL10 impairs tumor cell proliferation", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class II; CIITA; CD40; ICOS ligand / ICOSL / CD275; 4-1BB / CD137; CD74; CXCL10 / IP-10; Cell proliferation; CD80/CD86 costimulation; T cells; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1366", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "TS/A", "Dose": "10 nM", "Technique": "RT-PCR, Flow cytometry, propidium iodide staining", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CIITA and CD74, MHCII and CD74, PD-L1 expression , costimulatory molecules, 41BB, CD40, and ICOSL, the inhibitory ligand, PD-L1, and the T-cell chemoattractant, CXCL10 impairs tumor cell proliferation", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class II; CIITA; CD40; ICOS ligand / ICOSL / CD275; 4-1BB / CD137; CD74; CXCL10 / IP-10; Cell proliferation; CD80/CD86 costimulation; T cells; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/53", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 cells", "Dose": "100nM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "T cell attracting chemokine genes - Cxcl10", "Controlled_Terms_Function_enhanced_Number_increased": "CXCL10 / IP-10; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/94", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "23963286", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM793", "Dose": "12.5 nM-50nM", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "gp100, mart1, tyrp1 and tyrp2- melanoma antigens", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/95", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "23963286", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16", "Dose": "12.5 nM-50nM", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "gp100, mart1, tyrp1 and tyrp2- melanoma antigens", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/448", "Drug": "Panobinostat (PAN/LBH589)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "HDAC inhibitors", "KEGG_Drug__ID": "D10319", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO", "Single/Combination": "Single", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1 and TS/A,", "Dose": "20 mg/kg/day", "Technique": "RT-qPCR, flow cytometry, NanoString analysis", "Controlled_Technique": "MHC-II , MHC-I , CD74 , class II transcriptional activator (CIITA), CD80/CD86-related costimulatory activity, 4-1BB, CD40, ICOSL, CXCL10, CXCL13", "Immune_System-Function_enhanced/numbers_increased": "CD80; CD86; CD80/CD86 costimulation; MHC class I; MHC class II; CXCL10 / IP-10; CXCL13; CD40", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1141", "Drug": "PDX101 (belinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB05015", "Target/s_or_mechanism_of_action": "histone deacetylase inhibitor", "KEGG_Drug__ID": "D08870", "Pubchem_ID": "6918638", "STR_LINK_(SMILES)": "ONC(=O)\\C=C\\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "primary human melanomas", "Dose": "0.5-2 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1, PD-L2 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/681", "Drug": "Quisinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12985", "Target/s_or_mechanism_of_action": "HDAC inhibition → increased histone acetylation and HLA-I transcription", "KEGG_Drug__ID": "D10321", "Pubchem_ID": "11538455", "STR_LINK_(SMILES)": "CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO", "Single/Combination": "Single", "PMID": "33316946", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Human uveal melanoma", "System": "OMM1", "Dose": "40 nM, 48 h", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "HLA-I surface expression, HLA-A and HLA-B mRNA", "Immune_System-Function_enhanced/numbers_increased": "HLA-A; HLA-B; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/682", "Drug": "Quisinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12985", "Target/s_or_mechanism_of_action": "HDAC inhibition → increased histone acetylation and HLA-I transcription", "KEGG_Drug__ID": "D10321", "Pubchem_ID": "11538455", "STR_LINK_(SMILES)": "CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO", "Single/Combination": "Single", "PMID": "33316946", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Human uveal melanoma", "System": "OMM2.5", "Dose": "40 nM, 48 h", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "HLA-I surface expression, HLA-A and HLA-B mRNA", "Immune_System-Function_enhanced/numbers_increased": "HLA-A; HLA-B; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/683", "Drug": "Quisinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12985", "Target/s_or_mechanism_of_action": "HDAC inhibition → increased histone acetylation and HLA-I transcription", "KEGG_Drug__ID": "D10321", "Pubchem_ID": "11538455", "STR_LINK_(SMILES)": "CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO", "Single/Combination": "Single", "PMID": "33316946", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Human uveal melanoma", "System": "MP38", "Dose": "40 nM, 48 h", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "HLA-I surface expression, HLA-A and HLA-B mRNA", "Immune_System-Function_enhanced/numbers_increased": "HLA-A; HLA-B; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/948", "Drug": "Ricolinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "28408401", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "Peripheral blood mononuclear cells (PBMCs) from NSCLC patients or dissociated tumors", "Dose": "2.5μm", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ and CD4+ T cells, APC,s CD69 activation marker on conventional CD8+ and CD4+ T cells, CD14+ monocyte - MHC class II molecules, as well as CD86", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; CD86; CD4; CD8; CD69; T cells; CD4+ T cells; Monocytes;", "Immune_System-Function_inhibited/numbers_decreased": "CD4+FOXP3+ Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1389", "Drug": "Ricolinostat (ACY-1215)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "T-cells isolated from melanoma patient PBMC samples(activated via αCD3/CD28)", "Dose": "500nM", "Technique": "Luminex", "Controlled_Technique": "Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Th2 cytokine production (e.g. IL-4, IL-5, IL-6, IL-13)", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-4; IL-5; IL-6", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1143", "Drug": "Ricolinostat (ACY-1215)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "T-cells isolated from melanoma patient PBMC samples(activated via αCD3/CD28)", "Dose": "500nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8 + TBET+PD1+ T-cells, a less terminally differentiated phenotype, CD4+ T-cells ( CD45RA-CD45RO + CD62L + CCR7+ central memory markers),CD45RA-CD62L+ (central memory phenotype) in CD8+ IFNγ and TNF T-BET expression in T cells, T-BET expression in CD8+ and CD4+ T-cells", "Controlled_Terms_Function_enhanced_Number_increased": "PD-1 / PDCD1; CD4; CD8; TNF-α / TNF; IFN-γ; T cells; CD4+ T cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "GATA3 levels in CD 8, EOMES expression in CD8+ T-cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; T cells; CD8+ T cells; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1144", "Drug": "Ricolinostat (ACY-1215)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "T-cells harvested from melanoma patient PBMC", "Dose": "10nM to 2uM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "FOXP3-expressing Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1146", "Drug": "Ricolinostat (ACY-1215)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "isolated nTregs (CD4 + CD127-/lowCD25+) co-cultured with autologous CD8+ T-cells (Tcons) and activated via αCD3/CD28", "Dose": "500nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Ki67 expression in CD8+ Tcons", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1149", "Drug": "Ricolinostat (ACY-1215)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "T-cells from melanoma patient PBMC + co-cultured with CFSE-labeled, irradiated allogeneic PBMC (target cells)", "Dose": "500nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/507", "Drug": "JQ1", "Drug_category": "Others/combination", "Drugbank_ID": "DB17021", "Target/s_or_mechanism_of_action": "BRD4 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "46907787", "STR_LINK_(SMILES)": "CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C", "Single/Combination": "Single", "PMID": "35517410", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "LS174T", "Dose": "0.1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "HLA-ABC, MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "surface PD-L1", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 / CD274", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1465", "Drug": "Ricolinostat (ACY-1215)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30788349", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT-116", "Dose": "1-10 µM", "Technique": "Flow cytometry, Immunoblot analysis", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis, antiproliferation activity", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": "MARK/ERK pathway", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/420", "Drug": "Ricolinostat (ACY-1215)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30728070", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin -Metastatic Melanoma Patients", "System": "CD4+ naïve-derived iTregs from seven patient samples", "Dose": "500nM", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "inducible Tregs (iTregs)", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/54", "Drug": "Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "344SQ", "Dose": "(30nM)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "T cell attracting chemokine genes (Ccl5, Cxcl9 and Cxcl10)", "Controlled_Terms_Function_enhanced_Number_increased": "CCL5 / RANTES; CXCL10 / IP-10; CXCL9 / MIG; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/55", "Drug": "Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "CD11b+ cells-isolated from LKR", "Dose": "(30nM)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "T cell attracting chemokine genes (Ccl5, Cxcl9 and Cxcl10)", "Controlled_Terms_Function_enhanced_Number_increased": "CCL5 / RANTES; CXCL10 / IP-10; CXCL9 / MIG; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/78", "Drug": "Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "28167529", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SKOV3", "Dose": "10 nm", "Technique": "real-time RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Negative_Regulation": "IL-8 / CXCL8; IL-8/CXCL8"}, {"ID": "CANIMM/110", "Drug": "Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549", "Dose": "(30nM)", "Technique": "RT-PCR,ELISA", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell attracting chemokine genes (Ccl5, Cxcl9 and Cxcl10)", "Controlled_Terms_Function_enhanced_Number_increased": "CCL5 / RANTES; CXCL10 / IP-10; CXCL9 / MIG; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/111", "Drug": "Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "KRAS mutant LKR-13 (LKR)", "Dose": "(5nM–30nm)", "Technique": "RT-PCR, ELISA", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell attracting chemokine genes (Ccl5, Cxcl9 and Cxcl10), CCL5 and CXCL10 secretion in LKR cells", "Controlled_Terms_Function_enhanced_Number_increased": "CCL5 / RANTES; CXCL10 / IP-10; CXCL9 / MIG; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/57", "Drug": "SAHA (Vorinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "22419072", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H292", "Dose": "SAHA (5 μM)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/59", "Drug": "SAHA (Vorinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "22419072", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "TC-1", "Dose": "SAHA (5 μM)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/60", "Drug": "SAHA (Vorinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549", "Dose": "5 μM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/61", "Drug": "SAHA (Vorinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "SK-MES-1", "Dose": "5 μM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/62", "Drug": "SAHA (Vorinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "22419072", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 cells", "Dose": "SAHA (5 μM)", "Technique": "RT-PCR andwestern blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/96", "Drug": "SAHA (Vorinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "22419072", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16/F0 cells", "Dose": "SAHA (5 μM)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/856", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "25313353", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "HL60", "Dose": "0-100 nM", "Technique": "CCK-8 assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity", "Controlled_Terms_Function_enhanced_Number_increased": "Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/324", "Drug": "SAHA/Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "26862729", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "LNCaP +CD8+ T cells", "Dose": "3 μM", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells-mediated cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Cytotoxicity / cytolysis; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1233", "Drug": "SAHA/Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "26862729", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-231+CD8+ T cells", "Dose": "3 μM", "Technique": "111In-release assay,Flow cytometry", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells-mediated cytotoxicity, Antigen Processing Machinery-immune proteosome subunits LMP2 and LMP7, the peptide transporter TAP1, the chaperone calnexin, and the HLA class I heavy chain-associated β2-microglobulin. HLA class I antigens and ICAM-1,TAAs CEA and MUC1", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; β2-microglobulin / B2M; CD8; ICAM-1 / CD54; Cytotoxicity / cytolysis; Antigen presentation; TAP1; LMP2 / PSMB9; LMP7 / PSMB8; Calnexin; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1486", "Drug": "SAHA/Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "19759901", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "CLL cells", "Dose": "0.5 μM lenalidomide for 48 hours + IL21 (100 ng/ml)", "Technique": "immunoblot, AnnexinV-FITC/PI Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "IL21-mediated cytotoxicity in CLL B cells STAT1 and STAT3 phosphorylation", "Controlled_Terms_Function_enhanced_Number_increased": "IL-21; IL-6/JAK/STAT3 signaling; STAT1; STAT3; Cytotoxicity / cytolysis; B cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1104", "Drug": "Sodium butyrate", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "5222465", "STR_LINK_(SMILES)": "CCCC(=O)[O-].[Na+]", "Single/Combination": "Single Drug", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-86f", "Dose": "5mM sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D-L (MHC-1, MICA, UBLP2/5/6, CD112)", "Controlled_Terms_Function_enhanced_Number_increased": "CD112 / Nectin-2 / PVRL2; NKG2D / KLRK1; MICA; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD155", "Controlled_Terms_Unaffected": "CD155 / PVR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1105", "Drug": "Sodium butyrate", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "5222465", "STR_LINK_(SMILES)": "CCCC(=O)[O-].[Na+]", "Single/Combination": "Single Drug", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-55", "Dose": "5mM sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D-L (MHC-1, MICA, UBLP3, UBLP2/5/6, CD112)", "Controlled_Terms_Function_enhanced_Number_increased": "CD112 / Nectin-2 / PVRL2; NKG2D / KLRK1; ULBP3; MICA; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD155", "Controlled_Terms_Unaffected": "CD155 / PVR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1106", "Drug": "Sodium butyrate", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "5222465", "STR_LINK_(SMILES)": "CCCC(=O)[O-].[Na+]", "Single/Combination": "Single Drug", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-86c", "Dose": "5mM sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D-L (MHC-1, MICA, UBLP3, UBLP2/5/6, CD112)", "Controlled_Terms_Function_enhanced_Number_increased": "CD112 / Nectin-2 / PVRL2; NKG2D / KLRK1; ULBP3; MICA; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD155", "Controlled_Terms_Unaffected": "CD155 / PVR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1107", "Drug": "Sodium butyrate", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "5222465", "STR_LINK_(SMILES)": "CCCC(=O)[O-].[Na+]", "Single/Combination": "Single Drug", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-103", "Dose": "5mM sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D-L (MHC-1, MICA, UBLP3, UBLP2/5/6, CD112)", "Controlled_Terms_Function_enhanced_Number_increased": "CD112 / Nectin-2 / PVRL2; NKG2D / KLRK1; ULBP3; MICA; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD155", "Controlled_Terms_Unaffected": "CD155 / PVR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/987", "Drug": "Sodium butyrate", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "5222465", "STR_LINK_(SMILES)": "CCCC(=O)[O-].[Na+]", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "NCI-H929", "Dose": "2 mm sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "(HLA-ABC)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/994", "Drug": "Sodium butyrate", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "5222465", "STR_LINK_(SMILES)": "CCCC(=O)[O-].[Na+]", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "DB cells", "Dose": "2 mM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-DR expression,HLA-ABC", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-DR; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1637", "Drug": "Sodium butyrate (NaBu)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "5222465", "STR_LINK_(SMILES)": "CCCC(=O)[O-].[Na+]", "Single/Combination": "Single Drug", "PMID": "11120829", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "SK-N-MC (MC)", "Dose": "1 mM NaBu", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-DR (DR), MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/359", "Drug": "Suberoylanilide hydroxamic acid (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30745455", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Breast Carcinoma", "System": "MDA-MB-231(mutp53 carrying cell line)", "Dose": "0-10 µM, 0-20 µM for autophagy studies", "Technique": "Western blot, immunofluorescence assays", "Controlled_Technique": "Western blot/immunoblot analysis; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "p53 degradation", "Controlled_Terms_Function_enhanced_Number_increased": "p53 / TP53", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "impaired autophagy", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/360", "Drug": "Suberoylanilide hydroxamic acid (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30745455", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "DLD1 cells (mutp53 carrying cell line)", "Dose": "0-2.5 µM", "Technique": "Western blot, immunofluorescence assays", "Controlled_Technique": "Western blot/immunoblot analysis; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "p53 degradation", "Controlled_Terms_Function_enhanced_Number_increased": "p53 / TP53", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1622", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "17725605", "Cancer_Type": "Hpv16-Expressing Tumors", "Cancer_Type_Description": "Human Papilloma Virus 16-Associated Tumours", "System": "TC-1/A9 cells + spleen cells from animals immunized with TC-1 cells", "Dose": "10 ng/ml TSA", "Technique": "chromium-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic T lymphocyte (CTL)-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1633", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "19759901", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "lenalidomide-treated NK cells from a healthy donor + target CLL patient cells", "Dose": "10 μg/mL rituximab", "Technique": "standard 4-hour 51Cr-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell cytotoxicity, ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/3", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "19759901", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "lenalidomide-treated NK cells from patientsr + target CLL patient cells", "Dose": "10 μg/mL rituximab", "Technique": "standard 4-hour 51Cr-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell cytotoxicity, ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/732", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "19759901", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs from healthy donors cocultured with purified leukemia cells obtained from CLL patients for 4 hours", "Dose": "1 μM lenalidomide + rituximab (20 μg/mL)", "Technique": "CD107a lysosome-associated membrane protein-1 (LAMP-1) was used to measure NK-, NKT-like-, and CD8-cell cytotoxic activity", "Controlled_Technique": "Degranulation assay", "Immune_System-Function_enhanced/numbers_increased": "NK Cell-Mediated Natural Cytotoxicity and ADCC CD20 expression on leukemia cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD20 / MS4A1; Cytotoxicity / cytolysis; ADCC; NK cells; Antibody-dependent cytotoxicity; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/739", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "18046553", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "CD8+ T cells, isolated from ova-primed OT-I mice + B16F10 cells(Splenocytes and B16F10 cells (TSA- or the treated and untreated) were pulsed with ova, ova–peptide257–266 control peptide mgp100 and irradiated before use in the assay)", "Dose": "(500 nM for 48 h)", "Technique": "ELISPOT assay", "Controlled_Technique": "ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ producing CD8+ T cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; IFN-γ; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/758", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "27614429", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Mantle Cell Lymphoma (MCL)", "System": "JeKo-1 + pulsed with α-GalCer (100 ng/mL) and co-cultured with primary human NKT cells derived from healthy donor blood", "Dose": "1 μM TSA for 4 hours", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD1D-mediated antigen presentation by MCL cells , CD1D-mediated NKT cell activation IFNγ", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d; IFN-γ; Antigen presentation; NKT cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/759", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "27614429", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Mantle Cell Lymphoma (MCL)", "System": "SP53 +pulsed with α-GalCer (100 ng/mL) and co-cultured with primary human NKT cells derived from healthy donor blood", "Dose": "1 μM TSA for 4 hours", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD1D-mediated antigen presentation by MCL cells, CD1D-mediated NKT cell activation IFNγ", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d; IFN-γ; Antigen presentation; NKT cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1058", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "11120829", "Cancer_Type": "Plasmacytoma", "Cancer_Type_Description": "Plasmacytoma", "System": "J558", "Dose": "10 nM TSA", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "class I, II, and CD40", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II;MHC class I; CD40", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1154", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "18070359", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MHC class II negative B16", "Dose": "(50 nM-1 μM, 12–48 h)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class II, CD40 and CD86", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; CD40; CD86;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/816", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "11120829", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "SK-N-MC (MC)", "Dose": "50 nM TSA", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "class I, II, and CD40", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II;MHC class I; CD40", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/852", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "11120829", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "System": "Colon 26", "Dose": "50 nM TSA", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "class I, II, and CD40", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II;MHC class I; CD40", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/905", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "28871002", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "SNU449 + coculture with NK cells", "Dose": "0.5 μM TSA for 48 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/906", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "28871002", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "Huh7+ coculture with NK cells", "Dose": "0.5 μM TSA for 48 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/988", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "27614429", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Mantle Cell Lymphoma (MCL)", "System": "SP53", "Dose": "1 μM TSA for 0, 1, 2, 3, and 4 hours", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD1D", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/989", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "SUDHL-6", "Dose": "100 nm trichostatin A", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CIITA and HLA-DR", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR; CIITA", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/995", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "NCI-H929", "Dose": "50 nm trichostatin SA", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHCI (HLA-ABC)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1209", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "28871002", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "HepG2", "Dose": "2 μM TSA for 48 h", "Technique": "EZ-Cytox Enhanced cell viability assay,Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "cell proliferation inhibition, apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1210", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "28871002", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "Huh7", "Dose": "2 μM TSA for 48 h", "Technique": "EZ-Cytox Enhanced cell viability assay,Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "cell proliferation inhibition, apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1211", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "28871002", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "SNU449", "Dose": "2 μM TSA for 48 h", "Technique": "EZ-Cytox Enhanced cell viability assay,Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "cell proliferation inhibition, apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1246", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "28871002", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "HepG2 + coculture with NK cells", "Dose": "0.5 μM TSA for 48 h", "Technique": "Flow cytometry, LDH cytotoxicity assay kit ,NKG2D blocking antibody", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cytotoxicity mediated via NKG2D axis apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; Apoptosis; Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1325", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "28871002", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "HepG2 cells", "Dose": "0.5 and 1.0 μM TSA", "Technique": "qPCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "ULPB1, ULPB2, ULPB3, and major histocompatibility complex class I-related chain (MIC)-A and B, - NKG2D ligand", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; NKG2D / KLRK1; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1398", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "27614429", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Mantle Cell Lymphoma (MCL)", "System": "JeKo-1 cells", "Dose": "1 μM TSA for 0, 1, 2, 3, and 4 hours", "Technique": "Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1D", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1415", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "18046553", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16F10 cells", "Dose": "(250 and 500 nM for 24 h)", "Technique": "RT-PCR and real-time quantitative RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "TAP2, LMP2, LMP7 and Tapasin-antigen processing and presentation via the MHC class I pathway , CD40 and CD86 expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; CD40; CD86; Antigen presentation; TAP2; Tapasin; LMP2 / PSMB9; LMP7 / PSMB8; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1425", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "DB cells", "Dose": "TSA (100 nm)", "Technique": "Flow cytometry and quantitative RT-PCR, luciferase assay", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Bioluminescence/luciferase assay", "Immune_System-Function_enhanced/numbers_increased": "HLA-DR, HLA-ABC, CIITA expression, HLA-DRα", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-DR; CIITA; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1439", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "17725605", "Cancer_Type": "Hpv16-Expressing Tumors", "Cancer_Type_Description": "Human Papilloma Virus 16-Associated Tumours", "System": "TC-1/A9 (MHC class I-deficient)", "Dose": "10 ng/ml TSA", "Technique": "Flow cytometry, quantitative real-time RT-PCR,Western blot analysis", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC class I molecules TAP-1, TAP-2, LMP-2 and LMP-7", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; TAP1; TAP2; LMP2 / PSMB9; LMP7 / PSMB8;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1638", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "11120829", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "SK-N-MC (MC)", "Dose": "100 nM TSA", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-DR (DR),DP and DQ isotypes of MHC class II ,MHC class II,CD40", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR; CD40;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/17", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "18046553", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "Colon 26", "Dose": "(250 nM for 24 h)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "TAP1, TAP2, LMP2, LMP7, Tapasin and class I genes-antigen processing machinery", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Antigen presentation; TAP1; TAP2; Tapasin; LMP2 / PSMB9; LMP7 / PSMB8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/18", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "11120829", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "System": "Colon 26", "Dose": "100 nM TSA", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "IFN-g induced expression of CIITA and MHC class II, CD40", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; CIITA; CD40; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/63", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "22419072", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H292", "Dose": "TSA (1 μM)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/64", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "22419072", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "TC-1", "Dose": "TSA (1 μM)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/65", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "22419072", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "B16/F0 cells", "Dose": "TSA (1 μM)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/66", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549", "Dose": "250 ng/ml", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/67", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "SK-MES-1", "Dose": "250 ng/ml", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/68", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "22419072", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 cells", "Dose": "TSA (1 μM)", "Technique": "RT-PCR andwestern blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/90", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "11120829", "Cancer_Type": "Plasmacytoma", "Cancer_Type_Description": "Plasmacytoma", "System": "J558", "Dose": "100 nM TSA", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CIITA (102-fold) and Ia,CD40", "Controlled_Terms_Function_enhanced_Number_increased": "CIITA; CD40", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/93", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "18046553", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16F0", "Dose": "(250 nM for 24 h)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "TAP2, LMP7 and class I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; TAP2; LMP7 / PSMB8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1155", "Drug": "Tubastatin A", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "HDAC6 inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "49850262", "STR_LINK_(SMILES)": "CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "(B16–F10)", "Dose": "3 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1157", "Drug": "Tubastatin A", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "HDAC6 inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "49850262", "STR_LINK_(SMILES)": "CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "(B16–F10)", "Dose": "3 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1597", "Drug": "Tubastatin A", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "HDAC6 inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "49850262", "STR_LINK_(SMILES)": "CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM164", "Dose": "3 μM", "Technique": "qRT‐PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanoma antigens gp100, MART1, TYRP1 and TYRP2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1598", "Drug": "Tubastatin A", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "HDAC6 inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "49850262", "STR_LINK_(SMILES)": "CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM793", "Dose": "3 μM", "Technique": "qRT‐PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanoma antigens gp100, MART1, TYRP1 and TYRP2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1599", "Drug": "Tubastatin A", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "HDAC6 inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "49850262", "STR_LINK_(SMILES)": "CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "IPC298", "Dose": "3 μM", "Technique": "qRT‐PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanoma antigens gp100, MART1, TYRP1 and TYRP2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1601", "Drug": "Tubastatin A", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "HDAC6 inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "49850262", "STR_LINK_(SMILES)": "CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL30", "Dose": "3 μM", "Technique": "qRT‐PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanoma antigens gp100, MART1, TYRP1 and TYRP2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1150", "Drug": "Valproic acid", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "18046553", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16F10 cells", "Dose": "(500 μM for 48 h)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "class I expression substantially", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/992", "Drug": "Valproic acid", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "23789844", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "DB cells", "Dose": "5 mM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-DR expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1443", "Drug": "Valproic acid", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "THP-1", "Dose": "1 mM for 24 h", "Technique": "real-time quantitative RT-PCR,western blot,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME ,Apoptosis, Cell Cycle Arrest, Reduces Colony Forming Ability", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Apoptosis; Cell-cycle arrest; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/30", "Drug": "Valproic acid", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "Hut78", "Dose": "1 mM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/31", "Drug": "Valproic acid", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "Molt-4", "Dose": "1 mM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/32", "Drug": "Valproic acid", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "Z138", "Dose": "1 mM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/33", "Drug": "Valproic acid", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "Kasumi-1", "Dose": "1 mM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/34", "Drug": "Valproic acid", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "NB4", "Dose": "1 mM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/35", "Drug": "Valproic acid", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D00399", "Pubchem_ID": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "U937", "Dose": "1 mM for 24 h", "Technique": "real-time quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD86 expression cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; Cancer-testis antigens; PRAME antigen; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/47", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H441+NK cells purified from two healthy donor PBMCs", "Dose": "vorinostat (3 µM) for 4 consecutive days", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/58", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H460 +NK cells purified from two healthy donor PBMCs", "Dose": "vorinostat (3 µM) for 4 consecutive days", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/820", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29371976", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "Triple-negative MDA-MB231 + co-cultured with human PBMCs from healthy donors", "Dose": "1.5 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-DR, PD-L1 expression in tumor cells.", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class II; HLA-DR; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "Foxp3+ CTLA-4high Treg in PBMCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/436", "Drug": "TAK-117", "Drug_category": "PI3K inhibitor", "Drugbank_ID": "DB14935", "Target/s_or_mechanism_of_action": "Selective PI3Kα/p110α inhibition", "KEGG_Drug__ID": "—", "Pubchem_ID": "70798655", "STR_LINK_(SMILES)": "same", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "CAL-29", "Dose": "3.5 µM, 48 h", "Technique": "qRT-PCR, western blot", "Controlled_Technique": "PD-L1 mRNA increased", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 mRNA increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1612", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29371976", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "Triple-negative MDA-MB231", "Dose": "1-1.5 µM", "Technique": "western blot, qReal-Time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in tumor cells.", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/388", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H441", "Dose": "vorinostat (3 µM) for 4 consecutive days", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/389", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H460", "Dose": "vorinostat (3 µM) for 4 consecutive days", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MIC-A/B, PD-L1 expression", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/412", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "PC-3", "Dose": "vorinostat (3 µM) for 4 consecutive days", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MIC-A/B", "Controlled_Terms_Function_enhanced_Number_increased": "MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/414", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "DU145", "Dose": "vorinostat (3 µM) for 4 consecutive days", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MIC-A/B, PD-L1 expression", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/813", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "31737100", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioma", "System": "Fresh glioma samples +PBMC of human", "Dose": "2 μM suberoyanilide hydroxamic acid (SAHA) for 24 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CTLs-mediated cytotoxicity apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cytotoxicity / cytolysis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/814", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "31737100", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioma", "System": "U251 +PBMC of human", "Dose": "2 μM suberoyanilide hydroxamic acid (SAHA) for 24 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CTLs-mediated cytotoxicity apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cytotoxicity / cytolysis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/815", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "31737100", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioma", "System": "GL261+ CTLs from spleen and lymph nodes of tumor bearing mice", "Dose": "2 μM suberoyanilide hydroxamic acid (SAHA) for 24 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CTLs-mediated cytotoxicity apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cytotoxicity / cytolysis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1421", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30537988", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastric Cancer (GC)", "System": "HGC27 (50 ng/ml IFN-γ for 24 h )", "Dose": "0-2 μm", "Technique": "RT-qPCR ,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "B7-H1 expression in GC", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1463", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "31737100", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioma", "System": "GL261", "Dose": "2 μM suberoyanilide hydroxamic acid (SAHA) for 24 h", "Technique": "Flow cytometry, western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC-I, TAP1, TAP2 and LMP7", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; TAP1; TAP2; LMP7 / PSMB8;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1464", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "31737100", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioma", "System": "U251", "Dose": "2 μM suberoyanilide hydroxamic acid (SAHA) for 24 h", "Technique": "Flow cytometry, western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC-I, TAP1, TAP2, LMP2 and LMP7", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; TAP1; TAP2; LMP2 / PSMB9; LMP7 / PSMB8;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1501", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "16297208", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "MJ", "Dose": "(1, 2.5, and 5 microM)", "Technique": "Flow cytometry,Western blotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis, caspase-3, acetylated histones (H2B, H3, and H4), p21(WAF1) and bax proteins", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; BAX; p21 / CDKN1A", "Immune_System-Function_inhibited/numbers_decreased": "Stat6 and phospho-Stat6", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT6", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1502", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "16297208", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "Hut78", "Dose": "(1, 2.5, and 5 microM)", "Technique": "Flow cytometry,Western blotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis, caspase-3, acetylated histones (H2B, H3, and H4), p21(WAF1) and bax proteins", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; BAX; p21 / CDKN1A", "Immune_System-Function_inhibited/numbers_decreased": "Stat6 and phospho-Stat6", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT6", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1503", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "16297208", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas - Cutaneous T Cell Lymphomas (CTCL)", "System": "HH", "Dose": "(1, 2.5, and 5 microM)", "Technique": "Flow cytometry,Western blotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis, caspase-3, acetylated histones (H2B, H3, and H4), p21(WAF1) and bax proteins", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; BAX; p21 / CDKN1A", "Immune_System-Function_inhibited/numbers_decreased": "Stat6 and phospho-Stat6", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT6", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/16", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29050320", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical Cancer", "System": "HeLa cells", "Dose": "1 and 2 μM", "Technique": "Real time RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Negative_Regulation": "IL-8 / CXCL8; IL-8/CXCL8"}, {"ID": "CANIMM/56", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "KRAS mutant LKR-13 (LKR)", "Dose": null, "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "T cell attracting chemokine genes (Ccl5, Cxcl9 and Cxcl10)", "Controlled_Terms_Function_enhanced_Number_increased": "CCL5 / RANTES; CXCL10 / IP-10; CXCL9 / MIG; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/79", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29050320", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "OVCAR3", "Dose": "1 and 2 μM", "Technique": "Real time RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Negative_Regulation": "IL-8 / CXCL8; IL-8/CXCL8"}, {"ID": "CANIMM/81", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29050320", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "CAOV3", "Dose": "1 and 2 μM", "Technique": "Real time RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Negative_Regulation": "IL-8 / CXCL8; IL-8/CXCL8"}, {"ID": "CANIMM/82", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "28167529", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "CAOV3", "Dose": "1.5 μm", "Technique": "real-time RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Negative_Regulation": "IL-8 / CXCL8; IL-8/CXCL8"}, {"ID": "CANIMM/83", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "28167529", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "OVCAR3", "Dose": "1.5 μm", "Technique": "real-time RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Negative_Regulation": "IL-8 / CXCL8; IL-8/CXCL8"}, {"ID": "CANIMM/109", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 cells", "Dose": "10μM", "Technique": "RT-PCR,ELISA", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell attracting chemokine genes - Cxcl10", "Controlled_Terms_Function_enhanced_Number_increased": "CXCL10 / IP-10; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/112", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "28167529", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SKOV3", "Dose": "1.5 μm", "Technique": "real-time RT-PCR analysis,ELISA", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Negative_Regulation": "IL-8 / CXCL8; IL-8/CXCL8"}, {"ID": "CANIMM/137", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "29050320", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SKOV3", "Dose": "1 and 2 μM", "Technique": "Real time RT-PCR analysis,Western blotting analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Negative_Regulation": "IL-8 / CXCL8; IL-8/CXCL8"}, {"ID": "CANIMM/379", "Drug": "CC-4047/ACTIMID/ Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": null, "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal -Ectopic Colorectal Cancer", "System": "Splenocytes+CT 26", "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-y, IL-2, and GM-CSF,", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; GM-CSF / CSF2; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": "IL-4, IL-10", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-4; IL-10", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1078", "Drug": "IMiD1 (CC4047, CDC394, Actimid)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "12036884", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OCI-My-5", "Dose": "1 µM", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "caspase-8-(obligate mediator of apoptosis)", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-8; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1090", "Drug": "IMiD1 (CC4047, CDC394, Actimid)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "12036884", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "S6B45", "Dose": "1 µM", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "caspase-8-(obligate mediator of apoptosis)", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-8; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1101", "Drug": "IMiD1 (CC4047, CDC394, Actimid)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "12036884", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "Multiple myeloma patient cells", "Dose": "1 µM", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "caspase-8-(obligate mediator of apoptosis)", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-8; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1323", "Drug": "IMiD1 (CC4047, CDC394, Actimid)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "12036884", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "1 µM", "Technique": "colorimetric activity assay", "Controlled_Technique": "Colorimetric/biochemical activity assay", "Immune_System-Function_enhanced/numbers_increased": "caspase-8-(obligate mediator of apoptosis), Fas-mediated apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; Caspase-8; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "NF-κB", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1112", "Drug": "IMiD3 (CC5013, CDC501, Revimid)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "12036884", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "1 µM", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "caspase-8-(obligate mediator of apoptosis)", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-8; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/745", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "18772452", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "K562 + NK cells", "Dose": "50 nM dasatinib", "Technique": "coculture", "Controlled_Technique": "Cell co-culture/transwell assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells promotes cytokine expression and cytotoxic activity able to kill leukemic cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; NK cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/868", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "30104242", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "NB4", "Dose": "0-100 nM", "Technique": "CCK-8 assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity", "Controlled_Terms_Function_enhanced_Number_increased": "Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1201", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "30767211", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Follicular Lymphoma (FL)", "System": "RL", "Dose": "1 μmol/l lenalidomide", "Technique": "Apoptosis analysis by Annexin V and TO-PRO-3 staining", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC 31%", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1212", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "30767211", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Follicular Lymphoma (FL)", "System": "DOHH2", "Dose": "1 μmol/l lenalidomide", "Technique": "Apoptosis analysis by Annexin V and TO-PRO-3 staining", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC 58%", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1411", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "22010965", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "B-CLL", "System": "PBMCS (in v ivo treatemt)", "Dose": "101 umol/l", "Technique": "Flow cytometery, Luminex", "Controlled_Technique": "Cytokine/multiplex immunoassay; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IL-8, MIG, IP-10 and IL-4 in patients with complete or partaial remission CD40, CD80, CD83 and CD86", "Controlled_Terms_Function_enhanced_Number_increased": "CD40; CD80; CD83; CD86; IL-4; IL-8 / CXCL8; CXCL10 / IP-10; CXCL9 / MIG; IL-8/CXCL8; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": "IL-5, MIP1a, MIP1b, IL12/p70 in patients with Complete or partial remission", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-5; IL-12; CCL3 / MIP-1α; CCL4 / MIP-1β", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/737", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "29755666", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "CD8+ T cells isolated from PBMcs", "Dose": "10 mg qd lenalidomide and 0.4ug/m/ CEF peptide pool", "Technique": "three parameter FLUOROSPOT assay", "Controlled_Technique": "ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "\"IFN-γ, TNF-α and\n IL-2\"", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; TNF-α / TNF; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/738", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "29755666", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "PBMCs", "Dose": "10 mg qd lenalidomide and 0.4ug/m/ CEF peptide pool", "Technique": "IFN-Y ELISPOT assay", "Controlled_Technique": "ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "IFN-Y production by T cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1018", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": null, "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "PBMCS", "Dose": "1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD4 +/CD25 +/ FoxP3 + regulatory T cells PD-1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1; CD4; CD25 / IL2RA; T cells; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1019", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "20651070", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "PBMCs", "Dose": "1μM Lenalidomide", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+ gated effector cells IFN-y and IL-2 CD28, ICOS, ICOS-L", "Controlled_Terms_Function_enhanced_Number_increased": "CD28; ICOS / CD278; ICOS ligand / ICOSL / CD275; CD3; IL-2; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": "IL-6 SOCS1", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; SOCS1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1021", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "22733396", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "T cells and allo-DCs", "Dose": "1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4 + and CD8 + T cells, IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; IFN-γ; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4 +/CD25 +/ FoxP3 + regulatory T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD25 / IL2RA; T cells; Regulatory T cells / Tregs", "Immune_System_function_unaffected": "IL-10", "Controlled_Terms_Unaffected": "IL-10", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1022", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "24386306", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "RPMI 8226 + plus PBMCs from a healthy donor using membrane filters to avoid cell contact", "Dose": "3 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HM1.24 (CD317)", "Controlled_Terms_Function_enhanced_Number_increased": "CD317 / HM1.24", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1024", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "24386306", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "BMMCs from MM patients", "Dose": "3 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HM1.24 (CD317)", "Controlled_Terms_Function_enhanced_Number_increased": "CD317 / HM1.24", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/999", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "28881567", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Kaposi Sarcoma And Primary Effusion Lymphoma (PEL)", "System": "BCBL-1", "Dose": "1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ICAM-1, B7-2", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; ICAM-1 / CD54", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1376", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "19734418", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Raji cells", "Dose": "(1 µM)", "Technique": "Time course RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "TNF-related costimulatory molecules - 4-1BB ligand (4-1BBL/TNFSF9),4-1BBL", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; 4-1BB ligand / TNFSF9; TNF-α / TNF; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/37", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "19734418", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "U937", "Dose": "(1 µM)", "Technique": "Time course RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "TNF-related costimulatory molecules - 4-1BB ligand (4-1BBL/TNFSF9)", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; 4-1BB ligand / TNFSF9; TNF-α / TNF; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/116", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "27815572", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Jurkat T cells (JA16 clone)", "Dose": "(2,5 µM)", "Technique": "Transcription Low Density Array,RT-PCR analysis,quantitative real time RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "TNF-related costimulatory molecules - 4-1BB ligand (4-1BBL/TNFSF9) p21/WAF/CDKN1A cell cycle inhibitor", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; 4-1BB ligand / TNFSF9; TNF-α / TNF; p21 / CDKN1A; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/123", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "27287425", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "K562", "Dose": "1 µM DAC for 5 days", "Technique": "RT-PCR,Western blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTAs)-MAGE-A1, MAGE-A3, and SP17", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/124", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "27287425", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "SKM-1", "Dose": "1 µM DAC for 5 days", "Technique": "RT-PCR,Western blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTAs)-MAGE-A1, MAGE-A3, and SP17", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/126", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "27287425", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "MDS-L", "Dose": "1 µM DAC for 5 days", "Technique": "RT-PCR,Western blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTAs)-MAGE-A1, MAGE-A3, and SP17", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/205", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "19965642", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "primary CLL cells", "Dose": "depsipeptide -10 nmol/L,TRAIL (100 ng/mL)", "Technique": "Western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "TRAIL-induced apoptosis-phosphatidylserine externalization, processing of caspase-3 to its catalytically active large subunits (p19/p17) and cleavage of PARP", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Caspase-3; Caspase activation; Apoptosis; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/206", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "19965642", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "primary CLL cells", "Dose": "MS-275-0.25-2.5 µM/L TRAIL (100 ng/mL)", "Technique": "Western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "TRAIL-induced apoptosis-phosphatidylserine externalization, processing of caspase-3 to its catalytically active large subunits (p19/p17) and cleavage of PARP", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Caspase-3; Caspase activation; Apoptosis; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/406", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "primary MM cells+ Healthy NK cells", "Dose": "5μM", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/407", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "patient-derived NK cells+ autologous MM tumor cells", "Dose": "5μM", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/584", "Drug": "Lenalidomide (LEN)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "Suppresses TNF-α production and modulates NF-κB-associated signaling", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N", "Single/Combination": "Single", "PMID": "40528981", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "mouse HCC cell line", "System": "Hepa1–6", "Dose": "40 µmol/L in vitro", "Technique": "Western blot, RT-qPCR, ELISA, cGAS–STING signaling", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "expression of TNF-α mRNA and protein", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; TNF-α / TNF", "Controlled_Terms_Function_inhibited_Number_decreased": "no significant impact on the expression of IFN-β mRNA and protein", "Immune_System_function_unaffected": "Expression / abundance phenotype; IFN-β", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/585", "Drug": "Lenalidomide (LEN)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "Suppresses TNF-α production and modulates NF-κB-associated signaling+Suppresses TNF-α production and modulates NF-κB-associated signaling", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N", "Single/Combination": "Single", "PMID": "40528981", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Human HCC cell line", "System": "HepG2", "Dose": "40 µmol/L in vitro", "Technique": "Western blot, RT-qPCR, ELISA, cGAS–STING signaling", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "expression of TNF-α mRNA and protein", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; TNF-α / TNF", "Controlled_Terms_Function_inhibited_Number_decreased": "no significant impact on the expression of IFN-β mRNA and protein", "Immune_System_function_unaffected": "Expression / abundance phenotype; IFN-β", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1025", "Drug": "Lenalidomide (Lena)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "CD138+ MM cells from the bone marrow of MM patients", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICA and/or PVR/CD155 on primary cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD155 / PVR; MICA;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/541", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "Inhibits MEK1/2 → suppresses MAPK/ERK signaling", "KEGG_Drug__ID": "D10405", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "CN1CCN(CC1)C(=O)C2=C(C=C(C=C2F)F)NC3=C(C=C(C=C3)F)I", "Single/Combination": "Single", "PMID": "34389557", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CT26 murine colorectal carcinoma cells", "System": "MEK1 KO D12 CT26 cells", "Dose": "1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1290", "Drug": "Lenalidomide (Lena)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "NK cells, prepared from PBMCs of healthy donors, were incubated with SKO-007(J3) cells", "Dose": "(10 μM) for 72h", "Technique": "Flow cytometry, degranulation assay, blocking antibodies", "Controlled_Technique": "Flow cytometry; Immune suppression/blocking/depletion assay; Degranulation assay", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic function of natural killer (NK) cells", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1291", "Drug": "Lenalidomide (Lena)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "patient-derived NK cells against lenalidomide-treated autologous MM targets", "Dose": "(10 μM) for 72h", "Technique": "Flow cytometry, degranulation assay, blocking antibodies", "Controlled_Technique": "Flow cytometry; Immune suppression/blocking/depletion assay; Degranulation assay", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic function of natural killer (NK) cells", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1294", "Drug": "Lenalidomide (Lena)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "(10 μM) for 72h", "Technique": "immunofluorescence and Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PVR/CD155 on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD155 / PVR", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1295", "Drug": "Lenalidomide (Lena)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS27", "Dose": "(10 μM) for 72h", "Technique": "immunofluorescence and Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PVR/CD155 on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD155 / PVR", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1298", "Drug": "Lenalidomide (Lena)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "ARP-1", "Dose": "(10 μM) for 72h", "Technique": "immunofluorescence and Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MICA on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "MICA", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1299", "Drug": "Lenalidomide (Lena)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "JJN3", "Dose": "(10 μM) for 72h", "Technique": "immunofluorescence and Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MICA on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "MICA", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1413", "Drug": "Lenalidomide (Lena)", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "SKO-007(J3)", "Dose": "(10 μM) for 72h, 48 hr for Real-Time qPCR", "Technique": "Flow cytometry, Real-Time qRT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MICA and PVR/CD155 on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD155 / PVR; MICA;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/637", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Inhibits inducible PD-L1; tested in human myeloma cells", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single", "PMID": "30315115", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "human multiple myeloma", "System": "8226 — human multiple myeloma", "Dose": "IFN-γ stimulation with pomalidomide", "Technique": "Flow cytometry", "Controlled_Technique": "Antitumor immune benefit inferred from reduced PD-L1", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 mRNA and surface expression; IFN-γ response-associated genes", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; PD-L1 / CD274; IFN-γ", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/638", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Inhibits inducible PD-L1; mechanism studied in mouse myeloma cells", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single", "PMID": "30315115", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "mouse multiple myeloma", "System": "5TGM1 — mouse multiple myeloma", "Dose": "IFN-γ stimulation with pomalidomide", "Technique": "Flow cytometry", "Controlled_Technique": "Antitumor immune benefit inferred from reduced PD-L1", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 mRNA and surface expression; IFN-γ response-associated genes", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; PD-L1 / CD274; IFN-γ", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/639", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Suppresses IFN-γ-induced PD-L1 transcription", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single", "PMID": "30315115", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "human ovarian cancer", "System": "SKOV-3 — human ovarian cancer", "Dose": "IFN-γ stimulation with pomalidomide", "Technique": "Flow cytometry", "Controlled_Technique": "Antitumor immune benefit inferred from reduced PD-L1", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 mRNA and surface expression; IFN-γ response-associated genes", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; PD-L1 / CD274; IFN-γ", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/640", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Inhibits inducible PD-L1; sensitizes tumor cells to CTL killing", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single", "PMID": "30315115", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "human pancreatic cancer", "System": "BxPC-3 — human pancreatic cancer", "Dose": "IFN-γ stimulation with pomalidomide", "Technique": "Flow cytometry", "Controlled_Technique": "Antitumor immune benefit inferred from reduced PD-L1", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 mRNA and surface expression; IFN-γ response-associated genes", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; PD-L1 / CD274; IFN-γ", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1000", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "28881567", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Kaposi Sarcoma And Primary Effusion Lymphoma (PEL)", "System": "BCBL-1", "Dose": "1μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ICAM-1, B7-2", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; ICAM-1 / CD54", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "ICAM-3, MHC-II", "Controlled_Terms_Unaffected": "MHC class II;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1002", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "28881567", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Kaposi Sarcoma And Primary Effusion Lymphoma (PEL)", "System": "JSC-1", "Dose": "1μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ICAM-1, B7-2", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; ICAM-1 / CD54", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "ICAM-3, MHC-II", "Controlled_Terms_Unaffected": "MHC class II;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/542", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "Inhibits MEK1/2 → suppresses MAPK/ERK signaling", "KEGG_Drug__ID": "D10405", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "CN1CCN(CC1)C(=O)C2=C(C=C(C=C2F)F)NC3=C(C=C(C=C3)F)I", "Single/Combination": "Single", "PMID": "34389557", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CT26 murine colorectal carcinoma cells", "System": "MEK1 KO F3 CT26 cells", "Dose": "1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1020", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "20651070", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "PBMCs", "Dose": "1μM Pomalidomide", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+ gated effector cells IFN-y and IL-2 CD28, ICOS, ICOS-L", "Controlled_Terms_Function_enhanced_Number_increased": "CD28; ICOS / CD278; ICOS ligand / ICOSL / CD275; CD3; IL-2; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": "IL-6 SOCS1", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; SOCS1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/921", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "29780393", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "Primary AML cells", "Dose": "10um", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "HLA-ABC", "Controlled_Terms_Function_inhibited_Number_decreased": "MHC class I", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/922", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "29780393", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "MOLM-14", "Dose": "10um", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "HLA-ABC", "Controlled_Terms_Function_inhibited_Number_decreased": "MHC class I", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/924", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "29780393", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "HL-60", "Dose": "10um", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "HLA-ABC", "Controlled_Terms_Function_inhibited_Number_decreased": "MHC class I", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/925", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "29780393", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "Acute myeloid leukemia (AML) blasts", "Dose": "10um", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "MICA-B, ULBP1 (ligands for NKG2D), Nectin-2, and PVR (ligands for DNAM-1)", "Controlled_Terms_Unaffected": "CD112 / Nectin-2 / PVRL2; CD155 / PVR; NKG2D / KLRK1; ULBP1; MICA; MICA/MICB", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/996", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "28881567", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Kaposi Sarcoma And Primary Effusion Lymphoma (PEL)", "System": "BC-3", "Dose": "1μM, 10 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MHC-1", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/997", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "28881567", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Kaposi Sarcoma And Primary Effusion Lymphoma (PEL)", "System": "JSC-1", "Dose": "1μM, 10 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MHC-1", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/998", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "28881567", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Kaposi Sarcoma And Primary Effusion Lymphoma (PEL)", "System": "BJAB", "Dose": "1μM, 10 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MHC-1", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1296", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "(10 μM) for 72h", "Technique": "immunofluorescence and Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PVR/CD155 on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD155 / PVR", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1297", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS27", "Dose": "(10 μM) for 72h", "Technique": "immunofluorescence and Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PVR/CD155 on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD155 / PVR", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1301", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "ARP-1", "Dose": "(10 μM) for 72h", "Technique": "immunofluorescence and Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MICA on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "MICA", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1302", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "JJN3", "Dose": "(10 μM) for 72h", "Technique": "immunofluorescence and Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MICA on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "MICA", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1414", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26269456", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "SKO-007(J3)", "Dose": "(10 μM) for 72h, 48 hr for Real-Time qPCR", "Technique": "Flow cytometry, Real-Time qRT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MICA and PVR/CD155 on SKO-007(J3) cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD155 / PVR; MICA;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/664", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Suppresses IFN-γ-induced PD-L1 and IFN-γ signaling-related transcription", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single", "PMID": "30315115", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "SK-MEL-624 — human melanoma", "System": "SK-MEL-624 — human melanoma", "Dose": "IFN-γ stimulation with pomalidomide", "Technique": "Flow cytometry, RT-PCR/qPCR, RNA sequencing", "Controlled_Technique": "Potentially improved CTL activity through reduced tumor-cell PD-L1", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 mRNA and surface expression; IFN-γ response-associated genes", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; PD-L1 / CD274; IFN-γ", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/641", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Inhibits CTL-associated PD-L1 induction and enhances T-cell-mediated tumor killing", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single", "PMID": "30315115", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "mouse pancreatic cancer", "System": "Pan02 — mouse pancreatic cancer", "Dose": "10 μmol/L in coculture; 50 μmol/L in tumor-cell pretreatment experiments", "Technique": "CFSE labeling, flow cytometry, propidium iodide cell-death assay, IFN-γ ELISA", "Controlled_Technique": "Tumor-cell killing by CTLs; IFN-γ secretion", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 upregulation during T-cell coculture", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; T cells; PD-L1 / CD274", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/642", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Inhibits CTL-associated PD-L1 induction and enhances T-cell-mediated tumor killing", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single", "PMID": "30315115", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "mouse-derived pancreatic cancer cells", "System": "KPC — mouse-derived pancreatic cancer cells", "Dose": "10 μmol/L in coculture; 50 μmol/L in tumor-cell pretreatment experiments", "Technique": "CFSE labeling, flow cytometry, propidium iodide assay, IFN-γ ELISA", "Controlled_Technique": "Tumor-cell killing by CTLs; IFN-γ secretion", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 upregulation during T-cell coculture", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; T cells; PD-L1 / CD274", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1123", "Drug": "Thalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB01041", "Target/s_or_mechanism_of_action": "Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells", "KEGG_Drug__ID": "D00754", "Pubchem_ID": "5426", "STR_LINK_(SMILES)": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12", "Single/Combination": "Single Drug", "PMID": "12036884", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "100 µM", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "caspase-8-(obligate mediator of apoptosis)", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-8; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/202", "Drug": "Thalidomide / Immunomodulatory Derivatives", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB01041", "Target/s_or_mechanism_of_action": "Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells", "KEGG_Drug__ID": "D00754", "Pubchem_ID": "5426", "STR_LINK_(SMILES)": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12", "Single/Combination": "Single Drug", "PMID": "11418482", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "HS Sultan + Normal PBMCs treated with IL-2 for 72 hours and then by IMiD1 5 mg/mLdaily for 3 days. CD41, CD81, CD561, or CD141 cellswere depleted (more than 97% depletion by Flow cytometry analysis) using immunomagnetic beads", "Dose": "1-5µg/ml", "Technique": "standard 51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK-cell", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/213", "Drug": "Thalidomide / Immunomodulatory Derivatives", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB01041", "Target/s_or_mechanism_of_action": "Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells", "KEGG_Drug__ID": "D00754", "Pubchem_ID": "5426", "STR_LINK_(SMILES)": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12", "Single/Combination": "Single Drug", "PMID": "11418482", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "Labeled K562 (NK sensitive/LAK sensitive) + Normal PBMCs were treated with IL-2 for 72 hour", "Dose": "5µg/ml", "Technique": "standard 51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK-cell", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/225", "Drug": "Thalidomide / Immunomodulatory Derivatives", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB01041", "Target/s_or_mechanism_of_action": "Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells", "KEGG_Drug__ID": "D00754", "Pubchem_ID": "5426", "STR_LINK_(SMILES)": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12", "Single/Combination": "Single Drug", "PMID": "11418482", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S + Normal PBMCs treated with IL-2 for 72 hours and then by IMiD1 5 mg/mLdaily for 3 days. CD41, CD81, CD561, or CD141 cellswere depleted (more than 97% depletion by Flow cytometry analysis) using immunomagnetic beads", "Dose": "1-5µg/ml", "Technique": "standard 51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK-cell", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/782", "Drug": "Thalidomide / Immunomodulatory Derivatives", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB01041", "Target/s_or_mechanism_of_action": "Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells", "KEGG_Drug__ID": "D00754", "Pubchem_ID": "5426", "STR_LINK_(SMILES)": "O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12", "Single/Combination": "Single Drug", "PMID": "11418482", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "CD3 cells from 4 healthy donors and 4 patients with MM stimulated with anti-CD3 and treated with Thal/IMiDs daily for 5 days", "Dose": "1-5µg/ml", "Technique": "ELISA, . Proliferation was determined by measuring the uptake of tritiated thymidine (3[H]TdR", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cell viability/proliferation assay; Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "CD3 cells, CD 4, CD 8 IL-2 and IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "CD3; CD4; CD8; IL-2; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/482", "Drug": "TPH104", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Induces immunogenic cell death and release of damage-associated molecular patterns", "KEGG_Drug__ID": null, "Pubchem_ID": "18326651", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "33919653", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "MDA-MB-231 human TNBC cell line", "System": "MDA-MB-231", "Dose": "IC50: 140 nM at 72 h; 1–5 µM in selected assays", "Technique": "qPCR, ATP assay, immunofluorescence", "Controlled_Technique": "Extracellular ATP release increased; cell-surface calreticulin increased; TNF-α expression increased", "Immune_System-Function_enhanced/numbers_increased": "Calreticulin / CRT; TNF-α / TNF; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1311", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "KCNR", "Dose": "(0, 0.5, 1.0 and 2.5 μM) for 24 hours", "Technique": "Caspase-Glo3/7 Assay", "Controlled_Technique": "Apoptosis/cell viability assay; Caspase-Glo3/7 Assay", "Immune_System-Function_enhanced/numbers_increased": "caspase3/7-dependent apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1422", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "SY5Y", "Dose": "(0, 0.5, 1.0 and 2.5 μM) for 24 hours", "Technique": "Caspase-Glo3/7 Assay", "Controlled_Technique": "Apoptosis/cell viability assay; Caspase-Glo3/7 Assay", "Immune_System-Function_enhanced/numbers_increased": "caspase3/7-dependent apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1533", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Rhabdomyosarcoma", "Cancer_Type_Description": "Rhabdomyosarcoma", "System": "Rh18", "Dose": "(0, 0.5, 1.0 and 2.5 μM) for 24 hours", "Technique": "Caspase-Glo3/7 Assay", "Controlled_Technique": "Apoptosis/cell viability assay; Caspase-Glo3/7 Assay", "Immune_System-Function_enhanced/numbers_increased": "caspase3/7-dependent apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Ewing Sarcoma", "System": "TC32", "Dose": "(0, 0.5, 1.0 and 2.5 μM) for 24 hours", "Technique": "Caspase-Glo3/7 Assay", "Controlled_Technique": "Apoptosis/cell viability assay; Caspase-Glo3/7 Assay", "Immune_System-Function_enhanced/numbers_increased": "caspase3/7-dependent apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1221", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "21164517", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Myeloma", "System": "U266", "Dose": "0.5 - 2 μM", "Technique": "Flow cytometry using Annexin V/Propidium Iodide staining", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1222", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "21164517", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Myeloma", "System": "Kms.11", "Dose": "0.5 - 2 μM", "Technique": "Flow cytometry using Annexin V/Propidium Iodide staining", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1466", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "25216185", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116", "Dose": "(0, 0.5, 1, 2, 5 and 10 µM)", "Technique": "Western blot,Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 and JAK2 phosphorylation, presence of cleaved PARP", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; JAK2; PARP cleavage / PARP", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1468", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "25216185", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HT29", "Dose": "(0, 0.5, 1, 2, 5 and 10 µM)", "Technique": "Western blot,Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 and JAK2 phosphorylation, presence of cleaved PARP", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; JAK2; PARP cleavage / PARP", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1469", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "25216185", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "SW480", "Dose": "(0, 0.5, 1, 2, 5 and 10 µM)", "Technique": "Western blot,Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 and JAK2 phosphorylation, presence of cleaved PARP", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; JAK2; PARP cleavage / PARP", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1524", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "25149535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MO4 cell line, which lacks constitutive expression of P-STAT3, was treated with IL-6,", "Dose": "(0.5 μM, 1 μM, 5 μM and 10 μM) and 48 hours", "Technique": "Flow cytometry using Annexin-V/7-AAD staining, western blotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "inhibits P-STAT3 expression but does not induce apoptosis", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; Apoptosis; Expression / abundance phenotype; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1525", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "25149535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "K1735-C4 cell line, characerized by constitutive expression of P-STAT3", "Dose": "(0.5 μM, 1 μM, 5 μM and 10 μM) and 48 hours", "Technique": "Flow cytometry using Annexin-V/7-AAD staining, western blotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "inhibits P-STAT3 expression but does not induce apoptosis", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; Apoptosis; Expression / abundance phenotype; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1526", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "25149535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "1087-mel melanoma cells", "Dose": "(0.5 μM, 1 μM, 5 μM and 10 μM) and 48 hours", "Technique": "Flow cytometry using Annexin-V/7-AAD staining, western blotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "inhibits P-STAT3 expression but does not induce apoptosis", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; Apoptosis; Expression / abundance phenotype; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1552", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "25216185", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HT29", "Dose": "1 µM AZD1480 for 2 h followed by 4 ng/ml IL-6 for 2 h", "Technique": "immunofluorescence", "Controlled_Technique": "Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 phosphorylation", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1606", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "KCNR", "Dose": "(0, 0.5, 1, 2.5 μM)", "Technique": "Immunoblotting,qPCR and immunoblots", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "constitutive and IL-6-induced STAT3,STAT3 direct target genes", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1607", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "SY5Y", "Dose": "(0, 0.5, 1, 2.5 μM)", "Technique": "Immunoblotting,qPCR and immunoblots", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "constitutive and IL-6-induced STAT3,STAT3 direct target genes", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1630", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Rhabdomyosarcoma", "Cancer_Type_Description": "Rhabdomyosarcoma", "System": "Rh18", "Dose": "(0, 0.5, 1, 2.5 μM)", "Technique": "Immunoblotting,qPCR and immunoblots", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "constitutive and IL-6-induced STAT3,STAT3 direct target genes", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/543", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "Inhibits MEK1/2 → suppresses MAPK/ERK signaling", "KEGG_Drug__ID": "D10405", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "CN1CCN(CC1)C(=O)C2=C(C=C(C=C2F)F)NC3=C(C=C(C=C3)F)I", "Single/Combination": "Single", "PMID": "34389557", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CT26 murine colorectal carcinoma cells", "System": "MEK1 KO H11 CT26 cells", "Dose": "1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1631", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Ewing Sarcoma", "System": "TC32", "Dose": "(0, 0.5, 1, 2.5 μM)", "Technique": "Immunoblotting,qPCR and immunoblots", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "constitutive and IL-6-induced STAT3,STAT3 direct target genes", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/283", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "26660519", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Carcinoma Cells", "System": "A1847", "Dose": "AZD1480 (0.05, 0.1, 1, 5, 10 μmol/L) for 24 h", "Technique": "Immunoblot analysis with antibodies recognizing pSTAT3Y705 and total STAT3", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 activation, measured by evaluating pSTAT3Y705", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/284", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "26660519", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Carcinoma Cells", "System": "MOVCAR-5447", "Dose": "AZD1480 (0.05, 0.1, 1, 5, 10 μmol/L) for 24 h", "Technique": "Immunoblot analysis with antibodies recognizing pSTAT3Y705 and total STAT3", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 activation, measured by evaluating pSTAT3Y705", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/285", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "26660519", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Carcinoma Cells", "System": "MOVCAR-5009", "Dose": "AZD1480 (0.05, 0.1, 1, 5, 10 μmol/L) for 24 h", "Technique": "Immunoblot analysis with antibodies recognizing pSTAT3Y705 and total STAT3", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 activation, measured by evaluating pSTAT3Y705", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/322", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "26660519", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Carcinoma Cells", "System": "OVCAR-5", "Dose": "AZD1480 (0.05, 0.1, 1, 5, 10 μmol/L) for 24 h", "Technique": "Immunoblot analysis with antibodies recognizing pSTAT3Y705 and total STAT3, Annexin V staining and western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 activation, measured by evaluating pSTAT3Y705, apoptosis,cleaved PARP", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; Apoptosis; PARP cleavage / PARP", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/323", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "26660519", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Carcinoma Cells", "System": "OVCAR-8", "Dose": "AZD1480 (0.05, 0.1, 1, 5, 10 μmol/L) for 24 h", "Technique": "Immunoblot analysis with antibodies recognizing pSTAT3Y705 and total STAT3, Annexin V staining and western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 activation, measured by evaluating pSTAT3Y705, apoptosis,cleaved PARP", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; Apoptosis; PARP cleavage / PARP", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/421", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "25149535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "co-culture of splenocytes derived from healthy animals with grMDSC or moMDSC sorted from spleens of AZD1480 treated MO4 tumor-bearing mice", "Dose": "MO4 tumor-bearing mice were treated with AZD1480 at 30 mg/kg", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-γ secretion", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "suppressive function of both grMDSCs and moMDSCs on the proliferation of T cells.", "Controlled_Terms_Negative_Regulation": "Cell proliferation; T cells; Myeloid-derived suppressor cells / MDSCs; T-cell suppressive function"}, {"ID": "CANIMM/769", "Drug": "AZD6244 (MEKi)/Selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "25256614", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375 melanoma cells + M1 or M2 macrophages", "Dose": "2μM AZD6244 (MEKi)", "Technique": "Survival assay, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "protected melanoma cells from MEKi exposure, MITF (microphthalmia transcription factor)", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "TNFα expression and secretion by the macrophages", "Controlled_Terms_Unaffected": "TNF-α / TNF; Macrophages; Expression / abundance phenotype", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/864", "Drug": "MEK inhibitor selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "28807001", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "CT26 KRASG12D mutant mouse colorectal cancer cells", "Dose": "48 h treatment with selumetinib - (1-10 μM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "H2-Kd class-I MHC proteins", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "expression of PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1437", "Drug": "MEK inhibitor trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30546955", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCCVII mouse cells", "Dose": "trametinib (30 nM)", "Technique": "Flow cytometry,qRT-PCR, Western blotting", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CXCL9 and CXCL10 MHC-encoded class I molecule H-2Kk", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; CXCL10 / IP-10; CXCL9 / MIG;", "Immune_System-Function_inhibited/numbers_decreased": "Erk1/2 activation", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": "PD-L1", "Controlled_Terms_Unaffected": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/219", "Drug": "Selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "CL25", "Dose": "selumetinib (0-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1455", "Drug": "MEK inhibitor trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30546955", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SNU-1041", "Dose": "50 nM", "Technique": "Flow cytometry, Western blotting,siRNA transfections,qRT-PCR, ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell chemoattractants CXCL9 and CXCL10 IFN-γ-induced MHC class I, p-STAT1 expression, and this effect was enhanced in the presence of exogenous IFN-γ, STAT3", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; IFN-γ; CXCL10 / IP-10; CXCL9 / MIG; IL-6/JAK/STAT3 signaling; STAT1; STAT3; T cells; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IFN-γ-induced PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; IFN-γ; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/1457", "Drug": "MEK inhibitor trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30546955", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SNU-1066", "Dose": "50 nM", "Technique": "Flow cytometry, Western blotting,qRT-PCR, ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell chemoattractants CXCL9 and CXCL11 IFN-γ-induced MHC class I p-STAT1 expression, and this effect was enhanced in the presence of exogenous IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; IFN-γ; CXCL9 / MIG; STAT1; T cells; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ-induced PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; IFN-γ; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1458", "Drug": "MEK inhibitor trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30546955", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SNU-1076 cells", "Dose": "50 nM", "Technique": "Flow cytometry, Western blotting,qRT-PCR, ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell chemoattractants CXCL9 and CXCL12 IFN-γ-induced MHC class I, p-STAT1 expression, and this effect was enhanced in the presence of exogenous IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; IFN-γ; CXCL9 / MIG; STAT1; T cells; Expression / abundance phenotype; ; CXCL12 / SDF-1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IFN-γ-induced PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; IFN-γ; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/1459", "Drug": "MEK inhibitor trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30546955", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "HN31 cells", "Dose": "Cells were treated with trametinib (50 nM), IFN-γ (1 ng/ml) or the combination of trametinib and IFN-γ (pretreated with DMSO or trametinib one hour prior to the addition of IFN-γ) for 72 hours", "Technique": "Flow cytometry, Western blotting,qRT-PCR, ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell chemoattractants CXCL9 and CXCL13 p-STAT1 expression, and this effect was enhanced in the presence of exogenous IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL9 / MIG; CXCL13; STAT1; T cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1460", "Drug": "MEK inhibitor trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30546955", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "Detroit 562", "Dose": "Cells were treated with trametinib (50 nM), IFN-γ (1 ng/ml) or the combination of trametinib and IFN-γ (pretreated with DMSO or trametinib one hour prior to the addition of IFN-γ) for 72 hours", "Technique": "Flow cytometry, Western blotting,qRT-PCR, ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell chemoattractants CXCL9 and CXCL14 p-STAT1 expression, and this effect was enhanced in the presence of exogenous IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL9 / MIG; STAT1; T cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1461", "Drug": "MEK inhibitor trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30546955", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "FaDu", "Dose": "Cells were treated with trametinib (50 nM), IFN-γ (1 ng/ml) or the combination of trametinib and IFN-γ (pretreated with DMSO or trametinib one hour prior to the addition of IFN-γ) for 72 hours", "Technique": "Flow cytometry, Western blotting,qRT-PCR, ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell chemoattractants CXCL9 and CXCL15 p-STAT1 expression, and this effect was enhanced in the presence of exogenous IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL9 / MIG; STAT1; T cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/950", "Drug": "Selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "Splenocytes from HKP1 lung tumor-bearing mice", "Dose": "Pulsative traetment , selumetinib (0-1uM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "Maintained Ki-67, 4–1BB, CTLA-4, and PD-1 better in CD8+ T cells and CD4+Foxp3– effector T cells", "Controlled_Terms_Unaffected": "PD-1 / PDCD1; CTLA-4; 4-1BB / CD137; CD4; CD8; T cells; CD8+ T cells; Regulatory T cells / Tregs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/218", "Drug": "Selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "CL13", "Dose": "selumetinib (0-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/484", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "MEK1/MEK2 inhibition", "KEGG_Drug__ID": "D10405", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O", "Single/Combination": "Single", "PMID": "42183887", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "MDA-MB-231, human TNBC", "System": "In vitro human TNBC cells", "Dose": null, "Technique": "flow cytometry, Western blot", "Controlled_Technique": "Increased CRT expression", "Immune_System-Function_enhanced/numbers_increased": "Calreticulin / CRT; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/220", "Drug": "Selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "IO33", "Dose": "selumetinib (0-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/221", "Drug": "Selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "HKP1", "Dose": "selumetinib (0-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/222", "Drug": "Selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "LLC", "Dose": "selumetinib (0-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/393", "Drug": "Selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "Splenocytes from Pmel-1 TCR transgenic mice were pulsed with gp100 (Pmel) peptide", "Dose": "Pulsative traetment , selumetinib (0-1uM)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "CD44+CD62L effector memory CD8 T cells IFNγ", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD44; IFN-γ; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "differentiation of Pmel-1 CD8+ T cells, CD44+CD62L+ central memory CD8 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; CD44; T cells; CD8+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1158", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "System": "gp10025-33-activated pmel-1 mouse splenocytes", "Dose": "trametinib: L=0.005μM, M=0.25μM, H=1μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ expressing CD3+ CD8+ cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD3; CD8; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/821", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "28928458", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "ovalbumin-specific CD8+ OT-I T cells co-cultured with trametinib (MEKi) pre-treated AT3ova tumor cells", "Dose": "0–100 nM of trametinib for 12 h", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ cytokine production by these CD8+ OT-I T cells MHC-I expression, 4-1BB and OX-40 on T cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; 4-1BB / CD137; CD8; IFN-γ; T cells; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/822", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "28928458", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "ovalbumin-specific CD8+ OT-I T cells co-cultured with AT3ova tumor cells in contuinuing presence of trametinib (MEKi)", "Dose": "0–100 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IFNγ production", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/824", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "28928458", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "AT3ova", "Dose": "trametinib treatment alone (100 nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Fas, TRAIL, and NKG2D (RAE-1), MHC-I expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; CD95 / Fas / FAS; NKG2D / KLRK1; TRAIL; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/825", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "28928458", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "4T1Ch9", "Dose": "trametinib treatment alone (100 nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Fas, TRAIL, and NKG2D (RAE-1), MHC-I expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; CD95 / Fas / FAS; NKG2D / KLRK1; TRAIL; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/826", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "E0771-Ova", "Dose": "trametinib (50 nM", "Technique": "Flow cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "H2Kb-SIINFEKL", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/951", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "Splenocytes from HKP1 lung tumor-bearing mice", "Dose": "Long treatment with Traetinib(0.01-1uM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Ki-67, 4–1BB, CTLA-4, and PD-1 from T cells in a dose-dependent manner", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1; CTLA-4; 4-1BB / CD137; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/952", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "Splenocytes from HKP1 lung tumor-bearing mice", "Dose": "pulsative treatment with Traetinib(0.01-1uM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "Maintained Ki-67, 4–1BB, CTLA-4, and PD-1 better in CD8+ T cells and CD4+Foxp3– effector T cells", "Controlled_Terms_Unaffected": "PD-1 / PDCD1; CTLA-4; 4-1BB / CD137; CD4; CD8; T cells; CD8+ T cells; Regulatory T cells / Tregs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1359", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MM200 cells", "Dose": "trametinib (1 μM)", "Technique": "Western blot analysis,Flow cytometry, qPCR analysis", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression activation of ERK", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1360", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-RM cells", "Dose": "trametinib (1 μM)", "Technique": "Western blot analysis,Flow cytometry, qPCR analysis", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression activation of ERK", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1542", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "28928458", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "Ex vivo RNA extraction of trametinib-(1 mg/kg/day) treated 4T1Ch9", "Dose": "(1 mg/kg/day)", "Technique": "Affymetrix microarray analysis", "Controlled_Technique": "Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "immune genes such as CD3ε, CD4, CD8α, CD28, TCR-β, TNFs, and various chemokine receptors (CXCR4, CCR6,9, CXCL12,13, CCL19-21, genes associated with a Th1 signature (TNF, CCL5, CXCR5, CXCR3, Tbx21, Eomes, Icos, Stat4, Nfatc, Il27ra, Tnfsf4, CD40, Prf1)", "Controlled_Terms_Function_enhanced_Number_increased": "CD40; CD28; ICOS / CD278; CD4; TNF-α / TNF; CCL5 / RANTES; Perforin / PRF1; Th1 cells; CXCR4; CXCL12 / SDF-1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/157", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-231", "Dose": "trametinib (50 nM", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "pSTAT3, STAT 3", "Controlled_Terms_Function_enhanced_Number_increased": "STAT3 phosphorylation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/159", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "HCC1954", "Dose": "trametinib (50 nM", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "pSTAT3, STAT 3", "Controlled_Terms_Function_enhanced_Number_increased": "STAT3 phosphorylation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/160", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "HCC1143", "Dose": "trametinib (50 nM", "Technique": "Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "pSTAT3, STAT 3", "Controlled_Terms_Function_enhanced_Number_increased": "STAT3 phosphorylation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/223", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "CL13", "Dose": "Traetinib(0.01-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/226", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "CL25", "Dose": "Traetinib(0.01-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/227", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "IO33", "Dose": "Traetinib(0.01-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/228", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "HKP1", "Dose": "Traetinib(0.01-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/229", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "LLC", "Dose": "Traetinib(0.01-1uM)", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pERK in CD8+ T cells and CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; ERK / MAPK; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/312", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "wild-type BRAF (ME1007 )", "Dose": "trametinib (1 μM)", "Technique": "Western blot analysis", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression", "Controlled_Terms_Function_enhanced_Number_increased": "Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/314", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "wild-type BRAF ( ME4405)", "Dose": "trametinib (1 μM)", "Technique": "Western blot analysis", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD47 expression", "Controlled_Terms_Function_enhanced_Number_increased": "Expression / abundance phenotype; CD47", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/342", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "EMT6", "Dose": "trametinib (50 nM", "Technique": "Flow cytometery, Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "STAT3", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6/JAK/STAT3 signaling; STAT3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "MHC-I and PD-L1", "Controlled_Terms_Unaffected": "PD-L1 / CD274; MHC class I; PD-L1 immune checkpoint pathway;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/343", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "E0771 cells", "Dose": "trametinib (50 nM", "Technique": "Flow cytometery, Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-1 STAT3", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6/JAK/STAT3 signaling; STAT3;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "PD-L1", "Controlled_Terms_Unaffected": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/344", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MMTV-Neu cells", "Dose": "trametinib (50 nM", "Technique": "Flow cytometery, Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-I and PD-L1 pSTAT1, pSTAT3, STAT3, and pSTAT5", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; IL-6/JAK/STAT3 signaling; STAT3; PD-L1 immune checkpoint pathway; ; STAT3 phosphorylation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/345", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "4T1", "Dose": "trametinib (50 nM", "Technique": "Flow cytometery, Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-I and PD-L1 STAT3, STAT5", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; IL-6/JAK/STAT3 signaling; STAT3; STAT5; PD-L1 immune checkpoint pathway;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/394", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "Splenocytes from Pmel-1 TCR transgenic mice were pulsed with gp100 (Pmel) peptide", "Dose": "pulsative treatment with Traetinib(0.01-1uM)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "CD44+CD62L effector memory CD8 T cells IFNγ", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD44; IFN-γ; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "differentiation of Pmel-1 CD8+ T cells, CD44+CD62L+ central memory CD8 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; CD44; T cells; CD8+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/596", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "LLC", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 decreased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/597", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "CT26", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 decreased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/599", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "B78H1", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/600", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "H292", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 decreased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/606", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "H1299", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/598", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "B16", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II, CD80", "Immune_System-Function_enhanced/numbers_increased": "CD80; MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/601", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "HCT-116", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II, CD80", "Immune_System-Function_enhanced/numbers_increased": "CD80; MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 decreased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/603", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "AsPC-1", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II, CD80", "Immune_System-Function_enhanced/numbers_increased": "CD80; MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 decreased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/604", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "A375", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II, CD80", "Immune_System-Function_enhanced/numbers_increased": "CD80; MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/605", "Drug": "CKI27 (avutometinib)", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "Allosteric MEK inhibitor; binds MEK and prevents RAF-mediated MEK phosphorylation, thereby inhibiting MEK/ERK signaling", "KEGG_Drug__ID": "D12120", "Pubchem_ID": "72726305", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38885362", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "System": "H358", "Dose": "250 nM", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I, MHC-II, CD80", "Immune_System-Function_enhanced/numbers_increased": "CD80; MHC class I; MHC class II", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/483", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "Selective/reversible MEK1/MEK2 (MAP2K1/MAP2K2) inhibitor", "KEGG_Drug__ID": "D10405", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O", "Single/Combination": "Single", "PMID": "42183887", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "4T1,murine TNBC", "System": "In vitro 4T1 TNBC cells", "Dose": null, "Technique": "flow cytometry, Western blot", "Controlled_Technique": "Expression of CRT and HMGB1", "Immune_System-Function_enhanced/numbers_increased": "HMGB1; Calreticulin / CRT; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/865", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "MEK inhibitor Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway.", "KEGG_Drug__ID": "D10405", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1", "Single/Combination": "Single Drug", "PMID": "31671149", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "Activated CD8+ T cells+pooled B cells isolated from tumor draining lymph nodes of mice treated with cobimetinib", "Dose": "7.5 mg/kg of cobimetinib(MEKi) three times weekly via intraperitoneal injection", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Expansion of T cells interferon-gamma and granzyme B", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Granzyme B / GZMB; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/770", "Drug": "MEK inhibitors U0126", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2).", "KEGG_Drug__ID": null, "Pubchem_ID": "3006531", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "UACC903 melanoma cells -cultured with CTL specific for either MART-1 (left) or gp100 (right)", "Dose": "(10 μmol/L", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IFN-γ", "Controlled_Terms_Negative_Regulation": "IFN-γ"}, {"ID": "CANIMM/800", "Drug": "MEK inhibitors U0126", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2).", "KEGG_Drug__ID": null, "Pubchem_ID": "3006531", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "HLA-A2+ UACC903 melanoma cells- cultured with CTL specific for MART-1 or gp100 versus control lymphocytes\n (GFP-transduced) at various E:T ratios", "Dose": "(10 μmol/L)", "Technique": "ELISA,cytotoxicity assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1342", "Drug": "MEK inhibitors U0126", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2).", "KEGG_Drug__ID": null, "Pubchem_ID": "3006531", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "888 MEL", "Dose": "(10 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1343", "Drug": "MEK inhibitors U0126", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2).", "KEGG_Drug__ID": null, "Pubchem_ID": "3006531", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "624 MEL", "Dose": "(10 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1344", "Drug": "MEK inhibitors U0126", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2).", "KEGG_Drug__ID": null, "Pubchem_ID": "3006531", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL28", "Dose": "(10 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1346", "Drug": "MEK inhibitors U0126", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2).", "KEGG_Drug__ID": null, "Pubchem_ID": "3006531", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "UACC903", "Dose": "(10 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1347", "Drug": "MEK inhibitors U0126", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2).", "KEGG_Drug__ID": null, "Pubchem_ID": "3006531", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-Juso", "Dose": "(10 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1348", "Drug": "MEK inhibitors U0126", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2).", "KEGG_Drug__ID": null, "Pubchem_ID": "3006531", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "1300 MEL", "Dose": "(10 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1602", "Drug": "MEK inhibitors U0126", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2).", "KEGG_Drug__ID": null, "Pubchem_ID": "3006531", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Fresh tumor digests-isolated from patients with metastatic melanoma", "Dose": "(10 μmol/L)", "Technique": "Quantitative PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1616", "Drug": "MEKi PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB07101", "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "8505c", "Dose": "MEKi PD0325901 10μM", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression and mRNA exxpression phospho ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; ERK / MAPK; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1617", "Drug": "MEKi PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB07101", "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "BCPAP", "Dose": "MEKi PD0325901 10μM", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression and mRNA exxpression phospho ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; ERK / MAPK; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1566", "Drug": "Blocking antibody against CD47 (B6H12.2)", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-RM cells + blocking antibody against CD47 = human peripheral blood mononuclear cells (PBMC)", "Dose": "CD47 (B6H12.2, 10 μg/ml)", "Technique": "con-focal microscopy, phagocytic assay", "Controlled_Technique": "Microscopy", "Immune_System-Function_enhanced/numbers_increased": "phagocytosis by macrophages higher levels of CRT", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; Macrophages; Phagocytosis / trogocytosis; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1349", "Drug": "PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "888 MEL", "Dose": "(0.2 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1350", "Drug": "PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "624 MEL", "Dose": "(0.2 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1351", "Drug": "PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL28", "Dose": "(0.2 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1352", "Drug": "PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "UACC903", "Dose": "(0.2 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1353", "Drug": "PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-Juso", "Dose": "(0.2 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1354", "Drug": "PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "1300 MEL", "Dose": "(0.2 μmol/L)", "Technique": "Quantitative PCR, Flow cytometry, immunofluorescence", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MART-1 expression melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1558", "Drug": "PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "HLA-A2+ UACC903 melanoma cells- cultured with CTL specific for MART-1 or gp100 versus control lymphocytes\n (GFP-transduced) at various E:T ratios", "Dose": "(0.2 μmol/L)", "Technique": "intracellular staining for IFN-γ", "Controlled_Technique": "intracellular staining for IFN-γ", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1559", "Drug": "PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "HLA-A2+ 888 MEL melanoma cells- cultured with CTL specific for MART-1 or gp100 versus control lymphocytes\n (GFP-transduced) at various E:T ratios", "Dose": "(0.2 μmol/L)", "Technique": "intracellular staining for IFN-γ", "Controlled_Technique": "intracellular staining for IFN-γ", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1603", "Drug": "PD0325901", "Drug_category": "MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "20551059", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Fresh tumor digests-isolated from patients with metastatic melanoma", "Dose": "(0.2 μmol/L)", "Technique": "Quantitative PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "melanocyte differentiation antigens (MDA)-mRNA levels of gp100, MART-1, Tyrp-1, and Tyrp-2", "Controlled_Terms_Function_enhanced_Number_increased": "Melanoma differentiation antigens; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/450", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Selective MEK1/MEK2 inhibition → inhibition of RAS–RAF–MEK–ERK signaling; paradoxically causes sustained p38 activation", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "34165921", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "4T1 mouse mammary carcinoma", "System": "4T1", "Dose": "100 nM", "Technique": "Flow cytometry; CD73 expression analysis; CD73 enzymatic assay; Western blot", "Controlled_Technique": "cyclin D1 expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "CD73 expression and enzymatic activity increased, promoting immunosuppressive adenosine signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; Adenosine signaling", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/544", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Selective MEK1/MEK2 inhibition → inhibition of RAS–RAF–MEK–ERK signaling; sustained compensatory p38 activation", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "34165921", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CT26 mouse colon carcinoma cell line", "System": "CT26", "Dose": "100 nM", "Technique": "Flow cytometry; CD73 expression analysis; CD73 enzymatic assay; Western blot", "Controlled_Technique": "cyclin D1 expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "CD73 expression and enzymatic activity increased, resulting in enhanced immunosuppressive adenosine signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; Adenosine signaling", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/545", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Selective MEK1/MEK2 inhibition → inhibition of RAS–RAF–MEK–ERK signaling; sustained compensatory p38 activation", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "34165921", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "MC38 mouse colon adenocarcinoma cell line", "System": "MC38", "Dose": "100 nM", "Technique": "Flow cytometry; CD73 expression analysis; CD73 enzymatic assay; Western blot", "Controlled_Technique": "cyclin D1 expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "CD73 expression and enzymatic activity increased, enhancing the immunosuppressive adenosine pathway", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; Adenosine signaling", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/617", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Selective MEK1/MEK2 inhibition → inhibition of RAS–RAF–MEK–ERK signaling; sustained compensatory p38 activation", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "34165921", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "PC9 human EGFR-mutant non-small-cell lung cancer cell line", "System": "PC9", "Dose": "100 nM", "Technique": "Flow cytometry; CD73 expression analysis; CD73 enzymatic assay; Western blot", "Controlled_Technique": "cyclin D1 expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "CD73/adenosine pathway associated with suppression of T-cell activity", "Immune_System-Function_inhibited/numbers_decreased": "Adenosine signaling; T cells", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "CD73 expression and enzymatic activity increased after prolonged trametinib exposure, increasing immunosuppressive signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/618", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Selective MEK1/MEK2 inhibition → inhibition of RAS–RAF–MEK–ERK signaling; sustained compensatory p38 activation", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "34165921", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "A549 human non-small-cell lung cancer cell line", "System": "A549", "Dose": "100 nM", "Technique": "Flow cytometry; CD73 expression analysis; CD73 enzymatic assay; Western blot", "Controlled_Technique": "cyclin D1 expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "CD73 expression decreased rather than increased", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "No enhancement of CD73-mediated negative immune regulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/619", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Selective MEK1/MEK2 inhibition → inhibition of RAS–RAF–MEK–ERK signaling; sustained compensatory p38 activation", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "34165921", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "HCT116 human colon cancer cell line", "System": "HCT116", "Dose": "100 nM", "Technique": "Flow cytometry; CD73 expression analysis; CD73 enzymatic assay; Western blot", "Controlled_Technique": "cyclin D1 expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "CD73 expression decreased rather than increased", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "No enhancement of CD73-mediated negative immune regulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/455", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "MEK1/2 inhibition; MAPK/ERK suppression", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "E0771-Ova, ovalbumin-expressing E0771 derivative", "System": "E0771-OVA", "Dose": "50 nM; 72 h", "Technique": null, "Controlled_Technique": "increased H2Kb-SIINFEKL, MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/449", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Selective MEK1/MEK2 inhibition → inhibition of RAS–RAF–MEK–ERK signaling; sustained compensatory p38 activation", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "34165921", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "SKBr3 human breast cancer cell line", "System": "SKBR3", "Dose": "100 nM", "Technique": "Flow cytometry; CD73 expression analysis; CD73 enzymatic assay; Western blot", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "CD73 expression remained approximately unchanged", "Immune_System_function_unaffected": "Expression / abundance phenotype", "Controlled_Terms_Unaffected": "No significant increase in CD73-mediated negative immune regulation reported", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/451", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "MEK1/2 inhibition; MAPK/ERK suppression", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "MMTV-Neu murine mammary tumor", "System": "MMTV-Neu", "Dose": "50 nM; 24–72 h", "Technique": "Western blot; flow cytometry; STAT knockdown", "Controlled_Technique": "STAT1/3/5 activation; MHC-I increased; PD-L1 increased", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274; STAT1", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/452", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "MEK1/2 inhibition; MAPK/ERK suppression", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "4T1 murine mammary carcinoma", "System": "4T1", "Dose": "50 nM; 24–72 h", "Technique": "Western blot; flow cytometry; STAT knockdown", "Controlled_Technique": "STAT3 activation; detectable STAT5 activation; MHC-I increased; PD-L1 increased", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274; STAT3", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/454", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "MEK1/2 inhibition; MAPK/ERK suppression", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "E0771 murine mammary tumor", "System": "E0771", "Dose": "50 nM; 24–72 h", "Technique": "Western blot; flow cytometry; STAT knockdown", "Controlled_Technique": "STAT3 activation; MHC-I increased", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; STAT3", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "No significant PD-L1 increase", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/453", "Drug": "Trametinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "MEK1/2 inhibition; MAPK/ERK suppression", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Single", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "EMT6 murine mammary carcinoma", "System": "EMT6", "Dose": "50 nM; 24–72 h", "Technique": "Western blot; flow cytometry; STAT knockdown", "Controlled_Technique": "STAT3 activation; STAT5 activation detectable in responsive models", "Immune_System-Function_enhanced/numbers_increased": "STAT3", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "No significant PD-L1 increase", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1266", "Drug": "Anti PD-1 Nivolumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB09035", "Target/s_or_mechanism_of_action": "The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2.Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response", "KEGG_Drug__ID": "D10316", "Pubchem_ID": "348000000", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29100374", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "System": "Teff: PB-Tregs pretreated with anti-PD 1(1:1)", "Dose": "20 μg/mL of anti PD-1", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "peripheral CD4+CD25− T effector (Teff) cells proliferation IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD25 / IL2RA; IFN-γ; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/926", "Drug": "Anti-CD3 5 ug/mL", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31648326", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "CD3+CD8+ cells from AML mice", "Dose": "anti-CD3 5 ug/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD44+CD62L–, CD44+CD62L+, CD44–CD62L–", "Controlled_Terms_Function_enhanced_Number_increased": "CD44", "Immune_System-Function_inhibited/numbers_decreased": "CD44–CD62L+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD44", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1050", "Drug": "Anti-PD1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30940657", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Ductal Adenocarcinoma (PDA)", "System": "PDA slice cultures", "Dose": "PD-1 blocking mAb", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "EpCAM+ cells, CD45+ immune cells, including both CD4+ and CD8+ cells, CD8+ T cell migration into the juxtatumoral compartment", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells; CD8+ T cells; T-cell migration / chemotaxis; Cell migration and invasion", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1563", "Drug": "Blocking antibody against CD47 (B6H12.2)", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-RMu.S- resistance to vemurafenib by prolonged exposure to the inhibitor +blocking antibody against CD47+ human peripheral blood mononuclear cells (PBMC)", "Dose": "CD47 (B6H12.2, 10 μg/ml)", "Technique": "con-focal microscopy, phagocytic assay", "Controlled_Technique": "Microscopy", "Immune_System-Function_enhanced/numbers_increased": "macrophage phagocytosis of melanoma cells higher levels of CRT", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; Macrophages; Phagocytosis / trogocytosis; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1564", "Drug": "Blocking antibody against CD47 (B6H12.2)", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "melanoma cells from post-treatment primary cultures with increased CD47 expression", "Dose": "CD47 (B6H12.2, 10 μg/ml)", "Technique": "con-focal microscopy, phagocytic assay", "Controlled_Technique": "Microscopy", "Immune_System-Function_enhanced/numbers_increased": "macrophage phagocytosis of melanoma cells higher levels of CRT", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; Macrophages; Phagocytosis / trogocytosis; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1565", "Drug": "Blocking antibody against CD47 (B6H12.2)", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-CV + blocking antibody against CD47 + human peripheral blood mononuclear cells (PBMC)", "Dose": "CD47 (B6H12.2, 10 μg/ml)", "Technique": "con-focal microscopy, phagocytic assay", "Controlled_Technique": "Microscopy", "Immune_System-Function_enhanced/numbers_increased": "phagocytosis by macrophages higher levels of CRT", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; Macrophages; Phagocytosis / trogocytosis; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1568", "Drug": "Blocking antibody against CD47 (B6H12.2)", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29050218", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-CV.S - resistance to vemurafenib by prolonged exposure to the inhibitor +blocking antibody against CD47 = human peripheral blood mononuclear cells (PBMC)", "Dose": "CD47 (B6H12.2, 10 μg/ml)", "Technique": "con-focal microscopy, phagocytic assay", "Controlled_Technique": "Microscopy", "Immune_System-Function_enhanced/numbers_increased": "phagocytosis by macrophages higher levels of CRT", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; Macrophages; Phagocytosis / trogocytosis; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1479", "Drug": "BLU6864", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid - Human Papillary Thyroid Carcinoma", "System": "TPC1 cells", "Dose": "BLU6864(0-100nM)", "Technique": "Western BLot and Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C, HLA-A*02:01", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": "pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/734", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32195020", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "CAL-27", "Dose": "100 μg/mL cetuximab", "Technique": "transwell assay and cell migration, wound healing assay", "Controlled_Technique": "Cell co-culture/transwell assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "TLR4 -aggravated cell migration and invasion", "Controlled_Terms_Negative_Regulation": "TLR4; Cell migration and invasion"}, {"ID": "CANIMM/1434", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29293164", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "SW48 [wild type (WT)] + patient-derived NK cells", "Dose": "100 μg/mL", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing through ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1445", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29293164", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "SW480 (KRAS mutated)++ patient-derived NK cells", "Dose": "100 μg/mL", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing through ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1456", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29293164", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "Purified NK cells derived from 6 WT and 5 KRAS-mutated patients +autologous mCRC cells", "Dose": "100 μg/mL", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing through ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1500", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27217441", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "JHU-029 +Neutrophils cells", "Dose": "10 μg/mL", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "neutrophil mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity; Neutrophils", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1511", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "19319529", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-22B +NK cells", "Dose": "cetuximab (1 μg/ml)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1522", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30842158", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Cancer", "System": "Ho-1-u-1+NK cells", "Dose": "0.1 μg/ml", "Technique": "calcein release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "Cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1534", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30842158", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Cancer", "System": "OSC-19+NK cells", "Dose": "0.1 μg/ml", "Technique": "calcein release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "Cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1545", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30842158", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Cancer", "System": "HSC-4+NK cells", "Dose": "0.1 μg/ml", "Technique": "calcein release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "Cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1556", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30842158", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Cancer", "System": "SKN-3+NK cells", "Dose": "0.1 μg/ml", "Technique": "calcein release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "Cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1567", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30842158", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Cancer", "System": "SAS+NK cells", "Dose": "0.1 μg/ml", "Technique": "calcein release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "Cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1578", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30842158", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Cancer", "System": "Ca9-22+NK cells", "Dose": "0.1 μg/ml", "Technique": "calcein release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "Cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/191", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22922885", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Pleural Mesothelioma", "System": "MSTO-211H +human PBMCs", "Dose": "(2.5 μg/ml)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/413", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Ewing Sarcoma", "System": "A673+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/424", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Ewing Sarcoma", "System": "STA-ET2.1+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/435", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "OHS+ IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/447", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "OSA (SJSA-1)+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/458", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "SAOS-2+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/469", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U2-OS+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/480", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "ZK-58+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/491", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "HOS+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/502", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "S-DX+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/513", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "S-MTX+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/524", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "S-CDDP+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/535", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U-DX+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/546", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U-MTX+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/558", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U-CDDP+IL-15–activated /RestingNK cells", "Dose": "cetuximab (10^7 to 10 mg/mL as indicated)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/569", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22090361", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "Primary tumor cell cultures (n = 5) were generated from osteosarcoma biopsy (n = 1) and resection (n = 4) specimens derived from 4 different osteosarcoma patients+patient-derived NK cells", "Dose": null, "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/613", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27314237", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "System": "COLO320 (EGFR-, RASwt)+NK cells", "Dose": "5μg/ml", "Technique": "cytotoxicity assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing through ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/624", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27314237", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "System": "SW480 (EGFR+ RASmut; KRAS exon 2 c.35>T; p.G12V)+NK cells", "Dose": "5μg/ml", "Technique": "cytotoxicity assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing through ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/635", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27314237", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "System": "SW620 (EGFR+ RASmut; KRAS exon 2 c.35>T; p.G12V)+NK cells", "Dose": "5μg/ml", "Technique": "cytotoxicity assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing through ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/646", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27314237", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "System": "HT-29 (EGFR+, RASwt, BRAFmut)+NK cells", "Dose": "5μg/ml", "Technique": "cytotoxicity assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing through ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/657", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27314237", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "System": "Caco-2 (EGFR+, RASwt)+NK cells", "Dose": "5μg/ml", "Technique": "cytotoxicity assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing through ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/669", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27314237", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "System": "primary tumor material from five patients with CRC+NK cells", "Dose": "5μg/ml", "Technique": "cytotoxicity assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell killing through ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/735", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "23444227", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "EGFR853-861 peptide-specific CTL + DC (from a HLA-A 2.1+ healthy donors) + PCI-15B HNC cells (EGFR+, HLA-2.1−) + NK cells", "Dose": "10μg/m", "Technique": "ELISPOT assay", "Controlled_Technique": "ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "EGFR853-861-specific CTL activation IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1345", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "20865050", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "Esophageal - EAC (Esophageal Adenocarcinoma)", "System": "OE33 coculture with CTLs cytotoxic T lymphocytes", "Dose": "10 mg/ml trastuzumab for 48 hours", "Technique": "Cytometric Bead Array", "Controlled_Technique": "Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/866", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21788356", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "System": "A431-coculture of macrophages", "Dose": "Flow cytometry, \n assay.", "Technique": "Flow cytometry, \n assay.", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "M2 macrophages IL-10 and IL-8 PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; IL-8 / CXCL8; IL-10; IL-8/CXCL8; Macrophages; PD-L1 immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/869", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "Lim1215-KRAS WT, BRAF WT", "Dose": "cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "eIF2-α phosphorylation and phagocytosis - markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/870", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "OXCO-2", "Dose": "cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "eIF2-α phosphorylation and phagocytosis - markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/871", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "Caco-2", "Dose": "cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "eIF2-α phosphorylation and phagocytosis - markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/872", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "(CT26) expressing human EGFR (hEGFR-CT26)", "Dose": "cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ER stress response and phagocytosis-markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/873", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "DiFi", "Dose": "cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot,global mass-spectrometry-based quantitative proteomics using a technique called stable isotope labeling by amino acids in cell culture (SILAC)", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ER stress response and the translocation of CRT and ERp57 to the cell surface, eIF2-α phosphorylation - markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Calreticulin / CRT; ERp57 / PDIA3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/883", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25972070", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "JHU-029 EGFR+ HNC cells", "Dose": "(10 µg/ml, 72h)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ receptor α chain (CD119) (CD119)", "Controlled_Terms_Function_enhanced_Number_increased": "CD119 / IFN-γ receptor 1; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/884", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25972070", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "PCI-15B EGFR+ HNC cells", "Dose": "(10 µg/ml, 72h)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ receptor α chain (CD119) (CD119)", "Controlled_Terms_Function_enhanced_Number_increased": "CD119 / IFN-γ receptor 1; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/885", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25972070", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "JHU-028 EGFR+ HNC cells", "Dose": "(10 µg/ml, 72h)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ receptor α chain (CD119) (CD119)", "Controlled_Terms_Function_enhanced_Number_increased": "CD119 / IFN-γ receptor 1; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/886", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25972070", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "JHU-022 EGFR+ HNC cells", "Dose": "(10 µg/ml, 72h)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ receptor α chain (CD119) (CD119)", "Controlled_Terms_Function_enhanced_Number_increased": "CD119 / IFN-γ receptor 1; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/887", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27217441", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "Mature DC, NK cells and JHU-029 (MAGE-3+) tumor cells", "Dose": "cetuximab (10 μg/mL)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "cross-presentation of endogenous tumor antigen HLA-DR expression on DC", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR; Antigen presentation; Dendritic cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/959", "Drug": "5-aza-2′deoxycytidine (DAC)/Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "SK-MES-1", "Dose": "50 nM, 100 nM or 1 μM over 72 hours", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/888", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27217441", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "PBMCs from cetuximab clinical trial, (n=8)-(UPCI # 08-013, NCT 01218048)", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "increased EGFR-specific cytotoxic CD8+ T", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Cytotoxicity / cytolysis; EGFR", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/891", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25972070", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "JHU-029 plus NK cells in co-culture", "Dose": "cetuximab (IgG1, 10 µg/ml)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells IFNγ HLA-A and HLA-B/C", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A; HLA-B; IFN-γ; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/892", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "23444227", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "CD56+ NK cells+ PCI-15B", "Dose": "cetuximab (each 10μg/ml, 12h)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells,NK-DC cross-talk through NKG2D ligand IFN-γ secretion by NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; IFN-γ; NK cells; Dendritic cells; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1204", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25832655", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "JHU", "Dose": "cetuximab (10 μg/ml)", "Technique": "transwell plate-based ex vivo system,Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell co-culture/transwell assay", "Immune_System-Function_enhanced/numbers_increased": "dendritic cell maturation", "Controlled_Terms_Function_enhanced_Number_increased": "Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CTLA-4+ Treg", "Controlled_Terms_Negative_Regulation": "CTLA-4; Regulatory T cells / Tregs"}, {"ID": "CANIMM/1235", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21308409", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "IIB-BR-G", "Dose": "1 μg/ml Cetuximab", "Technique": "Flow cytometry, Calcein release\n assay.", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "antibody dependent cellular cytotoxicity (ADCC)", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1236", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21308409", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "IIB-BR- G MT", "Dose": "1 μg/ml Cetuximab", "Technique": "Flow cytometry, Calcein release\n assay.", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "antibody dependent cellular cytotoxicity (ADCC)", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1237", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21308409", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "IIB-BR-G + purified NK cells", "Dose": "1 μg/ml Cetuximab", "Technique": "Flow cytometry, Calcein release\n assay.", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK-mediated ADCC antibody dependent cellular cytotoxicity (ADCC)", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1238", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21308409", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "IIB-BR-G + purified NK cells", "Dose": "1 μg/ml Cetuximab", "Technique": "Flow cytometry, Calcein release\n assay.", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK-mediated ADCC antibody dependent cellular cytotoxicity (ADCC)", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1239", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27217441", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "JHU-029 +NK cells", "Dose": "10 μg/mL", "Technique": "Flow cytometry, 51Cr release assay", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells, NK cell killing through ADCC CD69, CD16, CD107a and CD137 on NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; CD16 / FcγRIIIa; CD69; CD107a / LAMP1; CD137; ADCC; NK cells; Antibody-dependent cytotoxicity; Degranulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1260", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27314237", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "System": "A431-(EGFR overexpressing) +NK cells", "Dose": "5μg/ml", "Technique": "Flow cytometry,ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "NK cells-degranulation, ADCC IFNγ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity; Degranulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/197", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26876213", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UDSCC2", "Dose": "5.0μg/ml", "Technique": "SDS-PAGE and immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "autophagy- associated with poor response to cetuximab therapy.", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/1261", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26579227", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "PCI15B + PBMC or purified monocytes from HNSCC patients with new active diseases", "Dose": "10 μg/mL cetuximab", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-12 p70 PD-L1,HLA-DR and CD86-on CD14+ monocytes within PBMC - M1-like phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class II; HLA-DR; CD86; IL-12; Macrophages; Monocytes; PD-L1 immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "IL-10 CD163", "Controlled_Terms_Function_inhibited_Number_decreased": "CD163; IL-10", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1262", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26579227", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "JHU029 + PBMC or purified monocytes from HNSCC patients with new active diseases", "Dose": "10 μg/mL cetuximab", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-12 p70 PD-L1,HLA-DR and CD86-on CD14+ monocytes within PBMC - M1-like phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class II; HLA-DR; CD86; IL-12; Macrophages; Monocytes; PD-L1 immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "IL-10 CD163", "Controlled_Terms_Function_inhibited_Number_decreased": "CD163; IL-10", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1283", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "23444227", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "DC + PCI-15B HNC cells +NK cells.", "Dose": "10μg/m", "Technique": "Flow cytometry,multiplex ELISA (Luminex™) analysis", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "DC maturation,DC cross-presentation, T cell migration Th1 polarizing cytokines-MCP-1, MIP-1β, IL-12p40/70, (CCR5 ligand), CXCL10 and MIG (CXCR3 ligands) HLA-DR, co-stimulatory molecule CD80,CD83,CD86,APM component TAP-1,CD137 -on DC,s", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR; CD80; CD83; CD86; 4-1BB / CD137; CD137; IL-12; CCL2 / MCP-1; CCL4 / MIP-1β; CXCL10 / IP-10; CXCL9 / MIG; Antigen presentation; TAP1; CD80/CD86 costimulation; T cells; Th1 cells; Dendritic cells; T-cell migration / chemotaxis; Cell migration and invasion", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1287", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "19319529", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-22B + purified NK cells, expressing FcγR IIIa-158 VV or FF", "Dose": "cetuximab (1 μg/ml)", "Technique": "Flow cytometry, multiplexed ELISA,51Cr release assay", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "NK cell activation, and T cell chemoattraction IFN-γ, IL-8, MIP-1α, MIP-1β, RANTES, and TNF-α- higher in 158 VV genotype activation markers CD 69 and CD 107a on NK cells with FcγRIIIa-higher in 158 VV genotype", "Controlled_Terms_Function_enhanced_Number_increased": "CD16 / FcγRIIIa; IL-8 / CXCL8; TNF-α / TNF; IFN-γ; CCL3 / MIP-1α; CCL4 / MIP-1β; CCL5 / RANTES; IL-8/CXCL8; T cells; NK cells; T-cell migration / chemotaxis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1320", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Epidermoid Carcinoma", "Cancer_Type_Description": "Epidermoid Carcinoma", "System": "A431", "Dose": "10 μg/ml", "Technique": "Flow cytometry, real-time quantitative PCR (qPCR)", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-ABC membrane expression, HLA-A, HLA-B, and HLA-C β2-m, LMP subunits, TAPs, as well as tapasin", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A; HLA-B; HLA-C; Tapasin; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1324", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "25972070", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "JHU-029 HNC", "Dose": "cetuximab (10 µg/ml)", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-B expression, HLA-A intracellular APM components LMP2, TAP1/2, tapasin, calnexin and calreticulin", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A; HLA-B; Antigen presentation; TAP1; Tapasin; LMP2 / PSMB9; Calnexin; Calreticulin / CRT; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1326", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Adenocarcinoma", "System": "H125", "Dose": "10 μg/ml", "Technique": "Flow cytometry, real-time quantitative PCR (qPCR)", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-ABC membrane expression, HLA-A, HLA-B, and HLA-C β2-m, LMP subunits, TAPs, as well as tapasin", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A; HLA-B; HLA-C; Tapasin; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1569", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "DiFi+ DCs", "Dose": "cetuximab (10 μg/mL)", "Technique": "confocal microscopy", "Controlled_Technique": "Microscopy; Confocal microscopy", "Immune_System-Function_enhanced/numbers_increased": "phagocytosis by dendritic cells-of tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "Dendritic cells; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/196", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26876213", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "PCI-13", "Dose": "5.0μg/ml", "Technique": "SDS-PAGE and immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "autophagy- associated with poor response to cetuximab therapy.", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/198", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26876213", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCC90", "Dose": "5.0μg/ml", "Technique": "SDS-PAGE and immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "autophagy- associated with poor response to cetuximab therapy.", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/199", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26876213", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UMSCC22b", "Dose": "5.0μg/ml", "Technique": "SDS-PAGE and immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "autophagy- associated with poor response to cetuximab therapy.", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/200", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32195020", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCC4", "Dose": "100 μg/mL cetuximab for 2 h, and then stimulated with 1 μg/mL LPS for 0, 15, 30, 60 min", "Technique": "western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "p-p65 and p-c-jun-increased signaling events downstream of TLR4", "Controlled_Terms_Negative_Regulation": "TLR4; c-Jun / JUN; p65 / RELA"}, {"ID": "CANIMM/332", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32195020", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "CAL-27", "Dose": "100 μg/mL cetuximab and stimulated with 1 μg/mL LPS for 24 h", "Technique": "ELISA,western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "TNF-α, PGE2 and NO-suggest TLR4 induced tumor-associated inflammation was increased after EGFR inhibition, COX2 (PGE2 synthetase) and iNOS (NO synthetase), MyD88 proteins", "Controlled_Terms_Negative_Regulation": "TNF-α / TNF; NOS2 / iNOS; COX-2 / PTGS2; PGE2; EGFR; TLR4"}, {"ID": "CANIMM/1006", "Drug": "IPH2101", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB06049", "Target/s_or_mechanism_of_action": "The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "U266", "Dose": "30 μg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "granzyme B", "Controlled_Terms_Function_enhanced_Number_increased": "Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1007", "Drug": "IPH2101", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB06049", "Target/s_or_mechanism_of_action": "The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "Primary MM cells", "Dose": "30 μg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "granzyme B", "Controlled_Terms_Function_enhanced_Number_increased": "Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/404", "Drug": "IPH2101", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB06049", "Target/s_or_mechanism_of_action": "The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "primary MM cells+ Healthy NK cells", "Dose": "30 μg/mL", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/405", "Drug": "IPH2101", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB06049", "Target/s_or_mechanism_of_action": "The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "patient-derived NK cells+ autologous MM tumor cells", "Dose": "30 μg/mL", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1321", "Drug": "Nimotuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB06192", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Epidermoid Carcinoma", "Cancer_Type_Description": "Epidermoid Carcinoma", "System": "A431", "Dose": "10 μg/ml", "Technique": "Flow cytometry, real-time quantitative PCR (qPCR)", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-ABC membrane expression, HLA-A, HLA-B, and HLA-C β2-m, LMP subunits, TAPs, as well as tapasin", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A; HLA-B; HLA-C; Tapasin; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1327", "Drug": "Nimotuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB06192", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Adenocarcinoma", "System": "H125", "Dose": "10 μg/ml", "Technique": "Flow cytometry, real-time quantitative PCR (qPCR)", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-ABC membrane expression, HLA-A, HLA-B, and HLA-C β2-m, LMP subunits, TAPs, as well as tapasin", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A; HLA-B; HLA-C; Tapasin; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/889", "Drug": "Panitumumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB01269", "Target/s_or_mechanism_of_action": "Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR.", "KEGG_Drug__ID": "D05350", "Pubchem_ID": "46505063", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27217441", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "JHU-029 +NK cells", "Dose": "10 μg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells CD69, CD16, CD107a and CD137 on NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; CD16 / FcγRIIIa; CD69; CD107a / LAMP1; CD137; NK cells; Degranulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1223", "Drug": "Rituximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30767211", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Follicular Lymphoma (FL)", "System": "RL", "Dose": "1 μg/ml rituximab", "Technique": "Apoptosis analysis by Annexin V and TO-PRO-3 staining", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC 25%", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1234", "Drug": "Rituximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30767211", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Follicular Lymphoma (FL)", "System": "DOHH2", "Dose": "1 μg/ml rituximab", "Technique": "Apoptosis analysis by Annexin V and TO-PRO-3 staining", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC 44%", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/551", "Drug": "Irinotecan", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Single", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "HCT116", "Dose": "25 µg/mL", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Increased PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1356", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "20865050", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "Esophageal - EAC (Esophageal Adenocarcinoma)", "System": "OE19 coculture with CTLs cytotoxic T lymphocytes+IFN-y", "Dose": "10 mg/ml trastuzumab for 48 hours", "Technique": "Cytometric Bead Array", "Controlled_Technique": "Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1051", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30596643", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "NK+ Panc-1 (HER2-low-expressing cell line), effector/target (E/T) ratio was set at 10:1", "Dose": "10 μg/ml of Tmab", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD137", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; CD137", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "PD-1, NKG2D", "Controlled_Terms_Unaffected": "PD-1 / PDCD1; NKG2D / KLRK1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1052", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30596643", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "NK+Capan-1 (HER2-high-expressing cell line), effector/target (E/T) ratio was set at 10:1", "Dose": "10 μg/ml of Tmab", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD137", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; CD137", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "PD-1, NKG2D", "Controlled_Terms_Unaffected": "PD-1 / PDCD1; NKG2D / KLRK1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/827", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29746929", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "BT474 -HER2-overexpressing breast cancer cell (The indicated HER2-overexpressing breast cancer cells were treated with trastuzumab (5 μg/ml, equivalent to ~30 nM) or a control IgG (rituximab) in monoculture or co-culture with PBMC (at a cancer cell: PBMC ratio of 1:5) for 48 h. After treatment, cell-free conditioned media from mono-cultures and co-cultures were collected and added into new cultures of the breast cancer cells by mixing the conditioned medium with fresh medium at a 1:1 ratio. After culture for another 48 h, the cells were harvested and stained with APC-conjugated anti-PD-L1 antibody and then subjected to Flow cytometry analysis)", "Dose": "trastuzumab (5 μg/ml, equivalent to ~30 nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ in the conditioned media from trastuzumab-treated co-cultures than in the conditioned media from control antibody-treated co-cultures)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Antibody / IgG / IgM", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 in HER2-overexpressing breast cancer cells co-cultured with human PBMC", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; HER2 / ERBB2; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/828", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29746929", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SKBR3- HER2-overexpressing breast cancer cell (The indicated HER2-overexpressing breast cancer cells were treated with trastuzumab (5 μg/ml, equivalent to ~30 nM) or a control IgG (rituximab) in monoculture or co-culture with PBMC (at a cancer cell: PBMC ratio of 1:5) for 48 h. After treatment, cell-free conditioned media from mono-cultures and co-cultures were collected and added into new cultures of the breast cancer cells by mixing the conditioned medium with fresh medium at a 1:1 ratio. After culture for another 48 h, the cells were harvested and stained with APC-conjugated anti-PD-L1 antibody and then subjected to Flow cytometry analysis)", "Dose": "trastuzumab (5 μg/ml, equivalent to ~30 nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ in the conditioned media from trastuzumab-treated co-cultures than in the conditioned media from control antibody-treated co-cultures)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Antibody / IgG / IgM", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 in HER2-overexpressing breast cancer cells co-cultured with human PBMC", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; HER2 / ERBB2; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/829", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29746929", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SUM190- HER2-overexpressing breast cancer cell(The indicated HER2-overexpressing breast cancer cells were treated with trastuzumab (5 μg/ml, equivalent to ~30 nM) or a control IgG (rituximab) in monoculture or co-culture with PBMC (at a cancer cell: PBMC ratio of 1:5) for 48 h. After treatment, cell-free conditioned media from mono-cultures and co-cultures were collected and added into new cultures of the breast cancer cells by mixing the conditioned medium with fresh medium at a 1:1 ratio. After culture for another 48 h, the cells were harvested and stained with APC-conjugated anti-PD-L1 antibody and then subjected to Flow cytometry analysis)", "Dose": "trastuzumab (5 μg/ml, equivalent to ~30 nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ in the conditioned media from trastuzumab-treated co-cultures than in the conditioned media from control antibody-treated co-cultures)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Antibody / IgG / IgM", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 in HER2-overexpressing breast cancer cells co-cultured with human PBMC", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; HER2 / ERBB2; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/830", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29746929", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "HCC1954- HER2-overexpressing breast cancer cell(The indicated HER2-overexpressing breast cancer cells were treated with trastuzumab (5 μg/ml, equivalent to ~30 nM) or a control IgG (rituximab) in monoculture or co-culture with PBMC (at a cancer cell: PBMC ratio of 1:5) for 48 h. After treatment, cell-free conditioned media from mono-cultures and co-cultures were collected and added into new cultures of the breast cancer cells by mixing the conditioned medium with fresh medium at a 1:1 ratio. After culture for another 48 h, the cells were harvested and stained with APC-conjugated anti-PD-L1 antibody and then subjected to Flow cytometry analysis)", "Dose": "trastuzumab (5 μg/ml, equivalent to ~30 nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ in the conditioned media from trastuzumab-treated co-cultures than in the conditioned media from control antibody-treated co-cultures)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Antibody / IgG / IgM", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 in HER2-overexpressing breast cancer cells co-cultured with human PBMC", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; HER2 / ERBB2; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/831", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28819024", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "Cocultute of Mature DCs and SKBR3", "Dose": "Trastuzumab was then added to the media at various concentrations (0 – 80 µg/mL) and cells\n were cultured for up to 24 hours", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Significant increases in HER2 uptake by DCs were observed in presence of Trastuzumab", "Controlled_Terms_Function_enhanced_Number_increased": "HER2 / ERBB2; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/386", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "18927310", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "System": "PBMCs stimulated with anti-CD3/anti-CD28 antibodies for 72 h", "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFNgamma-producing T cells IFNgamma", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/832", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28819024", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "Cocultute of Mature DCs and BT474", "Dose": "Trastuzumab was then added to the media at various concentrations (0 – 80 µg/mL) and cells\n were cultured for up to 24 hours", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Significant increases in HER2 uptake by DCs were observed in presence of Trastuzumab", "Controlled_Terms_Function_enhanced_Number_increased": "HER2 / ERBB2; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/833", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28735814", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SKBR3", "Dose": "PBMC-induced trastuzumab-mediated ADCC", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "increase in trastuzumab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/835", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28735814", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "PBMC-induced trastuzumab-mediated ADCC", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "increase in trastuzumab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1217", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "20865050", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "Esophageal - EAC (Esophageal Adenocarcinoma)", "System": "OE19", "Dose": "2.5 mg of trastuzumab", "Technique": "Flow cytometry, Annexin V and\n 7aad (Cell viablity assay)", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "HER-2", "Controlled_Terms_Function_enhanced_Number_increased": "HER2 / ERBB2", "Immune_System-Function_inhibited/numbers_decreased": "HER-2", "Controlled_Terms_Function_inhibited_Number_decreased": "HER2 / ERBB2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1218", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "20865050", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "Esophageal - EAC (Esophageal Adenocarcinoma)", "System": "OE33", "Dose": "2.5 mg of trastuzumab", "Technique": "Flow cytometry, Annexin V and\n 7aad (Cell viablity assay)", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "HER-2", "Controlled_Terms_Function_enhanced_Number_increased": "HER2 / ERBB2", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1292", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21387286", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SKBR3", "Dose": "0.021 mg/ml or 0.105 mg/ml", "Technique": "immunocytochemical staining, FACS analysis", "Controlled_Technique": "Flow cytometry; Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": "HER2", "Controlled_Terms_Function_enhanced_Number_increased": "HER2 / ERBB2", "Immune_System-Function_inhibited/numbers_decreased": "E‐cadherin", "Controlled_Terms_Function_inhibited_Number_decreased": "E-cadherin / CDH1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1293", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21387286", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "HCC1569", "Dose": "0.021 mg/ml or 0.105 mg/ml", "Technique": "immunocytochemical staining, FACS analysis", "Controlled_Technique": "Flow cytometry; Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": "E‐cadherin HER2", "Controlled_Terms_Function_enhanced_Number_increased": "E-cadherin / CDH1; HER2 / ERBB2", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1308", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30290143", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SKBR3 -Macrophages labeled by CMFDA were co-incubated with SKBR3", "Dose": "1-10 μg/ml", "Technique": "Flow cytometry, confocal microscopy", "Controlled_Technique": "Flow cytometry; Microscopy; Confocal microscopy", "Immune_System-Function_enhanced/numbers_increased": "phagocytosis of HER2+ cancer cells by human macrophages", "Controlled_Terms_Function_enhanced_Number_increased": "HER2 / ERBB2; Macrophages; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1309", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30290143", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "BT-474 Macrophages labeled by CMFDA were co-incubated with BT-474", "Dose": "1-10 μg/ml", "Technique": "Flow cytometry, confocal microscopy", "Controlled_Technique": "Flow cytometry; Microscopy; Confocal microscopy", "Immune_System-Function_enhanced/numbers_increased": "phagocytosis of HER2+ cancer cells by human macrophages", "Controlled_Terms_Function_enhanced_Number_increased": "HER2 / ERBB2; Macrophages; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1560", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30596643", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "NK+Capan-1 (HER2-high-expressing cell line), effector/target (E/T) ratio was set at 10:1", "Dose": "10 μg/ml of Tmab", "Technique": "LDH-releasing assays", "Controlled_Technique": "LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": "Tmab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1561", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30596643", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "NK+ Panc-1 (HER2-low-expressing cell line), effector/target (E/T) ratio was set at 10:1", "Dose": "10 μg/ml of Tmab", "Technique": "LDH-releasing assays", "Controlled_Technique": "LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": "Tmab-mediated ADCC against Panc-1 was elevated, the level was significantly weaker compared with that against Capan-1", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/121", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "20865050", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "Esophageal - EAC (Esophageal Adenocarcinoma)", "System": "OE19", "Dose": "2.5 mg of trastuzumab", "Technique": "RT-PCR and IHC/ICC,", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC); Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": "TAP-1 and Tapasin", "Controlled_Terms_Function_enhanced_Number_increased": "TAP1; Tapasin", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/122", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "20865050", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "Esophageal - EAC (Esophageal Adenocarcinoma)", "System": "OE33", "Dose": "2.5 mg of trastuzumab", "Technique": "RT-PCR and IHC/ICC,", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC); Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": "TAP-1, TAP-2 and Tapasin", "Controlled_Terms_Function_enhanced_Number_increased": "TAP1; TAP2; Tapasin", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/456", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Binds HER2/ERBB2 and blocks HER2 signaling; immune stimulation contributes to cytotoxicity", "KEGG_Drug__ID": "D03257", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "33292267", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2 + breast cancer", "System": "BT474 cancer cells + Jurkat CD4+ T cells", "Dose": "10, 25, 50, 100 µg/mL; 25 µg/mL used for subsequent experiments", "Technique": "western blot and ELISA", "Controlled_Technique": "TNF-α expression, CD4+ T-cells TNF-α increased. Trastuzumab + T cells: 81.4 ± 6.9% vs 100.2 ± 3% viability increase; p=0.01", "Immune_System-Function_enhanced/numbers_increased": "CD4; T cells; TNF-α / TNF; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/457", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Binds HER2/ERBB2 and blocks HER2 signaling; immune stimulation contributes to cytotoxicity", "KEGG_Drug__ID": "D03257", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "33292267", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2 + breast cancer", "System": "SKBR3 cancer cells + Jurkat CD4+ T cells", "Dose": "10, 25, 50, 100 µg/mL; 25 µg/mL used for subsequent experiments", "Technique": "western blot and ELISA", "Controlled_Technique": "TNF-α expression, CD4+ T-cells TNF-α increased. Trastuzumab + T cells: 81.4 ± 6.9% vs 100.2 ± 3% viability increase; p=0.01", "Immune_System-Function_enhanced/numbers_increased": "CD4; T cells; TNF-α / TNF; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/459", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Binds HER2/ERBB2 and blocks HER2 signaling; immune stimulation contributes to cytotoxicity", "KEGG_Drug__ID": "D03257", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "33292267", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2 + breast cancer", "System": "MDA-MB-453 cancer cells + Jurkat CD4+ T cells", "Dose": "10, 25, 50, 100 µg/mL; 25 µg/mL used for subsequent experiments", "Technique": "western blot and ELISA", "Controlled_Technique": "TNF-α expression, CD4+ T-cells TNF-α increased. Trastuzumab + T cells: 81.4 ± 6.9% vs 100.2 ± 3% viability increase; p=0.01", "Immune_System-Function_enhanced/numbers_increased": "CD4; T cells; TNF-α / TNF; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/460", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Binds HER2/ERBB2 and blocks HER2 signaling; limited effect because of low HER2 expression", "KEGG_Drug__ID": "D03257", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "33292267", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2 + breast cancer", "System": "MDA-MB-231 cancer cells + Jurkat CD4+ T cells", "Dose": "10, 25, 50, 100 µg/mL; 25 µg/mL used for subsequent experiments", "Technique": "western blot and ELISA", "Controlled_Technique": "TNF-α expression, CD4+ T-cells TNF-α increased. Trastuzumab + T cells: 81.4 ± 6.9% vs 100.2 ± 3% viability increase; p=0.01", "Immune_System-Function_enhanced/numbers_increased": "CD4; T cells; TNF-α / TNF; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/249", "Drug": "AICAR (mTOR inhibitor)", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB01700", "Target/s_or_mechanism_of_action": "acadesine is phosphorylated to AICAR to activate AMPK without changing the levels of the nucleotides.", "KEGG_Drug__ID": "C04677", "Pubchem_ID": "65110", "STR_LINK_(SMILES)": "NC(=O)C1=C(N)N(C=N1)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H1975", "Dose": "2 mmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/165", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/166", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB435", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/178", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT116", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/250", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "PC-9", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/251", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "Calu1", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/252", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "801BL", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/253", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H157", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/254", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H1975", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/255", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "HCC827/AR", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/288", "Drug": "AZD8055-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "(Du145)", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/256", "Drug": "Dual mTORC1/2 inhibitor, AZD8055", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "CL25", "Dose": "100 nmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/257", "Drug": "Dual mTORC1/2 inhibitor, AZD8055", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H157", "Dose": "100 nmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/259", "Drug": "Dual mTORC1/2 inhibitor, AZD8055", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB12774", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "25262965", "STR_LINK_(SMILES)": "COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H1975", "Dose": "100 nmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/224", "Drug": "Everolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB01590", "Target/s_or_mechanism_of_action": "Everolimus is a mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies", "KEGG_Drug__ID": "D02714", "Pubchem_ID": "46505248", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31052575", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "TC-1/Luc cells +E7-specific CD8+ T lymphocytes + mTORi-treated BMM-derived DCs", "Dose": "10 nM", "Technique": "luciferase activities of tumor growth were measured using IVIS® Imaging Systems", "Controlled_Technique": "Bioluminescence/luciferase assay", "Immune_System-Function_enhanced/numbers_increased": "BMM-Derived DCs", "Controlled_Terms_Function_enhanced_Number_increased": "Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1334", "Drug": "Everolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB01590", "Target/s_or_mechanism_of_action": "Everolimus is a mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies", "KEGG_Drug__ID": "D02714", "Pubchem_ID": "46505248", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "27206490", "Cancer_Type": "Bile Duct Carcinoma", "Cancer_Type_Description": "Cholangiocellular Carcinoma (CCA)", "System": "Everolimus treated CAFs", "Dose": "1 μM Everolimus", "Technique": "human cytokine array", "Controlled_Technique": "Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL 8, IL 13, MCP1, MIF and Serpin E1", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/432", "Drug": "Everolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB01590", "Target/s_or_mechanism_of_action": "FKBP12-dependent mTORC1 inhibition", "KEGG_Drug__ID": "D02714", "Pubchem_ID": "6442177", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "T24", "Dose": "100 nM, 48 h", "Technique": "qRT-PCR, western blot", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 mRNA and glycosylated PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/433", "Drug": "Everolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB01590", "Target/s_or_mechanism_of_action": "FKBP12-dependent mTORC1 inhibition", "KEGG_Drug__ID": "D02714", "Pubchem_ID": "6442177", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "CAL-29", "Dose": "100 nM, 48 h", "Technique": "qRT-PCR, western blot", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 mRNA and glycosylated PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/161", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/162", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB435", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/176", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT116", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/230", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "PC-9", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/231", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "Calu1", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/232", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "801BL", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/233", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H157", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/234", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H1975", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/235", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "HCC827/AR", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/286", "Drug": "INK128-mTOR inhibitor", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "(Du145)", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1490", "Drug": "INK128, a representative TORKinib, Sapanisertib", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H460", "Dose": "25–100 nM", "Technique": "Western Blotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1491", "Drug": "INK128, a representative TORKinib, Sapanisertib", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "INK128 inhibited both mTORC1 and mTORC2 signaling in neuroblastoma cells", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "HCC827", "Dose": "25–100 nM", "Technique": "Western Blotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/237", "Drug": "MTOR inhibitor (rapamycin; )", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "CL30", "Dose": "100 nmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1583", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "ES-2", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/238", "Drug": "MTOR inhibitor (rapamycin; )", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "IO33", "Dose": "100 nmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/239", "Drug": "MTOR inhibitor (rapamycin; )", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "CL25", "Dose": "100 nmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/240", "Drug": "MTOR inhibitor (rapamycin; )", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H157", "Dose": "100 nmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/241", "Drug": "MTOR inhibitor (rapamycin; )", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H1975", "Dose": "100 nmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1492", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H460", "Dose": "25–100 nM", "Technique": "Western Blotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1493", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "HCC827", "Dose": "25–100 nM", "Technique": "Western Blotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/163", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/164", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB435", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/177", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT116", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/242", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "PC-9", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/243", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "Calu1", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/244", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "801BL", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/245", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H157", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/246", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H1975", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/248", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "HCC827/AR", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/287", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31316145", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "(Du145)", "Dose": "100 nM of the given mTOR inhibitor for 16 h", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 levels", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/335", "Drug": "Rapamycin (\n Sirolimus)", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug__ID": "D00753", "Pubchem_ID": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "31052575", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "TC-1/Luc cells +E7-specific CD8+ T lymphocytes + mTORi-treated BMM-derived DCs", "Dose": "10 nM", "Technique": "luciferase activities of tumor growth were measured using IVIS® Imaging Systems", "Controlled_Technique": "Bioluminescence/luciferase assay", "Immune_System-Function_enhanced/numbers_increased": "BMM-Derived DCs", "Controlled_Terms_Function_enhanced_Number_increased": "Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/427", "Drug": "TAK-228", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "ATP-competitive mTORC1/2 inhibition", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "TCCSUP", "Dose": "50 nM", "Technique": "Western blot", "Controlled_Technique": "High HLA-I expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "high PD‐L1 expression", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/429", "Drug": "TAK-228", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "ATP-competitive mTORC1/2 inhibition", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "J82", "Dose": "50 nM", "Technique": "Western blot", "Controlled_Technique": "High HLA-I expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "low PD‐L1 expression", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/431", "Drug": "TAK-228", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "ATP-competitive mTORC1/2 inhibition", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "CAL-29", "Dose": "50 nM", "Technique": "qRT-PCR, western blot, flow cytometry", "Controlled_Technique": "High HLA-I expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "high PD‐L1 expression", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/425", "Drug": "TAK-228", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "ATP-competitive mTORC1/2 inhibition", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "T24", "Dose": "50 nM", "Technique": "qRT-PCR, western blot, flow cytometry", "Controlled_Technique": "Low HLA-I expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "high PD‐L1 expression", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/426", "Drug": "TAK-228", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "ATP-competitive mTORC1/2 inhibition", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "HT-1197", "Dose": "50 nM", "Technique": "Western blot", "Controlled_Technique": "Low HLA-I expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "high PD‐L1 expression", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/428", "Drug": "TAK-228", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "ATP-competitive mTORC1/2 inhibition", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "UM-UC-3", "Dose": "50 nM", "Technique": "Western blot", "Controlled_Technique": "Low HLA-I expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "low PD‐L1 expression", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/430", "Drug": "TAK-228", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "ATP-competitive mTORC1/2 inhibition", "KEGG_Drug__ID": "D11183", "Pubchem_ID": "45375953", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "RT4", "Dose": "50 nM", "Technique": "Western blot", "Controlled_Technique": "Low HLA-I expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "low PD‐L1 expression", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/446", "Drug": "Temsirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB06287", "Target/s_or_mechanism_of_action": "Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin)", "KEGG_Drug__ID": "D06068", "Pubchem_ID": "23724530", "STR_LINK_(SMILES)": "OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC", "Single/Combination": "Single Drug", "PMID": "31052575", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "TC-1/Luc cells +E7-specific CD8+ T lymphocytes + mTORi-treated BMM-derived DCs", "Dose": "2 µM", "Technique": "luciferase activities of tumor growth were measured using IVIS® Imaging Systems", "Controlled_Technique": "Bioluminescence/luciferase assay", "Immune_System-Function_enhanced/numbers_increased": "BMM-Derived DCs", "Controlled_Terms_Function_enhanced_Number_increased": "Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/958", "Drug": "5-aza-2′deoxycytidine (DAC)/Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549", "Dose": "50 nM, 100 nM or 1 μM over 72 hours", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1205", "Drug": "5-aza-2′deoxycytidine (DAC)/Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 cells pulsed with 100 ng/ml of the glycolipids α-GalCer or 7DW8-5 for 24 hours +iNKT cells", "Dose": "DAC (50 nM, 100 nM and 1 μM) at 24, 48 and 72 hours", "Technique": "co-culture, Flow cytometry, blocking antobody", "Controlled_Technique": "Flow cytometry; Cell co-culture/transwell assay", "Immune_System-Function_enhanced/numbers_increased": "iNKT cells CD107a-iNKT cell-mediated cytolytic degranulation", "Controlled_Terms_Function_enhanced_Number_increased": "CD107a / LAMP1; Degranulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1206", "Drug": "5-aza-2′deoxycytidine (DAC)/Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "SK-MES-1 cells pulsed with 100 ng/ml of the glycolipids α-GalCer or 7DW8-5 for 24 hours +iNKT cells", "Dose": "DAC (50 nM, 100 nM and 1 μM) at 24, 48 and 72 hours", "Technique": "co-culture, Flow cytometry, blocking antobody", "Controlled_Technique": "Flow cytometry; Cell co-culture/transwell assay", "Immune_System-Function_enhanced/numbers_increased": "iNKT cells CD107a-iNKT cell-mediated cytolytic degranulation", "Controlled_Terms_Function_enhanced_Number_increased": "CD107a / LAMP1; Degranulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/70", "Drug": "5-aza-2′deoxycytidine (DAC)/Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549", "Dose": "1 μM DAC", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1440", "Drug": "5-azacytidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "17725605", "Cancer_Type": "Hpv16-Expressing Tumors", "Cancer_Type_Description": "Human Papilloma Virus 16-Associated Tumours", "System": "TC-1/A9 (MHC class I-deficient)", "Dose": "50 µm 5-azaC", "Technique": "Flow cytometry, quantitative real-time RT-PCR,Western blot analysis", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC class I molecules apoptosis,TAP-1, TAP-2 and LMP-7", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Apoptosis; TAP1; TAP2; LMP7 / PSMB8;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1470", "Drug": "5-azacytidine (5-AC)", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "SW480", "Dose": null, "Technique": "immunoblotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/186", "Drug": "5-azacytidine (5-AC)", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116", "Dose": null, "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/461", "Drug": "5-Azacytidine (Azacitidine; 5-Aza)", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "Inhibits DNMT activity at low doses; DNA/RNA incorporation at higher doses; hypomethylation can increase antigen-presentation gene expression", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/665", "Drug": "5-Azacytidine (Azacitidine; 5-Aza)", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "Inhibits DNMT activity at low doses; DNA/RNA incorporation at higher doses; hypomethylation can increase antigen-presentation gene expression", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "melanoma", "System": "B16F10", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1427", "Drug": "5-fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "16957513", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "Colon cancer (SW480) cells", "Dose": "5-FU (5-fluorouracil) IC50 11.70 ug/ml", "Technique": "Immunocytochemistry\n and Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": "Fas", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1471", "Drug": "5-fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "SW480", "Dose": "10 mg/mL", "Technique": "immunoblotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/187", "Drug": "5-fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116", "Dose": "10 mg/mL", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/188", "Drug": "5-fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "LoVo", "Dose": "10 mg/mL", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/696", "Drug": "5-Fluorouracil (5-FU)", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Thymidylate synthase inhibition; disruption of DNA/RNA synthesis", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40380807", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "gastric cancer cell line", "System": "AGS", "Dose": "59.63 μM", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Increased cell-surface PD-L1 and MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Increased PD-L1 may promote inhibitory immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1584", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "OV-90", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/697", "Drug": "5-Fluorouracil (5-FU)", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Thymidylate synthase inhibition; disruption of DNA/RNA synthesis", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40380807", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "gastric cancer cell line", "System": "SNU-1", "Dose": "33.7 μM", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Increased PD-L1 and MHC-I, predominantly in apoptotic cells", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Increased PD-L1 may promote inhibitory immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/577", "Drug": "5-FU", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single", "PMID": "32078695", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "esophageal cancer cells (OE33 cells", "System": "OE33", "Dose": "0, 10 and 100 μM cisplatin", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "No significant differences were observed in CD1d expression in OE33 cells", "Immune_System_function_unaffected": "Expression / abundance phenotype; CD1d", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/700", "Drug": "5-FU", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single", "PMID": "32078695", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "upper gastrointestinal cancer", "System": "Invariant natural killer T (iNKT) cells+CD1d-transfected HeLa cells", "Dose": "10 or 100 μM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "inhibited CD107a externalization", "Immune_System-Function_inhibited/numbers_decreased": "CD107a / LAMP1", "Controlled_Terms_Function_inhibited_Number_decreased": "No significant decrease in IFN-γ expression by viable iNKT cells, No significant difference in granzyme B or perforin production by activated iNKT cells", "Immune_System_function_unaffected": "Expression / abundance phenotype; Granzyme B / GZMB; IFN-γ", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1159", "Drug": "Azacitidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-624", "Dose": "5µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1160", "Drug": "Azacitidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-888", "Dose": "5µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/928", "Drug": "Azacitidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "23242597", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Myelodysplastic Syndrome (MDS)", "System": "Treg from three patients-stimulation with CD3/CD28 beads", "Dose": "(2 μM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Th1 cells", "Controlled_Terms_Negative_Regulation": "Th1 cells"}, {"ID": "CANIMM/361", "Drug": "Azacitidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "24162015", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Fibrosarcoma", "System": "MCA205", "Dose": "7.5, 15, 30 µM", "Technique": "cytoplasmic GFP-HMGB1 fluorescence intensit, immunostaining, immunofluorescence,western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 release", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/362", "Drug": "Azacitidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "24162015", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U2OS", "Dose": "7.5, 15, 30 µM", "Technique": "cytoplasmic GFP-HMGB1 fluorescence intensit, immunostaining, immunofluorescence,western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 release", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1269", "Drug": "Azacytidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "28404876", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "KG1a", "Dose": "(1 μM or 5 μM)", "Technique": "sandwich ELISA,Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "NKG2DL (MICA, MICB, ULBPs1-3)-on the surface of AML cells", "Controlled_Terms_Function_enhanced_Number_increased": "MICA; MICB; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": "release of soluble sNKG2DL from AML cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Soluble NKG2D ligand", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1270", "Drug": "Azacytidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "28404876", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "NB4 cells", "Dose": "(1 μM or 5 μM)", "Technique": "sandwich ELISA,Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "NKG2DL (MICA, MICB, ULBPs1-3)-on the surface of AML cells", "Controlled_Terms_Function_enhanced_Number_increased": "MICA; MICB; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": "release of soluble sNKG2DL from AML cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Soluble NKG2D ligand", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1487", "Drug": "Azacytidine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "20126405", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "KG-1a cells", "Dose": "(0–3 µM)", "Technique": "Flow cytometry, western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis markers-Annexin V (early apoptosis) and 7-AAD (late apoptosis),PARP cleavage", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; PARP cleavage / PARP; Annexin V; 7-AAD", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/929", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28321548", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs from 4 patients", "Dose": "(0.1 to 10 μM) for 7 days", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ILT2 expression on the surface of both healthy and leukemic B cells,", "Controlled_Terms_Function_enhanced_Number_increased": "B cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "ILT2 on NK cells from CLL patients", "Controlled_Terms_Function_inhibited_Number_decreased": "NK cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1310", "Drug": "Cetuximab + GILF chemotherapy", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441\n DB00762\n DB11596\n DB00544\n DB00002", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase,\n Irinotecan inhibits the action of topoisomerase I,\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects,\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA,\n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D02368,D08086, D04715, D00584, D03455", "Pubchem_ID": "60750, 60838, 149436, 3385, 46507042", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, \n CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": null, "PMID": "21618510", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer Cells", "System": "WiDr + DC,s", "Dose": null, "Technique": "Flow cytometry,Transmission electron microscopy", "Controlled_Technique": "Flow cytometry; Microscopy; Electron microscopy", "Immune_System-Function_enhanced/numbers_increased": "DC-mediated phagocytosis/trogocytosis of these tumor cells CD80, CD83, CD86 and HLA-DR on the surface of DCs", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR; CD80; CD83; CD86; CD80/CD86 costimulation; Dendritic cells; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1313", "Drug": "Cetuximab + GILF chemotherapy", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441\n DB00762\n DB11596\n DB00544\n DB00002", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase,\n Irinotecan inhibits the action of topoisomerase I,\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects,\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA,\n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D02368,D08086, D04715, D00584, D03455", "Pubchem_ID": "60750, 60838, 149436, 3385, 46507042", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, \n CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": null, "PMID": null, "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer Cells", "System": "HT29 + DC,s", "Dose": null, "Technique": "Flow cytometry,Transmission electron microscopy", "Controlled_Technique": "Flow cytometry; Microscopy; Electron microscopy", "Immune_System-Function_enhanced/numbers_increased": "DC-mediated phagocytosis/trogocytosis of these tumor cells CD80, CD83, CD86 and HLA-DR on the surface of DCs", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR; CD80; CD83; CD86; CD80/CD86 costimulation; Dendritic cells; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/768", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28404876", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "NKL cells co-cultured with K562 cells", "Dose": "1 μM DAC", "Technique": "cell lysis assay", "Controlled_Technique": "Cell lysis assay", "Immune_System-Function_enhanced/numbers_increased": "NKL cells", "Controlled_Terms_Function_enhanced_Number_increased": "NKL cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/790", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "30210693", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "CD3+ T cells from CLL patients were stimulated with autologous irradiated CD19+ CLL cells", "Dose": "2 μM", "Technique": "CFSE assay", "Controlled_Technique": "Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "CD4+ and CD8+ T cells IFNγ from both CD4+ and CD8+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; IFN-γ; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/733", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "30210693", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs from healthy donors cocultured with purified leukemia cells obtained from CLL patients for 4 hours", "Dose": "1 μM lenalidomide", "Technique": "CD107a lysosome-associated membrane protein-1 (LAMP-1) was used to measure NK-, NKT-like-, and CD8-cell cytotoxic activity", "Controlled_Technique": "Degranulation assay", "Immune_System-Function_enhanced/numbers_increased": "NK Cell-Mediated Natural Cytotoxicity and ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/750", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28337274", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "T cells from CLL patients (upon lenalidomide/anti-CD3 stimulation)", "Dose": "0.5 μM", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL21", "Controlled_Terms_Function_enhanced_Number_increased": "IL-21", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/760", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "23671644", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "Spleen and lymph node cells from EL4 immunized BALB/c mice +h DAC-d EL4 cells", "Dose": null, "Technique": "ELISA,Cell Counting Kit-8", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell proliferation IL-2 and IFN-γ CD80 expression in EL4 cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; IL-2; IFN-γ; Cell proliferation; T cells; T-cell proliferation; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/786", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "27416831", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "IL-2 treated lymphocytes exposed to irradiated 4T1 cells", "Dose": "1.5 or 3.0 μM decitabin", "Technique": "ELISA IFN-γ release assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1161", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-624", "Dose": "500nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1162", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel-888", "Dose": "500nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/927", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "26692933", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "HL-60 cell", "Dose": "DAC (0.2, 0.5 and 1.0 μM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "apoptosis marker-Annexin V (early apoptosis) ,NKG2DL expression on HL-60 cells-MICA/B, ULBP-1 and ULBP-3,SOCS-1 and SOCS-3", "Controlled_Terms_Function_enhanced_Number_increased": "ULBP1; ULBP3; MICA; SOCS1; SOCS3; Apoptosis; Annexin V; Expression / abundance phenotype; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": "STAT3, JAK, JAK2, phosphorylated STAT3, phosphorylated JAK1 and phosphorylated JAK2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; JAK1; JAK2; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1213", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "26692933", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "Human NK92 cells used as effector cells, and HL-60 cells as target cells", "Dose": "DAC (0.2-1.0 μM)", "Technique": "CFSE staining-Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1247", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "17545540", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Mel 275", "Dose": "1 µM /L", "Technique": "Flow cytometry,Cytotoxicity assay,IFN-g release assay", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "CTL IFNγ HLA class I antigens and of ICAM-1", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; ICAM-1 / CD54; IFN-γ; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1271", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28404876", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "KG1a", "Dose": "(1 μM or 5 μM)", "Technique": "sandwich ELISA,Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "NKG2DL (MICA, MICB, ULBPs1-3)-on the surface of AML cells", "Controlled_Terms_Function_enhanced_Number_increased": "MICA; MICB; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": "release of soluble sNKG2DL from AML cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Soluble NKG2D ligand", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1272", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28404876", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "NB4 cells", "Dose": "(1 μM or 5 μM)", "Technique": "sandwich ELISA,Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "NKG2DL (MICA, MICB, ULBPs1-3)-on the surface of AML cells", "Controlled_Terms_Function_enhanced_Number_increased": "MICA; MICB; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": "release of soluble sNKG2DL from AML cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Soluble NKG2D ligand", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1314", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "27416831", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "4T1", "Dose": "(0, 0.75, 1.5, and 3.0 μM) of decitabine for 24 and 48 h", "Technique": "Flow cytometry,qPCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "Her-2-neu and MHC class I molecules on tumor cells cancer testis antigens", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HER2 / ERBB2; Cancer-testis antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1377", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24270737", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "KG-1", "Dose": "0-10 µM", "Technique": "RT-PCR analysis,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "PD-L1, PD-L2, PD-1 and CTLA4 expression in AML cell lines,", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-1 / PDCD1; CTLA-4; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1379", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24270737", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "THP1 cells", "Dose": "0-10 µM", "Technique": "RT-PCR analysis,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "PD-L1, PD-L2, PD-1 and CTLA4 expression in AML cell lines,", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-1 / PDCD1; CTLA-4; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1405", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "23671644", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "EL4 cells", "Dose": "(0.25 µM)", "Technique": "Flow cytometric analysis + RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD80 expression in EL4 cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1426", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "11668505", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MSR3-mel", "Dose": "10 µM", "Technique": "RT-PCR analysis,cytokine release assay,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Cytotoxicity/release assay; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "MAGE-specific cytotoxic T lymphocytes HLA-A and -B,cell surface expression of HLA class I antigens", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A; Cytotoxicity / cytolysis; T cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1488", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "20126405", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "KG-1a cells", "Dose": "(0–3 µM)", "Technique": "Flow cytometry, western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis markers-Annexin V (early apoptosis) and 7-AAD (late apoptosis),PARP cleavage", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; PARP cleavage / PARP; Annexin V; 7-AAD", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1575", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "27416831", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SKBR3", "Dose": "3 μM", "Technique": "qPCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer testis antigens", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1576", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "27416831", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "3 μM", "Technique": "qPCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer testis antigens", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1580", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "CAOV-3", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1581", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "CAOV-4", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1582", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "COV413", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1585", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "OVCAR-3", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1586", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SK-OV-3", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1587", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SW626", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1588", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "TOV-21G", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1590", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "TOV-112D", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1591", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "18791715", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "TTB-6", "Dose": "1-10 µM", "Technique": "PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis antigens (CTA) on ovarian cell line", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1639", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "BE2C", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1640", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "NBL-S", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1641", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "Kelly", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1642", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "NGP", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1643", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "SHSY5Y", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/38", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28321548", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "blood from CLL patients", "Dose": "0.5 μM or 1 μM lenalidomide", "Technique": "Whole blood depletion assays,quantitative RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "IL21 mRNA depleted CLL cells in whole blood", "Controlled_Terms_Function_enhanced_Number_increased": "IL-21", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/39", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "27013443", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "AML blasts from patients treated with DAC", "Dose": "DAC (20 mg/m2)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2DL on AML blasts", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/4", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "EB2M17", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/40", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "23671644", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - (Acute Myelogenous Leukemia, M5)", "System": "U937", "Dose": "1 µM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD80 expression in EL4 cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/41", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "23671644", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - (Acute Myelogenous Leukemia, M5)", "System": "THP-1", "Dose": "1 µM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD80 expression in EL4 cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/42", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "23671644", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia -(Acute Myelogenous Leukemia, M3)", "System": "NB4", "Dose": "1 µM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD80 expression in EL4 cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/43", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "23671644", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia -(T-Cell Acute Lymphoblastic Leukemia)", "System": "Molt-4", "Dose": "1 µM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD80 expression in EL4 cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/5", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "IMR32SKN-AS", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/6", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "SKN-SH", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/7", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "SKNMC", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/8", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "21626030", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "System": "CHP134", "Dose": "1 µM", "Technique": "RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens-(MAGE-A1/ MAGE-A3/ NY-ESO-1) on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/127", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "20381863", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "HL60", "Dose": "200 nM", "Technique": "RT-PCR,, Western blot analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens- NY-ESO-1, MAGEA1, MAGEA3 and MAGEB2 on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/128", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "20381863", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "THP-1", "Dose": "200 nM", "Technique": "RT-PCR,, Western blot analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens- NY-ESO-1, MAGEA1, MAGEA3 and MAGEB2 on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/129", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "20381863", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "Kasumi-1", "Dose": "200 nM", "Technique": "RT-PCR,, Western blot analysis,", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cancer-testis (CT) antigens- NY-ESO-1, MAGEA1, MAGEA3 and MAGEB2 on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/130", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28404876", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "KG1a", "Dose": "(0.25, 0.5 and 1 μM)", "Technique": "qRT-PCR, western blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tissue inhibitor of metalloproteinase-3 (TIMP3)", "Controlled_Terms_Function_enhanced_Number_increased": "TIMP3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/131", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28404876", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "NB4 cells", "Dose": "(0.25, 0.5 and 1 μM)", "Technique": "qRT-PCR, western blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tissue inhibitor of metalloproteinase-3 (TIMP3)", "Controlled_Terms_Function_enhanced_Number_increased": "TIMP3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/132", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "28337274", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "CLL cells", "Dose": "0.5 μM lenalidomide for 48 hours", "Technique": "immunoblot,Quantitative RT-PCR assessment", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "IL21R mRNA and protein in CLL", "Controlled_Terms_Function_enhanced_Number_increased": "IL-21 receptor / IL21R", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/138", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "17929270", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer - Metastatic Prostate Cancer", "System": "LNCaP", "Dose": "0-10 µM", "Technique": "western blotting, RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "prostate cancer-testis antigen, SSX-2 on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/139", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "17929270", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer - Metastatic Prostate Cancer", "System": "DU145", "Dose": "0-10 µM", "Technique": "western blotting, RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "prostate cancer-testis antigen, SSX-2 on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/140", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24584817", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "HOS, Hs39.T, MG-63, and SAOS,", "Dose": "1 μM", "Technique": "RT-PCR,Western blot analysis,Flow cytomery", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MAGE-A1, MAGE-A3, and NYESO-1,CT antigens antigens on sarcoma", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/901", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat) and Rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB00073", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993, \n D02994", "Pubchem_ID": "12136798, 46505820", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "OCI-Ly3", "Dose": "10 µg/ml Rituximab,1, 2, 4 and 8 µM Chidamide", "Technique": "MTT test", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/141", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24584817", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "ESTTC-975", "Dose": "1 μM", "Technique": "RT-PCR,Western blot analysis,Flow cytomery", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MAGE-A1, MAGE-A3, and NYESO-1,CT antigens antigens on sarcoma", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/142", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24584817", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "ES-TTC-816", "Dose": "1 μM", "Technique": "RT-PCR,Western blot analysis,Flow cytomery", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MAGE-A1, MAGE-A3, and NYESO-1,CT antigens antigens on sarcoma", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/143", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24584817", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "RD", "Dose": "1 μM", "Technique": "RT-PCR,Western blot analysis,Flow cytomery", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I, Class II, and ICAM-1 molecules MAGE-A1, MAGE-A3, and NYESO-1,CT antigens antigens on sarcoma", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; ICAM-1 / CD54; Cancer-testis antigens; MAGE antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/144", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24584817", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "SJCRH30", "Dose": "1 μM", "Technique": "RT-PCR,Western blot analysis,Flow cytomery", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I, Class II, and ICAM-1 molecules MAGE-A1, MAGE-A3, and NYESO-1,CT antigens antigens on sarcoma", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; ICAM-1 / CD54; Cancer-testis antigens; MAGE antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/145", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24584817", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "A204", "Dose": "1 μM", "Technique": "RT-PCR,Western blot analysis,Flow cytomery", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I, Class II, and ICAM-1 molecules MAGE-A1, MAGE-A3, and NYESO-1,CT antigens antigens on sarcoma", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; ICAM-1 / CD54; Cancer-testis antigens; MAGE antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/146", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24584817", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "A673", "Dose": "1 μM", "Technique": "RT-PCR,Western blot analysis,Flow cytomery", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I, Class II, and ICAM-1 molecules MAGE-A1, MAGE-A3, and NYESO-1,CT antigens antigens on sarcoma", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; ICAM-1 / CD54; Cancer-testis antigens; MAGE antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/148", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24584817", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "MG-63", "Dose": "1 μM", "Technique": "RT-PCR,Western blot analysis,Flow cytomery", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I, Class II, and ICAM-1 molecules MAGE-A1, MAGE-A3, and NYESO-1,CT antigens antigens on sarcoma", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; ICAM-1 / CD54; Cancer-testis antigens; MAGE antigens;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/149", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "20381863", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "U937", "Dose": "200 nM", "Technique": "RT-PCR,, Western blot analysis, Elispot assays,Chromium release assay", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Cytotoxicity/release assay; ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "antigen-specific recognition by CD8+ T-cell clones cancer-testis (CT) antigens- NY-ESO-1, MAGEA1, MAGEA3 and MAGEB2 on cancer cell lines", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells; Antigen-specific recognition; Cancer-testis antigens; MAGE antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/363", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24162015", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Fibrosarcoma", "System": "MCA205", "Dose": "10, 20, 40 µM", "Technique": "cytoplasmic GFP-HMGB1 fluorescence intensit, immunostaining, immunofluorescence,western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 release", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/364", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "24162015", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U2OS", "Dose": "10, 20, 40 µM", "Technique": "cytoplasmic GFP-HMGB1 fluorescence intensit, immunostaining, immunofluorescence,western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 release", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/462", "Drug": "Decitabine (DAC)", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "DNMT1 trapping/inhibition → DNA hypomethylation; may reactivate previously silenced genes", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/666", "Drug": "Decitabine (DAC)", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "DNMT1 trapping/inhibition → DNA hypomethylation; may reactivate previously silenced genes", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "melanoma", "System": "B16F10", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/742", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00585", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "23202296", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "PBMCs from 13 patients", "Dose": null, "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-17A", "Controlled_Terms_Negative_Regulation": "IL-17 / IL-17A"}, {"ID": "CANIMM/775", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00587", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "23202296", "Cancer_Type": "Thymoma", "Cancer_Type_Description": "Thymoma", "System": "MDSCs of EL4 tumor–bearing mice", "Dose": null, "Technique": "`ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-1β secretion from MDSCs", "Controlled_Terms_Negative_Regulation": "IL-1 family; Myeloid-derived suppressor cells / MDSCs"}, {"ID": "CANIMM/776", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "23202296", "Cancer_Type": "Thymoma", "Cancer_Type_Description": "Thymoma", "System": "splenic MDSCs from EL4 tumor–bearing WT + naive CD4+CD62L+ T cells +IL-1Ra (10 nM)", "Dose": "(50 mg per kg body weight)", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-17 production by CD4+ T cells in an IL-1–dependent manner,", "Controlled_Terms_Negative_Regulation": "CD4; IL-1 family; IL-17 / IL-17A; T cells; CD4+ T cells"}, {"ID": "CANIMM/857", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00586", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "23202296", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "human MDSCs", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Caspase-1 activation in MDSC", "Controlled_Terms_Negative_Regulation": "Caspase-1; Caspase activation; Myeloid-derived suppressor cells / MDSCs"}, {"ID": "CANIMM/1618", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "28637493", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Squamous Cell Carcinoma (OSCC).", "System": "WSU-HN6", "Dose": "10 μM 5-FU", "Technique": "real-time qPCR + western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "pro-IL-1β in OSCC tissues NLRP3 in OSCC tissues", "Controlled_Terms_Negative_Regulation": "IL-1 family; NLRP3 inflammasome"}, {"ID": "CANIMM/1619", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "28637493", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Squamous Cell Carcinoma (OSCC).", "System": "CAL27", "Dose": "10 μM 5-FU", "Technique": "real-time qPCR + western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "pro-IL-1β in OSCC tissues NLRP3 in OSCC tissues", "Controlled_Terms_Negative_Regulation": "IL-1 family; NLRP3 inflammasome"}, {"ID": "CANIMM/823", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02374", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "19997099", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT116 (colon)+T cells were isolated from pathologically healthy donor buffy coats", "Dose": null, "Technique": "MTT assay.", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic T cells", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/879", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02373", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "19997099", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "A549 (lung)+T cells were isolated from pathologically healthy donor buffy coats", "Dose": null, "Technique": "MTT assay.", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic T cells", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/774", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "23202296", "Cancer_Type": "Thymoma", "Cancer_Type_Description": "Thymoma", "System": "MDSCs of EL4 tumor–bearing mice", "Dose": null, "Technique": "`ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-1β secretion from MDSCs", "Controlled_Terms_Negative_Regulation": "IL-1 family; Myeloid-derived suppressor cells / MDSCs"}, {"ID": "CANIMM/1053", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02370", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "26449615", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "HPAF-II lines", "Dose": "0.001 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICA/B", "Controlled_Terms_Function_enhanced_Number_increased": "MICA; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1054", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02369", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "26449615", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "PANC-1", "Dose": "0.001 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic activity of γδ T cells MICA/B", "Controlled_Terms_Function_enhanced_Number_increased": "MICA; Cytotoxicity / cytolysis; T cells; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1059", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02371", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "19997099", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "PC3 (prostate)", "Dose": "GEM (1 μm)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "Human leucocyte antigen class 1 on tumors", "Controlled_Terms_Unaffected": "HLA class I antigen", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/836", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "31776206", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Murine Mammary Cancer", "System": "human CD14+ monocytes from PBMCS", "Dose": "CM from GEM-treated human breast cancer (MDA-MB-231) cells", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD11b+CD14+CD33+ cells, (CD14+CD33+HLA-DRlow) GM-CSF", "Controlled_Terms_Function_enhanced_Number_increased": "CD11b / ITGAM; GM-CSF / CSF2", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/837", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "31776206", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Murine Mammary Cancer", "System": "Mouse E0771 cells", "Dose": "GEM (3–10 uM) + CM from nontreated E0771 cells", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "M-MDSC\n (CD11b+Ly6ChighLy6G-) GM-CSF PD-L1 and IDO1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; CD11b / ITGAM; GM-CSF / CSF2; IDO1/IDO; Myeloid-derived suppressor cells / MDSCs; PD-L1 immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/838", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02370", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "30733494", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "0.3 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "death receptor CD95 (fas) on live cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/853", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02369", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "30733494", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT116", "Dose": "0.6 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "death receptor CD95 (fas) on live cells kinases ERK and JNK", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; ERK / MAPK", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/854", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02369", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "26156960", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT116", "Dose": "1 μm", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA1 expression in tumour cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Expression / abundance phenotype; HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/855", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02369", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "19997099", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT116 (colon)", "Dose": "GEM (1 μm)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Human leucocyte antigen class 1 on tumors", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/893", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "24582211", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Cancer", "System": "SCCVII", "Dose": "(0–500 nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "induces apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/916", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "19997099", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Kidney", "System": "Caki2 (kidney)", "Dose": "GEM (1 μm)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "Human leucocyte antigen class 1 on tumors", "Controlled_Terms_Unaffected": "HLA class I antigen", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/953", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02373", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "26439264", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC(Lung)", "System": "RERF-LC-AI", "Dose": "1 or 10 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICA, MICB, and ULBP–2/5/6 on tumor cells- NKG2D ligands", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICA; MICB; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/954", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02373", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "29930882", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 (lung)", "Dose": "100 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "HLA-A,B,C", "Controlled_Terms_Function_inhibited_Number_decreased": "MHC class I; HLA-A", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/955", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02372", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "26439264", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC(Lung)", "System": "A549", "Dose": "1 or 10 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated cytotoxicity MHC class I molecules, MICA, and ULBP–2/5/6 on tumor cells- NKG2D ligands", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICA; Cytotoxicity / cytolysis; NK cells; NKG2D ligand; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/957", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02371", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "26156960", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung/Breast", "System": "Immature DCs +supernatants derived from A549 or MCF7 tumour cells", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T cells CD80, CD83 and CD86 on DCs", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; CD83; CD86; CD80/CD86 costimulation; T cells; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "natural killer (NK), T-cell and regulatory T-cell (T-reg)", "Controlled_Terms_Unaffected": "T cells; Regulatory T cells / Tregs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/960", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "30733494", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "A549", "Dose": "1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "death receptor CD95 (fas) on live cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/961", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "26156960", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "A549", "Dose": "1 μm", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA1 expression in tumour cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Expression / abundance phenotype; HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/962", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "19997099", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "A549 (lung)", "Dose": "GEM (1 μm)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Human leucocyte antigen class 1 on tumors", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1357", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "24128051", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC(Lung)", "System": "H292 cells", "Dose": "0·05 μm", "Technique": "real-time PCR + Western blot+Flow cytometry", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "lymphokine-activated killer (LAK) cells FasL expressionon tumor cells Gemcitabine induces apoptosis of mFasL-expressing H292 cells +induces caspase-8 and caspase-3 cleavage in H292 cells", "Controlled_Terms_Function_enhanced_Number_increased": "Fas ligand / FasL / FASLG; Caspase-3; Caspase-8; Caspase activation; Apoptosis; LAK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1543", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "30733494", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT116", "Dose": "100 nM", "Technique": "microarray", "Controlled_Technique": "Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "death receptor CD95 (fas) on live cells TRAILR1 and 2, and immune cell activatory NKG2D ligands, such as MICB and ULBP2 ,TNFRSF10D", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; NKG2D / KLRK1; ULBP2; MICB; TRAIL-R1 / DR4 / TNFRSF10A; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/607", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Ribonucleotide reductase inhibition; DNA synthesis inhibition; induces ICD", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Murine Lewis lung carcinoma (LLC)", "System": "LLC", "Dose": "2 µg/mL; 24 h", "Technique": "Western blot; flow cytometry; ELISA; apoptosis assay", "Controlled_Technique": "Increased CRT and HSP90; increased DC activation (CD11c+major histocompatibility complex (MHC)-II+), chemokines (CCL5, CXCL3, and CXCL10)", "Immune_System-Function_enhanced/numbers_increased": "CD11c / ITGAX; Calreticulin / CRT; Dendritic cells; CXCL10 / IP-10; CCL5 / RANTES", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/608", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Ribonucleotide reductase inhibition; DNA synthesis inhibition; induces ICD", "KEGG_Drug__ID": "D02368", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Murine CMT-64 lung cancer cell line", "System": "CMT-64", "Dose": "2 µg/mL; 24 h", "Technique": "Western blot; flow cytometry; apoptosis assay", "Controlled_Technique": "Increased CRT and HSP90; increased DC activation (CD11c+major histocompatibility complex (MHC)-II+), chemokines (CCL5, CXCL3, and CXCL10)", "Immune_System-Function_enhanced/numbers_increased": "CD11c / ITGAX; Calreticulin / CRT; Dendritic cells; CXCL10 / IP-10; CCL5 / RANTES", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1628", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02369", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "24128051", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC(Lung)", "System": "COLO 699", "Dose": "0·05 μm", "Technique": "real-time PCR + Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "FasL expressionon tumor cells Gemcitabine induces apoptosis of mFasL-expressing H292 cells", "Controlled_Terms_Function_enhanced_Number_increased": "Fas ligand / FasL / FASLG; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1629", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02370", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "24128051", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC(Lung)", "System": "16-HBE", "Dose": "0·05 μm", "Technique": "real-time PCR + Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "FasL expressionon tumor cells Gemcitabine induces apoptosis of mFasL-expressing H292 cells", "Controlled_Terms_Function_enhanced_Number_increased": "Fas ligand / FasL / FASLG; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/71", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug__ID": "D02370", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "29872551", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549", "Dose": "200 nM", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/632", "Drug": "CX-5461", "Drug_category": "Others/combination", "Drugbank_ID": "DB16846", "Target/s_or_mechanism_of_action": "Inhibits RNA polymerase I and rDNA transcription; induces nucleolar stress and DNA-damage response", "KEGG_Drug__ID": null, "Pubchem_ID": "12254622", "STR_LINK_(SMILES)": "CC1=NC=C(CNC(C2=C3N(C(C=CC=C4)=C4S3)C5=C(C=CC(N6CCCN(C)CC6)=N5)C2=O)=O)N=C1", "Single/Combination": "Single", "PMID": "41315184", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human multiple-myeloma cell line", "System": "RPMI-8226", "Dose": "200 nM, 48 h", "Technique": "Flow cytometry; NK-cell CD107a degranulation assay; Western blot; qPCR", "Controlled_Technique": "Increased expression of NK-activating ligands; increased HLA-ABC", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "HLA-E-mediated inhibition of NK-cell activity", "Immune_System-Function_inhibited/numbers_decreased": "NK cells", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "HLA-E upregulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1441", "Drug": "5-azacytidine and trichostatin A (TSA)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00928, DB04297", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.\n TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444, 444732", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,\n C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Combination", "PMID": "17725605", "Cancer_Type": "Hpv16-Expressing Tumors", "Cancer_Type_Description": "Human Papilloma Virus 16-Associated Tumours", "System": "TC-1/A9 (MHC class I-deficient)", "Dose": "50 µm 5-azaC and 10 ng/ml TSA", "Technique": "Flow cytometry, quantitative real-time RT-PCR,Western blot analysis", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC class I molecules apoptosis,APM genes, namely TAP-2 and LMP-7", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Apoptosis; Antigen presentation; TAP2; LMP7 / PSMB8;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/912", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat) and Rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB00073", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993, \n D02994", "Pubchem_ID": "12136798, 46505820", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "Su-DHL-6", "Dose": "10 µg/ml Rituximab,5, 10, 20 and 40 µM Chidamide", "Technique": "MTT test", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/940", "Drug": "5-azacytidine+BI 836858, a fully human, Fc-engineered, anti-CD33 antibody", "Drug_category": "Others/combination", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "27013443", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "primary AML blasts+autologous NK-cell", "Dose": "5-azacytidine (2 µM)+ BI 836858 or BI 836847 (10 μg/mL)", "Technique": "Flow cytometry, ADCC assay", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK-cell activation-natural killer ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/941", "Drug": "5-azacytidine+BI 836858, a fully human, Fc-engineered, anti-CD33 antibody", "Drug_category": "Others/combination", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "27013443", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "primary AML blasts +allogenic NK-cell", "Dose": "5-azacytidine (2 µM)+ BI 836858 or BI 836847 (10 μg/mL)", "Technique": "Flow cytometry, ADCC assay", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK-cell activation-natural killer ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1057", "Drug": "5-fluorouracil (5-FU)+IFN-a", "Drug_category": "Others/combination", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D00584", "Pubchem_ID": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "25368252", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "Panc02 cells", "Dose": "5-FU (10 mM)+IFN-a (1000 IU/mL).", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "major histocompatibility complex class I and NKG2D ligands on tumor", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; NKG2D / KLRK1; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/752", "Drug": "7A7", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "D122-reactive CD8+ T cells were incubated with D122", "Dose": "(1 μg/ml, 96 h)", "Technique": "ELISA,vitro lactate dehydrogenase assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells-mediated lysis. IFN-γ production by D122-specific CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; IFN-γ; Cytotoxicity / cytolysis; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/841", "Drug": "7A7 a surrogate antibody that recognizes murine EGFR", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Mama", "System": "4T1", "Dose": "1 μg/ml", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-I expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/860", "Drug": "7A7 a surrogate antibody that recognizes murine EGFR", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "CT26", "Dose": "1 μg/ml", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-I expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1315", "Drug": "7A7 a surrogate antibody that recognizes murine EGFR", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Mama", "System": "F3II", "Dose": "1 μg/ml", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC-I expression, H-2K and H-2D β2-m, LMP subunits, PA28α, BLH, TAPs, ERAAP1, tapasin, calnexin, calreticulin, PDI, as well as ERp57", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Tapasin; Calnexin; Calreticulin / CRT; ERp57 / PDIA3; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1328", "Drug": "7A7 a surrogate antibody that recognizes murine EGFR", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "D122", "Dose": "1 μg/ml", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC-I expression, H-2K and H-2D β2-m, LMP subunits, PA28α, BLH, TAPs, ERAAP1, tapasin, calnexin, calreticulin, PDI, as well as ERp57", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Tapasin; Calnexin; Calreticulin / CRT; ERp57 / PDIA3; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/726", "Drug": "Afatinib followed by Trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB08916, DB00072", "Target/s_or_mechanism_of_action": "Afatinib is a potent and selective, irreversible ErbB family blocker. Afatinib covalently binds to and irreversibly blocks signaling from all homo and heterodimers formed by the ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4.\n Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D09724, D03257", "Pubchem_ID": "10184653,\n 46507516", "STR_LINK_(SMILES)": "CN(C)C\\C=C\\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1", "Single/Combination": "Combination", "PMID": "28735814", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SKBR3", "Dose": "Afatinib 2 μM concentration and a 48 h timepoint for TKI exposure", "Technique": "High content analysis, LDH-release ADCC assays", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay; LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "decreased HER2 levels in SKBR3 (afatinib 0.8 ± 0.1 fold)", "Controlled_Terms_Function_inhibited_Number_decreased": "HER2 / ERBB2; Expression / abundance phenotype", "Immune_System_function_unaffected": "trastuzumab-mediated ADCC", "Controlled_Terms_Unaffected": "ADCC; Antibody-dependent cytotoxicity", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/727", "Drug": "Afatinib followed by Trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB08916, DB00072", "Target/s_or_mechanism_of_action": "Afatinib is a potent and selective, irreversible ErbB family blocker. Afatinib covalently binds to and irreversibly blocks signaling from all homo and heterodimers formed by the ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4.\n Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D09724, D03257", "Pubchem_ID": "10184653,\n 46507516", "STR_LINK_(SMILES)": "CN(C)C\\C=C\\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1", "Single/Combination": "Combination", "PMID": "28735814", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "Afatinib 2 μM concentration and a 48 h timepoint for TKI exposure", "Technique": "High content analysis, LDH-release ADCC assays", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay; LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "decreased HER2 levels in SKBR3 (afatinib 0.7 ± 0.2 fold)", "Controlled_Terms_Function_inhibited_Number_decreased": "HER2 / ERBB2; Expression / abundance phenotype", "Immune_System_function_unaffected": "trastuzumab-mediated ADCC", "Controlled_Terms_Unaffected": "ADCC; Antibody-dependent cytotoxicity", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/932", "Drug": "Anti-CD3 5 ug/mL+ trametinib 10 nM", "Drug_category": "Others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "31648326", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "CD3+CD8+ cells from AML mice", "Dose": "anti-CD3 5 ug/mL+ trametinib 10 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD44+CD62L–,", "Controlled_Terms_Function_enhanced_Number_increased": "CD44", "Immune_System-Function_inhibited/numbers_decreased": "CD44–CD62L+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD44", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/736", "Drug": "Anti-PD-1 and romidepsin", "Drug_category": "Others/combination", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Combination", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "LKR + tumor CD8 and CD4 T cells", "Dose": null, "Technique": "ELISPOT assay", "Controlled_Technique": "ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "CD8 and CD4 cells that produce IFNγ IFNγ", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/84", "Drug": "Apicidin", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Apicidin is a fungal metabolite, as well as a histone deacetylase inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "6918328", "STR_LINK_(SMILES)": "CC[C@H](C)[C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC3=CN(C4=CC=CC=C43)OC)CCCCCC(=O)CC", "Single/Combination": "Single Drug", "PMID": "28167529", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SKOV3", "Dose": "0-10 μm", "Technique": "real-time RT-PCR analysis", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Negative_Regulation": "IL-8 / CXCL8; IL-8/CXCL8"}, {"ID": "CANIMM/933", "Drug": "Azacitidine (AZA) in combination with allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "29138222", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "THP-1 +allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Dose": "0.1 to 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell–mediated killing", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/935", "Drug": "Azacitidine (AZA) in combination with allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "29138222", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "KG1a cells+allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Dose": "0.1 to 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell–mediated killing", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/936", "Drug": "Azacitidine (AZA) in combination with allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00928", "Target/s_or_mechanism_of_action": "As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D03021", "Pubchem_ID": "9444", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "29138222", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "Primary AML cells obtained from 5 different patients +HSPC-NK cells", "Dose": "1 µM AZA", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell–mediated killing", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1226", "Drug": "AZD1480", "Drug_category": "Others/combination", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Combination", "PMID": "21164517", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Myeloma", "System": "U266", "Dose": "0.5 - 3 μM AZD1480, IL-6 4ng/ml", "Technique": "Flow cytometry using Annexin V/Propidium Iodide staining", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "AZD1480 induces apoptosis of myeloma cells growth stimulated by IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1227", "Drug": "AZD1480", "Drug_category": "Others/combination", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Combination", "PMID": "21164517", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Myeloma", "System": "Kms.11", "Dose": "0.5 - 3 μM AZD1480, IL-6 4ng/ml", "Technique": "Flow cytometry using Annexin V/Propidium Iodide staining", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "AZD1480 induces apoptosis of myeloma cells growth stimulated by IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1519", "Drug": "AZD1480", "Drug_category": "Others/combination", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Combination", "PMID": "25216185", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116", "Dose": "0 - 5 μM AZD1480, IL-6 4ng/ml", "Technique": "western blot analysis, Flow cytometry using Annexin V/Propidium Iodide staining", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "IL-6-inducible JAK2/STAT3 signaling", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; IL-6/JAK/STAT3 signaling; STAT3; JAK2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1520", "Drug": "AZD1480", "Drug_category": "Others/combination", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Combination", "PMID": "25216185", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HT29", "Dose": "0 - 5 μM AZD1480, IL-6 4ng/ml", "Technique": "western blot analysis, Flow cytometry using Annexin V/Propidium Iodide staining", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "IL-6-inducible JAK2/STAT3 signaling", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; IL-6/JAK/STAT3 signaling; STAT3; JAK2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1521", "Drug": "AZD1480", "Drug_category": "Others/combination", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug__ID": null, "Pubchem_ID": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Combination", "PMID": "25216185", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "SW480", "Dose": "0 - 5 μM AZD1480, IL-6 4ng/ml", "Technique": "western blot analysis, Flow cytometry using Annexin V/Propidium Iodide staining", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "IL-6-inducible JAK2/STAT3 signaling", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; IL-6/JAK/STAT3 signaling; STAT3; JAK2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/315", "Drug": "AZD6244 (MEKi) and BMS-345541 (IKKi)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Combination", "PMID": "25256614", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "WM266-4", "Dose": "1μM AZD6244 (MEKi) and 0.5μM BMS-345541 (IKKi)", "Technique": "Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cleavage of caspase3- apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/316", "Drug": "AZD6244 (MEKi) and BMS-345541 (IKKi)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Combination", "PMID": "25256614", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "1μM AZD6244 (MEKi) and 0.5μM BMS-345541 (IKKi)", "Technique": "Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cleavage of caspase3- apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/317", "Drug": "AZD6244 (MEKi) and BMS-345541 (IKKi)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Combination", "PMID": "25256614", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "BRafV600E-4434 melanoma cells", "Dose": "0.5μM AZD6244 (MEKi) and 0.1μM BMS-345541 (IKKi)", "Technique": "Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cleavage of caspase3- apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/318", "Drug": "AZD6244 (MEKi)/selumetinib and BMS-345541 (IKKi)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug__ID": "D09666", "Pubchem_ID": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Combination", "PMID": "25256614", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "501mel human melanoma cells", "Dose": "1μM AZD6244 (MEKi) and 0.5μM BMS-345541 (IKKi)", "Technique": "Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cleavage of caspase3- apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/751", "Drug": "B7-H3 × CD3 BiAb with MEK inhibitor trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "32984002", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small-Cell Lung Cancer (NSCLC) And Bladder Cancer (BC)", "System": "A549, H460, T24", "Dose": "BiAb 5μg/mL.", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/965", "Drug": "B7-H3 × CD3 BiAb with MEK inhibitor trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "32984002", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small-Cell Lung Cancer (NSCLC) And Bladder Cancer (BC)", "System": "H460, T24", "Dose": "BiAb 5μg/mL+ 10μM trametinib+ T cell", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD25, CD69", "Controlled_Terms_Function_enhanced_Number_increased": "CD25 / IL2RA; CD69", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4+/CD8+ T\n cells", "Controlled_Terms_Unaffected": "CD4; CD8; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/260", "Drug": "B7-H3 × CD3 BiAb with MEK inhibitor trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "32984002", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small-Cell Lung Cancer (NSCLC) And Bladder Cancer (BC)", "System": "A549, H460, T24", "Dose": "10μM trametinib", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "B7-H3 expression", "Controlled_Terms_Function_enhanced_Number_increased": "B7-H3 / CD276; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "Posphorylated MEK", "Controlled_Terms_Function_inhibited_Number_decreased": "MEK phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/636", "Drug": "Belantamab mafodotin (GSK2857916)", "Drug_category": "Others/combination", "Drugbank_ID": "DB15719", "Target/s_or_mechanism_of_action": "Binds BCMA (TNFRSF17) on multiple myeloma cells; delivers MMAF, inducing apoptosis. Promotes immunogenic cell death (ICD), DAMP release, and dendritic-cell maturation.", "KEGG_Drug__ID": "D11595", "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "34253590", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human BCMA-positive NCI-H929 cells; human monocyte-derived immature dendritic cells used in co-culture experiments", "System": "NCI-H929 cells", "Dose": "0.1, 1, and 10 µg/mL; tumor cells treated for 48 h, followed by 24 h dendritic-cell co-culture", "Technique": "Flow cytometry; ELISA; extracellular ATP assay; immunoblotting", "Controlled_Technique": "calreticulin, HMGB1 and ATP release, HSP70/HSP90-associated signals, IL-8 release, and dendritic-cell maturation markers CD40, CD83, and CD86; increased PERK/eIF2α phosphorylation and BAP31 cleavage", "Immune_System-Function_enhanced/numbers_increased": "CD83; CD86; HMGB1; Calreticulin / CRT; IL-8 / CXCL8; CD40", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/634", "Drug": "BMH-21", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits RNA polymerase I, promotes degradation of the RPA194 subunit and induces nucleolar stress", "KEGG_Drug__ID": null, "Pubchem_ID": "3508054", "STR_LINK_(SMILES)": "CN(C)CCNC(=O)C1=CC=CN2C1=NC3=CC4=CC=CC=C4C=C3C2=O", "Single/Combination": "Single", "PMID": "41315184", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human multiple-myeloma cell line", "System": "RPMI-8226", "Dose": "400 nM, 48 h", "Technique": "Flow cytometry for HLA-E, HLA-ABC, CD38; NK-cell degranulation and ADCC assays", "Controlled_Technique": "Enhanced NK-cell activation", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D (an activating receptor) and TIGIT (an inhibitory receptor)", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "NR", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "No significant HLA-E upregulation reported under the tested conditions", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/633", "Drug": "BMH-21", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits RNA polymerase I, promotes degradation of the RPA194 subunit and induces nucleolar stress", "KEGG_Drug__ID": null, "Pubchem_ID": "3508054", "STR_LINK_(SMILES)": "CN(C)CCNC(=O)C1=CC=CN2C1=NC3=CC4=CC=CC=C4C=C3C2=O", "Single/Combination": "Single", "PMID": "41315184", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human multiple-myeloma cell line", "System": "SKO-007(J3)", "Dose": "400 nM, 48 h", "Technique": "Flow cytometry; NK-cell CD107a degranulation assay; IFN-γ/TNF-α measurement; Western blot; qPCR", "Controlled_Technique": "Increased NK-cell degranulation; increased IFN-γ and TNF-α production; increased NK-activating ligand expression", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ; Degranulation; TNF-α / TNF; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D (an activating receptor) and TIGIT (an inhibitory receptor)", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "No significant HLA-E upregulation reported under the tested conditions", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/275", "Drug": "Bortezomib +mocetinostat (mgcd0103)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00188, DB11830", "Target/s_or_mechanism_of_action": "Bortezomib is a reversible inhibitor of the 26S proteasome, which is made up of a 20S core complexed with a 19S regulatory complex. Individual β-subunits allow specific catalytic action of the 20S core.\n Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D03150, D09641", "Pubchem_ID": "387447, 9865515", "STR_LINK_(SMILES)": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,\n NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Combination", "PMID": "20880107", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Hodgkin Lymphoma", "System": "HD-LM2(of T cell origin)", "Dose": "MGCD0103 (1 μmol/l), bortezomib (20 nmol/l)", "Technique": "Western blot, Flow cyto metry", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "induction of apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "NF-kB activation", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB activation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/276", "Drug": "Bortezomib +mocetinostat (mgcd0103)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00188, DB11830", "Target/s_or_mechanism_of_action": "Bortezomib is a reversible inhibitor of the 26S proteasome, which is made up of a 20S core complexed with a 19S regulatory complex. Individual β-subunits allow specific catalytic action of the 20S core.\n Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D03150, D09641", "Pubchem_ID": "387447, 9865515", "STR_LINK_(SMILES)": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,\n NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Combination", "PMID": "20880107", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Hodgkin Lymphoma", "System": "L428 (of B cell origin)", "Dose": "MGCD0103 (1 μmol/l), bortezomib (20 nmol/l)", "Technique": "Western blot, Flow cyto metry", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "induction of apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "NF-kB activation", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB activation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/277", "Drug": "Bortezomib +mocetinostat (mgcd0103)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00188, DB11830", "Target/s_or_mechanism_of_action": "Bortezomib is a reversible inhibitor of the 26S proteasome, which is made up of a 20S core complexed with a 19S regulatory complex. Individual β-subunits allow specific catalytic action of the 20S core.\n Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor", "KEGG_Drug__ID": "D03150, D09641", "Pubchem_ID": "387447, 9865515", "STR_LINK_(SMILES)": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,\n NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "Single/Combination": "Combination", "PMID": "20880107", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Hodgkin Lymphoma", "System": "KMH2(of B cell origin)", "Dose": "MGCD0103 (1 μmol/l), bortezomib (20 nmol/l)", "Technique": "Western blot, Flow cyto metry", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "induction of apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "NF-kB activation", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB activation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1589", "Drug": "Cetuximab + ALT-803 ( genetically modified IL-15 plus the IL-15 receptor alpha protein (IL15Rα) fused to the Fc portion of IgG1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31338557", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "Cal27 +Purifed human CD56+ NK cells incubated overnight stimulated with ALT-803 (10 ng/ml)", "Dose": "100 μg/ml cetuximab", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/668", "Drug": "Bortezomib( a proteasome inhibitor) and SAHA( Vorinostat)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00188, DB02546", "Target/s_or_mechanism_of_action": "Bortezomib is a reversible inhibitor of the 26S proteasome, which is made up of a 20S core complexed with a 19S regulatory complex. Individual β-subunits allow specific catalytic action of the 20S core.\n Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D03150,D06320", "Pubchem_ID": "387447, 5311", "STR_LINK_(SMILES)": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "25591912", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical Cancer", "System": "Luciferase-expressing TC-1 tumor cells +HPV16 E7-specific CTLs", "Dose": "bortezomib (3.5 nM) and SAHA (12.5 μM) for 24 h", "Technique": "IVIS luminescence imaging system for Bioluminescence signals-quantification of luminescence intensity", "Controlled_Technique": "Bioluminescence/luciferase assay; Bioluminescence/luciferase assay", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cell-mediated cytotoxicity.", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Cytotoxicity / cytolysis; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1480", "Drug": "BRAFi PLX4720+ IFNy", "Drug_category": "Others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "3601R", "Dose": "BRAFi PLX4720 10μM) +mIFN-y (200ng/ml)", "Technique": "FACS, western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1625", "Drug": "BRAFi PLX4720+ IFNy", "Drug_category": "Others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "8505c", "Dose": "BRAFi PLX4720 (10μM )+hIFN-y (500U/ml)", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression and mRNA exxpression phospho ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; ERK / MAPK; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1626", "Drug": "BRAFi PLX4720+ IFNy", "Drug_category": "Others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "BCPAP", "Dose": "BRAFi PLX4720 (10μM )+hIFN-y (500U/ml)", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression and mRNA exxpression phospho ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; ERK / MAPK; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1627", "Drug": "BRAFi PLX4720+ IFNy", "Drug_category": "Others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "SW1736", "Dose": "BRAFi PLX4720 (10μM )+hIFN-y (500U/ml)", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/85", "Drug": "Carboplatin +paclitaxel", "Drug_category": "Others/combination", "Drugbank_ID": "DB00958, DB01229", "Target/s_or_mechanism_of_action": "1. Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules within the cell. 2.Pacilitaxel-Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "1. D01363, 2. D00491", "Pubchem_ID": "38904, 36314", "STR_LINK_(SMILES)": "carboplatin-[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], pacilitaxel- [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Combination", "PMID": "20683396", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SKOV-3", "Dose": null, "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Macrophage chemoattractant protein-1 (MCP-1)", "Controlled_Terms_Negative_Regulation": "CCL2 / MCP-1; Macrophages"}, {"ID": "CANIMM/840", "Drug": "Carboplatin and a taxane", "Drug_category": "Others/combination", "Drugbank_ID": "DB00958", "Target/s_or_mechanism_of_action": "Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules within the cell.", "KEGG_Drug__ID": "D01363", "Pubchem_ID": "38904", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]", "Single/Combination": "Combination", "PMID": "29500278", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-231 TNBC cells or BT474 HER2+ Breast cancer cells +post-NT patient sera", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "ALDEFLUOR+ (% of MDA-MB-231) and ESA+CD44+CD24−/low (% of BT474)-)-cancer stem-like cell (CSC) phenotype and contributing to tumor relapse", "Controlled_Terms_Negative_Regulation": "CD44; ALDEFLUOR-positive cells"}, {"ID": "CANIMM/19", "Drug": "Celecoxib", "Drug_category": "Others/combination", "Drugbank_ID": "DB00482", "Target/s_or_mechanism_of_action": "celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme.", "KEGG_Drug__ID": "D00567", "Pubchem_ID": "2662", "STR_LINK_(SMILES)": "CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F", "Single/Combination": "Single Drug", "PMID": "27926489", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "System": "769-p", "Dose": null, "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "granulocyte-macrophage colony stimulating factor (GM-CSF)", "Controlled_Terms_Function_inhibited_Number_decreased": "GM-CSF / CSF2; Macrophages; Granulocytes", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/20", "Drug": "Celecoxib and sunitinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB00482, DB01268", "Target/s_or_mechanism_of_action": "celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme. \n sunitinib Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D00567,D06402", "Pubchem_ID": "2662, 5329102", "STR_LINK_(SMILES)": "CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,\n CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "27926489", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "System": "769-p", "Dose": null, "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "granulocyte-macrophage colony stimulating factor (GM-CSF)", "Controlled_Terms_Function_inhibited_Number_decreased": "GM-CSF / CSF2; Macrophages; Granulocytes", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/900", "Drug": "CEP32496", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Medullary Carcinoma", "System": "TT cells", "Dose": "CEP32496(0-100nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/966", "Drug": "CEP32496", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung - Human Lung Adenocarcinoma", "System": "LC-2/ad", "Dose": "CEP32496(0-100nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1536", "Drug": "Cetuximab + (STING)-The intracellular DNA sensor stimulator of interferon genes", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "29496049", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "iDC+ NK + PCI15B", "Dose": "cetuximab (10ug/ml), cGAMP (10 ug/ml)-a STING activator", "Technique": "Western Blot,Flow cytometry,ELISA", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "DC maturation and NK activation phosphorylation of IRF3, IFNγ CD86, CD83 and HLA-DR and PD-L1 expression on DCs", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class II; HLA-DR; CD83; CD86; IFN-γ; Dendritic cells; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; IRF3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/201", "Drug": "Cetuximab + (STING)-The intracellular DNA sensor stimulator of interferon genes", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "29496049", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "iDC+ NK + JHU029", "Dose": "cetuximab (10ug/ml), cGAMP (10 ug/ml)-a STING activator", "Technique": "Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "phosphorylation of IRF3", "Controlled_Terms_Function_enhanced_Number_increased": "IRF3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1600", "Drug": "Cetuximab + ALT-803 ( genetically modified IL-15 plus the IL-15 receptor alpha protein (IL15Rα) fused to the Fc portion of IgG1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31338557", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCC2 + Purifed human CD56+ NK cells incubated overnight stimulated with ALT-803 (10 ng/ml)", "Dose": "100 μg/ml cetuximab", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1611", "Drug": "Cetuximab + ALT-803 ( genetically modified IL-15 plus the IL-15 receptor alpha protein (IL15Rα) fused to the Fc portion of IgG1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31338557", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCC47 + Purifed human CD56+ NK cells incubated overnight stimulated with ALT-803 (10 ng/ml)", "Dose": "100 μg/ml cetuximab", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/371", "Drug": "Cetuximab + GILF regimen (Gem, Iri, Levofolinic acid and 5-FU)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441\n DB00762\n DB11596\n DB00544\n DB00002", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase,\n Irinotecan inhibits the action of topoisomerase I,\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects,\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA,\n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D02368,D08086, D04715, D00584, D03455", "Pubchem_ID": "60750, 60838, 149436, 3385, 46507042", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, \n CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "HT29 cells rteated with drugs + IL-2-activated human PBMCs +cetuximab", "Dose": "gemcitabine at final concentration of 50 lg/ml +, levofolinic acid was added at a concentration of\n 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/372", "Drug": "Cetuximab + GILF regimen (Gem, Iri, Levofolinic acid and 5-FU)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441\n DB00762\n DB11596\n DB00544\n DB00002", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase,\n Irinotecan inhibits the action of topoisomerase I,\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects,\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA,\n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D02368,D08086, D04715, D00584, D03455", "Pubchem_ID": "60750, 60838, 149436, 3385, 46507042", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, \n CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "WiDr cells treated with drugs + IL-2-activated human PBMCs +cetuximab", "Dose": "gemcitabine at final concentration of 50 lg/ml +, levofolinic acid was added at a concentration of\n 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/373", "Drug": "Cetuximab + GILF regimen (Gem, Iri, Levofolinic acid and 5-FU)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441\n DB00762\n DB11596\n DB00544\n DB00002", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase,\n Irinotecan inhibits the action of topoisomerase I,\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects,\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA,\n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D02368,D08086, D04715, D00584, D03455", "Pubchem_ID": "60750, 60838, 149436, 3385, 46507042", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, \n CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "SW620 cells treated wirh drugs + IL-2-activated human PBMCs +Cetuximab", "Dose": "gemcitabine at final concentration of 50 lg/ml +, levofolinic acid was added at a concentration of\n 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1240", "Drug": "Cetuximab + IL-12", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "22770960", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-SCC47 + Purified NK cells were incubated overnight with IL-12", "Dose": "IL-12 (10 ng/mL),100 ug/mL of cetuximab", "Technique": "Cr-51 release assay,Flow cytometry", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC of NK cells p-ERK activation", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/923", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat) and Rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB00073", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993, \n D02994", "Pubchem_ID": "12136798, 46505820", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "Su-DHL-8", "Dose": "10 µg/ml Rituximab, 2, 4, 8 and 16 µM Chidamide", "Technique": "MTT test", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/374", "Drug": "Cetuximab + GILF regimen (Gem, Iri, Levofolinic acid and 5-FU)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441\n DB00762\n DB11596\n DB00544\n DB00002", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase,\n Irinotecan inhibits the action of topoisomerase I,\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects,\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA,\n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D02368,D08086, D04715, D00584, D03455", "Pubchem_ID": "60750, 60838, 149436, 3385, 46507042", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, \n CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "LoVo cells treated wirh drugs + IL-2-activated human PBMCs +Cetuximab", "Dose": "gemcitabine at final concentration of 50 lg/ml +, levofolinic acid was added at a concentration of\n 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/375", "Drug": "Cetuximab + IFL (irinotecan + 5-fluoruracil + levofolinic acid)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB00762, DB11596, DB00544", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR., Irinotecan inhibits the action of topoisomerase I\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D03455, D08086, D04715, D00584", "Pubchem_ID": "46507042, 60838, 149436, 3385", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "HT29 cells rteated with drugs + IL-2-activated human PBMCs +cetuximab", "Dose": "levofolinic acid was added at a concentration of 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/376", "Drug": "Cetuximab + IFL (irinotecan + 5-fluoruracil + levofolinic acid)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB00762, DB11596, DB00544", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR., Irinotecan inhibits the action of topoisomerase I\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D03455, D08086, D04715, D00584", "Pubchem_ID": "46507042, 60838, 149436, 3385", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "WiDr cells treated with drugs + IL-2-activated human PBMCs +cetuximab", "Dose": "levofolinic acid was added at a concentration of 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/377", "Drug": "Cetuximab + IFL (irinotecan + 5-fluoruracil + levofolinic acid)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB00762, DB11596, DB00544", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR., Irinotecan inhibits the action of topoisomerase I\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D03455, D08086, D04715, D00584", "Pubchem_ID": "46507042, 60838, 149436, 3385", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "SW620 cells treated wirh drugs + IL-2-activated human PBMCs +Cetuximab", "Dose": "levofolinic acid was added at a concentration of 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/378", "Drug": "Cetuximab + IFL (irinotecan + 5-fluoruracil + levofolinic acid)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB00762, DB11596, DB00544", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR., Irinotecan inhibits the action of topoisomerase I\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D03455, D08086, D04715, D00584", "Pubchem_ID": "46507042, 60838, 149436, 3385", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "SW620 cells treated wirh drugs + IL-2-activated human PBMCs +Cetuximab", "Dose": "levofolinic acid was added at a concentration of 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/529", "Drug": "Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "12000240", "STR_LINK_(SMILES)": "C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "CTIAC11", "Dose": "10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Little IFN-β induction alone", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1241", "Drug": "Cetuximab + IL-12", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "22770960", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "Cal27+ Purified NK cells were incubated overnight with IL-12", "Dose": "IL-12 (10 ng/mL),100 ug/mL of cetuximab", "Technique": "Cr-51 release assay,Flow cytometry", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC of NK cells p-ERK activation", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1242", "Drug": "Cetuximab + IL-12", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "22770960", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-SCC74B+ + Purified NK cells were incubated overnight with IL-12", "Dose": "IL-12 (10 ng/mL),100 ug/mL of cetuximab", "Technique": "Cr-51 release assay,Flow cytometry", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC of NK cells p-ERK activation", "Controlled_Terms_Function_enhanced_Number_increased": "ERK / MAPK; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/787", "Drug": "Cetuximab + IL-2, IL-12, or IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "17962339", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Human Breast Adenocarcinoma", "System": "SKBR3 + Purified human NK were incubated overnight in medium supplemented with 0.1 nmol/L IL-2, 10 ng/mL IL-12, or 10 ng/mL IL-21.", "Dose": "100 ug/mL of cetuximab", "Technique": "ELISA, chromium release assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell IFN-γ,NK cell ADCC against cetuximab-treated human cancer cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/788", "Drug": "Cetuximab + IL-2, IL-12, or IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "17962339", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Human Breast Adenocarcinoma", "System": "MDA-MB-468+Purified human NK were incubated overnight in medium supplemented with 0.1 nmol/L IL-2, 10 ng/mL IL-12, or 10 ng/mL IL-21.", "Dose": "100 ug/mL of cetuximab", "Technique": "ELISA, chromium release assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell IFN-γ,NK cell ADCC against cetuximab-treated human cancer cells, chemotaxis of naive\n and activated T cells IFN-γ,IL-8, RANTES, macrophage inflammatory protein-a, and\n macrophage inflammatory protein-1h", "Controlled_Terms_Function_enhanced_Number_increased": "IL-8 / CXCL8; IFN-γ; CCL5 / RANTES; IL-8/CXCL8; ADCC; T cells; NK cells; Macrophages; Antibody-dependent cytotoxicity; T-cell migration / chemotaxis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/793", "Drug": "Cetuximab + IL-2, IL-12, or IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "17962339", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non – Small Cell Lung Carcinoma", "System": "H460 +Purified human NK were incubated overnight in medium supplemented with 0.1 nmol/L IL-2, 10 ng/mL IL-12, or 10 ng/mL IL-21.", "Dose": "100 ug/mL of cetuximab", "Technique": "ELISA, chromium release assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell IFN-γ,NK cell ADCC against cetuximab-treated human cancer cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/794", "Drug": "Cetuximab + IL-2, IL-12, or IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "17962339", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non – Small Cell Lung Carcinoma", "System": "A549+Purified human NK were incubated overnight in medium supplemented with 0.1 nmol/L IL-2, 10 ng/mL IL-12, or 10 ng/mL IL-21.", "Dose": "100 ug/mL of cetuximab", "Technique": "ELISA, chromium release assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell IFN-γ,NK cell ADCC against cetuximab-treated human cancer cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/795", "Drug": "Cetuximab + IL-2, IL-12, or IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "17962339", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "BxPC3 +Purified human NK were incubated overnight in medium supplemented with 0.1 nmol/L IL-2, 10 ng/mL IL-12, or 10 ng/mL IL-21.", "Dose": "100 ug/mL of cetuximab", "Technique": "ELISA, chromium release assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell IFN-γ,NK cell ADCC against cetuximab-treated human cancer cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/796", "Drug": "Cetuximab + IL-2, IL-12, or IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "17962339", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "HPAC+Purified human NK were incubated overnight in medium supplemented with 0.1 nmol/L IL-2, 10 ng/mL IL-12, or 10 ng/mL IL-21.", "Dose": "100 ug/mL of cetuximab", "Technique": "ELISA, chromium release assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell IFN-γ,NK cell ADCC against cetuximab-treated human cancer cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/797", "Drug": "Cetuximab + IL-2, IL-12, or IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "17962339", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "PANC-1 + Purified human NK were incubated overnight in medium supplemented with 0.1 nmol/L IL-2, 10 ng/mL IL-12, or 10 ng/mL IL-21.", "Dose": "100 ug/mL of cetuximab", "Technique": "ELISA, chromium release assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell IFN-γ,NK cell ADCC against cetuximab-treated human cancer cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1478", "Drug": "Cetuximab + IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27435400", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT-116 MUT (mutKRAS)++ Purified human NK cells +10 ng/ml IL-21", "Dose": null, "Technique": "chromium release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1489", "Drug": "Cetuximab + IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27435400", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT-116 WT (wtKRAS)++ Purified human NK cells +10 ng/ml IL-21", "Dose": null, "Technique": "chromium release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/313", "Drug": "Cetuximab + IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27435400", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Adenocarcinoma", "System": "AsPc1-KRAS mutant +Purified NK cells from patients with pancreatic adenocarcinoma in medium supplemented with 10 ng/ml IL-21", "Dose": null, "Technique": "chromium release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/798", "Drug": "Cetuximab + IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27435400", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic - Human Pancreatic Adenocarcinoma", "System": "Panc-1+ Purified human NK cells +10 ng/ml IL-21", "Dose": null, "Technique": "chromium release assay,ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/799", "Drug": "Cetuximab + IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27435400", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic - Human Pancreatic Adenocarcinoma", "System": "MiaPaCa2 + Purified human NK cells +10 ng/ml IL-21", "Dose": null, "Technique": "chromium release assay,ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC,NK cell IFN-γ production IFN-γ ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1285", "Drug": "Cetuximab + IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27435400", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic - Human Pancreatic Adenocarcinoma", "System": "AsPc1+ Purified human NK cells +10 ng/ml IL-21", "Dose": null, "Technique": "chromium release assay,ELISA,Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC,NK cell IFN-γ production , migration of T cells IFN-γ,IL-8, MIP-1α, MIP-1β, and RANTES ADCC,phosphorylation of ERK and STAT1, respectively, within NK cells-NK cell signal transduction via activation of ERK and STAT1", "Controlled_Terms_Function_enhanced_Number_increased": "IL-8 / CXCL8; IFN-γ; CCL3 / MIP-1α; CCL4 / MIP-1β; CCL5 / RANTES; IL-8/CXCL8; STAT1; ERK / MAPK; ADCC; T cells; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1286", "Drug": "Cetuximab + IL-21", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27435400", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic - Human Pancreatic Adenocarcinoma", "System": "BxPc3 + Purified human NK cells +10 ng/ml IL-21", "Dose": null, "Technique": "chromium release assay,ELISA,Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated ADCC,NK cell IFN-γ production ,migration of T cells IFN-γ ADCC,phosphorylation of ERK and STAT1, respectively, within NK cells-NK cell signal transduction via activation of ERK and STAT1", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; STAT1; ERK / MAPK; ADCC; T cells; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/899", "Drug": "Cetuximab + ipilimumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB06186", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.", "KEGG_Drug__ID": "D03455, D04603", "Pubchem_ID": "46507042, 347910341", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "25832655", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "JHU029- labeled with CFSE +peipheral NK cells + intratumoral Treg", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/902", "Drug": "Cetuximab + motolimod", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB12303", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR. Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042, 16049404", "STR_LINK_(SMILES)": "CCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C1=CC=C(C=C1)C(=O)N1CCCC1", "Single/Combination": "Combination", "PMID": "29061643", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UPCI:SCC090 cell cocultured with CD14+ monocytes from HNSCC patients", "Dose": "Cetuximab (10ug/ml) and motolimod (250nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD86 (an M1 marker)", "Controlled_Terms_Function_enhanced_Number_increased": "CD86", "Immune_System-Function_inhibited/numbers_decreased": "myeloid-derived suppressor cell (MDSC) CD163 (M2 marker),CD16", "Controlled_Terms_Function_inhibited_Number_decreased": "CD16 / FcγRIIIa; CD163; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "macrophage PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; Macrophages; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/890", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat) and Rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB00073", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993, \n D02994", "Pubchem_ID": "12136798, 46505820", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "Su-DHL-10", "Dose": "10 µg/ml Rituximab,5, 10, 20 and 40 µM Chidamide", "Technique": "MTT test", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/903", "Drug": "Cetuximab + motolimod", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB12303", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR. Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042, 16049404", "STR_LINK_(SMILES)": "CCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C1=CC=C(C=C1)C(=O)N1CCCC1", "Single/Combination": "Combination", "PMID": "29061643", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "JHU029 cells cocultured with CD14+ monocytes from HNSCC patients", "Dose": "Cetuximab (10ug/ml) and motolimod (250nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD86 (an M1 marker)", "Controlled_Terms_Function_enhanced_Number_increased": "CD86", "Immune_System-Function_inhibited/numbers_decreased": "myeloid-derived suppressor cell (MDSC) CD163 (M2 marker),CD16", "Controlled_Terms_Function_inhibited_Number_decreased": "CD16 / FcγRIIIa; CD163; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "macrophage PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; Macrophages; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/789", "Drug": "Cetuximab + natural killer cell-activating cytokines", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "22770960", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-SCC47 + Purified NK cells were incubated overnight with IL-2 (100 IU), IL-15 (10 ng/mL), or IL-21 (10 ng/mL)", "Dose": "100 ug/mL of cetuximab", "Technique": "Cr-51 release assay, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC of NK cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/791", "Drug": "Cetuximab + natural killer cell-activating cytokines", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "22770960", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "Cal27+ Purified NK cells were incubated overnight with IL-2 (100 IU), IL-15 (10 ng/mL), or IL-21 (10 ng/mL)", "Dose": "100 ug/mL of cetuximab", "Technique": "Cr-51 release assay, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC of NK cells IFN-γ,MIP-1α, RANTES, and IL-8", "Controlled_Terms_Function_enhanced_Number_increased": "IL-8 / CXCL8; IFN-γ; CCL3 / MIP-1α; CCL5 / RANTES; IL-8/CXCL8; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/792", "Drug": "Cetuximab + natural killer cell-activating cytokines", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": null, "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-SCC74B+ + Purified NK cells were incubated overnight with IL-2 (100 IU), IL-15 (10 ng/mL), or IL-21 (10 ng/mL)", "Dose": "100 ug/mL of cetuximab", "Technique": "Cr-51 release assay, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC of NK cells IFN-γ,MIP-1α, RANTES, and IL-8", "Controlled_Terms_Function_enhanced_Number_increased": "IL-8 / CXCL8; IFN-γ; CCL3 / MIP-1α; CCL5 / RANTES; IL-8/CXCL8; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/150", "Drug": "Cetuximab +IFNγ and TNFα", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30192802", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-SCC4-stimulated with 50IU/mL IFNγ and 30ng/mL TNFα", "Dose": "1μg/mL cetuximab", "Technique": "RT-qPCR,Enzyme-linked immunosorbent assay-ELISA,Western blotting", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CCL2, CCL5, CXCL9, CXCL10 and IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; CCL2 / MCP-1; CCL5 / RANTES; CXCL10 / IP-10; CXCL9 / MIG", "Immune_System-Function_inhibited/numbers_decreased": "IL-1β Raf-MEK-ERK pathway and PI3K-AKT-mTOR, phosphorylation of p38 and ERK5", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; ERK / MAPK; AKT; PI3K", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/151", "Drug": "Cetuximab +IFNγ and TNFα", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30192802", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-SCC47-stimulated with 50IU/mL IFNγ and 30ng/mL TNFα", "Dose": "1μg/mL cetuximab", "Technique": "RT-qPCR,Enzyme-linked immunosorbent assay-ELISA,Western blotting", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CCL2, CCL5, CXCL9, CXCL10 and IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; CCL2 / MCP-1; CCL5 / RANTES; CXCL10 / IP-10; CXCL9 / MIG", "Immune_System-Function_inhibited/numbers_decreased": "IL-1β Raf-MEK-ERK pathway and PI3K-AKT-mTOR, phosphorylation of p38 and ERK5", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; ERK / MAPK; AKT; PI3K", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/152", "Drug": "Cetuximab +IFNγ and TNFα", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30192802", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-SCC104-stimulated with 50IU/mL IFNγ and 30ng/mL TNFα", "Dose": "1μg/mL cetuximab", "Technique": "RT-qPCR,Enzyme-linked immunosorbent assay-ELISA,Western blotting", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CCL2, CCL5, CXCL9, CXCL10 and IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; CCL2 / MCP-1; CCL5 / RANTES; CXCL10 / IP-10; CXCL9 / MIG", "Immune_System-Function_inhibited/numbers_decreased": "IL-1β Raf-MEK-ERK pathway and PI3K-AKT-mTOR, phosphorylation of p38 and ERK5", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; ERK / MAPK; AKT; PI3K", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/153", "Drug": "Cetuximab +IFNγ and TNFα", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30192802", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UM-SCC19-stimulated with 50IU/mL IFNγ and 30ng/mL TNFα", "Dose": "1μg/mL cetuximab", "Technique": "RT-qPCR,Enzyme-linked immunosorbent assay-ELISA,Western blotting", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CCL2, CCL5, CXCL9, CXCL10 and IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; CCL2 / MCP-1; CCL5 / RANTES; CXCL10 / IP-10; CXCL9 / MIG", "Immune_System-Function_inhibited/numbers_decreased": "IL-1β", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/839", "Drug": "Cetuximab +IL-2 or IL-15", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "21308409", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast -Triple Negative Breast Cancer (TNBC))", "System": "IIB-BR-G + purified NK cells- in presence of IL-2 (100 IU/ml) or IL-15 (10 ng/ml).", "Dose": "Flow cytometry, \n assay.", "Technique": "Flow cytometry, \n assay.", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ NK activating receptors CD16 and NKG2D", "Controlled_Terms_Function_enhanced_Number_increased": "CD16 / FcγRIIIa; NKG2D / KLRK1; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/895", "Drug": "Cetuximab +Poly-ICLC (a TLR3 agonist)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30377565", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Nasopharyngeal Cancer (NPC)", "System": "DC, NK and C666-1 cells + autologous CD8 + T cells", "Dose": "10µg/ml cetuximab", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8 + T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/897", "Drug": "Cetuximab +Poly-ICLC (a TLR3 agonist)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30377565", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Nasopharyngeal Cancer (NPC)", "System": "C666-1 + Myeloid-derived dendritic cells stimulated with 50µg/ml Poly-ICLC", "Dose": "10µg/ml cetuximab", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "DC maturation and stimulation CD83 and co-stimulatory markers CD80 and CD86-on Dendritic cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; CD83; CD86; CD80/CD86 costimulation; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1284", "Drug": "Cetuximab +Poly-ICLC (a TLR3 agonist)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30377565", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Nasopharyngeal Cancer (NPC)", "System": "C666-1 + NK cells from healthy controls’ and NPC patients’stimulated with 10µg/ml Poly-ICLC", "Dose": "10µg/ml cetuximab", "Technique": "Flow cytometry, BATDA europium release assay,ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "CD56+ CD16+ NK cell- (ADCC) IFN-ɣ-by NK cells CD107a+ granzyme B+ high-on NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD16 / FcγRIIIa; CD56 / NCAM1; CD107a / LAMP1; ADCC; Granzyme B / GZMB; NK cells; Antibody-dependent cytotoxicity; Degranulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/803", "Drug": "Cetuximab +VTX-2337 (motolimod)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB12303", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR. Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042, 16049404", "STR_LINK_(SMILES)": "CCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C1=CC=C(C=C1)C(=O)N1CCCC1", "Single/Combination": "Combination", "PMID": "23685782", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "EGFR+ HNC cell lines -UM-22B + PBMC", "Dose": "VTX-2337 (250nM) ,cetuximab (10μg/mL)", "Technique": "51Cr release assays,cytokine ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cytotoxicity/release assay; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "NK cells TNFα, IFNγ, and IL-12p40 cetuximab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "TNF-α / TNF; IFN-γ; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/894", "Drug": "Cetuximab +VTX-2337 (motolimod)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB12303", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR. Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042, 16049404", "STR_LINK_(SMILES)": "CCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C1=CC=C(C=C1)C(=O)N1CCCC1", "Single/Combination": "Combination", "PMID": "23685782", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "HLA-A*0201+ DC, NK cells + PCI-15B HNC cells coculture with autologous CD8+ T", "Dose": "VTX-2337 (800nM), cetuximab (10μg/mL)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD3; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/896", "Drug": "Cetuximab +VTX-2337 (motolimod)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB12303", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR. Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042, 16049404", "STR_LINK_(SMILES)": "CCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C1=CC=C(C=C1)C(=O)N1CCCC1", "Single/Combination": "Combination", "PMID": "23685782", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "Co-cultures of DC, NK cells and PCI-15B HNC cell", "Dose": "TLR8 agonist (VTX-2337, 800nM, 48 h), cetuximab (10μg/mL)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "DC CD80, CD83, and CD86", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; CD83; CD86; CD80/CD86 costimulation; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/898", "Drug": "Cetuximab +VTX-2337 (motolimod)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002, DB12303", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR. Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042, 16049404", "STR_LINK_(SMILES)": "CCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C1=CC=C(C=C1)C(=O)N1CCCC1", "Single/Combination": "Combination", "PMID": "23685782", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Cancer (HNC)", "System": "EGFR+ HNC cell lines - PCI-15B +PBMC", "Dose": "VTX-2337 (250nM) ,cetuximab (10μg/mL)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell degranulation", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; Degranulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1467", "Drug": "Cetuximab-based therapy", "Drug_category": "Others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D03455", "Pubchem_ID": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "25769300", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "System": "K562 + NK-cell from patients", "Dose": "10 μg/mL of cetuximab", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/532", "Drug": "Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "12000240", "STR_LINK_(SMILES)": "C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "Panc02", "Dose": "10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Little IFN-β induction alone", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/934", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat) and Rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB00073", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993, \n D02994", "Pubchem_ID": "12136798, 46505820", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "OCI-Ly7", "Dose": "10 µg/ml Rituximab,1, 2, 4 and 8 µM Chidamide", "Technique": "MTT test", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1512", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat) and Rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB00073", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993, \n D02994", "Pubchem_ID": "12136798, 46505820", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "OCI-Ly7", "Dose": "5 µM Chidamide and/or 10 µg/ml Rituximab", "Technique": "western blotting,Flow cytometry- propidium iodide (PI) staining for apoptosis detection", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "CD20 and ac-Histone-H3 (Lys27) expression apoptosis-PARP cleavage", "Controlled_Terms_Function_enhanced_Number_increased": "CD20 / MS4A1; Apoptosis; PARP cleavage / PARP; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/278", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat) and Rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB00073", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993, \n D02994", "Pubchem_ID": "12136798, 46505820", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "System": "Su-DHL-6", "Dose": "5 µM Chidamide and/or 10 µg/ml Rituximab", "Technique": "western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD20 and ac-Histone-H3 (Lys27) expression", "Controlled_Terms_Function_enhanced_Number_increased": "CD20 / MS4A1; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/702", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)+decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "THP-1 cells + PRAME-specific CTLs", "Dose": null, "Technique": "Cytotoxicity Assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "PRAME-specific CTL", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Cancer-testis antigens; PRAME antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1444", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)+decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31934307", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Myeloid Leukemia", "System": "K562", "Dose": "4 μg/mL chidamide and 8 μmol/L decitabine", "Technique": "western blotting, Flow cytometry,RT-qPCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cell cycle arrest at the G0/G1 phase, apoptosis-apoptotic gene Bax, cleaved PARP-1 and caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-9; Caspase activation; Apoptosis; Cell-cycle arrest; PARP cleavage / PARP; BAX", "Immune_System-Function_inhibited/numbers_decreased": "phosphorylation of PI3K/AKT/mTOR pathway components PI3K, AKT and mTOR.", "Controlled_Terms_Function_inhibited_Number_decreased": "AKT; PI3K", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1446", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)+decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31934307", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Myeloid Leukemia", "System": "THP-1", "Dose": "4 μg/mL chidamide and 20 μmol/L decitabine", "Technique": "western blotting, Flow cytometry,RT-qPCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cell cycle arrest at the G0/G1 phase, apoptosis-apoptotic gene Bax, cleaved PARP-1 and caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-9; Caspase activation; Apoptosis; Cell-cycle arrest; PARP cleavage / PARP; BAX", "Immune_System-Function_inhibited/numbers_decreased": "phosphorylation of PI3K/AKT/mTOR pathway components PI3K, AKT and mTOR , antiapoptotic gene Bcl-2", "Controlled_Terms_Function_inhibited_Number_decreased": "AKT; PI3K; Apoptosis; BCL-2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1517", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)+decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31934307", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Myeloid Leukemia", "System": "K562", "Dose": "chidamide at 8 μg/mL in combination with decitabine at 8 μmol/L for 24, 48, 72, 96 h", "Technique": "CCK-8 assay,Flow cytometry, Western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "proliferation of myeloma cells inhibited", "Controlled_Terms_Function_enhanced_Number_increased": "Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1518", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)+decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31934307", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Myeloid Leukemia", "System": "THP-1", "Dose": "0.5 μg/mL chidamide combined with 20 μmol/L decitabine for 24, 48, 72, and 96 h", "Technique": "CCK-8 assay,Flow cytometry, Western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "proliferation of myeloma cells inhibited", "Controlled_Terms_Function_enhanced_Number_increased": "Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/45", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)+decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "Kasumi-1", "Dose": "chidamde (1 µM), decitabine (Dac, 0.25 mM)", "Technique": "RT-qPCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; PRAME antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/46", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)+decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "NB4", "Dose": "chidamde (1 µM), decitabine (Dac, 0.25 mM)", "Technique": "RT-qPCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; PRAME antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/48", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)+decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "THP-1", "Dose": "chidamde (1 µM), decitabine (Dac, 0.25 mM)", "Technique": "RT-qPCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; PRAME antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/49", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat)+decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug__ID": "D10993", "Pubchem_ID": "12136798", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "23940586", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "U937", "Dose": "chidamde (1 µM), decitabine (Dac, 0.25 mM)", "Technique": "RT-qPCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cancer testis antigen- PRAME", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens; PRAME antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/723", "Drug": "Chidamide combined with decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB01262", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor, Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D10993, D03665", "Pubchem_ID": "12136798, 451668", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1,\n NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "30210693", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "K562 cells were co-cultured with effector cells", "Dose": "anti-ILT2 blocking antibody (10 μg/ml) lenalidomide (LND, 1 μM)", "Technique": "calcein assay", "Controlled_Technique": "Calcein assay", "Immune_System-Function_enhanced/numbers_increased": "NK Cell Cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/503", "Drug": "JQ1", "Drug_category": "Others/combination", "Drugbank_ID": "DB17021", "Target/s_or_mechanism_of_action": "BRD4 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "46907787", "STR_LINK_(SMILES)": "CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C", "Single/Combination": "Single", "PMID": "35517410", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "MC38", "Dose": "0.1 μM, 48 h", "Technique": "RNA-seq, qPCR, flow cytometry", "Controlled_Technique": "H2-Kb, MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1/CD274", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 / CD274", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1207", "Drug": "Chidamide combined with decitabine", "Drug_category": "Others/combination", "Drugbank_ID": "DB06334, DB01262", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor, Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D10993, D03665", "Pubchem_ID": "12136798, 451668", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1,\n NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "30210693", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs obtained from 14 CLL patients", "Dose": "anti-ILT2 blocking antibody (10 μg/ml), lenalidomide (LND, 1 μM)", "Technique": "Flow cytometry, CFSE assay (PBMCs from 11 CLL patients)", "Controlled_Technique": "Flow cytometry; Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells,NK cell proliferation in CLL, intracellular levels of perforin on NK cells CD69 on NK cells leukemic cell apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "CD69; Apoptosis; Cell proliferation; Perforin / PRF1; NK cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/440", "Drug": "Chloroquine (CQ)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00608", "Target/s_or_mechanism_of_action": "Raises endosomal/lysosomal pH", "KEGG_Drug__ID": "D02366", "Pubchem_ID": "2719", "STR_LINK_(SMILES)": "CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/663", "Drug": "Chloroquine (CQ)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00608", "Target/s_or_mechanism_of_action": "Raises endosomal/lysosomal pH", "KEGG_Drug__ID": "D02366", "Pubchem_ID": "2719", "STR_LINK_(SMILES)": "CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "melanoma", "System": "B16F10", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/874", "Drug": "Cobimetinib+anti CD40+ anti- IgM", "Drug_category": "Others/combination", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "MEK inhibitor Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway.", "KEGG_Drug__ID": "D10405", "Pubchem_ID": "16222096", "STR_LINK_(SMILES)": "OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1", "Single/Combination": "Combination", "PMID": "31671149", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "Isolated splenic B cells", "Dose": "cobimetinib(0.5 μM) +anti-CD40(8 mg/ml,)+ anti-IgM((1 mg/ml)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "B10 cells, TIM1+ B cells, T2-MZP cells (CD21hi, CD23hi, and CD24hi)", "Controlled_Terms_Function_enhanced_Number_increased": "B cells; T2-MZP cells", "Immune_System-Function_inhibited/numbers_decreased": "T2-MZP cells (CD21hi, CD23hi, and CD24hi)", "Controlled_Terms_Function_inhibited_Number_decreased": "T2-MZP cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/771", "Drug": "Combined vaccine + axitinib therapy", "Drug_category": "Others/combination", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug__ID": "D03218", "Pubchem_ID": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Combination", "PMID": "22504156", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MACS-isolated CD8+ T cells from TIL and TDLN were longitudinally analyzed for their ability to produce IFN-γ in response to syngenic DC pulsed with OVA254–262 (SIINFEKL) peptide for 48 hours at a 10:1 E:T ratio", "Dose": null, "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/631", "Drug": "CX-5461", "Drug_category": "Others/combination", "Drugbank_ID": "DB16846", "Target/s_or_mechanism_of_action": "Inhibits RNA polymerase I and rDNA transcription; induces nucleolar stress and DNA-damage response", "KEGG_Drug__ID": null, "Pubchem_ID": "12254622", "STR_LINK_(SMILES)": "CC1=NC=C(CNC(C2=C3N(C(C=CC=C4)=C4S3)C5=C(C=CC(N6CCCN(C)CC6)=N5)C2=O)=O)N=C1", "Single/Combination": "Single", "PMID": "41315184", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human multiple-myeloma cell line", "System": "SKO-007(J3)", "Dose": "200 nM, 48 h", "Technique": "Flow cytometry; NK-cell CD107a degranulation assay; Western blot; qPCR", "Controlled_Technique": "Increased expression of NK-activating ligands; increased HLA-ABC", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "HLA-E upregulation reduced NK-cell degranulation", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; NK cells", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Increased HLA-E, an inhibitory NK-cell ligand", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; NK cells", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1049", "Drug": "CXCR4 inhibitor AMD 3100 /\n Plerixafor", "Drug_category": "Others/combination", "Drugbank_ID": "DB06809", "Target/s_or_mechanism_of_action": "Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered.", "KEGG_Drug__ID": "D08971", "Pubchem_ID": "65015", "STR_LINK_(SMILES)": "C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Single Drug", "PMID": "30802149", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "ID8-luc cells", "Dose": "AMD3100 at 10 μg/ml", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CXCR4 and CXCL12", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCR4; CXCL12 / SDF-1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1179", "Drug": "Dabrafenib+trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10064, D10175", "Pubchem_ID": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "System": "gp10025-33-activated pmel-1 mouse splenocytes", "Dose": "Dabrafenib: L=0.1μM, M=5μM, H=20μM and trametinib: L=0.005μM, M=0.25μM, H=1μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ expressing CD3+ CD8+ cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD3; CD8; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1180", "Drug": "Dacarbazine+ IFNγ", "Drug_category": "Others/combination", "Drugbank_ID": "DB00851", "Target/s_or_mechanism_of_action": "The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog, and interaction with SH groups. Dacarbazine is not cell cycle-phase specific.", "KEGG_Drug__ID": "D00288", "Pubchem_ID": "5351166", "STR_LINK_(SMILES)": "CN(C)\\N=N\\C1=C(N=CN1)C(N)=O", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "20 μM dacarbazine+2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "MHC Class I molecules (HLA-A,B,C), MHC Class II molecule\n (HLA-DR)", "Controlled_Terms_Unaffected": "MHC class I; MHC class II; HLA-DR; HLA-A;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1333", "Drug": "Decitabine (DAC, a DNA demethylation drug) and γδ T cells", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "29910819", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "HOS", "Dose": "(DAC) (5 µM)", "Technique": "MTS assays,PCR and Flow cytometry", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic effects of γδ T cells NKG2DLs MICB and ULBP1 on OS cells", "Controlled_Terms_Function_enhanced_Number_increased": "ULBP1; MICB; Cytotoxicity / cytolysis; T cells; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1335", "Drug": "Decitabine (DAC, a DNA demethylation drug) and γδ T cells", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "29910819", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U2OS cells", "Dose": "(DAC) (5 µM)", "Technique": "PCR and Flow cytometry", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic effects of γδ T cells NKG2DLs MICB and ULBP1 on OS cells", "Controlled_Terms_Function_enhanced_Number_increased": "ULBP1; MICB; Cytotoxicity / cytolysis; T cells; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/133", "Drug": "Decitabine (DAC) + selinexor", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262, DB11942", "Target/s_or_mechanism_of_action": "deitabine: Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses, Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound", "KEGG_Drug__ID": "D03665, D11222", "Pubchem_ID": "451668, \n 71481097", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1,\n FC(F)(F)C1=CC(=CC(=C1)C1=NN(\\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F", "Single/Combination": "Combination", "PMID": "25716206", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "OCI-AML3", "Dose": "decitabine (IC50 twofold dilutions, 4 μM to 250 nM) followed by selinexor (IC50 twofold dilutions, 400nm to 25nM) for 24 hours", "Technique": "WST-1 assay,qRT-PCR, western blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis,CDKN1A and FOXO3A expression levels", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; p21 / CDKN1A; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/134", "Drug": "Decitabine (DAC) + selinexor", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262, DB11942", "Target/s_or_mechanism_of_action": "deitabine: Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses, Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound", "KEGG_Drug__ID": "D03665, D11222", "Pubchem_ID": "451668, \n 71481097", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1,\n FC(F)(F)C1=CC(=CC(=C1)C1=NN(\\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F", "Single/Combination": "Combination", "PMID": "25716206", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "MV4-11)", "Dose": "decitabine (IC50 twofold dilutions, 4 μM to 250 nM) followed by selinexor (IC50 twofold dilutions, 400nm to 25nM) for 24 hours", "Technique": "WST-1 assay,qRT-PCR, western blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis,CDKN1A and FOXO3A expression levels", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; p21 / CDKN1A; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/135", "Drug": "Decitabine (DAC) + selinexor", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262, DB11942", "Target/s_or_mechanism_of_action": "deitabine: Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses, Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound", "KEGG_Drug__ID": "D03665, D11222", "Pubchem_ID": "451668, \n 71481097", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1,\n FC(F)(F)C1=CC(=CC(=C1)C1=NN(\\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F", "Single/Combination": "Combination", "PMID": "25716206", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "MOLM-13", "Dose": "decitabine (IC50 twofold dilutions, 4 μM to 250 nM) followed by selinexor (IC50 twofold dilutions, 400nm to 25nM) for 24 hours", "Technique": "WST-1 assay,qRT-PCR, western blot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis,CDKN1A and FOXO3A expression levels", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; p21 / CDKN1A; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/937", "Drug": "Decitabine (DAC) in combination with allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "29138222", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "THP-1 +allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Dose": "0.01 to 0.1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell–mediated killing", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/938", "Drug": "Decitabine (DAC) in combination with allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "29138222", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "KG1a cells+allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Dose": "0.01 to 0.1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell–mediated killing", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/939", "Drug": "Decitabine (DAC) in combination with allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "29138222", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "Primary AML cells obtained from 5 different patients +HSPC-NK cells", "Dose": "0.1 µM DAC", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell–mediated killing", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/942", "Drug": "Decitabine (DAC)+BI 836858, a fully human, Fc-engineered, anti-CD33 antibody", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "27013443", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "primary AML blasts +autologous NK-cell", "Dose": "DAC (500 nM)+ BI 836858 or BI 836847 (10 μg/mL)", "Technique": "Flow cytometry, ADCC assay", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK-cell activation-natural killer ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/943", "Drug": "Decitabine (DAC)+BI 836858, a fully human, Fc-engineered, anti-CD33 antibody", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug__ID": "D03665", "Pubchem_ID": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "27013443", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "primary AML blasts +allogenic NK-cell", "Dose": "DAC (500 nM)+ BI 836858 or BI 836847 (10 μg/mL)", "Technique": "Flow cytometry, ADCC assay", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK-cell activation-natural killer ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/859", "Drug": "Decitabine + Vorinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262, DB02546", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses.\n Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D03665, D06320", "Pubchem_ID": "451668, 5311", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "22461695", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "System": "LS411N", "Dose": "0 - 1 μM (both drugs) + FasL (200 ng/ml)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "FasL-induced apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Fas ligand / FasL / FASLG; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1436", "Drug": "Decitabine + Vorinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262, DB02546", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses.\n Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D03665, D06320", "Pubchem_ID": "451668, 5311", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "22461695", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "System": "LS411N", "Dose": "0 - 1 μM (both drugs)", "Technique": "Flow cytometry, RT PCR, Western blotting analysis", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "Fas protein level on the tumor cell surface, BNIP3 and Bik ,FasL-induced apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; Fas ligand / FasL / FASLG; Apoptosis; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "Bcl-xL protein", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-xL / BCL2L1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1219", "Drug": "Decitabine and Vorinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262, DB02546", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses.\n Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D03665, D06320", "Pubchem_ID": "451668, 5311", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "28881658", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "HL-60", "Dose": "0.1 μM DAC, 0.25 μM and 0.75 μM VOR", "Technique": "Annexin V PI staining-Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptotic cell death, caspase 8, 9 and 3/7 activity", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-8; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1523", "Drug": "Decitabine and Vorinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB01262, DB02546", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses.\n Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D03665, D06320", "Pubchem_ID": "451668, 5311", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "28881658", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "System": "OCI-AML3", "Dose": "0.1 μM DAC, 0.25 μM and 0.75 μM VOR", "Technique": "Annexin V PI staining-Flow cytometry, western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptotic cell death, caspase 8, 9 and 3/7 activity", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-8; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1203", "Drug": "Depsipeptide (FK228) or Romidepsin +FasL", "Drug_category": "Others/combination", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Combination", "PMID": "18185535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16/F10", "Dose": "depsipeptide (5 nM) and recombinant FLAG-tagged FasL (10 ng/ ml ) and multimerized with anti-FLAG M2 antibodies (1 mg/ ml ) for 16 hours.", "Technique": "Flow cytometry,Caspase-Glo 3/7 Assay system (Promega)", "Controlled_Technique": "Flow cytometry; Apoptosis/cell viability assay; Bioluminescence/luciferase assay; Caspase-Glo3/7 Assay", "Immune_System-Function_enhanced/numbers_increased": "apoptotic cell death after Fas–FasL crosslinking, (whereas B16/ F10 cells were resistant to apoptosis with Fas crosslinking alone), Caspase-3/7 activity", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; Fas ligand / FasL / FASLG; Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/930", "Drug": "Depsipeptide ++tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)", "Drug_category": "Others/combination", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug__ID": "D06637", "Pubchem_ID": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Combination", "PMID": "16818655", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "CD19+ CLL cells", "Dose": "0.5 to 1μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "BID, DR5, and p73 CD154", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL-R2 / DR5 / TNFRSF10B; BID", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/97", "Drug": "Depsipeptide and 5-fluorouracil", "Drug_category": "Others/combination", "Drugbank_ID": "DB06176,\n DB00544", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor. Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D06637, D00584", "Pubchem_ID": "57515973, 3385", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C, FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "27509880", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT-116", "Dose": "Dep (1 nM)", "Technique": "caspase-3 activation assay, qRT-PCR method", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "MHC class II genes, including HLA-DPB1, HLA-DQB1, HLA-DRA, and HLA-DRB1", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "MHC class I genes including HLA-A, HLA-B-HLA-C", "Controlled_Terms_Unaffected": "MHC class I; HLA-A; HLA-B; HLA-C;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/98", "Drug": "Depsipeptide and 5-fluorouracil", "Drug_category": "Others/combination", "Drugbank_ID": "DB06176,\n DB00544", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor. Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D06637, D00584", "Pubchem_ID": "57515973, 3385", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C, FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "27509880", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT-116", "Dose": "5-FU (1.75 µM) + Dep (1 nM)", "Technique": "caspase-3 activation assay, qRT-PCR method", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "MHC class II genes, including HLA-DPB1, HLA-DQB1, HLA-DRA, and HLA-DRB1 caspase-3/7 activation", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; HLA-DR; Caspase-3; Caspase activation;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/765", "Drug": "Dex with IMiD1", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "12036884", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "1 µM of both drugs", "Technique": "The DNA binding activity of NF-κB in MM.1S cells was quantified by enzyme-linked immunosorbent assay using the Trans-AM NF-κB p65 Transcription Factor Assay Kit", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "NF-κB", "Controlled_Terms_Function_inhibited_Number_decreased": "NF-κB", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/442", "Drug": "DM1 (emtansine)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40175391", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2-positive", "System": "Au565 cells", "Dose": "Titrated concentrations; 3-day ICD experiment", "Technique": "ATP, HMGB1, calreticulin assays", "Controlled_Technique": "Extracellular ATP release, HMGB1 release, Surface calreticulin (CRT)  on tumor cells undergoing ICD", "Immune_System-Function_enhanced/numbers_increased": "HMGB1; Calreticulin / CRT; Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/968", "Drug": "Docetaxel+cisplatin", "Drug_category": "Others/combination", "Drugbank_ID": "1. DB01248 (APRD00932) 2. DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "1. Inhibition of tubulin depolymerization, 2. Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "1. D07866, 2. D00275", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C2", "Single/Combination": "Combination", "PMID": "24868562", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Nonsmall-Cell Lung Cancer (NSCLC)", "System": "PBMCs from NSCLC patients+docetaxe", "Dose": "1 μg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "T reg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/622", "Drug": "Doxorubicin + Celecoxib", "Drug_category": "Others/combination", "Drugbank_ID": "DB00997 + DB00482", "Target/s_or_mechanism_of_action": "Doxorubicin induces DNA damage and immunogenic cell death; celecoxib inhibits COX-2 and suppresses PI3K/AKT-associated IDO1 expression", "KEGG_Drug__ID": "D03899+D00567", "Pubchem_ID": "31703 + 2662", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O and CC1=CC(=NN1C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=C(C=C3)C(F)(F)F", "Single/Combination": "Combination", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Murine Lewis lung carcinoma (LLC) cell line", "System": "LLC", "Dose": "25 mg/kg; 50 mg/kg", "Technique": "Flow cytometry; ROS assay; apoptosis assay; Western blot", "Controlled_Technique": "DOX-associated ICD; celecoxib may enhance ROS-associated ER stress and antitumor immunogenicity", "Immune_System-Function_enhanced/numbers_increased": "Reactive oxygen species / ROS; Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "IDO1-associated immunosuppression may decrease", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Reduced IDO1-associated negative immune regulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/623", "Drug": "Doxorubicin + Celecoxib", "Drug_category": "Others/combination", "Drugbank_ID": "DB00997 + DB00482", "Target/s_or_mechanism_of_action": "Doxorubicin induces DNA damage and immunogenic cell death; celecoxib inhibits COX-2 and suppresses PI3K/AKT-associated IDO1 expression", "KEGG_Drug__ID": "D03899+D00567", "Pubchem_ID": "31703 + 2662", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O and CC1=CC(=NN1C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=C(C=C3)C(F)(F)F", "Single/Combination": "Combination", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Murine CMT-64 lung cancer cell line", "System": "CMT-64", "Dose": "25 mg/kg; 50 mg/kg", "Technique": "Flow cytometry; ROS assay; apoptosis assay; Western blot", "Controlled_Technique": "DOX-associated ICD; celecoxib may enhance ROS-associated ER stress and antitumor immunogenicity", "Immune_System-Function_enhanced/numbers_increased": "Reactive oxygen species / ROS; Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "IDO1-associated immunosuppression may decrease", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Reduced IDO1-associated negative immune regulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/519", "Drug": "Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "12000240", "STR_LINK_(SMILES)": "C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "MC38", "Dose": "10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Little IFN-β induction alone", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/522", "Drug": "Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "12000240", "STR_LINK_(SMILES)": "C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "HT29", "Dose": "10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Little IFN-β induction alone", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/526", "Drug": "Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "12000240", "STR_LINK_(SMILES)": "C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "CT26", "Dose": "10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Little IFN-β induction alone", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1043", "Drug": "Entinostat (MS-275) and IFN-γ", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS-11", "Dose": "1 μM entinostat (MS-275) and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1044", "Drug": "Entinostat (MS-275) and IFN-γ", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "1 μM entinostat (MS-275) and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1046", "Drug": "Entinostat (MS-275) and IFN-γ", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "1 μM entinostat (MS-275) and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/779", "Drug": "Entinostat + anti-PD-1", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "28698201", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "System": "MDSCs isolated from tumors of entinostat/anti-PD-1 treated mice + stimulated CD8+ T cells", "Dose": "entinostat (5mg/kg), anti-PD-1 (10mg/kg)", "Technique": "3H-thymidine uptake", "Controlled_Technique": "Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells, Granzyme B", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Granzyme B / GZMB; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs( increased intra-tumor numbers of PMN-MDSC and M-MDSC, but these cells have lost the majority of their immunosuppressive activity)", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/280", "Drug": "Entinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841, DB11948", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "OVCAR-3 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours, , Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/291", "Drug": "Entinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841, DB11949", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SK-OV-3+NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours, , Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/302", "Drug": "Entinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841, DB11950", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "HEY-T30 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours, , Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/358", "Drug": "Entinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841, DB11951", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "DU145 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours, , Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/369", "Drug": "Entinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841, DB11952", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "PC-3 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours, , Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/69", "Drug": "Entinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841, DB11945", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung - Small Cell Lung Cancer", "System": "H1882 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours, , Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/80", "Drug": "Entinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841, DB11946", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H441+NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours, , Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/91", "Drug": "Entinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841, DB11947", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H460 +NK cells purified from two healthy donor PBMCs", "Dose": "entinostat (500 nM) for 72 hours, , Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1048", "Drug": "Entinostat and azacytidine", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841, DB00928", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.\n As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D09338,\n D03021", "Pubchem_ID": "4261, 9444", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, \n NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "28498806", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "ID8", "Dose": "entinostat-5 μM, azacytidine-150 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC II expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1249", "Drug": "Erlotinib+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00530,DB00002", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D07907, D03455", "Pubchem_ID": "176870, 46507042", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Combination", "PMID": "31546690", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "IGROV-1 co-incubated with purified unstimulated NK cells", "Dose": "Cetuximab - 1 µg/mL+erlotinib (1 µM) for 7 days and 6 weeks", "Technique": "Flow cytometry, ELISpot assay", "Controlled_Technique": "Flow cytometry; ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "NK cytotoxicity and NK-specific tumor cell lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IFNγ,NK-activating cytokine IL18 MHC class I polypeptide-related sequence A (MICA) and MHC class I polypeptide-related sequence B (MICB)", "Controlled_Terms_Negative_Regulation": "MHC class I; MICA; MICB; IL-18; IFN-γ; ; MICA/MICB"}, {"ID": "CANIMM/1250", "Drug": "Erlotinib+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00530,DB00002", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D07907, D03455", "Pubchem_ID": "176870, 46507042", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Combination", "PMID": "31546690", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SKOV-3-1 co-incubated with purified unstimulated NK cells", "Dose": "Cetuximab - 1 µg/mL+erlotinib (1 µM) for 7 days and 6 weeks", "Technique": "Flow cytometry, ELISpot assay", "Controlled_Technique": "Flow cytometry; ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "NK cytotoxicity and NK-specific tumor cell lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IFNγ- MHC class I polypeptide-related sequence A (MICA) and MHC class I polypeptide-related sequence B (MICB)", "Controlled_Terms_Negative_Regulation": "MHC class I; MICA; MICB; IFN-γ; ; MICA/MICB"}, {"ID": "CANIMM/875", "Drug": "FOLFIRI+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "Lim1215-KRAS WT, BRAF WT", "Dose": "The concentrations used for FOLFIRI single component were: calcium levofolinate (20 µM), 5-fluorouracil (20 µM) and irinotecan (60 µM),cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "eIF2-α phosphorylation and phagocytosis - markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/876", "Drug": "FOLFIRI+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "OXCO-2", "Dose": "The concentrations used for FOLFIRI single component were: calcium levofolinate (20 µM), 5-fluorouracil (20 µM) and irinotecan (60 µM),cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "eIF2-α phosphorylation and phagocytosis - markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/877", "Drug": "FOLFIRI+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "Caco-2", "Dose": "The concentrations used for FOLFIRI single component were: calcium levofolinate (20 µM), 5-fluorouracil (20 µM) and irinotecan (60 µM),cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "eIF2-α phosphorylation and phagocytosis - markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/878", "Drug": "FOLFIRI+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116-KRAS mut", "Dose": "The concentrations used for FOLFIRI single component were: calcium levofolinate (20 µM), 5-fluorouracil (20 µM) and irinotecan (60 µM),cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "eIF2-α phosphorylation and phagocytosis - markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/880", "Drug": "FOLFIRI+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "Lim1215 KRASG12D-KRAS mut", "Dose": "The concentrations used for FOLFIRI single component were: calcium levofolinate (20 µM), 5-fluorouracil (20 µM) and irinotecan (60 µM),cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "eIF2-α phosphorylation and phagocytosis - markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/881", "Drug": "FOLFIRI+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "(CT26) expressing human EGFR (hEGFR-CT26)", "Dose": "The concentrations used for FOLFIRI single component were: calcium levofolinate (20 µM), 5-fluorouracil (20 µM) and irinotecan (60 µM),cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ER stress response and phagocytosis-markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/882", "Drug": "FOLFIRI+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "DiFi", "Dose": "The concentrations used for FOLFIRI single component were: calcium levofolinate (20 µM), 5-fluorouracil (20 µM) and irinotecan (60 µM),cetuximab (10 μg/mL)", "Technique": "Flow cytometry, westen blot,global mass-spectrometry-based quantitative proteomics using a technique called stable isotope labeling by amino acids in cell culture (SILAC)", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ER stress response and the translocation of CRT and ERp57 to the cell surface- markers of Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Calreticulin / CRT; ERp57 / PDIA3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1570", "Drug": "FOLFIRI+cetuximab", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27135741", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "DiFi+ DCs", "Dose": "The concentrations used for FOLFIRI single component were: calcium levofolinate (20 µM), 5-fluorouracil (20 µM) and irinotecan (60 µM),cetuximab (10 μg/mL)", "Technique": "confocal microscopy", "Controlled_Technique": "Microscopy; Confocal microscopy", "Immune_System-Function_enhanced/numbers_increased": "phagocytosis by dendritic cells-of tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "Dendritic cells; Phagocytosis / trogocytosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/621", "Drug": "Gemcitabine + Celecoxib", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441 + DB00482", "Target/s_or_mechanism_of_action": "Ribonucleotide reductase/DNA synthesis inhibition by GEM; COX-2/PGE2 and PI3K/AKT/IDO1 pathway suppression by celecoxib; increased ROS and ER stress", "KEGG_Drug__ID": "D02368+D00567", "Pubchem_ID": "60750 + 2662", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F and CC1=CC(=NN1C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=C(C=C3)C(F)(F)F", "Single/Combination": "Combination", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Murine CMT-64 lung cancer cell line", "System": "CMT-64", "Dose": "GEM 2 µg/mL and celecoxib 40 µM; 24 h", "Technique": "Flow cytometry; ROS assay; Western blot; apoptosis assay", "Controlled_Technique": "Increased ROS and apoptosis; enhanced GEM-associated ICD", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis; Reactive oxygen species / ROS; Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Reduced IDO1-associated immunosuppression", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "celecoxib suppresses the IDO1-mediated negative immune-regulatory pathway", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/620", "Drug": "Gemcitabine + Celecoxib", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441 + DB00482", "Target/s_or_mechanism_of_action": "Ribonucleotide reductase/DNA synthesis inhibition by GEM; COX-2/PGE2 and PI3K/AKT/IDO1 pathway suppression by celecoxib; increased ROS and ER stress", "KEGG_Drug__ID": "D02368+D00567", "Pubchem_ID": "60750 + 2662", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F and CC1=CC(=NN1C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=C(C=C3)C(F)(F)F", "Single/Combination": "Combination", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Murine Lewis lung carcinoma (LLC) cell line", "System": "LLC", "Dose": "GEM 2 µg/mL and celecoxib 40 µM; 24 h", "Technique": "Flow cytometry; ROS assay; Western blot; apoptosis assay", "Controlled_Technique": "Increased ROS and apoptosis; enhanced GEM-associated ICD; increased tumor immunogenicity and potential DC activation", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis; Reactive oxygen species / ROS; Immunogenic cell death; Dendritic cells", "Controlled_Terms_Function_enhanced_Number_increased": "Reduced IDO1-associated immunosuppression; reduced tumor-cell survival", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "celecoxib suppresses the IDO1-mediated negative immune-regulatory pathway", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/179", "Drug": "GILF regimen (Gem, Iri, Levofolinic acid and 5-FU)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441\n DB00762\n DB11596\n DB00544", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase\n Irinotecan inhibits the action of topoisomerase I\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D02368,D08086, D04715, D00584", "Pubchem_ID": "60750, 60838, 149436, 3385", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, \n CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "HT29", "Dose": "gemcitabine at final concentration of 50 lg/ml +, levofolinic acid was added at a concentration of\n 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": "cytofluorimetric and Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "up-regulation of EGFR on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "EGFR; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/181", "Drug": "GILF regimen (Gem, Iri, Levofolinic acid and 5-FU)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441\n DB00762\n DB11596\n DB00544", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase\n Irinotecan inhibits the action of topoisomerase I\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D02368,D08086, D04715, D00584", "Pubchem_ID": "60750, 60838, 149436, 3385", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, \n CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "WiDr", "Dose": "gemcitabine at final concentration of 50 lg/ml +, levofolinic acid was added at a concentration of\n 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": "cytofluorimetric and Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "up-regulation of EGFR on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "EGFR; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/182", "Drug": "GILF regimen (Gem, Iri, Levofolinic acid and 5-FU)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00441\n DB00762\n DB11596\n DB00544", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase\n Irinotecan inhibits the action of topoisomerase I\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D02368,D08086, D04715, D00584", "Pubchem_ID": "60750, 60838, 149436, 3385", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, \n CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "SW620", "Dose": "gemcitabine at final concentration of 50 lg/ml +, levofolinic acid was added at a concentration of\n 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": "cytofluorimetric and Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "up-regulation of EGFR on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "EGFR; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/625", "Drug": "Glaucocalyxin A", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits STAT3 phosphorylation/activation; induces apoptosis and G2/M cell-cycle arrest", "KEGG_Drug__ID": null, "Pubchem_ID": "10471963", "STR_LINK_(SMILES)": "C[C@@]12CCC(=O)C([C@H]1C[C@H]([C@]34[C@H]2CC[C@H]([C@H]3O)C(=C)C4=O)O)(C)C", "Single/Combination": "Single", "PMID": "34923957", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human plasma-cell malignancy", "System": "RPMI-8226", "Dose": "0–80 μM for 24, 48 and 72 h; apoptosis assays at 10 μM for 24 h", "Technique": "Annexin V-FITC/PI flow cytometry, Western blot, qPCR", "Controlled_Technique": "cleaved PARP and cleaved caspase-3, caspase 3 mRNA", "Immune_System-Function_enhanced/numbers_increased": "PARP cleavage / PARP; Caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "anti-apoptosis-related protein (Bcl-2) , decreased the levels of p-STAT3. STAT3", "Immune_System-Function_inhibited/numbers_decreased": "Apoptosis; Expression / abundance phenotype; BCL-2; STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/626", "Drug": "Glaucocalyxin A", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits STAT3 phosphorylation; reduces anti-apoptotic Bcl-2 and increases caspase-associated apoptosis", "KEGG_Drug__ID": null, "Pubchem_ID": "10471963", "STR_LINK_(SMILES)": "C[C@@]12CCC(=O)C([C@H]1C[C@H]([C@]34[C@H]2CC[C@H]([C@H]3O)C(=C)C4=O)O)(C)C", "Single/Combination": "Single", "PMID": "34923957", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human plasma-cell malignancy", "System": "LP1", "Dose": "0–80 μM for 24, 48 and 72 h; selected apoptosis experiments at 10 μM for 24 h", "Technique": "Annexin V-FITC/PI flow cytometry, Western blot, qPCR", "Controlled_Technique": "cleaved PARP and cleaved caspase-3, caspase 3 mRNA", "Immune_System-Function_enhanced/numbers_increased": "PARP cleavage / PARP; Caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "anti-apoptosis-related protein (Bcl-2) , decreased the levels of p-STAT3. STAT3", "Immune_System-Function_inhibited/numbers_decreased": "Apoptosis; Expression / abundance phenotype; BCL-2; STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/627", "Drug": "Glaucocalyxin A", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits STAT3 phosphorylation and promotes apoptosis", "KEGG_Drug__ID": null, "Pubchem_ID": "10471963", "STR_LINK_(SMILES)": "C[C@@]12CCC(=O)C([C@H]1C[C@H]([C@]34[C@H]2CC[C@H]([C@H]3O)C(=C)C4=O)O)(C)C", "Single/Combination": "Single", "PMID": "34923957", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human plasma-cell malignancy", "System": "U266", "Dose": "0–80 μM for 24, 48 and 72 h; selected apoptosis experiments at 10 μM for 24 h", "Technique": "Annexin V-FITC/PI flow cytometry, Western blot, qPCR", "Controlled_Technique": "cleaved PARP and cleaved caspase-3, caspase 3 mRNA", "Immune_System-Function_enhanced/numbers_increased": "PARP cleavage / PARP; Caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "anti-apoptosis-related protein (Bcl-2) , decreased the levels of p-STAT3. STAT3", "Immune_System-Function_inhibited/numbers_decreased": "Apoptosis; Expression / abundance phenotype; BCL-2; STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/504", "Drug": "JQ1", "Drug_category": "Others/combination", "Drugbank_ID": "DB17021", "Target/s_or_mechanism_of_action": "BRD4 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "46907787", "STR_LINK_(SMILES)": "CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C", "Single/Combination": "Single", "PMID": "35517410", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "HCT116", "Dose": "0.1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "HLA-ABC, MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "surface PD-L1", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 / CD274", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/628", "Drug": "Glaucocalyxin A", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits STAT3 phosphorylation and activation; induces apoptosis", "KEGG_Drug__ID": null, "Pubchem_ID": "10471963", "STR_LINK_(SMILES)": "C[C@@]12CCC(=O)C([C@H]1C[C@H]([C@]34[C@H]2CC[C@H]([C@H]3O)C(=C)C4=O)O)(C)C", "Single/Combination": "Single", "PMID": "34923957", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human plasma-cell malignancy", "System": "OCI-MY5", "Dose": "0–80 μM for 24, 48 and 72 h; selected apoptosis experiments at 10 μM for 24 h", "Technique": "Annexin V-FITC/PI flow cytometry, Western blot, qPCR", "Controlled_Technique": "cleaved PARP and cleaved caspase-3, caspase 3 mRNA", "Immune_System-Function_enhanced/numbers_increased": "PARP cleavage / PARP; Caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "anti-apoptosis-related protein (Bcl-2) , decreased the levels of p-STAT3. STAT3", "Immune_System-Function_inhibited/numbers_decreased": "Apoptosis; Expression / abundance phenotype; BCL-2; STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/629", "Drug": "Glaucocalyxin A", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits STAT3 phosphorylation; reduces STAT3-associated survival signaling", "KEGG_Drug__ID": null, "Pubchem_ID": "10471963", "STR_LINK_(SMILES)": "C[C@@]12CCC(=O)C([C@H]1C[C@H]([C@]34[C@H]2CC[C@H]([C@H]3O)C(=C)C4=O)O)(C)C", "Single/Combination": "Single", "PMID": "34923957", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human plasma-cell malignancy", "System": "OPM2", "Dose": "0–80 μM for 24, 48 and 72 h; selected apoptosis experiments at 10 μM for 24 h", "Technique": "Annexin V-FITC/PI flow cytometry, Western blot, qPCR", "Controlled_Technique": "cleaved PARP and cleaved caspase-3, caspase 3 mRNA", "Immune_System-Function_enhanced/numbers_increased": "PARP cleavage / PARP; Caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "anti-apoptosis-related protein (Bcl-2) , decreased the levels of p-STAT3. STAT3", "Immune_System-Function_inhibited/numbers_decreased": "Apoptosis; Expression / abundance phenotype; BCL-2; STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/630", "Drug": "Glaucocalyxin A", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits STAT3 phosphorylation; reduces STAT3-associated survival signaling", "KEGG_Drug__ID": null, "Pubchem_ID": "10471963", "STR_LINK_(SMILES)": "C[C@@]12CCC(=O)C([C@H]1C[C@H]([C@]34[C@H]2CC[C@H]([C@H]3O)C(=C)C4=O)O)(C)C", "Single/Combination": "Single", "PMID": "34923957", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human plasma-cell malignancy", "System": "KMS11", "Dose": "10 μM for 24 h in the reported STAT3/apoptosis experiments", "Technique": "Annexin V-FITC/PI flow cytometry, Western blot, qPCR", "Controlled_Technique": "cleaved PARP and cleaved caspase-3, caspase 3 mRNA", "Immune_System-Function_enhanced/numbers_increased": "PARP cleavage / PARP; Caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "anti-apoptosis-related protein (Bcl-2) , decreased the levels of p-STAT3. STAT3", "Immune_System-Function_inhibited/numbers_decreased": "Apoptosis; Expression / abundance phenotype; BCL-2; STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1003", "Drug": "Ibrutinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "26660519", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "H11 tumor cells were incubated with ibrutinib (1 µM) for 24 hours and then cocultured with splenocytes or purified splenic T cells from mice that had been treated with the ibrutinib/CpG combination", "Dose": "ibrutinib (1 µM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/183", "Drug": "IFL (irinotecan + 5-fluoruracil + levofolinic acid)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762, DB11596, DB00544", "Target/s_or_mechanism_of_action": "Irinotecan inhibits the action of topoisomerase I\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D08086, D04715, D00584", "Pubchem_ID": "60838, 149436, 3385", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "HT29", "Dose": "levofolinic acid was added at a concentration of 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": "cytofluorimetric and Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "up-regulation of EGFR on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "EGFR; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/184", "Drug": "IFL (irinotecan + 5-fluoruracil + levofolinic acid)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762, DB11596, DB00544", "Target/s_or_mechanism_of_action": "Irinotecan inhibits the action of topoisomerase I\n As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects\n Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D08086, D04715, D00584", "Pubchem_ID": "60838, 149436, 3385", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, \n NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, \n FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "20399639", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Carcinoma", "System": "SW620", "Dose": "levofolinic acid was added at a concentration of 2 microg/ml (10)4 M) +5-FU was added at a concentration of 500 microgram/ml + irinotecan at a concentration of\n 100 microgram/ml", "Technique": "cytofluorimetric and Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "up-regulation of EGFR on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "EGFR; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1438", "Drug": "IFN-γ + MEK inhibitor trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10175", "Pubchem_ID": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "30546955", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCCVII mouse cells", "Dose": "trametinib (30 nM), IFN-γ (1 ng/ml)", "Technique": "Flow cytometry,qRT-PCR, Western blotting", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CXCL9 and CXCL10 MHC-encoded class I molecule H-2Kk", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; CXCL10 / IP-10; CXCL9 / MIG;", "Immune_System-Function_inhibited/numbers_decreased": "Erk1/2 activation", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway"}, {"ID": "CANIMM/1450", "Drug": "ILT2 Blockade(HP-F1 antibody, which blocks the interaction between ILT2 and its ligands)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "30619281", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "HL60", "Dose": "0-8 µM", "Technique": "CCK-8 assay,Flow cytometry,westen blot, DNA ladder assay and a Flow cytometry analysis with Annexin V/PI double staining,Western blotting,qRT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity,Cell cycle arrest,p21 protein,apoptosis-Bax protein increased", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell-cycle arrest; Cell proliferation; BAX; p21 / CDKN1A", "Immune_System-Function_inhibited/numbers_decreased": "Bcl-2 and Procaspase-3", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1451", "Drug": "ILT2 Blockade(HP-F1 antibody, which blocks the interaction between ILT2 and its ligands) + IL-2", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30619281", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "NB4", "Dose": "0-8 µM", "Technique": "CCK-8 assay,Flow cytometry,westen blot, DNA ladder assay and a Flow cytometry analysis with Annexin V/PI double staining,Western blotting,qRT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity,Cell cycle arrest,p21 protein,apoptosis-Bax protein increased", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell-cycle arrest; Cell proliferation; BAX; p21 / CDKN1A", "Immune_System-Function_inhibited/numbers_decreased": "Bcl-2 and Procaspase-3", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1452", "Drug": "ILT2 Blockade(HP-F1 antibody, which blocks the interaction between ILT2 and its ligands) + IL-2", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30619281", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "HL60", "Dose": "chidamide (0.5 μM) combined with decitabine (5 μM) for 72 h", "Technique": "CCK-8 assay,Flow cytometry,westen blot, DNA ladder assay and a Flow cytometry analysis with Annexin V/PI double staining,Western blotting,qRT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity,Cell cycle arrest,p21 protein,apoptosis-Bax protein increased", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell-cycle arrest; Cell proliferation; BAX; p21 / CDKN1A", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1453", "Drug": "ILT2 Blockade(HP-F1 antibody, which blocks the interaction between ILT2 and its ligands) and lenalidomide", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30619281", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "NB4", "Dose": "chidamide (0.5 μM) combined with decitabine (5 μM) for 72 h", "Technique": "CCK-8 assay,Flow cytometry,westen blot, DNA ladder assay and a Flow cytometry analysis with Annexin V/PI double staining,Western blotting,qRT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity,Cell cycle arrest,p21 protein,apoptosis-Bax protein increased", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell-cycle arrest; Cell proliferation; BAX; p21 / CDKN1A", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/564", "Drug": "Irinotecan+ AZD7762", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 ;Chk1/Chk2 inhibition", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "SW620", "Dose": "IRI 25 µg/mL; AZD7762 100 nM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "Reduced MHC-I expression as AZD7762 Interfered with the MHC-I increase induced by topoisomerase inhibition", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/565", "Drug": "Irinotecan+ AZD7762", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 ;Chk1/Chk2 inhibition", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "RKO", "Dose": "IRI 25 µg/mL; AZD7762 100 nM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "Reduced MHC-I expression as AZD7762 Interfered with the MHC-I increase induced by topoisomerase inhibition", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/566", "Drug": "Irinotecan+ AZD7762", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 ;Chk1/Chk2 inhibition", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "HT-29", "Dose": "IRI 25 µg/mL; AZD7762 100 nM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "Reduced MHC-I expression as AZD7762 Interfered with the MHC-I increase induced by topoisomerase inhibition", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/567", "Drug": "Irinotecan+KU60019", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 ,ATM inhibition", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "SW620", "Dose": "IRI 25 µg/mL; KU60019 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "Reduced MHC-I expression", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/568", "Drug": "Irinotecan+KU60019", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 ,ATM inhibition", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "RKO", "Dose": "IRI 25 µg/mL; KU60019 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "Reduced MHC-I expression", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/570", "Drug": "Irinotecan+KU60019", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 ,ATM inhibition", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "HT-29", "Dose": "IRI 25 µg/mL; KU60019 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "Reduced MHC-I expression", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/561", "Drug": "Irinotecan+SM-7366", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 and NF-κB pathway inhibitor", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "SW620", "Dose": "5 µM; 25 µg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Combination therapy enhanced the surface expression of MHC I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/562", "Drug": "Irinotecan+SM-7366", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 and NF-κB pathway inhibitor", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "HCT116", "Dose": "5 µM; 25 µg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Combination therapy enhanced the surface expression of MHC I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/563", "Drug": "Irinotecan+SM-7366", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 and NF-κB pathway inhibitor", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "HT-29", "Dose": "5 µM; 25 µg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Combination therapy enhanced the surface expression of MHC I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/571", "Drug": "Irinotecan+VE822", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 , ATR inhibition", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "SW620", "Dose": "IRI 25 µg/mL; VE-822 100 nM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/572", "Drug": "Irinotecan+VE822", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 , ATR inhibition", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "RKO", "Dose": "IRI 25 µg/mL; VE-822 100 nM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "Reduced MHC-I expression", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/573", "Drug": "Irinotecan+VE822", "Drug_category": "Others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1 , ATR inhibition", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "HT-29", "Dose": "IRI 25 µg/mL; VE-822 100 nM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "Reduced MHC-I expression", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/508", "Drug": "JQ1", "Drug_category": "Others/combination", "Drugbank_ID": "DB17021", "Target/s_or_mechanism_of_action": "BRD4 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "46907787", "STR_LINK_(SMILES)": "CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C", "Single/Combination": "Single", "PMID": "35517410", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "MC38-OVA + OT-I CD8+ T cells", "Dose": "JQ1 pretreatment 0.1μM, 48 h; OVA peptide 100 ng/mL", "Technique": "Antigen-specific CTL assay", "Controlled_Technique": "CD8+ T-cell-mediated tumor-cell killing by promoting MHC-I-mediated antigen presentation", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; CD8; T cells; Antigen presentation", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/505", "Drug": "JQ1", "Drug_category": "Others/combination", "Drugbank_ID": "DB17021", "Target/s_or_mechanism_of_action": "BRD4 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "46907787", "STR_LINK_(SMILES)": "CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C", "Single/Combination": "Single", "PMID": "35517410", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "DLD1", "Dose": "0.1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "HLA-ABC, MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "surface PD-L1", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 / CD274", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1134", "Drug": "JQ1 (BET inhibitor) in combination with ricolinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "46907787, 53340666", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C,\n ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "31015208", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "primary CD138+ cells collected from patients with MM (n = 10)", "Dose": "500 nM JQ1, 3 μM ricolinostat", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antimyeloma activity", "Controlled_Terms_Function_enhanced_Number_increased": "Antimyeloma activity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1505", "Drug": "JQ1 (BET inhibitor) in combination with ricolinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "46907787, 53340666", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C,\n ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "31015208", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "LP-1", "Dose": "500 nM JQ1, 3 μM ricolinostat", "Technique": "immunoblotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis induction-caspase-3 cleavage and DNA fragmentation", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "c-MYC and BCL-2 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-2; FOS / c-MYC; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/281", "Drug": "JQ1 (BET inhibitor) in combination with ricolinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "46907787, 53340666", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C,\n ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "31015208", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "500 nM JQ1, 3 μM ricolinostat", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis induction-caspase-3 cleavage and DNA fragmentation", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "c-MYC and BCL-2 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-2; FOS / c-MYC; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/282", "Drug": "JQ1 (BET inhibitor) in combination with ricolinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug__ID": "D10661", "Pubchem_ID": "46907787, 53340666", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C,\n ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "31015208", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "RPMI-8226", "Dose": "500 nM JQ1, 3 μM ricolinostat", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis induction-caspase-3 cleavage and DNA fragmentation", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "c-MYC and BCL-2 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "BCL-2; FOS / c-MYC; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1145", "Drug": "JQ1 (BET inhibitor) in combination with vorinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "46907787, 5311", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C,\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "31015208", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "LP-1", "Dose": "500 nM JQ1, 1 μM vorinostat", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antimyeloma activity", "Controlled_Terms_Function_enhanced_Number_increased": "Antimyeloma activity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1156", "Drug": "JQ1 (BET inhibitor) in combination with vorinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "46907787, 5311", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C,\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "31015208", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "500 nM JQ1, 1 μM vorinostat", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antimyeloma activity", "Controlled_Terms_Function_enhanced_Number_increased": "Antimyeloma activity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1167", "Drug": "JQ1 (BET inhibitor) in combination with vorinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug__ID": "D06320", "Pubchem_ID": "46907787, 5311", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C,\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "31015208", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "primary CD138+ cells collected from patients with MM (n = 10)", "Dose": "500 nM JQ1, 1 μM vorinostat", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antimyeloma activity", "Controlled_Terms_Function_enhanced_Number_increased": "Antimyeloma activity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/963", "Drug": "JQ1, an inhibitor of the BET family of bromodomain proteins", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma.", "KEGG_Drug__ID": null, "Pubchem_ID": "46907787", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C", "Single/Combination": "Single Drug", "PMID": "28408401", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "FOXP3+ Tregs present within dissociated tumors from NSCLC patients", "Dose": "2.5μm", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "FOXP3, CTLA-4, and PD-1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1; CTLA-4; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/533", "Drug": "Luminespib + Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition+Inhibits caspases, including caspase-associated apoptotic signaling", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077 + 12000240", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C and C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "Panc02", "Dose": "0.5 + 10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Increased IFN-β, CXCL10, ISG15, and type I IFN signaling", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/728", "Drug": "Lapatinib followed by Trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB01259, DB00072", "Target/s_or_mechanism_of_action": "Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (HER1/EGFR/ERBB1) and human epidermal growth factor receptor type 2 (HER2/ERBB2)with a dissociation half-life of ≥300 minutes.\n Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D04024, D03257", "Pubchem_ID": "208908, 46507516", "STR_LINK_(SMILES)": "CS(=O(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "28735814", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "Lapatinib 2 μM concentration and a 48 h timepoint for TKI exposure", "Technique": "High content analysis, LDH-release ADCC assays", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay; LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": "increased HER2 levels in MCF-7 (1.3 ± 0.1 fold increase)", "Controlled_Terms_Function_enhanced_Number_increased": "HER2 / ERBB2; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "trastuzumab-mediated ADCC", "Controlled_Terms_Unaffected": "ADCC; Antibody-dependent cytotoxicity", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/729", "Drug": "Lapatinib followed by Trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB01259, DB00072", "Target/s_or_mechanism_of_action": "Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (HER1/EGFR/ERBB1) and human epidermal growth factor receptor type 2 (HER2/ERBB2)with a dissociation half-life of ≥300 minutes.\n Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D04024, D03257", "Pubchem_ID": "208908, 46507516", "STR_LINK_(SMILES)": "CS(=O(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "28735814", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SKBR3", "Dose": "Lapatinib 2 μM concentration and a 48 h timepoint for TKI exposure", "Technique": "High content analysis, LDH-release ADCC assays", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay; LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": "increased HER2 levels in SKBR3\n (2.1 ± 0.6 fold increase)", "Controlled_Terms_Function_enhanced_Number_increased": "HER2 / ERBB2; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "trastuzumab-mediated ADCC", "Controlled_Terms_Unaffected": "ADCC; Antibody-dependent cytotoxicity", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/730", "Drug": "Lapatinib followed by Trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB01259, DB00072", "Target/s_or_mechanism_of_action": "Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (HER1/EGFR/ERBB1) and human epidermal growth factor receptor type 2 (HER2/ERBB2)with a dissociation half-life of ≥300 minutes.\n Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D04024, D03257", "Pubchem_ID": "208908, 46507516", "STR_LINK_(SMILES)": "CS(=O(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "28735814", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "PBMC samples displaying higher direct cytotoxicity against K562,", "Dose": "Lapatinib", "Technique": "High content analysis, LDH-release ADCC assays", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay; LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": "increase in trastuzumab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1178", "Drug": "Lenalidomide (CC-5013, IMiD3) + anti-CD40 SGN-40", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "16357183", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "lenalidomide-1 µM and anti-CD40 SGN-40= 2-10µg", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "MM cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Multiple myeloma cell death", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1189", "Drug": "Lenalidomide (CC-5013, IMiD3) + anti-CD40 SGN-40", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "16357183", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM1R", "Dose": "lenalidomide-10 µM and anti-CD40 SGN-40= 2-10µg", "Technique": "MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "MM cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Multiple myeloma cell death", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/236", "Drug": "Lenalidomide (CC-5013, IMiD3) + anti-CD40 SGN-40", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "16357183", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM patient PBMCs + autologous MM cell lysis", "Dose": "SGN-40 (1 µg/mL), lenalidomide (2 µM/L)", "Technique": "calcein-AM release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "antibody-dependent cell-mediated cytotoxicity (ADCC)", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1215", "Drug": "Lenalidomide (CC-5013, IMiD3) + anti-CD40 SGN-40", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "16357183", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "12BM", "Dose": "lenalidomide-10 µM and anti-CD40 SGN-40= 2-10µg", "Technique": "MTT assay, Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "MM cell death, cleavage of caspase-3, caspase-8, and\n PARP -markers of apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase-8; Caspase activation; Apoptosis; PARP cleavage / PARP; Multiple myeloma cell death", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1216", "Drug": "Lenalidomide (CC-5013, IMiD3) + anti-CD40 SGN-40", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "16357183", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "28BM", "Dose": "lenalidomide-10 µM and anti-CD40 SGN-40= 2-10µg", "Technique": "MTT assay, Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "MM cell death, cleavage of caspase-3, caspase-8, and\n PARP -markers of apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase-8; Caspase activation; Apoptosis; PARP cleavage / PARP; Multiple myeloma cell death", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1243", "Drug": "Lenalidomide (CC-5013, IMiD3) + anti-CD40 SGN-40", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "16357183", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "12BM + freshly isolated PBMC effectors at E/T\n ratios of 5:1, 10:1, and 40:1", "Dose": "SGN-40 (2 µg/mL), lenalidomide (2 µM/L)", "Technique": "calcein-AM release assay, Flow cytometry", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "CD56+ CD3+ NK cells, double-positive NK cells (CD16+CD56+CD3+as well as LFA 1+CD56+CD3+) antibody-dependent cell-mediated cytotoxicity (ADCC)", "Controlled_Terms_Function_enhanced_Number_increased": "CD3; CD16 / FcγRIIIa; CD56 / NCAM1; LFA-1; Cytotoxicity / cytolysis; ADCC; NK cells; Antibody-dependent cytotoxicity;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/576", "Drug": "Luminespib + Z-VAD-FMK", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Hsp90 inhibition combined with broad caspase inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "5497174", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C and C[C@@H](C(=O)N[C@@H](CC(=O)OC)C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1", "Single/Combination": "combination", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "MC38", "Dose": "0.5 + 20 µM; 24 h", "Technique": "RT-qPCR, immunoblotting", "Controlled_Technique": "Increased IFN-β and downstream signaling", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1244", "Drug": "Lenalidomide (CC-5013, IMiD3) + anti-CD40 SGN-40", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "16357183", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "12BM + freshly isolated PBMC effectors at E/T\n ratios of 5:1, 10:1, and 40:1", "Dose": "SGN-40 (2 µg/mL), lenalidomide (2 µM/L)", "Technique": "calcein-AM release assay, Flow cytometry", "Controlled_Technique": "Flow cytometry; Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "CD56+ CD3+ NK cells, double-positive NK cells (CD16+CD56+CD3+as well as LFA 1+CD56+CD3+) antibody-dependent cell-mediated cytotoxicity (ADCC)", "Controlled_Terms_Function_enhanced_Number_increased": "CD3; CD16 / FcγRIIIa; CD56 / NCAM1; LFA-1; Cytotoxicity / cytolysis; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1033", "Drug": "Lenalidomide + defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "24386306", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "BMMCs from MM patient", "Dose": "Len (3 µM) for 24 hours, and incubated in the presence of YB-AHM (0.1 µg/mL) for 24 hours", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1035", "Drug": "Lenalidomide + defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "24386306", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "RPMI 8226 and KMS-11 cells exhibitING SP fractions (MM drug-resistant) + PBMCs from 3 normal donors", "Dose": "Len (3 µM) , YB-AHM (0.1 µg/mL) combination for 24 hours", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ADCC activity against SP cells HM1.24 (CD317)", "Controlled_Terms_Function_enhanced_Number_increased": "CD317 / HM1.24; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1224", "Drug": "Lenalidomide + defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "24386306", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "PBMCs from 3 normal donors + RPMI 8226 cell", "Dose": "YB-AHM (0.1 µg/mL) for 4 hours, Len (3 µM) for 48 hours", "Technique": "Flow cytometric PKH26 assay. ADCC activity was determined by percentages of 7AAD+ dead cells in PKH26-labeled target MM cells", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1225", "Drug": "Lenalidomide + defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "24386306", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "PBMCs from patient with MM + RPMI 8226 cell", "Dose": "YB-AHM (0.1 µg/mL) for 4 hours, Len (3 µM) for 48 hours", "Technique": "Flow cytometric PKH26 assay. ADCC activity was determined by percentages of 7AAD+ dead cells in PKH26-labeled target MM cells", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1027", "Drug": "Lenalidomide + IFN-γ", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS-11", "Dose": "Lenalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1028", "Drug": "Lenalidomide + IFN-γ", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "Lenalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1029", "Drug": "Lenalidomide + IFN-γ", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "Lenalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1030", "Drug": "Lenalidomide + IFN-γ + panobinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB06603", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D04687, D10019", "Pubchem_ID": "216326, 6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "Lenalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ +25 nM panobinostat", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1031", "Drug": "Lenalidomide + IFN-γ + panobinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB06603", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D04687, D10019", "Pubchem_ID": "216326, 6918837", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,\n CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS-11", "Dose": "Lenalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ +25 nM panobinostat", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1032", "Drug": "Lenalidomide + IFN-γ + panobinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB06603", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D04687, D10019", "Pubchem_ID": "216326, 6918837", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "Lenalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ +25 nM panobinostat", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/778", "Drug": "Lenalidomide + IL21 )", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "27287425", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Raji cells followed by γ-irradiation (to prevent further cell proliferation) + purified T lymphocytes from healthy donors", "Dose": "SAHA (2.5 µM)", "Technique": "ELISA , [3H]-thymidine uptake assay for T cell proliferation", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cell viability/proliferation assay; Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "T cell proliferation", "Controlled_Terms_Function_enhanced_Number_increased": "Cell proliferation; T cells; T-cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1026", "Drug": "Lenalidomide +IPH2101", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB06049", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "Primary MM cells", "Dose": "5μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "UBLP-1", "Controlled_Terms_Function_enhanced_Number_increased": "ULBP1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1047", "Drug": "Lenalidomide +IPH2101", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB06049", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "U266", "Dose": "5μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICA , DR4, ULBP-2, CD112", "Controlled_Terms_Function_enhanced_Number_increased": "CD112 / Nectin-2 / PVRL2; ULBP2; MICA; TRAIL-R1 / DR4 / TNFRSF10A;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "ULBP-1, CD155, ULBP-3, and ULBP-4", "Controlled_Terms_Unaffected": "CD155 / PVR; ULBP1; ULBP3; ULBP4", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/408", "Drug": "Lenalidomide +IPH2101", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB06049", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "primary MM cells+ Healthy NK cells", "Dose": "5μM lenalidomide+30 μg/mL IPH2101", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/409", "Drug": "Lenalidomide +IPH2101", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB06049", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "22031859", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "patient-derived NK cells+ autologous MM tumor cells", "Dose": "5μM lenalidomide+30 μg/mL IPH2101", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/713", "Drug": "Lenalidomide +rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00073", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.", "KEGG_Drug__ID": "D04687, \n D02994", "Pubchem_ID": "216326, \n 46505820", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "18628480", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Mantle Cell Lymphoma (MCL)", "System": "CD20+ Jeko-1 (rituximab-coated)", "Dose": "(0.001-10 10 µM/L), 20 µg/mL rituximab", "Technique": "lactate dehydrogenase release assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell cytotoxicity, ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/718", "Drug": "Lenalidomide +rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00073", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.", "KEGG_Drug__ID": "D04687, \n D02994", "Pubchem_ID": "216326, \n 46505820", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "18628480", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - NHL", "System": "Namalwa(rituximab-coated NHL cell lines) + Purified NK cells", "Dose": "(0.001-10 10 µM/L), 20 µg/mL rituximab", "Technique": "lactate dehydrogenase release assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell cytotoxicity, ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/719", "Drug": "Lenalidomide +rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00073", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.", "KEGG_Drug__ID": "D04687, \n D02994", "Pubchem_ID": "216326, \n 46505820", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "18628480", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - NHL", "System": "primary tumor cells derived from three patients with B-CLL who have been treated with fludarabine plus cyclophosphamide, two of whom had relapsed after treatment + Purified NK cells", "Dose": "(0.001-10 10 µM/L), 20 µg/mL rituximab", "Technique": "lactate dehydrogenase release assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell cytotoxicity, ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; NK cells; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/264", "Drug": "PI3K inhibitor (LY294002; )", "Drug_category": "PI3K inhibitor", "Drugbank_ID": "DB02656", "Target/s_or_mechanism_of_action": "Protein kinase inhibitors, the mode of action of LY294002 is through competition with ATP for binding the PI3K active site", "KEGG_Drug__ID": "C15195", "Pubchem_ID": "3973", "STR_LINK_(SMILES)": "O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H157", "Dose": "1 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/720", "Drug": "Lenalidomide +rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00073", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.", "KEGG_Drug__ID": "D04687, \n D02994", "Pubchem_ID": "216326, \n 46505820", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "18628480", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - NHL", "System": "Raji (rituximab-coated NHL cell lines) + Purified NK cells", "Dose": "(0.001-10 10 µM/L), 20 µg/mL rituximab", "Technique": "lactate dehydrogenase release assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell cytotoxicity, monocyte-mediated lysis, ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; NK cells; Monocytes; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/721", "Drug": "Lenalidomide +rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00073", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.", "KEGG_Drug__ID": "D04687, \n D02994", "Pubchem_ID": "216326, \n 46505820", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "18628480", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - NHL", "System": "Farage (rituximab-coated NHL cell lines) +Purified NK cells", "Dose": "(0.001-10 10 µM/L), 20 µg/mL rituximab", "Technique": "lactate dehydrogenase release assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell cytotoxicity, monocyte-mediated lysis,ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; NK cells; Monocytes; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1380", "Drug": "Lenalidomide +rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00073", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.", "KEGG_Drug__ID": "D04687, \n D02994", "Pubchem_ID": "216326, \n 46505820", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "18772452", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Raji cells", "Dose": "(250 nM)", "Technique": "Time course RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "TNF-related costimulatory molecules - 4-1BB ligand (4-1BBL/TNFSF9),4-1BBL", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; 4-1BB ligand / TNFSF9; TNF-α / TNF; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/44", "Drug": "Lenalidomide +rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00073", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.", "KEGG_Drug__ID": "D04687, \n D02994", "Pubchem_ID": "216326, \n 46505820", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "25313353", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "U937", "Dose": "(250 nM)", "Technique": "Time course RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "TNF-related costimulatory molecules - 4-1BB ligand (4-1BBL/TNFSF9)", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; 4-1BB ligand / TNFSF9; TNF-α / TNF; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/117", "Drug": "Lenalidomide +rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00073", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.", "KEGG_Drug__ID": "D04687, \n D02994", "Pubchem_ID": "216326, \n 46505820", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "18772452", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Jurkat T cells (JA16 clone)", "Dose": "(500 nM)", "Technique": "Transcription Low Density Array,RT-PCR analysis,quantitative real time RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "TNF-related costimulatory molecules - 4-1BB ligand (4-1BBL/TNFSF9) p21/WAF/CDKN1A cell cycle inhibitor", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; 4-1BB ligand / TNFSF9; TNF-α / TNF; p21 / CDKN1A; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1004", "Drug": "Lenalidomide and\n pomalidomide", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB08910", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D04687, D08976", "Pubchem_ID": "216326, 134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,\n NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "28881567", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Kaposi Sarcoma And Primary Effusion Lymphoma (PEL)", "System": "BCBL-1", "Dose": "10 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MHC-1", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/780", "Drug": "Lenalidomide and alemtuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480,DB00087", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.", "KEGG_Drug__ID": "D04687, \n D02802", "Pubchem_ID": "216326, 46507379", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "27815572", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Raji cells followed by γ-irradiation (to prevent further cell proliferation) + purified T lymphocytes from healthy donors", "Dose": "(250 nM)", "Technique": "ELISA , [3H]-thymidine uptake assay for T cell proliferation", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cell viability/proliferation assay; Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "T cell proliferation", "Controlled_Terms_Function_enhanced_Number_increased": "Cell proliferation; T cells; T-cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/207", "Drug": "Lenalidomide and IL-2", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D04687", "Pubchem_ID": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30619281", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Jurkat", "Dose": "0.25 µM/L,TRAIL-(20 and 100 ng/mL, respectively)", "Technique": "Western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "TRAIL-induced apoptosis-phosphatidylserine externalization, processing of caspase-3 to its catalytically active large subunits (p19/p17) and cleavage of PARP", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Caspase-3; Caspase activation; Apoptosis; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/501", "Drug": "Macrocarpal I", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Binds TUBB2B (beta-tubulin) and PARP1; disrupts microtubule polymerization and DNA repair; activates PERK/eIF2A/ATF4/CHOP signaling and induces immunogenic cell death", "KEGG_Drug__ID": null, "Pubchem_ID": "10028546", "STR_LINK_(SMILES)": "CC(C)C[C@@H]([C@@H]1CC[C@@]([C@H]2[C@]1(CC[C@H](C2)C(C)(C)O)C)(C)O)C3=C(C(=C(C(=C3O)C=O)O)C=O)O", "Single/Combination": "Single", "PMID": "39987121", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Human colorectal adenocarcinoma cell line", "System": "DLD1", "Dose": "10, 50 and 100 µM in specified assays; 50 µM used for time-course and selected mechanistic assays", "Technique": "Immunofluorescence; flow cytometry; HMGB1 reporter assay; extracellular ATP assay; apoptosis and ferroptosis assays; western blot", "Controlled_Technique": "expression of ICD-associated DAMPs (CRT, HMGB1, and ATP)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1; Calreticulin / CRT; Immunogenic cell death; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "Induced tumor-cell apoptosis and ferroptosis; inhibited microtubule polymerization and PARP1 activity", "Immune_System-Function_inhibited/numbers_decreased": "Apoptosis", "Controlled_Terms_Function_inhibited_Number_decreased": "NR", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "NR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1245", "Drug": "Lenalidomide-rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00002", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D04687, D03455", "Pubchem_ID": "216326, 46507042", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30767211", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Follicular Lymphoma (FL)", "System": "RL", "Dose": "1 μmol/l lenalidomide and 1 μg/ml rituximab", "Technique": "Apoptosis analysis by Annexin V and TO-PRO-3 staining", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC 57%", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1256", "Drug": "Lenalidomide-rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00002", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D04687, D03455", "Pubchem_ID": "216326, 46507042", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30767211", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Follicular Lymphoma (FL)", "System": "DOHH2", "Dose": "1 μmol/l lenalidomide and 1 μg/ml rituximab", "Technique": "Apoptosis analysis by Annexin V and TO-PRO-3 staining", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "ADCC 69%", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/403", "Drug": "Lenalidomide-rituximab", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB00002", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug__ID": "D04687, D03455", "Pubchem_ID": "216326, 46507042", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30767211", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Follicular Lymphoma (FL)", "System": "PBMCs from FL patients", "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "interferon-y (IFN-y), granulocyte macrophage\n colony-stimulating factor (GM-CSF) and\n tumour necrosis factor-a (TNF-a)", "Controlled_Terms_Function_enhanced_Number_increased": "TNF-α / TNF; GM-CSF / CSF2; Macrophages; Granulocytes; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/743", "Drug": "Lenalidomide+thalidomide+pomalidomide", "Drug_category": "Others/combination", "Drugbank_ID": "DB00480, DB01041, DB08910", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Previous research indicate that thalidomide binds to cerebron, a component of the E3 ubiquitin ligase complex, to selectively degrade the transcription factor IKZF3 and IKZF1. These 2 transcription factors are vital for the proliferation and survival of malignant myeloma cells.\n Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D04687, D00754, D08976", "Pubchem_ID": "216326, 5426, 134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O\n O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12\n NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "19638977", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "CT26 cells", "Dose": "0.01 to 30 mM.", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "VEGF", "Controlled_Terms_Function_inhibited_Number_decreased": "VEGF", "Immune_System_function_unaffected": "IP10 and TIMP1", "Controlled_Terms_Unaffected": "CXCL10 / IP-10", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/518", "Drug": "Luminespib (AUY922)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "MC38", "Dose": "0.5 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Marginal IFN-β induction", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/521", "Drug": "Luminespib (AUY922)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "HT29", "Dose": "0.5 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Marginal IFN-β induction", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/525", "Drug": "Luminespib (AUY922)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "CT26", "Dose": "0.5 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Marginal IFN-β induction", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/528", "Drug": "Luminespib (AUY922)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "CTIAC11", "Dose": "0.5 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Marginal IFN-β induction", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/531", "Drug": "Luminespib (AUY922)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Hsp90 inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "Panc02", "Dose": "0.5 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Marginal IFN-β induction", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/520", "Drug": "Luminespib + Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition+Inhibits caspases, including caspase-associated apoptotic signaling", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077 + 12000240", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C and C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "MC38", "Dose": "0.5 + 10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Increased IFN-β, CXCL10, ISG15, and type I IFN signaling", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/523", "Drug": "Luminespib + Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition+Inhibits caspases, including caspase-associated apoptotic signaling", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077 + 12000240", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C and C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "HT29", "Dose": "0.5 + 10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Increased IFN-β, CXCL10, ISG15, and type I IFN signaling", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/527", "Drug": "Luminespib + Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition+Inhibits caspases, including caspase-associated apoptotic signaling", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077 + 12000240", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C and C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "CT26", "Dose": "0.5 + 10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Increased IFN-β, CXCL10, ISG15, and type I IFN signaling", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/530", "Drug": "Luminespib + Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition+Inhibits caspases, including caspase-associated apoptotic signaling", "KEGG_Drug__ID": null, "Pubchem_ID": "135539077 + 12000240", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C and C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Single", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "CTIAC11", "Dose": "0.5 + 10 µM; 24 h", "Technique": "ELISA, RT-qPCR", "Controlled_Technique": "Increased IFN-β, CXCL10, ISG15, and type I IFN signaling", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/500", "Drug": "Macrocarpal I", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Binds TUBB2B (beta-tubulin) and PARP1; disrupts microtubule polymerization and DNA repair; activates PERK/eIF2A/ATF4/CHOP signaling and induces immunogenic cell death", "KEGG_Drug__ID": null, "Pubchem_ID": "10028546", "STR_LINK_(SMILES)": "CC(C)C[C@@H]([C@@H]1CC[C@@]([C@H]2[C@]1(CC[C@H](C2)C(C)(C)O)C)(C)O)C3=C(C(=C(C(=C3O)C=O)O)C=O)O", "Single/Combination": "Single", "PMID": "39987121", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Human colorectal adenocarcinoma cell line", "System": "SW620", "Dose": "10, 50 and 100 µM in specified assays; 50 µM used for time-course and selected mechanistic assays", "Technique": "Immunofluorescence; flow cytometry; HMGB1 reporter assay; extracellular ATP assay, western blot", "Controlled_Technique": "expression of ICD-associated DAMPs (CRT, HMGB1, and ATP), activating the PERK/eIF2A/ATF4/CHOP signaling pathway, induces apoptosis and ferroptosis in tumor cells", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis; HMGB1; eIF2α / EIF2S1; Calreticulin / CRT; Immunogenic cell death; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "Induced tumor-cell apoptosis and ferroptosis; inhibited microtubule polymerization and PARP1 activity", "Immune_System-Function_inhibited/numbers_decreased": "Apoptosis", "Controlled_Terms_Function_inhibited_Number_decreased": "NR", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "NR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/761", "Drug": "MC1568", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "HDAC Inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "11381449", "STR_LINK_(SMILES)": "CN1C=C(C=C1/C=C/C(=O)NO)/C=C/C(=O)C2=CC(=CC=C2)F", "Single/Combination": "Single Drug", "PMID": "27614429", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Mantle Cell Lymphoma (MCL)", "System": "JeKo-1 + co-cultured with DN32.D3 and N38-3C3", "Dose": "50 nM MC1568 for 4 h,", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD1D-mediated antigen presentation IL-2 levels", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d; IL-2; Antigen presentation; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1620", "Drug": "MEKi PD0325901", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "SW1736", "Dose": "MEKi PD0325901 10μM", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1621", "Drug": "MEKi PD0325901+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB07101", "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "8505c", "Dose": "MEKi PD0325901(10μM )+hIFN-y (500U/ml)", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression and mRNA exxpression phospho ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; ERK / MAPK; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1623", "Drug": "MEKi PD0325901+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB07101", "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "BCPAP", "Dose": "MEKi PD0325901(10μM )+hIFN-y (500U/ml)", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression and mRNA exxpression phospho ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; ERK / MAPK; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1624", "Drug": "MEKi PD0325901+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB07101", "Target/s_or_mechanism_of_action": "PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug__ID": null, "Pubchem_ID": "9826528", "STR_LINK_(SMILES)": "[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "System": "SW1736", "Dose": "MEKi PD0325901(10μM )+hIFN-y (500U/ml)", "Technique": "Quantitative PCR, Western blot", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 protein expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/582", "Drug": "Melarsoprol (MEL)", "Drug_category": "Others/combination", "Drugbank_ID": "DB12864", "Target/s_or_mechanism_of_action": "DNA damage; activates cGAS–STING–TBK1–IRF3 signaling, promoting IFN-β production", "KEGG_Drug__ID": "D00832", "Pubchem_ID": "10311", "STR_LINK_(SMILES)": "C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO", "Single/Combination": "Single", "PMID": "40528981", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "mouse HCC cell line", "System": "Hepa1–6", "Dose": "20 µmol/L in vitro", "Technique": "Western blot, RT-qPCR, ELISA, cGAS–STING signaling", "Controlled_Technique": "expression of IFN-β mRNA and protein,", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/583", "Drug": "Melarsoprol (MEL)", "Drug_category": "Others/combination", "Drugbank_ID": "DB12864", "Target/s_or_mechanism_of_action": "DNA damage; activates cGAS–STING–TBK1–IRF3 signaling, promoting IFN-β production", "KEGG_Drug__ID": "D00832", "Pubchem_ID": "10311", "STR_LINK_(SMILES)": "C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO", "Single/Combination": "Single", "PMID": "40528981", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Human HCC cell line", "System": "HepG2", "Dose": "20 µmol/L in vitro", "Technique": "Western blot, RT-qPCR, ELISA, cGAS–STING signaling", "Controlled_Technique": "expression of IFN-β mRNA and protein,", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/586", "Drug": "Melarsoprol (MEL)+Lenalidomide (LEN)", "Drug_category": "Others/combination", "Drugbank_ID": "DB12864+DB00480", "Target/s_or_mechanism_of_action": "DNA damage; activates cGAS–STING–TBK1–IRF3 signaling, promoting IFN-β production", "KEGG_Drug__ID": "D00832+\t\nD04687", "Pubchem_ID": "10311+216326", "STR_LINK_(SMILES)": "C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO and C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N", "Single/Combination": "combination", "PMID": "40528981", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "mouse HCC cell line", "System": "Hepa1–6", "Dose": "20 µmol/L in vitro  and 40 µmol/L in vitro", "Technique": "Western blot, RT-qPCR, ELISA, cGAS–STING signaling", "Controlled_Technique": "maintenance of IFN-β", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": "reduction of TNF-α", "Immune_System-Function_inhibited/numbers_decreased": "TNF-α / TNF", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/587", "Drug": "Melarsoprol (MEL)+Lenalidomide (LEN)", "Drug_category": "Others/combination", "Drugbank_ID": "DB12864+DB00480", "Target/s_or_mechanism_of_action": "DNA damage; activates cGAS–STING–TBK1–IRF3 signaling, promoting IFN-β production", "KEGG_Drug__ID": "D00832+\t\nD04687", "Pubchem_ID": "10311+216326", "STR_LINK_(SMILES)": "C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO and C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N", "Single/Combination": "combination", "PMID": "40528981", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Human HCC cell line", "System": "HepG2", "Dose": "20 µmol/L in vitro  and 40 µmol/L in vitro", "Technique": "Western blot, RT-qPCR, ELISA, cGAS–STING signaling", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/279", "Drug": "MiD1 + TRAIL/Apo2L", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "12036884", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "1 µM IMiD1 for 4 hours, and a low concentration of TRAIL/Apo2L (50 ng/mL)", "Technique": "ImmImmunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "ICAM-1 antiapoptotic proteins cIAP-2 and FLIP", "Controlled_Terms_Function_inhibited_Number_decreased": "ICAM-1 / CD54; Apoptosis; cIAP-2 / BIRC3; FLIP / CFLAR", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/689", "Drug": "Mitomycin C (MMC)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "DNA crosslinking and inhibition of DNA synthesis", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40380807", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "gastric cancer cell line", "System": "AGS", "Dose": "1.254μM", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Increased cell-surface PD-L1 and MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Increased PD-L1 may promote inhibitory immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/690", "Drug": "Mitomycin C (MMC)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "DNA crosslinking and inhibition of DNA synthesis", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40380807", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "gastric cancer cell line", "System": "SNU-1", "Dose": "0.85μM", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Increased cell-surface PD-L1 and MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Increased PD-L1 may promote inhibitory immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1428", "Drug": "MMC (mitomycin)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00305", "Target/s_or_mechanism_of_action": "Mitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitomycin is cell cycle phase-nonspecific.", "KEGG_Drug__ID": "D00208", "Pubchem_ID": "5746", "STR_LINK_(SMILES)": "[H][C@]12CN3C4=C([C@@H](COC(N)=O)[C@@]3(OC)[C@@]1([H])N2)C(=O)C(N)=C(C)C4=O", "Single/Combination": "Single Drug", "PMID": "16957513", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "Colon cancer (SW480) cells", "Dose": "MMC (mitomycin) IC 50: 3.12ug/ml", "Technique": "Immunocytochemistry\n and Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": "Fas, FasL", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; Fas ligand / FasL / FASLG", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/834", "Drug": "MPT0G612", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "a Novel HDAC6 Inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31652644", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "DLD-1", "Dose": "0-5 µM", "Technique": "SRB and MTT assay", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "antiproliferation activity", "Controlled_Terms_Function_enhanced_Number_increased": "Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/845", "Drug": "MPT0G612", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "a Novel HDAC6 Inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31652644", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HT-29", "Dose": "0-5 µM", "Technique": "SRB and MTT assay, propidium iodide (PI) staining", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis, antiproliferation activity, apoptotic cell death-related proteins (cleaved PARP and caspase 3/8/9), cell cycle arrest", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; Cell-cycle arrest; Cell proliferation; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ-Induced PD-L1 Expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; IFN-γ; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1473", "Drug": "MPT0G612", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "a Novel HDAC6 Inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31652644", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HT-29", "Dose": "0-10 μm", "Technique": "propidium iodide (PI) staining-Flow cytometry,western blot analysis-two critical autophagic biomarkers LC3B-II and p62", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis induction-apoptotic cell death-related proteins (cleaved PARP and caspase 3/8/9)", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ-Induced PD-L1 Expression in CRC Cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; IFN-γ; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1474", "Drug": "MPT0G612", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "a Novel HDAC6 Inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31652644", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116 cells", "Dose": "0-10 μm", "Technique": "propidium iodide (PI) staining-Flow cytometry,western blot analysis-two critical autophagic biomarkers LC3B-II and p62", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis induction-apoptotic cell death-related proteins (cleaved PARP and caspase 3/8/9) , autophagy- LC3B-II formation and downregulation of p62", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; Autophagy / macroautophagy; PARP cleavage / PARP; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ-Induced PD-L1 Expression in CRC Cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; IFN-γ; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/321", "Drug": "MPT0G612", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "a Novel HDAC6 Inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31652644", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116", "Dose": "0-5 µM", "Technique": "SRB and MTT assay, propidium iodide (PI) staining, western blot analysis, immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis, antiproliferation activity, apoptotic cell death-related proteins (cleaved PARP and caspase 3/8/9), cell cycle arrest,", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; Cell-cycle arrest; Cell proliferation; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": "IFN-γ-Induced PD-L1 Expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; IFN-γ; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Autophagy activation -with LC3B-II formation and p62 degradation", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/189", "Drug": "MPT0G612 + chloroquine", "Drug_category": "Others/combination", "Drugbank_ID": "DB00608", "Target/s_or_mechanism_of_action": "a Novel HDAC6 Inhibitor, Chloroquine inhibits the action of heme polymerase in malarial trophozoites, preventing the conversion of heme to hemazoin.11,15,16 Plasmodium species continue to accumulate toxic heme, killing the parasite.11", "KEGG_Drug__ID": "D02366", "Pubchem_ID": "2719", "STR_LINK_(SMILES)": "CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12", "Single/Combination": "Combination", "PMID": "31652644", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116", "Dose": "MPT0G612 0-5 µM and chloroquine upto 25 µM", "Technique": "western blot analysis", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptotic cell death- activated caspase 3/9 and PARP", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": "autophagy", "Controlled_Terms_Function_inhibited_Number_decreased": "Autophagy / macroautophagy", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/327", "Drug": "MRX-2843", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32642716", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "System": "MRX-2843-treated anti-inflammatory macrophages", "Dose": "MRX-2843 100 nM", "Technique": "cytokine array assay, Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL-8 and CCL2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/328", "Drug": "MRX-2843", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32642716", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "System": "MRX-2843-treated pro-inflammatory macrophages", "Dose": "MRX-2843 100 nM", "Technique": "cytokine array assay, Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL-8 and CCL2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/329", "Drug": "MRX-2843", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32642716", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "System": "U251 cells", "Dose": "MRX-2843 100 nM", "Technique": "cytokine array assay, Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL-8 and CCL2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/330", "Drug": "MRX-2843", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32642716", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "System": "GSC923", "Dose": "MRX-2843 100 nM", "Technique": "cytokine array assay, Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL-8 and CCL2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/331", "Drug": "MRX-2843", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32642716", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "System": "GSC407 cells", "Dose": "MRX-2843 100 nM", "Technique": "cytokine array assay, Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL-8 and CCL2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/931", "Drug": "MS-275 (entinostat) ++tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)", "Drug_category": "Others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug__ID": "D09338", "Pubchem_ID": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "16818655", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs", "Dose": "2.5-7.5 mg/day", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "BID, DR5, and p73 CD154", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL-R2 / DR5 / TNFRSF10B; BID", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/724", "Drug": "Neratinib followed by Trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB11828, DB00072", "Target/s_or_mechanism_of_action": "Neratinib binds to and irreversibly inhibits EGFR, HER2, and HER4 [FDA Label]. This prevents auotphoshorylation of tyrosine residues on the receptor and reduces oncogenic signalling through the mitogen-activated protein kinase and Akt pathways.\n Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "9915743, 46507516", "STR_LINK_(SMILES)": "CCOC1=C(NC(=O)\\C=C\\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N", "Single/Combination": "Combination", "PMID": "28735814", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SKBR3", "Dose": "Neratinib 2 μM concentration and a 48 h timepoint for TKI exposure", "Technique": "High content analysis, LDH-release ADCC assays", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay; LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": "trastuzumab-mediated ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": "decreased HER2 levels in SKBR3 (neratinib\n 0.6 ± 0.1 fold)", "Controlled_Terms_Function_inhibited_Number_decreased": "HER2 / ERBB2; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/725", "Drug": "Neratinib followed by Trastuzumab", "Drug_category": "Others/combination", "Drugbank_ID": "DB11828, DB00072", "Target/s_or_mechanism_of_action": "Neratinib binds to and irreversibly inhibits EGFR, HER2, and HER4 [FDA Label]. This prevents auotphoshorylation of tyrosine residues on the receptor and reduces oncogenic signalling through the mitogen-activated protein kinase and Akt pathways.\n Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "9915743, 46507516", "STR_LINK_(SMILES)": "CCOC1=C(NC(=O)\\C=C\\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N", "Single/Combination": "Combination", "PMID": "28735814", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "Neratinib 2 μM concentration and a 48 h timepoint for TKI exposure", "Technique": "High content analysis, LDH-release ADCC assays", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay; LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "decreased HER2 levels in SKBR3 (0.3 ± 0.1 fold)", "Controlled_Terms_Function_inhibited_Number_decreased": "HER2 / ERBB2; Expression / abundance phenotype", "Immune_System_function_unaffected": "trastuzumab-mediated ADCC", "Controlled_Terms_Unaffected": "ADCC; Antibody-dependent cytotoxicity", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/208", "Drug": "Ofatumumab and lenalidomide", "Drug_category": "Others/combination", "Drugbank_ID": "DB06650, DB00480", "Target/s_or_mechanism_of_action": "Ofatumumab is an anti-CD20 monoclonal antibody that binds to the small and large extracellular loops of the CD20 molecule. The Fab domain of ofatumumab binds to CD20, and this drug-target interaction does not result in immediate shedding and internalization of CD20 from the plasma membrane of B lymphocytes\n In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug__ID": "D09314, D04687", "Pubchem_ID": "347910355, 216326", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "26733610", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "K562 cells", "Dose": "0.25 µM/L,TRAIL-(20 and 100 ng/mL, respectively)", "Technique": "Western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "TRAIL-induced apoptosis-phosphatidylserine externalization, processing of caspase-3 to its catalytically active large subunits (p19/p17) and cleavage of PARP", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Caspase-3; Caspase activation; Apoptosis; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/655", "Drug": "Olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074", "Target/s_or_mechanism_of_action": "Inhibits PARP1/2-mediated DNA repair", "KEGG_Drug__ID": "D09730", "Pubchem_ID": "23725625", "STR_LINK_(SMILES)": "C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "SW684", "Dose": "5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "percentage of OCT4+ cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/656", "Drug": "Olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074", "Target/s_or_mechanism_of_action": "Inhibits PARP1/2-mediated DNA repair", "KEGG_Drug__ID": "D09730", "Pubchem_ID": "23725625", "STR_LINK_(SMILES)": "C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "402.91", "Dose": "5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "percentage of OCT4+ cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/658", "Drug": "Olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074", "Target/s_or_mechanism_of_action": "Inhibits PARP1/2-mediated DNA repair", "KEGG_Drug__ID": "D09730", "Pubchem_ID": "23725625", "STR_LINK_(SMILES)": "C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "DMR", "Dose": "5 µM in vitro; animal dose NR", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "percentage of OCT4+ cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/659", "Drug": "Olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074", "Target/s_or_mechanism_of_action": "Inhibits PARP1/2-mediated DNA repair", "KEGG_Drug__ID": "D09730", "Pubchem_ID": "23725625", "STR_LINK_(SMILES)": "C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "MES-SA", "Dose": "5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "percentage of OCT4+ cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/660", "Drug": "Olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074", "Target/s_or_mechanism_of_action": "Inhibits PARP1/2-mediated DNA repair", "KEGG_Drug__ID": "D09730", "Pubchem_ID": "23725625", "STR_LINK_(SMILES)": "C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "S018", "Dose": "5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "percentage of OCT4+ cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/661", "Drug": "Olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074", "Target/s_or_mechanism_of_action": "Inhibits PARP1/2-mediated DNA repair", "KEGG_Drug__ID": "D09730", "Pubchem_ID": "23725625", "STR_LINK_(SMILES)": "C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "S006", "Dose": "5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "percentage of OCT4+ cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/717", "Drug": "Olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074", "Target/s_or_mechanism_of_action": "Inhibits PARP1/2-mediated DNA repair", "KEGG_Drug__ID": "D09730", "Pubchem_ID": "23725625", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40986050", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Sarcoma", "System": "HT-1080", "Dose": "5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "percentage of OCT4+ cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/486", "Drug": "Olaparib + AZD1775", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074 + DB11740", "Target/s_or_mechanism_of_action": "Combined PARP and WEE1 inhibition increases replication catastrophe/DNA damage and activates cGAS–STING signaling", "KEGG_Drug__ID": "D09713 + D11361", "Pubchem_ID": "23725625 + 24856436", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wildtype TNBC", "System": "HCC1806", "Dose": "olaparib 1 µM (5 µM MDA-MB-231) + AZD1775 200 nM; 72 h", "Technique": "Chou–Talalay synergy; clonogenic assay; RNA-seq; western blot; flow cytometry; tumor growth; survival; immune profiling", "Controlled_Technique": "STING/pTBK1/pIRF3 signaling,  CXCL10, IFIT3, ISG15, MX1, OAS2, OASL, TNF,  MHC-I/II genes expression and antigen-processing genes expression Tap1, , TAPBP, PSMB9, tumor-cell surface MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; TNF-α / TNF; CXCL10 / IP-10; TAP1; Tapasin; LMP2 / PSMB9; Antigen presentation; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/487", "Drug": "Olaparib + AZD1775", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074 + DB11740", "Target/s_or_mechanism_of_action": "Combined PARP and WEE1 inhibition increases replication catastrophe/DNA damage and activates cGAS–STING signaling", "KEGG_Drug__ID": "D09713 + D11361", "Pubchem_ID": "23725625 + 24856436", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wildtype TNBC", "System": "MDA-MB-468", "Dose": "olaparib 1 µM (5 µM MDA-MB-231) + AZD1775 200 nM; 72 h", "Technique": "Chou–Talalay synergy; clonogenic assay; RNA-seq; western blot; flow cytometry; tumor growth; survival; immune profiling", "Controlled_Technique": "STING/pTBK1/pIRF3 signaling,  CXCL10, IFIT3, ISG15, MX1, OAS2, OASL, TNF,  MHC-I/II genes expression and antigen-processing genes expression Tap1, , TAPBP, PSMB9, tumor-cell surface MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; TNF-α / TNF; CXCL10 / IP-10; TAP1; Tapasin; LMP2 / PSMB9; Antigen presentation; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/488", "Drug": "Olaparib + AZD1775", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074 + DB11740", "Target/s_or_mechanism_of_action": "Combined PARP and WEE1 inhibition increases replication catastrophe/DNA damage and activates cGAS–STING signaling", "KEGG_Drug__ID": "D09713 + D11361", "Pubchem_ID": "23725625 + 24856436", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wildtype TNBC", "System": "MDA-MB-231", "Dose": "olaparib 1 µM (5 µM MDA-MB-231) + AZD1775 200 nM; 72 h", "Technique": "Chou–Talalay synergy; clonogenic assay; RNA-seq; western blot; flow cytometry; tumor growth; survival; immune profiling", "Controlled_Technique": "STING/pTBK1/pIRF3 signaling,  CXCL10, IFIT3, ISG15, MX1, OAS2, OASL, TNF,  MHC-I/II genes expression and antigen-processing genes expression Tap1, , TAPBP, PSMB9, tumor-cell surface MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; TNF-α / TNF; CXCL10 / IP-10; TAP1; Tapasin; LMP2 / PSMB9; Antigen presentation; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/489", "Drug": "Olaparib + AZD1775", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074 + DB11740", "Target/s_or_mechanism_of_action": "Combined PARP and WEE1 inhibition increases replication catastrophe/DNA damage and activates cGAS–STING signaling", "KEGG_Drug__ID": "D09713 + D11361", "Pubchem_ID": "23725625 + 24856436", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wildtype TNBC", "System": "MDA-MB-436", "Dose": "olaparib 1 µM (5 µM MDA-MB-231) + AZD1775 200 nM; 72 h", "Technique": "Chou–Talalay synergy; clonogenic assay; RNA-seq; western blot; flow cytometry; tumor growth; survival; immune profiling", "Controlled_Technique": "STING/pTBK1/pIRF3 signaling,  CXCL10, IFIT3, ISG15, MX1, OAS2, OASL, TNF,  MHC-I/II genes expression and antigen-processing genes expression Tap1, , TAPBP, PSMB9, tumor-cell surface MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; TNF-α / TNF; CXCL10 / IP-10; TAP1; Tapasin; LMP2 / PSMB9; Antigen presentation; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/644", "Drug": "Tuvusertib (M1774)", "Drug_category": "Others/combination", "Drugbank_ID": "DB18790", "Target/s_or_mechanism_of_action": "ATR inhibitor", "KEGG_Drug__ID": "D12882", "Pubchem_ID": "90199447", "STR_LINK_(SMILES)": "CN1C=NC=C1C2=C(C=NC=C2NC(=O)C3=C4N=CC(=CN4N=C3N)F)F", "Single/Combination": "Single", "PMID": "41417226", "Cancer_Type": "Prostate", "Cancer_Type_Description": "DU145", "System": "Human NK cells", "Dose": "0.5 µM, 48 h pretreatment of tumor cells", "Technique": "flow cytometry; NK-cell lysis assay using xCELLigence RTCA", "Controlled_Technique": "TRAIL-R2 , NKG2D ligand ULBP-1", "Immune_System-Function_enhanced/numbers_increased": "TRAIL; NKG2D / KLRK1; TRAIL-R2 / DR5 / TNFRSF10B", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "TRAIL-R1", "Immune_System_function_unaffected": "TRAIL", "Controlled_Terms_Unaffected": "PD-L1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/490", "Drug": "Olaparib + AZD1775", "Drug_category": "Others/combination", "Drugbank_ID": "DB09074 + DB11740", "Target/s_or_mechanism_of_action": "Combined PARP and WEE1 inhibition increases replication catastrophe/DNA damage and activates cGAS–STING signaling", "KEGG_Drug__ID": "D09713 + D11361", "Pubchem_ID": "23725625 + 24856436", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wildtype TNBC", "System": "MDA-MB-453", "Dose": "olaparib 1 µM (5 µM MDA-MB-231) + AZD1775 200 nM; 72 h", "Technique": "Chou–Talalay synergy; clonogenic assay; RNA-seq; western blot; flow cytometry; tumor growth; survival; immune profiling", "Controlled_Technique": "STING/pTBK1/pIRF3 signaling,  CXCL10, IFIT3, ISG15, MX1, OAS2, OASL, TNF,  MHC-I/II genes expression and antigen-processing genes expression Tap1, , TAPBP, PSMB9, tumor-cell surface MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; TNF-α / TNF; CXCL10 / IP-10; TAP1; Tapasin; LMP2 / PSMB9; Antigen presentation; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1036", "Drug": "Panobinostat + IFN-γ-", "Drug_category": "Others/combination", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "25 nM panobinostat and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1447", "Drug": "Panobinostat + IFN-γ-", "Drug_category": "Others/combination", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS-11", "Dose": "25 nM panobinostat and 100 U/ml of IFN-γ", "Technique": "Flow cytometry,RT-PCR,western bloting", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "phosphorylated STAT1 (p-STAT1),IFN-γR1", "Controlled_Terms_Function_enhanced_Number_increased": "STAT1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1448", "Drug": "Panobinostat + IFN-γ-", "Drug_category": "Others/combination", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D10019", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "25 nM panobinostat and 100 U/ml of IFN-γ", "Technique": "Flow cytometry,RT-PCR,western bloting", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "phosphorylated STAT1 (p-STAT1),IFN-γR1", "Controlled_Terms_Function_enhanced_Number_increased": "STAT1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1549", "Drug": "Pemetrexed + sildenafil", "Drug_category": "Others/combination", "Drugbank_ID": "DB00642, DB00203", "Target/s_or_mechanism_of_action": "Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. \n sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP", "KEGG_Drug__ID": "D07472, \n D08514", "Pubchem_ID": "446556, \n 5212", "STR_LINK_(SMILES)": "NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,\n CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1", "Single/Combination": "Combination", "PMID": "28812434", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "Afatinib-resistant H1975 cells", "Dose": "[pemetrexed (1 uM) + sildenafil (2 uM)", "Technique": "immuno-fluorescence", "Controlled_Technique": "Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MHCA", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1, PD-L2 and ODC", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1550", "Drug": "Pemetrexed + sildenafil", "Drug_category": "Others/combination", "Drugbank_ID": "DB00642, DB00203", "Target/s_or_mechanism_of_action": "Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. \n sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP", "KEGG_Drug__ID": "D07472, \n D08514", "Pubchem_ID": "446556, \n 5212", "STR_LINK_(SMILES)": "NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,\n CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1", "Single/Combination": "Combination", "PMID": "28812434", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "LLC cells", "Dose": "[pemetrexed (1 uM) + sildenafil (2 uM)", "Technique": "immuno-fluorescence", "Controlled_Technique": "Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MHCA", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1, PD-L2 and ODC", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1551", "Drug": "Pemetrexed + sildenafil + sodium valproate", "Drug_category": "Others/combination", "Drugbank_ID": "DB00642, DB00203, DB00313", "Target/s_or_mechanism_of_action": "Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. \n sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP.\n Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug__ID": "D07472, \n D08514,\n D00399", "Pubchem_ID": "446556, \n 5212, 3121", "STR_LINK_(SMILES)": "NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,\n CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1,\n CCCC(CCC)C(O)=O", "Single/Combination": "Combination", "PMID": "28812434", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "LLC cells", "Dose": "[pemetrexed (1 uM) + sildenafil (2 uM) + sodium valproate (250 uM)", "Technique": "immuno-fluorescence", "Controlled_Technique": "Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "MHCA", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1, PD-L2 and ODC", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/357", "Drug": "PLX4720+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug__ID": null, "Pubchem_ID": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "10 μM10 μM PLX4720+100 U/mL IFNγ", "Technique": "Flow cytometery, Immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I molecules (HLA-A,B,C)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A;", "Immune_System-Function_inhibited/numbers_decreased": "Phospho-ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1168", "Drug": "Pmel-1 ACT+Dobrafenib+ Trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10064, D10175", "Pubchem_ID": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Gp10025-33–activated pmel-1 mouse splenocytes", "Dose": "D (0.1 mM)/T (0.005 mM),", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD3+CD8+ IFN-Y", "Controlled_Terms_Function_inhibited_Number_decreased": "CD3; CD8; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1177", "Drug": "Vemurafenib+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MALME-3M", "Dose": "500 nM vemurafenib+20-2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "MHC class I(HLA-A,B,C), MHC class II (HLA-D,R)", "Controlled_Terms_Unaffected": "MHC class I; MHC class II; HLA-A;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1169", "Drug": "Pmel-1 ACT+Dobrafenib+ Trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10064, D10175", "Pubchem_ID": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Gp10025-33–activated pmel-1 mouse splenocytes", "Dose": "D (5 mM)/T (0.25 mM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD3+CD8+ IFN-Y", "Controlled_Terms_Function_inhibited_Number_decreased": "CD3; CD8; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1170", "Drug": "Pmel-1 ACT+Dobrafenib+ Trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D10064, D10175", "Pubchem_ID": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Gp10025-33–activated pmel-1 mouse splenocytes", "Dose": "D (20 mM)/T (1 mM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD3+CD8+ IFN-Y", "Controlled_Terms_Function_inhibited_Number_decreased": "CD3; CD8; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1037", "Drug": "Pomalidomide + IFN-γ", "Drug_category": "Others/combination", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS-11", "Dose": "pomalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1038", "Drug": "Pomalidomide + IFN-γ", "Drug_category": "Others/combination", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "pomalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1039", "Drug": "Pomalidomide + IFN-γ", "Drug_category": "Others/combination", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug__ID": "D08976", "Pubchem_ID": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "pomalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1040", "Drug": "Pomalidomide + IFN-γ + panobinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB08910, DB06603", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.\n Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D08976, D10019", "Pubchem_ID": "134780, 6918837", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,\n CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "KMS-11", "Dose": "pomalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ +25 nM panobinostat", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1041", "Drug": "Pomalidomide + IFN-γ + panobinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB08910, DB06603", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.\n Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D08976, D10019", "Pubchem_ID": "134780, 6918837", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,\n CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "MM.1S cells", "Dose": "pomalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ +25 nM panobinostat", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1042", "Drug": "Pomalidomide + IFN-γ + panobinostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB08910, DB06603", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.\n Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug__ID": "D08976, D10019", "Pubchem_ID": "134780, 6918837", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,\n CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "30956773", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "System": "OPM-2", "Dose": "pomalidomide 1.0 or 0.1 μM and 100 U/ml of IFN-γ +25 nM panobinostat", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression by MM cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/685", "Drug": "Quisinostat + Tazemetostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12985 + DB12887", "Target/s_or_mechanism_of_action": "Combined HDAC and EZH2 inhibition; epigenetic regulation of HLA-I expression", "KEGG_Drug__ID": "D10321 + D11444", "Pubchem_ID": "11538455 + 66558664", "STR_LINK_(SMILES)": "CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO and CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5", "Single/Combination": "Combination", "PMID": "33316946", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Human uveal melanoma", "System": "OMM1", "Dose": "Quisinostat 40 nM + Tazemetostat 5 µM, 48 h", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "HLA-I expression maintained/increased relative to control", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/686", "Drug": "Quisinostat + Tazemetostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12985 + DB12887", "Target/s_or_mechanism_of_action": "Combined HDAC and EZH2 inhibition; epigenetic regulation of HLA-I expression", "KEGG_Drug__ID": "D10321 + D11444", "Pubchem_ID": "11538455 + 66558664", "STR_LINK_(SMILES)": "CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO and CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5", "Single/Combination": "Combination", "PMID": "33316946", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Human uveal melanoma", "System": "OMM2.5", "Dose": "Quisinostat 40 nM + Tazemetostat 5 µM, 48 h", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "HLA-I surface expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/687", "Drug": "Quisinostat + Tazemetostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12985 + DB12887", "Target/s_or_mechanism_of_action": "Combined HDAC and EZH2 inhibition; epigenetic regulation of HLA-I expression", "KEGG_Drug__ID": "D10321 + D11444", "Pubchem_ID": "11538455 + 66558664", "STR_LINK_(SMILES)": "CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO and CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5", "Single/Combination": "Combination", "PMID": "33316946", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Human uveal melanoma", "System": "MP38", "Dose": "Quisinostat 40 nM + Tazemetostat 5 µM, 48 h", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "HLA-I surface expression", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/265", "Drug": "PI3K inhibitor (LY294002; )", "Drug_category": "PI3K inhibitor", "Drugbank_ID": "DB02656", "Target/s_or_mechanism_of_action": "Protein kinase inhibitors, the mode of action of LY294002 is through competition with ATP for binding the PI3K active site", "KEGG_Drug__ID": "C15195", "Pubchem_ID": "3973", "STR_LINK_(SMILES)": "O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "H1975", "Dose": "1 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1181", "Drug": "Regorafenib and NU", "Drug_category": "Others/combination", "Drugbank_ID": "DB08896", "Target/s_or_mechanism_of_action": "Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. \n NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor", "KEGG_Drug__ID": "D10138", "Pubchem_ID": "11167602, 11327430", "STR_LINK_(SMILES)": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1, \n C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56", "Single/Combination": "Combination", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "C8161, a human melanoma cell line which lacks BRAFV600 or NRAS mutations", "Dose": "1 μM Reg + 1 μM NU", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-I", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1182", "Drug": "Regorafenib and NU", "Drug_category": "Others/combination", "Drugbank_ID": "DB08896", "Target/s_or_mechanism_of_action": "Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. \n NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor", "KEGG_Drug__ID": "D10138", "Pubchem_ID": "11167602, 11327430", "STR_LINK_(SMILES)": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1, \n C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56", "Single/Combination": "Combination", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "UACC-257", "Dose": "4 μM Reg and 2 μM NU", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-I", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1183", "Drug": "Regorafenib and NU", "Drug_category": "Others/combination", "Drugbank_ID": "DB08896", "Target/s_or_mechanism_of_action": "Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. \n NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor", "KEGG_Drug__ID": "D10138", "Pubchem_ID": "11167602, 11327430", "STR_LINK_(SMILES)": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1, \n C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56", "Single/Combination": "Combination", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SK-MEL-119", "Dose": "4 μM Reg and 2 μM NU", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-I", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/858", "Drug": "Ricolinostat (ACY-1215) and 5-fluorouracil", "Drug_category": "Others/combination", "Drugbank_ID": "DB12376, DB00544", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor. Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug__ID": "D10661 , D00584", "Pubchem_ID": "53340666, 3385", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1,\n C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C, FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "30788349", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT-116", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "apoptosis, antiproliferation activity", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1472", "Drug": "SGI-1027 (SGI)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "SW480", "Dose": null, "Technique": "immunoblotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "Ifng, Ifngr1 Cd274 (Pdl1) and Pdcd1lg2 (Pdl2) tumor programmed cell death 1 ligand 1 (PD-L1) level, phosphorylation of STAT1 and its downstream transcription factor IRF1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; CD274; IFN-γ; STAT1; IRF-1; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/190", "Drug": "SGI-1027 (SGI)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116", "Dose": null, "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/203", "Drug": "SGI-1776(inhibitor of PIM kinase activity) and sunitinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB12494, DB01268", "Target/s_or_mechanism_of_action": "SGI-1776 has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias, Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "24795070, 5329102", "STR_LINK_(SMILES)": "CN1CCC(CNC2=NN3C(C=C2)=NC=C3C2=CC=CC(OC(F)(F)F)=C2)CC1, CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "22015557", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "System": "786-O", "Dose": "5 μ SGI-1776, 5 μ sunitinib", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "c-Myc levels", "Controlled_Terms_Function_inhibited_Number_decreased": "FOS / c-MYC; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/204", "Drug": "SGI-1776(inhibitor of PIM kinase activity) and sunitinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB12494, DB01268", "Target/s_or_mechanism_of_action": "SGI-1776 has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias, Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "24795070, 5329102", "STR_LINK_(SMILES)": "CN1CCC(CNC2=NN3C(C=C2)=NC=C3C2=CC=CC(OC(F)(F)F)=C2)CC1, CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "22015557", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "System": "Caki-1", "Dose": "5 μ SGI-1776, 5 μ sunitinib", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "c-Myc levels", "Controlled_Terms_Function_inhibited_Number_decreased": "FOS / c-MYC; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/915", "Drug": "Sodium butyrate and 5-aza-2′-deoxycytidine (DAC)", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "17725605", "Cancer_Type": "Hpv16-Expressing Tumors", "Cancer_Type_Description": "Human Papilloma Virus 16-Associated Tumours", "System": "TC-1/A9 (MHC class I-deficient)", "Dose": "5 µm DAC,35 µm sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I molecules", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/108", "Drug": "Sorafenib + anti-CTLA-4", "Drug_category": "Others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "25845968", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "System": "MDSCs isolated from tumor-bearing mice and CD8+ T cells isolated from naïve mice", "Dose": null, "Technique": "coculture, RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Cell co-culture/transwell assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSCs IL-10 Arg1, TGF-β, cyclooxygenase 2 (COX2), IDO1, IDO2, and NOS2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; TGF-β; IDO1/IDO; NOS2 / iNOS; ARG1 / arginase-1; COX-2 / PTGS2; Myeloid-derived suppressor cells / MDSCs; TGF-β / TGF-beta", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1306", "Drug": "Sorafenib + TLR3 agonist: lysine-stabilized polyinosinic-polycytidylic-acid (poly-ICLC)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "26287667", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "SNU449", "Dose": "50 μg/ml poly-ICLC and 15 μM Sorafenib", "Technique": "Flow cytometry,Microscopy", "Controlled_Technique": "Flow cytometry; Microscopy", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis-(Annexin-V and Topro-3-positive cells)", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Annexin V", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1307", "Drug": "Sorafenib + TLR3 agonist: lysine-stabilized polyinosinic-polycytidylic-acid (poly-ICLC)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "26287667", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "SNU475", "Dose": "50 μg/ml poly-ICLC and 15 μM Sorafenib", "Technique": "Flow cytometry,Microscopy", "Controlled_Technique": "Flow cytometry; Microscopy", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis-(Annexin-V and Topro-3-positive cells)", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Annexin V", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/434", "Drug": "TAK-117", "Drug_category": "PI3K inhibitor", "Drugbank_ID": "DB14935", "Target/s_or_mechanism_of_action": "Selective PI3Kα/p110α inhibition", "KEGG_Drug__ID": "—", "Pubchem_ID": "70798655", "STR_LINK_(SMILES)": "TAK-117 canonical SMILES", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Bladder cancer", "System": "T24", "Dose": "3.5 µM, 48 h", "Technique": "qRT-PCR, western blot", "Controlled_Technique": "PD-L1 mRNA increased", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 mRNA increased", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1362", "Drug": "Sorafenib + TLR3 agonist: lysine-stabilized polyinosinic-polycytidylic-acid (poly-ICLC)", "Drug_category": "Others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "26287667", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "Hepa 1-6 cells", "Dose": "50 μg/ml poly-ICLC and 15 μM Sorafenib", "Technique": "Flow cytometry,Microscopy,densitometry, western blot,quantitative-PCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Immunostaining/image analysis; Microscopy", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis-(Annexin-V and Topro-3-positive cells)", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis; Annexin V", "Immune_System-Function_inhibited/numbers_decreased": "phosphorylations of AKT (Ser473), MEK1/2 (Ser217/221) and ERK1/2 (Thr202/Tyr204), Survivin gene (BIRC5)", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK; MEK1/2 / MAP2K1/2; AKT; Survivin / BIRC5", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1483", "Drug": "Sorafenib and YC-1, a soluble guanylyl cyclase (sGC) activator", "Drug_category": "Others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "24418169", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "HepG2", "Dose": "(5 μmol/L) and YC-1 (10 μmol/L)", "Technique": "Flow cytometry, western blot analysis", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "S cell cycle arrest, apoptosis-Increased activation of PARP ,extrinsic or death receptor pathway, which activates caspase 8,SHP-1 activity", "Controlled_Terms_Function_enhanced_Number_increased": "SHP-1 / PTPN6; Caspase-8; Caspase activation; Apoptosis; Cell-cycle arrest; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": "(p-STAT3),(p-ERK1/2), cyclin D1 and survivin", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; ERK / MAPK; Survivin / BIRC5; Cyclin D1 / CCND1; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1484", "Drug": "Sorafenib and YC-1, a soluble guanylyl cyclase (sGC) activator", "Drug_category": "Others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "24418169", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "BEL-7402", "Dose": "(5 μmol/L) and YC-1 (10 μmol/L)", "Technique": "Flow cytometry, western blot analysis", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "S cell cycle arrest, apoptosis-Increased activation of PARP ,extrinsic or death receptor pathway, which activates caspase 8,SHP-1 activity", "Controlled_Terms_Function_enhanced_Number_increased": "SHP-1 / PTPN6; Caspase-8; Caspase activation; Apoptosis; Cell-cycle arrest; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": "(p-STAT3),(p-ERK1/2), cyclin D1 and survivin", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; ERK / MAPK; Survivin / BIRC5; Cyclin D1 / CCND1; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1485", "Drug": "Sorafenib and YC-1, a soluble guanylyl cyclase (sGC) activator", "Drug_category": "Others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "24418169", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "HCCLM3 cells", "Dose": "(5 μmol/L) and YC-1 (10 μmol/L)", "Technique": "Flow cytometry, western blot analysis", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "S cell cycle arrest, apoptosis-Increased activation of PARP ,extrinsic or death receptor pathway, which activates caspase 8,SHP-1 activity", "Controlled_Terms_Function_enhanced_Number_increased": "SHP-1 / PTPN6; Caspase-8; Caspase activation; Apoptosis; Cell-cycle arrest; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": "(p-STAT3),(p-ERK1/2), cyclin D1 and survivin", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; ERK / MAPK; Survivin / BIRC5; Cyclin D1 / CCND1; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1184", "Drug": "Sorafenib+ IFNγ", "Drug_category": "Others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "10 μM Sorafenib+2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I molecules (HLA-A,B,C)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A;", "Immune_System-Function_inhibited/numbers_decreased": "MHC Class II molecule\n (HLA-DR)", "Controlled_Terms_Function_inhibited_Number_decreased": "MHC class II; HLA-DR;", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/319", "Drug": "Taxol", "Drug_category": "Others/combination", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "12389115", "Cancer_Type": "Urethera", "Cancer_Type_Description": "Urothelial - Human Urothelial Cancer", "System": "T24", "Dose": "Taxol 0.8 microg/ml", "Technique": "Western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "Fas and FasL", "Controlled_Terms_Unaffected": "CD95 / Fas / FAS; Fas ligand / FasL / FASLG", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/677", "Drug": "Tazemetostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12887", "Target/s_or_mechanism_of_action": "EZH2 inhibition → reduced H3K27me3-mediated transcriptional repression", "KEGG_Drug__ID": "D11444", "Pubchem_ID": "66558664", "STR_LINK_(SMILES)": "CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5", "Single/Combination": "Single", "PMID": "33316946", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Human uveal melanoma", "System": "OMM1", "Dose": "5 µM, 48 h", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "HLA-I surface expression unaffected", "Immune_System_function_unaffected": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/678", "Drug": "Tazemetostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12887", "Target/s_or_mechanism_of_action": "EZH2 inhibition → reduced H3K27me3-mediated transcriptional repression", "KEGG_Drug__ID": "D11444", "Pubchem_ID": "66558664", "STR_LINK_(SMILES)": "CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5", "Single/Combination": "Single", "PMID": "33316946", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Human uveal melanoma", "System": "OMM2.5", "Dose": "5 µM, 48 h", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "Slight increase in HLA-A mRNA", "Immune_System-Function_enhanced/numbers_increased": "HLA-A", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "HLA-I surface expression unaffected", "Immune_System_function_unaffected": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/679", "Drug": "Tazemetostat", "Drug_category": "Others/combination", "Drugbank_ID": "DB12887", "Target/s_or_mechanism_of_action": "EZH2 inhibition → reduced H3K27me3-mediated transcriptional repression", "KEGG_Drug__ID": "D11444", "Pubchem_ID": "66558664", "STR_LINK_(SMILES)": "CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5", "Single/Combination": "Single", "PMID": "33316946", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Human uveal melanoma", "System": "MP38", "Dose": "5 µM, 48 h", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "Slight increase in HLA-A mRNA", "Immune_System-Function_enhanced/numbers_increased": "HLA-A", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "HLA-I surface expression unaffected", "Immune_System_function_unaffected": "Expression / abundance phenotype; MHC class I", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1171", "Drug": "Temozolomide+ IFNγ", "Drug_category": "Others/combination", "Drugbank_ID": "DB00853", "Target/s_or_mechanism_of_action": "TMZ is a DNA alkylating agent known to induce cell cycle arrest at G2/M and to eventually lead to apoptosis.", "KEGG_Drug__ID": "D06067", "Pubchem_ID": "5394", "STR_LINK_(SMILES)": "CN1N=NC2=C(N=CN2C1=O)C(N)=O", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "10 μM temozolomide+2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "MHC Class I molecules (HLA-A,B,C), MHC Class II molecule\n (HLA-DR)", "Controlled_Terms_Unaffected": "MHC class I; MHC class II; HLA-DR; HLA-A;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/481", "Drug": "TPH104-conditioned medium", "Drug_category": "Others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Products released by TPH104-treated tumor cells stimulate dendritic-cell maturation", "KEGG_Drug__ID": "NR", "Pubchem_ID": "18326651", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "33919653", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Mouse bone-marrow-derived dendritic cells (BMDCs) exposed to conditioned medium from treated MDA-MB-231 cells", "System": "MDA-MB-231 media+ BMDCs", "Dose": "Conditioned medium from cells treated with 1 or 5 µM TPH104; BMDC exposure for 48 h", "Technique": "Flow cytometry, qPCR, ELISA", "Controlled_Technique": "CD86-high and MHC-II-high BMDC populations increased; TNF-α mRNA increased by 67%, IL-6 by 327%, and IL-12A by 45% at 5 µM conditioned-medium treatment", "Immune_System-Function_enhanced/numbers_increased": "CD86; MHC class II; TNF-α / TNF; IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "CD86-low and MHC-II-low BMDC populations decreased", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; MHC class II; CD86; Dendritic cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Total CD11c+ population and IL-1β expression showed no significant change", "Immune_System_function_unaffected": "Expression / abundance phenotype; CD11c / ITGAX", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1185", "Drug": "Vemurafenib+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "625 nM vemurafenib+2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I molecules (HLA-A,B,C), β2\n microblobulin, MHC Class II molecules (HLA-D,R)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-A;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/492", "Drug": "Trabectedin + IL-12", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Human TNBC", "System": "MDA-MB-436", "Dose": "10 ng/mL + 2.5 nmol/L", "Technique": "RT-PCR, flow cytometery", "Controlled_Technique": "CD69 expression, IFN-γ (IFNG) and granzyme B (GZMB), T-BET (Tbx21),TRAIL (TNFSF10) and Fas ligand (FASLG), lymphotactin (XCL1), Phospho-STAT4 levels , increased NK-cell cytotoxicity, higher levels of IFN-γ, TNF-α and granzyme B", "Immune_System-Function_enhanced/numbers_increased": "TRAIL; Granzyme B / GZMB; IFN-γ; TNF-α / TNF; Cytotoxicity / cytolysis; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "AN", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "trabectedin has a direct stimulatory effect on NK cells and can be combined with IL-12 to activate NK cells in the presence of TNBC", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells; IL-12", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/493", "Drug": "Trabectedin + IL-12", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Human TNBC", "System": "MDA-MB-231", "Dose": "10 ng/mL + 2.5 nmol/L", "Technique": "RT-PCR, flow cytometery", "Controlled_Technique": "CD69 expression, IFN-γ (IFNG) and granzyme B (GZMB), T-BET (Tbx21),TRAIL (TNFSF10) and Fas ligand (FASLG), lymphotactin (XCL1), Phospho-STAT4 levels , increased NK-cell cytotoxicity, higher levels of IFN-γ, TNF-α and granzyme B", "Immune_System-Function_enhanced/numbers_increased": "TRAIL; Granzyme B / GZMB; IFN-γ; TNF-α / TNF; Cytotoxicity / cytolysis; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "AN", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "trabectedin has a direct stimulatory effect on NK cells and can be combined with IL-12 to activate NK cells in the presence of TNBC", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells; IL-12", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/494", "Drug": "Trabectedin + IL-12", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Human TNBC", "System": "MDA-MB-468", "Dose": "10 ng/mL + 2.5 nmol/L", "Technique": "RT-PCR, flow cytometery", "Controlled_Technique": "CD69 expression, IFN-γ (IFNG) and granzyme B (GZMB), T-BET (Tbx21),TRAIL (TNFSF10) and Fas ligand (FASLG), lymphotactin (XCL1), Phospho-STAT4 levels , increased NK-cell cytotoxicity, higher levels of IFN-γ, TNF-α and granzyme B", "Immune_System-Function_enhanced/numbers_increased": "TRAIL; Granzyme B / GZMB; IFN-γ; TNF-α / TNF; Cytotoxicity / cytolysis; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "AN", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "trabectedin has a direct stimulatory effect on NK cells and can be combined with IL-12 to activate NK cells in the presence of TNBC", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells; IL-12", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/495", "Drug": "Trabectedin + IL-12", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug__ID": "D06199", "Pubchem_ID": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Human TNBC", "System": "K562", "Dose": "10 ng/mL + 2.5 nmol/L", "Technique": "Human NK-cell cytotoxicity assay", "Controlled_Technique": "increased NK-cell cytotoxicity", "Immune_System-Function_enhanced/numbers_increased": "Cytotoxicity / cytolysis", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "AN", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "trabectedin has a direct stimulatory effect on NK cells and can be combined with IL-12 to activate NK cells in the presence of TNBC", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells; IL-12", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/648", "Drug": "Trabectedin + olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109 + DB09074", "Target/s_or_mechanism_of_action": "DNA damage and DNA repair inhibition; cGAS–STING pathway activation", "KEGG_Drug__ID": "D06199 + D09730", "Pubchem_ID": "108150 + 23725625", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma", "System": "HT-1080", "Dose": "0.5 nM + 5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/649", "Drug": "Trabectedin + olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109 + DB09074", "Target/s_or_mechanism_of_action": "Combined DNA damage and DNA repair inhibition", "KEGG_Drug__ID": "D06199 + D09730", "Pubchem_ID": "108150 + 23725625", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O and C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Combination", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "SW684", "Dose": "0.5 nM + 5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/650", "Drug": "Trabectedin + olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109 + DB09074", "Target/s_or_mechanism_of_action": "DNA damage; DNA repair inhibition; cGAS–STING signaling", "KEGG_Drug__ID": "D06199 + D09730", "Pubchem_ID": "108150 + 23725625", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "402.91", "Dose": "0.5 nM + 5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/651", "Drug": "Trabectedin + olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109 + DB09074", "Target/s_or_mechanism_of_action": "Combined DNA damage and repair inhibition", "KEGG_Drug__ID": "D06199 + D09730", "Pubchem_ID": "108150 + 23725625", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O and C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Combination", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "DMR", "Dose": "0.5 nM + 5 µM in vitro; animal dose NR", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/652", "Drug": "Trabectedin + olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109 + DB09074", "Target/s_or_mechanism_of_action": "DNA damage; DNA repair inhibition", "KEGG_Drug__ID": "D06199 + D09730", "Pubchem_ID": "108150 + 23725625", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O and C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Combination", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "MES-SA", "Dose": "0.5 nM + 5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/653", "Drug": "Trabectedin + olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109 + DB09074", "Target/s_or_mechanism_of_action": "DNA damage; repair inhibition; cGAS–STING pathway activation", "KEGG_Drug__ID": "D06199 + D09730", "Pubchem_ID": "108150 + 23725625", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O and C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F", "Single/Combination": "Combination", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "S018", "Dose": "0.5 nM + 5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/654", "Drug": "Trabectedin + olaparib", "Drug_category": "Others/combination", "Drugbank_ID": "DB05109 + DB09074", "Target/s_or_mechanism_of_action": "DNA damage; repair inhibition; cGAS–STING pathway activation", "KEGG_Drug__ID": "D06199 + D09730", "Pubchem_ID": "108150 + 23725625", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "40986050", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": null, "System": "S006", "Dose": "0.5 nM + 5 µM", "Technique": "gene expression; flow cytometry", "Controlled_Technique": "POU5F1 mRNA, increased the percentage of OCT4+ cells", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/348", "Drug": "Trametinib+Erlotinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08911, DB00530", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity. \n Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D10175,\n D07907", "Pubchem_ID": "11707110, 176870", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,\n COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Combination", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MMTV-Neu cells", "Dose": "trametinib (50 nM) + Erlotinib (0.5 μM)", "Technique": "Flow cytometery, Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-1 pSTAT1, pSTAT3, STAT3, and pSTAT5", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6/JAK/STAT3 signaling; STAT3; ; STAT3 phosphorylation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "PD-L1", "Controlled_Terms_Unaffected": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/346", "Drug": "Trametinib+Lapatinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08911, DB01259", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity. \n Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (HER1/EGFR/ERBB1) and human epidermal growth factor receptor type 2 (HER2/ERBB2)with a dissociation half-life of ≥300 minutes.", "KEGG_Drug__ID": "D10175, D04024", "Pubchem_ID": "11707110, 208908", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,\n CS(=O(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "33062958", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MMTV-Neu cells", "Dose": "trametinib (50 nM) + Lapatinib (0.1 μM)", "Technique": "Flow cytometery, Immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "pSTAT1, pSTAT3, STAT3", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6/JAK/STAT3 signaling; STAT3; STAT3 phosphorylation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "MHC-I and PD-L1", "Controlled_Terms_Unaffected": "PD-L1 / CD274; MHC class I; PD-L1 immune checkpoint pathway;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/693", "Drug": "Trastuzumab deruxtecan (T-DXd)", "Drug_category": "Others/combination", "Drugbank_ID": "DB14962", "Target/s_or_mechanism_of_action": "HER2 targeting; TOP1 inhibition; DNA damage and cGAS–STING/type-I IFN pathway activation", "KEGG_Drug__ID": "D11529", "Pubchem_ID": "384585505", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "39449023", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Human gastric adenocarcinoma", "System": "SNU-484", "Dose": "trastuzumab (1 µg/ml), and T-DXd (1 µg/ml) for 72 h", "Technique": "RNA sequencing; gene-set enrichment; RT-qPCR; immunoblotting", "Controlled_Technique": "IFN-I signalling and antigen-presentation-associated gene signatures enriched in reported transcriptomic analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 upregulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/441", "Drug": "Trastuzumab deruxtecan (T-DXd)", "Drug_category": "Others/combination", "Drugbank_ID": "DB14962", "Target/s_or_mechanism_of_action": "Fcγ-receptor activation; antibody-dependent cellular phagocytosis (ADCP); ICD", "KEGG_Drug__ID": "D11529", "Pubchem_ID": "384585505", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40175391", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2-positive", "System": "Au565 cells", "Dose": "Titrated concentrations; 3-day ICD experiment", "Technique": "ATP, HMGB1, calreticulin assays", "Controlled_Technique": "Extracellular ATP release, HMGB1 release, Surface calreticulin (CRT)  on tumor cells undergoing ICD", "Immune_System-Function_enhanced/numbers_increased": "HMGB1; Calreticulin / CRT; Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/694", "Drug": "Trastuzumab deruxtecan (T-DXd)", "Drug_category": "Others/combination", "Drugbank_ID": "DB14962", "Target/s_or_mechanism_of_action": "HER2 targeting; TOP1 inhibition; DNA damage and cGAS–STING/type-I IFN pathway activation", "KEGG_Drug__ID": "D11529", "Pubchem_ID": "384585505", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "39449023", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Human gastric adenocarcinoma; HER2-amplified", "System": "NCI-N87", "Dose": "trastuzumab (1 µg/ml), and T-DXd (1 µg/ml) for 72 h", "Technique": "RNA-seq; RT-qPCR; immunoblotting; ELISA; flow cytometry; DC and PBMC coculture", "Controlled_Technique": "Induction of gene expression linked to IFN-I signaling , increased mRNA transcription of central ISGs (IFNβ1, CXCL10, IFIT1, ISG15, and RIG1) and increased secretion of chemokines such as CCL5 and CXCL10,  upregulation of DC activation markers, CD8+ T-cell activation and effector functions", "Immune_System-Function_enhanced/numbers_increased": "CD8; T cells; Dendritic cells; CXCL10 / IP-10; CCL5 / RANTES; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 upregulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/443", "Drug": "Trastuzumab deruxtecan (T-DXd)", "Drug_category": "Others/combination", "Drugbank_ID": "DB14962", "Target/s_or_mechanism_of_action": "Fcγ-receptor activation; antibody-dependent cellular phagocytosis (ADCP); ICD", "KEGG_Drug__ID": "D11529", "Pubchem_ID": "384585505", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40175391", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2-positive", "System": "Au565 cells with human macrophages or mouse bone-marrow-derived macrophages", "Dose": null, "Technique": "Phagocytosis flow cytometry; ELISA; flow cytometry", "Controlled_Technique": "Macrophage HLA-A2, HLA-DR, CD80, CD40 and CCR7; antigen-presentation and chemokine genes; inflammatory cytokines", "Immune_System-Function_enhanced/numbers_increased": "CD80; HLA-DR; Macrophages; CD40", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "CD47 upregulation was observed after DXd treatment", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; CD47", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/444", "Drug": "Trastuzumab deruxtecan (T-DXd)", "Drug_category": "Others/combination", "Drugbank_ID": "DB14962", "Target/s_or_mechanism_of_action": "Fcγ-receptor activation; antibody-dependent cellular phagocytosis (ADCP); ICD", "KEGG_Drug__ID": "D11529", "Pubchem_ID": "384585505", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40175391", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2-positive", "System": "Human dendritic cells + Au565 cells", "Dose": null, "Technique": "Phagocytosis flow cytometry; ELISA; flow cytometry", "Controlled_Technique": "Macrophage HLA-A2, HLA-DR, CD80, CD40 and CCR7; antigen-presentation and chemokine genes; inflammatory cytokines", "Immune_System-Function_enhanced/numbers_increased": "CD80; HLA-DR; Macrophages; CD40", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "CD47 upregulation was observed after DXd treatment", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; CD47", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/692", "Drug": "Trastuzumab deruxtecan (T-DXd)", "Drug_category": "Others/combination", "Drugbank_ID": "DB14962", "Target/s_or_mechanism_of_action": "HER2 targeting; TOP1 inhibition; DNA damage and cGAS–STING/type-I IFN pathway activation", "KEGG_Drug__ID": "D11529", "Pubchem_ID": "384585505", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "39449023", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Human gastric adenocarcinoma; very low HER2 expression", "System": "SNU-601", "Dose": "Multiple concentrations; assay-specific", "Technique": "immunoblotting", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 upregulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/695", "Drug": "Trastuzumab deruxtecan (T-DXd)", "Drug_category": "Others/combination", "Drugbank_ID": "DB14962", "Target/s_or_mechanism_of_action": "HER2 targeting; TOP1 inhibition; DNA damage and cGAS–STING/type-I IFN pathway activation", "KEGG_Drug__ID": "D11529", "Pubchem_ID": "384585505", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "39449023", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Human gastric adenocarcinoma; HER2-amplified", "System": "SNU-216", "Dose": "Assay-specific concentrations; see article methods", "Technique": "immunoblotting", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 upregulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1055", "Drug": "Trastuzumab+ Anti CD137 mAB", "Drug_category": "Others/combination", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30596643", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "NK+Capan-1 (HER2-high-expressing cell line) + αCD137 (Anti-CD137 mAb), effector/target (E/T) ratio was set at 10:1", "Dose": "10 μg/ml of Tmab +10 μg/ml αCD137", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "cell surface CD69 of NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD69; NK cells", "Immune_System-Function_inhibited/numbers_decreased": "perforin—and granzyme-B- double-positive NK cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Granzyme B / GZMB; Perforin / PRF1; NK cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1562", "Drug": "Trastuzumab+ Anti CD137 mAB", "Drug_category": "Others/combination", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "30596643", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "NK+ Panc-1 (HER2-low-expressing cell line) + αCD137 (Anti-CD137 mAb), effector/target (E/T) ratio was set at 10:1", "Dose": "10 μg/ml of Tmab + 10 μg/ml αCD137", "Technique": "LDH-releasing assays", "Controlled_Technique": "LDH-releasing assays", "Immune_System-Function_enhanced/numbers_increased": "enhanced Tmab-mediated ADCC against Panc-1", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/944", "Drug": "Trichostatin A +tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)", "Drug_category": "Others/combination", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Combination", "PMID": "16818655", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs obtained from 10 CLL patients", "Dose": "lenalidomide (LND; 1 μM) and IL-2 (50 U/mL)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-E expression", "Controlled_Terms_Function_enhanced_Number_increased": "Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "classical MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": "MHC class I;", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/647", "Drug": "Tuvusertib (M1774)", "Drug_category": "Others/combination", "Drugbank_ID": "DB18790", "Target/s_or_mechanism_of_action": "ATR inhibitor", "KEGG_Drug__ID": "D12882", "Pubchem_ID": "90199447", "STR_LINK_(SMILES)": "CN1C=NC=C1C2=C(C=NC=C2NC(=O)C3=C4N=CC(=CN4N=C3N)F)F", "Single/Combination": "Single", "PMID": "41417226", "Cancer_Type": "Prostate", "Cancer_Type_Description": "DU145", "System": "PD-L1-targeting high-affinity NK (PD-L1 t-haNK) cells", "Dose": "0.5 µM, 48 h tumor-cell pretreatment", "Technique": "NK-cell cytotoxicity/lysis assay", "Controlled_Technique": "PD-L1 t-haNK-mediated lysis ↑ ~1.5-fold", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": "No specific immune-cell decrease", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "No reported reduction in t-haNK viability", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1 ↑, increasing the target available for PD-L1-directed killing", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/645", "Drug": "Tuvusertib (M1774)", "Drug_category": "Others/combination", "Drugbank_ID": "DB18790", "Target/s_or_mechanism_of_action": "ATR inhibitor", "KEGG_Drug__ID": "D12882", "Pubchem_ID": "90199447", "STR_LINK_(SMILES)": "CN1C=NC=C1C2=C(C=NC=C2NC(=O)C3=C4N=CC(=CN4N=C3N)F)F", "Single/Combination": "Single", "PMID": "41417226", "Cancer_Type": "Prostate", "Cancer_Type_Description": "22Rv1", "System": "Human NK cells", "Dose": "0.5 µM, 48 h pretreatment of tumor cells", "Technique": "flow cytometry; NK-cell lysis assay using xCELLigence RTCA", "Controlled_Technique": "TRAIL-R2", "Immune_System-Function_enhanced/numbers_increased": "TRAIL; TRAIL-R2 / DR5 / TNFRSF10B", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "TRAIL-R1, NKG2D ligand ULBP-1", "Immune_System_function_unaffected": "TRAIL", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1230", "Drug": "Vemurafenib (BRAF-I) +IFN a", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "26851802", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Colo38, M21, and SK-MEL-37 cells", "Dose": "vemurafenib (500 nM) and/or IFNα-2b (10 000 IU/mL)", "Technique": "Flow cytometry analysis of annexin V and PI staining", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "increased HLA-A, B, and C antigen, calnexin, and\n calreticulin expression, HLA-DR, DQ and DP antigens increased cleaved PARP ( inhibited the proliferation and induced apoptosis)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-DR; HLA-A; Apoptosis; Cell proliferation; Calnexin; Calreticulin / CRT; PARP cleavage / PARP; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/422", "Drug": "Vemurafenib (BRAF-I) +IFN a", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "26851802", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SK-Mel-37", "Dose": "vemurafenib (500 nM) and/or IFNα-2b (10 000 IU/mL)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1163", "Drug": "Vemurafenib + Sodium butyrate", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257, 5222465", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,\n CCCC(=O)[O-].[Na+]", "Single/Combination": "Combination", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-86f", "Dose": "1 uM Vemurafenib+5 mM sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D-L (MHC-1, MICA, UBLP2/5/6, CD112)", "Controlled_Terms_Function_enhanced_Number_increased": "CD112 / Nectin-2 / PVRL2; NKG2D / KLRK1; MICA; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD155", "Controlled_Terms_Unaffected": "CD155 / PVR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1164", "Drug": "Vemurafenib + Sodium butyrate", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257, 5222465", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,\n CCCC(=O)[O-].[Na+]", "Single/Combination": "Combination", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-55", "Dose": "1 uM Vemurafenib+5 mM sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D-L (MHC-1, MICA, UBLP3, UBLP2/5/6, CD112)", "Controlled_Terms_Function_enhanced_Number_increased": "CD112 / Nectin-2 / PVRL2; NKG2D / KLRK1; ULBP3; MICA; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD155", "Controlled_Terms_Unaffected": "CD155 / PVR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1165", "Drug": "Vemurafenib + Sodium butyrate", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257, 5222465", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,\n CCCC(=O)[O-].[Na+]", "Single/Combination": "Combination", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-86c", "Dose": "1 uM Vemurafenib+5 mM sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D-L (MHC-1, MICA, UBLP3, UBLP2/5/6, CD112)", "Controlled_Terms_Function_enhanced_Number_increased": "CD112 / Nectin-2 / PVRL2; NKG2D / KLRK1; ULBP3; MICA; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD155", "Controlled_Terms_Unaffected": "CD155 / PVR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1166", "Drug": "Vemurafenib + Sodium butyrate", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257, 5222465", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,\n CCCC(=O)[O-].[Na+]", "Single/Combination": "Combination", "PMID": "29308322", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-103", "Dose": "1 uM Vemurafenib+5 mM sodium butyrate", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NKG2D-L (MHC-1, MICA, UBLP3, UBLP2/5/6, CD112)", "Controlled_Terms_Function_enhanced_Number_increased": "CD112 / Nectin-2 / PVRL2; NKG2D / KLRK1; ULBP3; MICA; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD155", "Controlled_Terms_Unaffected": "CD155 / PVR", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/804", "Drug": "Vemurafenib+cobimetinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "32912923", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SK28R+NK cells", "Dose": "vemurafenib and\n cobimetinib (5 μM+10 nM)", "Technique": "Flow cytometery, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD107+/IFNγ+ polyfunctional NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/805", "Drug": "Vemurafenib+cobimetinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "32912923", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "M14R+NK cells", "Dose": "vemurafenib and\n cobimetinib (5 μM+10 nM)", "Technique": "Flow cytometery, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD107+/IFNγ+ polyfunctional NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/806", "Drug": "Vemurafenib+cobimetinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "32912923", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SK28 S+NK cells", "Dose": "vemurafenib and\n cobimetinib (5 μM+10 nM)", "Technique": "Flow cytometery, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD107+/IFNγ+ polyfunctional NK cells", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; NK cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/807", "Drug": "Vemurafenib+cobimetinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "32912923", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "M14S+ NK cells", "Dose": "vemurafenib and\n cobimetinib (5 μM+10 nM)", "Technique": "Flow cytometery, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD107+/IFNγ+ polyfunctional NK cells", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; NK cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1172", "Drug": "Vemurafenib+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "HT-144", "Dose": "500 nM vemurafenib+20-2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I(HLA-A,B,C), MHC class II (HLA-D,R)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-A;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1173", "Drug": "Vemurafenib+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "UACC-62", "Dose": "500 nM vemurafenib+20-2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I(HLA-A,B,C), MHC class II (HLA-D,R)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-A;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1174", "Drug": "Vemurafenib+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL-28", "Dose": "500 nM vemurafenib+20-2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I(HLA-A,B,C), MHC class II (HLA-D,R) CIITA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-A; CIITA;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1175", "Drug": "Vemurafenib+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL-3", "Dose": "500 nM vemurafenib+20-2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "MHC class I(HLA-A,B,C), MHC class II (HLA-D,R)", "Controlled_Terms_Unaffected": "MHC class I; MHC class II; HLA-A;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1176", "Drug": "Vemurafenib+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "SKMEL-5", "Dose": "500 nM vemurafenib+20-2000 U/mL IFNγ", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "MHC class I(HLA-A,B,C), MHC class II (HLA-D,R)", "Controlled_Terms_Unaffected": "MHC class I; MHC class II; HLA-A;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1636", "Drug": "Vemurafenib+IFN-y", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "10 μM Vemurafenib+2000 U/mL IFNγ", "Technique": "Flow cytometery, Immunoblotting, Real time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC Class I molecules (HLA-A,B,C), β2\n microblobulin, MHC Class II molecules (HLA-D,R) CIITA, NLRC5, gamma-interferon-inducible lysosomal thiol\n reductase (GILT)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-A; CIITA; NLRC5;", "Immune_System-Function_inhibited/numbers_decreased": "Phospho-ERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1635", "Drug": "Vemurafenib+IFNα2b", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug__ID": "D09996", "Pubchem_ID": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "23483066", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "500 nM Vemurafenib+909 U/mL IFNα2b", "Technique": "Flow cytometery, Immunoblotting, Real time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I(HLA-A,B,C), MHC class II (HLA-D,R)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; HLA-A;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1280", "Drug": "Vemurafenib+trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881, DB08911", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D09996, D10175", "Pubchem_ID": "42611257, 11707110", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "30221038", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-63 melanoma cells", "Dose": "vemurafenib, 0.5 uM+50 nM trametinib", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFNy+ CD8+ PBMCS increased after short term treatment", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": "IFNy+ CD8+ TIL decreased/impaired during long term treatment resulting to double drugresistant melanoma cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; T cells; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1281", "Drug": "Vemurafenib+trametinib", "Drug_category": "Others/combination", "Drugbank_ID": "DB08881, DB08911", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug__ID": "D09996, D10175", "Pubchem_ID": "42611257, 11707110", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "30221038", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Ma-Mel-86c melanoma cells", "Dose": "vemurafenib, 0.5 uM+50 nM trametinib", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFNy+ CD8+ TIL increased after short term treatment", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": "IFNy+ CD8+ TIL decreased/impaired during long term treatment resulting to double drugresistant melanoma cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; T cells; IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/509", "Drug": "Venetoclax", "Drug_category": "Others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug__ID": "49846579", "Pubchem_ID": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Single", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CRC cell", "System": "HT-29", "Dose": "1.25, 2.5 and 5 µM; 24 hours; time-course experiments at 5 µM", "Technique": "qRT-PCR, ELISA, Western blot", "Controlled_Technique": "CCL5, CXCL10 and IFN-β expression/secretion, STING, TBK1, and IRF3 phosphorylation", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10; CCL5 / RANTES; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/510", "Drug": "Venetoclax", "Drug_category": "Others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug__ID": "49846579", "Pubchem_ID": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Single", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CRC cell", "System": "SW480", "Dose": "5 µM; 24 hours", "Technique": "qRT-PCR, ELISA, Western blot", "Controlled_Technique": "CCL5, CXCL10 and IFN-β expression/secretion, STING, TBK1, and IRF3 phosphorylation", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10; CCL5 / RANTES; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/511", "Drug": "Venetoclax", "Drug_category": "Others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug__ID": "49846579", "Pubchem_ID": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Single", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CRC cell", "System": "SW620", "Dose": "5 µM; 24 hours", "Technique": "qRT-PCR, ELISA, Western blot", "Controlled_Technique": "CCL5, CXCL10 and IFN-β expression/secretion, STING, TBK1, and IRF3 phosphorylation", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10; CCL5 / RANTES; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/512", "Drug": "Venetoclax", "Drug_category": "Others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug__ID": "49846579", "Pubchem_ID": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Single", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CRC cell", "System": "SW48", "Dose": "5 µM; 24 hours", "Technique": "qRT-PCR, ELISA, Western blot", "Controlled_Technique": "CCL5, CXCL10 and IFN-β expression/secretion, STING, TBK1, and IRF3 phosphorylation", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10; CCL5 / RANTES; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/514", "Drug": "Venetoclax", "Drug_category": "Others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug__ID": "49846579", "Pubchem_ID": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Single", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CRC cell", "System": "RKO", "Dose": "5 µM; 24 hours", "Technique": "qRT-PCR, ELISA, Western blot", "Controlled_Technique": "CCL5, CXCL10 and IFN-β expression/secretion, STING, TBK1, and IRF3 phosphorylation", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10; CCL5 / RANTES; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/516", "Drug": "Venetoclax", "Drug_category": "Others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug__ID": "49846579", "Pubchem_ID": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Single", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CRC cell", "System": "MC38", "Dose": "Exact dose not verified", "Technique": "qRT-PCR, ELISA, Western blot", "Controlled_Technique": "CCL5, CXCL10 and IFN-β expression/secretion, STING, TBK1, and IRF3 phosphorylation", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10; CCL5 / RANTES; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/517", "Drug": "Venetoclax", "Drug_category": "Others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug__ID": "49846579", "Pubchem_ID": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Single", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CRC cell", "System": "EMT6", "Dose": "Exact dose not verified", "Technique": "qRT-PCR, ELISA, Western blot", "Controlled_Technique": "CCL5, CXCL10 and IFN-β expression/secretion, STING, TBK1, and IRF3 phosphorylation", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CXCL10 / IP-10; CCL5 / RANTES; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/515", "Drug": "Venetoclax", "Drug_category": "Others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug__ID": "49846579", "Pubchem_ID": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Single", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CRC cell", "System": "CT26", "Dose": "Dose varies by experiment; mouse study reported 100 mg/kg orally daily", "Technique": "qRT-PCR, ELISA, Western blot", "Controlled_Technique": "CCL5, CXCL10 and IFN-β expression/secretion, STING, TBK1, and IRF3 phosphorylation, Immune-related gene expression and CD8+ T-cell infiltration", "Immune_System-Function_enhanced/numbers_increased": "IFN-β; CD8; T cells; CXCL10 / IP-10; CCL5 / RANTES; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/575", "Drug": "VER-50589 + Emricasan", "Drug_category": "Others/combination", "Drugbank_ID": "DB06964+DB05408", "Target/s_or_mechanism_of_action": "Hsp90 and caspase inhibition", "KEGG_Drug__ID": null, "Pubchem_ID": "135446210+12000240", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)OC)C3=CC(=C(C=C3O)O)Cl and C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "combination", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "System": "MC38", "Dose": "2.5 + 10 µM; 24 h", "Technique": "RT-qPCR", "Controlled_Technique": "Increased IFN-β signaling", "Immune_System-Function_enhanced/numbers_increased": "IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/964", "Drug": "Vinorelbine and cisplatin", "Drug_category": "Others/combination", "Drugbank_ID": "1. DB00361 (APRD00101), 2. DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "1. Tubulin beta chain 2. Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "1. D08680, 2. D00275", "Pubchem_ID": null, "STR_LINK_(SMILES)": "1. Vinorebine- [H][C@]89C=C(CC)CN(Cc1c([nH]c2ccccc12)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@@]5([H])[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]7(CC)C=CCN6CC[C@]45[C@@]67[H])C8)C9, 2. cisplatin-[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Combination", "PMID": "22316209", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "NCI-H1703", "Dose": "cisplatin (0.5 μg/mL) + vinorelbine (0.04 μg/mL)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/395", "Drug": "Vinorelbine and cisplatin", "Drug_category": "Others/combination", "Drugbank_ID": "1. DB00361 (APRD00101), 2. DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "1. Tubulin beta chain 2. Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "1. D08680, 2. D00275", "Pubchem_ID": null, "STR_LINK_(SMILES)": "1. Vinorebine- [H][C@]89C=C(CC)CN(Cc1c([nH]c2ccccc12)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@@]5([H])[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]7(CC)C=CCN6CC[C@]45[C@@]67[H])C8)C9, 2. cisplatin-[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Combination", "PMID": "22316209", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "A549", "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1431", "Drug": "Vorinostat (V) + mithramycin A (MA)", "Drug_category": "Others/combination", "Drugbank_ID": "vorinostat (V): DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). Mithramycin (also known as Plicamycin) is an antineoplastic antibiotic produced by Streptomyces plicatus. Mithramycin A is a DNA/RNA polymerase inhibitor, DNA-binding transcriptional inhibitor, antibiotic, and observed to facilitate tumor necrosis factor (TNF)-α and Fas ligand-induced apoptosis.", "KEGG_Drug__ID": "vorinostat (V): D06320", "Pubchem_ID": "vorinostat (V): 5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,\n C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]", "Single/Combination": "Combination", "PMID": "28536458", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin Cancer - Merkel Cell Carcinoma-Skin Cancer", "System": "MKL-2", "Dose": "vorinostat (V) 1.25 µM, 0.3 µM for mithramycin A", "Technique": "RT-qPCR,immunofluorescence ,confocal microscopy and Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Microscopy; Confocal microscopy; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HLA class-I APM components LMP2, LMP7, TAP1 and TAP2", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Antigen presentation; TAP1; TAP2; LMP2 / PSMB9; LMP7 / PSMB8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1432", "Drug": "Vorinostat (V) + mithramycin A (MA)", "Drug_category": "Others/combination", "Drugbank_ID": "vorinostat (V): DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). Mithramycin (also known as Plicamycin) is an antineoplastic antibiotic produced by Streptomyces plicatus. Mithramycin A is a DNA/RNA polymerase inhibitor, DNA-binding transcriptional inhibitor, antibiotic, and observed to facilitate tumor necrosis factor (TNF)-α and Fas ligand-induced apoptosis.", "KEGG_Drug__ID": "vorinostat (V): D06320", "Pubchem_ID": "vorinostat (V): 5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,\n C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]", "Single/Combination": "Combination", "PMID": "28536458", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin Cancer - Merkel Cell Carcinoma-Skin Cancer", "System": "WaGa", "Dose": "vorinostat (V) 1.25 µM, 0.3 µM for mithramycin A", "Technique": "RT-qPCR,immunofluorescence ,confocal microscopy and Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Microscopy; Confocal microscopy; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HLA class-I APM components LMP2, LMP7, TAP1 and TAP2", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Antigen presentation; TAP1; TAP2; LMP2 / PSMB9; LMP7 / PSMB8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1433", "Drug": "Vorinostat (V) + mithramycin A (MA)", "Drug_category": "Others/combination", "Drugbank_ID": "vorinostat (V): DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). Mithramycin (also known as Plicamycin) is an antineoplastic antibiotic produced by Streptomyces plicatus. Mithramycin A is a DNA/RNA polymerase inhibitor, DNA-binding transcriptional inhibitor, antibiotic, and observed to facilitate tumor necrosis factor (TNF)-α and Fas ligand-induced apoptosis.", "KEGG_Drug__ID": "vorinostat (V): D06320", "Pubchem_ID": "vorinostat (V): 5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,\n C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]", "Single/Combination": "Combination", "PMID": "28536458", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin Cancer - Merkel Cell Carcinoma-Skin Cancer", "System": "MKL-1", "Dose": "vorinostat (V) 1.25 µM, 0.3 µM for mithramycin A", "Technique": "RT-qPCR,immunofluorescence ,confocal microscopy and Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Microscopy; Confocal microscopy; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HLA class-I APM components LMP2, LMP7, TAP1 and TAP2", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Antigen presentation; TAP1; TAP2; LMP2 / PSMB9; LMP7 / PSMB8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1435", "Drug": "Vorinostat (V) + mithramycin A (MA)", "Drug_category": "Others/combination", "Drugbank_ID": "vorinostat (V): DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). Mithramycin (also known as Plicamycin) is an antineoplastic antibiotic produced by Streptomyces plicatus. Mithramycin A is a DNA/RNA polymerase inhibitor, DNA-binding transcriptional inhibitor, antibiotic, and observed to facilitate tumor necrosis factor (TNF)-α and Fas ligand-induced apoptosis.", "KEGG_Drug__ID": "vorinostat (V): D06320", "Pubchem_ID": "vorinostat (V): 5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,\n C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]", "Single/Combination": "Combination", "PMID": "28536458", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin Cancer - Merkel Cell Carcinoma-Skin Cancer", "System": "BroLi", "Dose": "vorinostat (V) 1.25 µM, 0.3 µM for mithramycin A", "Technique": "RT-qPCR,immunofluorescence ,confocal microscopy and Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunofluorescence assay; Microscopy; Confocal microscopy; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HLA class-I APM components LMP2, LMP7, TAP1 and TAP2", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Antigen presentation; TAP1; TAP2; LMP2 / PSMB9; LMP7 / PSMB8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/102", "Drug": "Vorinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546, DB11945", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H441+NK cells purified from two healthy donor PBMCs", "Dose": "vorinostat (3 µM) for 4 consecutive days, Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/114", "Drug": "Vorinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546, DB11945", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCL", "System": "NCI-H460 +NK cells purified from two healthy donor PBMCs", "Dose": "vorinostat (3 µM) for 4 consecutive days, Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/263", "Drug": "PI3K inhibitor (LY294002; )", "Drug_category": "PI3K inhibitor", "Drugbank_ID": "DB02656", "Target/s_or_mechanism_of_action": "Protein kinase inhibitors, the mode of action of LY294002 is through competition with ATP for binding the PI3K active site", "KEGG_Drug__ID": "C15195", "Pubchem_ID": "3973", "STR_LINK_(SMILES)": "O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "CL25", "Dose": "1 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/380", "Drug": "Vorinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546, DB11945", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "DU145 +NK cells purified from two healthy donor PBMCs", "Dose": "vorinostat (3 µM) for 4 consecutive days, Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/391", "Drug": "Vorinostat + Avelumab ( anti-PD-1)", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546, DB11945", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM).\n Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1.", "KEGG_Drug__ID": "D06320, \n D10817", "Pubchem_ID": "5311, \n 347911260", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate", "System": "PC-3 +NK cells purified from two healthy donor PBMCs", "Dose": "vorinostat (3 µM) for 4 consecutive days, Avelumab - 2 ng/mL", "Technique": "111In-release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK lysis and ADCC-mediated lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; ADCC; Antibody-dependent cytotoxicity", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1577", "Drug": "Vorinostat combined with azacitidine", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546, DB00928", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D06320, D03021", "Pubchem_ID": "5311, 9444", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,\n NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "29371976", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "4T1", "Dose": "vorinostat (Vor 1.5μM) ,azacitidine (Aza 5μM)", "Technique": "qReal-Time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in tumor cells,", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1579", "Drug": "Vorinostat combined with azacitidine", "Drug_category": "Others/combination", "Drugbank_ID": "DB02546, DB00928", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug__ID": "D06320, D03021", "Pubchem_ID": "5311, 9444", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,\n NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "29371976", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "EMT6", "Dose": "vorinostat (Vor 1.5μM) ,azacitidine (Aza 5μM)", "Technique": "qReal-Time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression in tumor cells,", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/72", "Drug": "Zebularine (Zeb) +Trichostatin A (TSA)", "Drug_category": "Others/combination", "Drugbank_ID": "DB03068, DB04297", "Target/s_or_mechanism_of_action": "A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.\n TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug__ID": null, "Pubchem_ID": "100016, 444732", "STR_LINK_(SMILES)": "OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC=NC1=O,\n C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Combination", "PMID": "22419072", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 cells", "Dose": "TSA (0.5 μM),zebularine (50-100 μM)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD1d", "Controlled_Terms_Function_enhanced_Number_increased": "CD1d", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/688", "Drug": "Panobinostat (PAN/LBH589)+IFN-γ", "Drug_category": "Pan-histone deacetylase inhibitor", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "HDAC inhibitors", "KEGG_Drug__ID": "D10319", "Pubchem_ID": "6918837", "STR_LINK_(SMILES)": "CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO", "Single/Combination": "combination", "PMID": "31720815", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1 and TS/A,", "Dose": "20 mg/kg/day", "Technique": "flow cytometry", "Controlled_Technique": "MHCII, MHC I, CD74,PD-L1 expression, STAT1, PD-L1, and\nCXCL10", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; MHC class II; PD-L1 / CD274; CXCL10 / IP-10; STAT1; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1268", "Drug": "Plerixafor (AMD3100)", "Drug_category": "Phenylmethylamines", "Drugbank_ID": "DB06809", "Target/s_or_mechanism_of_action": "Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered.", "KEGG_Drug__ID": "D08971", "Pubchem_ID": "65015", "STR_LINK_(SMILES)": "C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Single Drug", "PMID": "29100374", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "System": "Teff: PB-Tregs pretreated with AMD3100 (1:1)", "Dose": "10 μM of AMD3100", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "peripheral CD4+CD25− T effector (Teff) cells proliferation IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD25 / IL2RA; IFN-γ; Cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1186", "Drug": "Domatinostat (4SC-202)", "Drug_category": "phenylpyrazoles", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Single Drug", "PMID": "31703604", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "A375", "Dose": "domatinostat (0.5 µM), IFN-γ (10 ng/mL)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "(HLA-ABC)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1187", "Drug": "Domatinostat (4SC-202)", "Drug_category": "phenylpyrazoles", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Single Drug", "PMID": "31703604", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "HMCB", "Dose": "domatinostat (0.5 µM), IFN-γ (10 ng/mL)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "(HLA-ABC)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1188", "Drug": "Domatinostat (4SC-202)", "Drug_category": "phenylpyrazoles", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Single Drug", "PMID": "31703604", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MEWO", "Dose": "domatinostat (0.5 µM), IFN-γ (10 ng/mL)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "(HLA-ABC)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1319", "Drug": "Domatinostat (4SC-202)", "Drug_category": "phenylpyrazoles", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Single Drug", "PMID": "31703604", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "murine CT26", "Dose": "domatinostat (0.5 µM, 1 µM)", "Technique": "qPCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC class I and II", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/261", "Drug": "PI3K inhibitor (LY294002; )", "Drug_category": "PI3K inhibitor", "Drugbank_ID": "DB02656", "Target/s_or_mechanism_of_action": "Protein kinase inhibitors, the mode of action of LY294002 is through competition with ATP for binding the PI3K active site", "KEGG_Drug__ID": "C15195", "Pubchem_ID": "3973", "STR_LINK_(SMILES)": "O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "CL30", "Dose": "1 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/262", "Drug": "PI3K inhibitor (LY294002; )", "Drug_category": "PI3K inhibitor", "Drugbank_ID": "DB02656", "Target/s_or_mechanism_of_action": "Protein kinase inhibitors, the mode of action of LY294002 is through competition with ATP for binding the PI3K active site", "KEGG_Drug__ID": "C15195", "Pubchem_ID": "3973", "STR_LINK_(SMILES)": "O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "IO33", "Dose": "1 µmol/L", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/579", "Drug": "Carboplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00958", "Target/s_or_mechanism_of_action": "Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules within the cell.", "KEGG_Drug__ID": "D01363", "Pubchem_ID": "426756", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]", "Single/Combination": "Single", "PMID": "32078695", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "esophageal cancer cells (OE33 cells", "System": "OE33", "Dose": "0, 10 and 100 μM cisplatin", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "No significant differences were observed in CD1d expression in OE33 cells", "Immune_System_function_unaffected": "Expression / abundance phenotype; CD1d", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/703", "Drug": "Carboplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00958", "Target/s_or_mechanism_of_action": "Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules within the cell.", "KEGG_Drug__ID": "D01363", "Pubchem_ID": "426756", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]", "Single/Combination": "Single", "PMID": "32078695", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "upper gastrointestinal cancer", "System": "Invariant natural killer T (iNKT) cells+CD1d-transfected HeLa cells", "Dose": "10 or 50 μM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "No significant decrease in IFN-γ expression by viable iNKT cells, No significant difference in granzyme B or perforin production by activated iNKT cells", "Immune_System_function_unaffected": "Expression / abundance phenotype; Granzyme B / GZMB; IFN-γ", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/86", "Drug": "Carboplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00958", "Target/s_or_mechanism_of_action": "Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules within the cell.", "KEGG_Drug__ID": "D01363", "Pubchem_ID": "38904", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "20683396", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "MA-148", "Dose": "(5 microg/mL)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Macrophage chemoattractant protein-1 (MCP-1)", "Controlled_Terms_Negative_Regulation": "CCL2 / MCP-1; Macrophages"}, {"ID": "CANIMM/87", "Drug": "Carboplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00958", "Target/s_or_mechanism_of_action": "Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules within the cell.", "KEGG_Drug__ID": "D01363", "Pubchem_ID": "38904", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "20683396", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SKOV-3", "Dose": "(5 microg/mL)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Macrophage chemoattractant protein-1 (MCP-1)", "Controlled_Terms_Negative_Regulation": "CCL2 / MCP-1; Macrophages"}, {"ID": "CANIMM/1190", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "21765211", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Blm Melanoma Cells", "System": "BLM melanoma cells", "Dose": "10 μg/ml cisplatin", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L2 expression dephosphorylation of STAT6 in tumor cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L2 / PDCD1LG2; STAT6; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/817", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "14617634", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "S-Type Neuroblastoma", "System": "SH-EP1", "Dose": "10 μg/ml", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Caspase-3 and caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "caspase-8", "Controlled_Terms_Unaffected": "Caspase-8; Caspase activation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1530", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "22396773", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "ZR-75-1", "Dose": "6 µM", "Technique": "immunoblotting, Flow cytometry, ELISA assay", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-β MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; IFN-β;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/698", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515", "Target/s_or_mechanism_of_action": "DNA crosslinking and DNA damage", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "2767", "STR_LINK_(SMILES)": "N.N.Cl[Pt]Cl", "Single/Combination": "Single", "PMID": "40380807", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "gastric cancer cell line", "System": "AGS", "Dose": "22.56μM", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Increased cell-surface PD-L1 and MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Increased PD-L1 may promote inhibitory immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/699", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515", "Target/s_or_mechanism_of_action": "DNA crosslinking and DNA damage", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "2767", "STR_LINK_(SMILES)": "N.N.Cl[Pt]Cl", "Single/Combination": "Single", "PMID": "40380807", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "gastric cancer cell line", "System": "SNU-1", "Dose": "13.92μM", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Increased cell-surface PD-L1 and MHC-I", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "Increased PD-L1 may promote inhibitory immune-checkpoint signaling", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 immune checkpoint pathway; Expression / abundance phenotype; PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/578", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515", "Target/s_or_mechanism_of_action": "DNA crosslinking and DNA damage", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "84691", "STR_LINK_(SMILES)": "N.N.Cl[Pt]Cl", "Single/Combination": "Single", "PMID": "32078695", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "esophageal cancer cells (OE33 cells", "System": "OE33", "Dose": "0, 10 and 100 μM cisplatin", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "downregulation of CD1d in OE33 cells", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; CD1d", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/77", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "26689911", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Malignant Mesothelioma (MM)", "System": "H2461", "Dose": "(0–100 μM)", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NLRP3", "Controlled_Terms_Negative_Regulation": "NLRP3 inflammasome"}, {"ID": "CANIMM/119", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "23079474", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SK-OV-3", "Dose": "20 μM", "Technique": "Microarray analysis +RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IRF-1 and IRF-7 are induced by CDDP in ovarian cancer cell lines", "Controlled_Terms_Negative_Regulation": "IRF-1; IRF-7"}, {"ID": "CANIMM/701", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515", "Target/s_or_mechanism_of_action": "DNA crosslinking and DNA damage", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "84691", "STR_LINK_(SMILES)": "N.N.Cl[Pt]Cl", "Single/Combination": "Single", "PMID": "32078695", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "upper gastrointestinal cancer", "System": "Invariant natural killer T (iNKT) cells+CD1d-transfected HeLa cells", "Dose": "10 or 100 μM", "Technique": "Flow cytometry", "Controlled_Technique": "significant increase of granzyme B and perforin", "Immune_System-Function_enhanced/numbers_increased": "Granzyme B / GZMB; Perforin / PRF1", "Controlled_Terms_Function_enhanced_Number_increased": "inhibited IFN-γ production and CD107a externalization, PI9 expression decreased at high doses", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; CD107a / LAMP1; IFN-γ", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/340", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "26689911", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Malignant Mesothelioma (MM)", "System": "Hmeso", "Dose": "(0–100 μM)", "Technique": "Western blot analysis or ELISA", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-1β, IL-18, FGF2 and HMGB1 NLRP3 inflammasome, capsase-1", "Controlled_Terms_Negative_Regulation": "IL-1 family; IL-18; FGF2; NLRP3 inflammasome; HMGB1"}, {"ID": "CANIMM/341", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "26689911", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Malignant Mesothelioma (MM)", "System": "H2373", "Dose": "(0–100 μM)", "Technique": "Western blot analysis or ELISA", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-1β, IL-18, FGF2 and HMGB1 NLRP3 inflammasome, capsase-1", "Controlled_Terms_Negative_Regulation": "IL-1 family; IL-18; FGF2; NLRP3 inflammasome; HMGB1"}, {"ID": "CANIMM/772", "Drug": "Teniposide", "Drug_category": "Podophyllotoxins", "Drugbank_ID": "DB00444", "Target/s_or_mechanism_of_action": "Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.", "KEGG_Drug__ID": "D02698", "Pubchem_ID": "452548", "STR_LINK_(SMILES)": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1", "Single/Combination": "Single Drug", "PMID": "31408442", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16-OVA cells treated with teniposide or DMSO for 16 hours, then cocultures with BMDC and OT-I cells", "Dose": null, "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell, T cells expressing the activation marker CD69 and effector molecule granzyme B (Gzm B) IL-2 and IFN-γ ( significantly increased in T cells)", "Controlled_Terms_Function_enhanced_Number_increased": "CD69; IL-2; IFN-γ; Granzyme B / GZMB; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/416", "Drug": "Cisplatin and carboplatin", "Drug_category": "Platinum Compounds", "Drugbank_ID": "cisplatin-DB00515 (APRD00359), Carboplatin-DB00958 (APRD00466)", "Target/s_or_mechanism_of_action": "Cisplatin-Formation of DNA cross-links/alkylation and Carboplatin by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate.", "KEGG_Drug__ID": null, "Pubchem_ID": "Cisplatin-5702198 , Carboplatin-‎426756", "STR_LINK_(SMILES)": "Cisplatin-[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] and Carboplatin-[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]", "Single/Combination": null, "PMID": "7795278", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcomas", "System": "mouse sarcoma-180 cells + cisplatin (10 micrograms/ml) and carboplatin (50 micrograms/ml)-treated macrophages", "Dose": "cisplatin (10 micrograms/ml) and carboplatin (50 micrograms/ml)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "interleukin-1 alpha and tumor necrosis factor-alpha Cytotoxicity", "Controlled_Terms_Function_enhanced_Number_increased": "IL-1 family; TNF-α / TNF; Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/73", "Drug": "Cisplatin-based NAC", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": null, "PMID": "31404614", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "Lewis lung carcinoma", "Dose": null, "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression on tumor", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/120", "Drug": "Cisplatin-based NAC", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": null, "PMID": "31404614", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "LNM-R cells", "Dose": "dose-dependent manner( MAX 8 μM)", "Technique": "RT-PCR + Immunocytochemistry", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression on tumor AKT ACTIVATION", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; AKT; PD-L1 immune checkpoint pathway; Expression / abundance phenotype"}, {"ID": "CANIMM/1429", "Drug": "CP (cisplatin)", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug__ID": "D00275", "Pubchem_ID": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "16957513", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "Colon cancer (SW480) cells", "Dose": "CP (cisplatin) IC50 3.40 ug/ml", "Technique": "Immunocytochemistry\n and Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": "Fas, FasL", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; Fas ligand / FasL / FASLG", "Immune_System-Function_inhibited/numbers_decreased": "FasL", "Controlled_Terms_Function_inhibited_Number_decreased": "Fas ligand / FasL / FASLG", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1303", "Drug": "Oxaliplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "21151176", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U2OS", "Dose": "(300 mM)", "Technique": "automated image acquisition and analysis + Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "formation of stress granules and macroautophagy-immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Autophagy / macroautophagy", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1304", "Drug": "Oxaliplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "21151176", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U2OS", "Dose": "(600 mM)", "Technique": "automated image acquisition and analysis + Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "phosphorylation of the eukaryotic translation initiation factor 2α (eIF2α)-a marker of immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; eIF2α / EIF2S1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1305", "Drug": "Oxaliplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "21151176", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "U2OS", "Dose": "(600 mM)", "Technique": "automated image acquisition and analysis + Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "translocation of calreticulin (CRT) from the lumen of the endoplasmic reticulum (ER) to the cell surface-Immunogenic cell death marker", "Controlled_Terms_Function_enhanced_Number_increased": "Immunogenic cell death; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1475", "Drug": "Oxaliplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "SW480", "Dose": "10 μM", "Technique": "immunoblotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/192", "Drug": "Oxaliplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116", "Dose": "10 μM", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/193", "Drug": "Oxaliplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "LoVo", "Dose": "10 μM", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/842", "Drug": "Oxaliplatin (OXP)", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "30733494", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "0.6 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "death receptor CD95 (fas) on live cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/861", "Drug": "Oxaliplatin (OXP)", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "30733494", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT116", "Dose": "1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "death receptor CD95 (fas) on live cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/969", "Drug": "Oxaliplatin (OXP)", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "26156960", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung/Breast", "System": "Immature DCs +supernatants derived from A549 or MCF7 tumour cells", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T cells CD80, CD83 and CD86 on DCs", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; CD83; CD86; CD80/CD86 costimulation; T cells; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/970", "Drug": "Oxaliplatin (OXP)", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug__ID": "D01790", "Pubchem_ID": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "30733494", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "A549", "Dose": "1 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "death receptor CD95 (fas) on live cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1531", "Drug": "Etoposide", "Drug_category": "Podophyllotoxins", "Drugbank_ID": "DB00773", "Target/s_or_mechanism_of_action": "Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.", "KEGG_Drug__ID": "D00125", "Pubchem_ID": "36462", "STR_LINK_(SMILES)": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O", "Single/Combination": "Single Drug", "PMID": "22396773", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "ZR-75-1", "Dose": "1 µM", "Technique": "immunoblotting, Flow cytometry, ELISA assay", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-β MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; IFN-β;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1312", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "18771959", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "System": "isolated Treg and Teff", "Dose": null, "Technique": "(3)H-thymidine proliferation assays", "Controlled_Technique": "Cell viability/proliferation assay; Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1317", "Drug": "Teniposide", "Drug_category": "Podophyllotoxins", "Drugbank_ID": "DB00444", "Target/s_or_mechanism_of_action": "Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.", "KEGG_Drug__ID": "D02698", "Pubchem_ID": "452548", "STR_LINK_(SMILES)": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1", "Single/Combination": "Single Drug", "PMID": "31408442", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "MC38", "Dose": "0-10 µM", "Technique": "HMGB1-Gluc reporter assay,qPCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "T cell CXCL10 (ICD marker) MHC-I and MHC-II expression on the tumor cell surface, β2m (B2m), an essential component of MHC-I,genes directing peptide cleavage (Erap1), peptide transporters (Tap1 and Tap2), and transporter-MHC interactions (Tapbp) Immunogenic cell death,apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; β2-microglobulin / B2M; CXCL10 / IP-10; Apoptosis; Immunogenic cell death; TAP1; TAP2; T cells; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1318", "Drug": "Teniposide", "Drug_category": "Podophyllotoxins", "Drugbank_ID": "DB00444", "Target/s_or_mechanism_of_action": "Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.", "KEGG_Drug__ID": "D02698", "Pubchem_ID": "452548", "STR_LINK_(SMILES)": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1", "Single/Combination": "Single Drug", "PMID": "31408442", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "System": "CT26", "Dose": "0-10 µM", "Technique": "HMGB1-Gluc reporter assay.Flow cytometry,qPCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC-I and MHC-II expression on the tumor cell surface, β2m (B2m), an essential component of MHC-I,genes directing peptide cleavage (Erap1), peptide transporters (Tap1 and Tap2), and transporter-MHC interactions (Tapbp) Immunogenic cell death,apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; β2-microglobulin / B2M; Apoptosis; Immunogenic cell death; TAP1; TAP2; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1332", "Drug": "Teniposide", "Drug_category": "Podophyllotoxins", "Drugbank_ID": "DB00444", "Target/s_or_mechanism_of_action": "Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.", "KEGG_Drug__ID": "D02698", "Pubchem_ID": "452548", "STR_LINK_(SMILES)": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1", "Single/Combination": "Single Drug", "PMID": "31408442", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "System": "PDAC murine pancreatic cancer cells", "Dose": null, "Technique": "Flow cytometry,qPCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC-I and MHC-II expression on the tumor cell surface, β2m (B2m), an essential component of MHC-I,genes directing peptide cleavage (Erap1), peptide transporters (Tap1 and Tap2), and transporter-MHC interactions (Tapbp)", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; β2-microglobulin / B2M; TAP1; TAP2; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1337", "Drug": "Teniposide", "Drug_category": "Podophyllotoxins", "Drugbank_ID": "DB00444", "Target/s_or_mechanism_of_action": "Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.", "KEGG_Drug__ID": "D02698", "Pubchem_ID": "452548", "STR_LINK_(SMILES)": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1", "Single/Combination": "Single Drug", "PMID": "31408442", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "OVA-expressing B16 mouse melanoma cells (B16-OVA) + cocultured with bone marrow–derived DCs (BMDCs) and OVA-specific CD8+ T cell hybridoma B3Z cells, B16", "Dose": null, "Technique": "HMGB1-Gluc reporter assay,qPCR, Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "T cell, T cells expressing the activation marker CD69 and effector molecule granzyme B (Gzm B) CXCL10 (ICD marker), IL-2 and IFN-γ ( significantly increased in T cells), IFN-β, CCL5, and CXCL10 MHC-I and MHC-II expression on the tumor cell surface, β2m (B2m), an essential component of MHC-I,genes directing peptide cleavage (Erap1), peptide transporters (Tap1 and Tap2), and transporter-MHC interactions (Tapbp), CD80, CD86, MHC-I, MHC-II, and CD40 on BMDCs (BMDC maturation, antigen presentation, and subsequent T cell activation) Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; β2-microglobulin / B2M; CD40; CD80; CD86; CD69; IL-2; IFN-β; IFN-γ; CCL5 / RANTES; CXCL10 / IP-10; Immunogenic cell death; Antigen presentation; TAP1; TAP2; Granzyme B / GZMB; CD80/CD86 costimulation; T cells; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/100", "Drug": "Resveratrol", "Drug_category": "Polyphenolic phytoalexin", "Drugbank_ID": "DB02709", "Target/s_or_mechanism_of_action": "resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme", "KEGG_Drug__ID": "C03582", "Pubchem_ID": "445154", "STR_LINK_(SMILES)": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "11406544", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "SEM", "Dose": "50 mM resveratrol", "Technique": "RT-PCR, colorimetric\n assay using the caspase-9 activation kit", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay; Colorimetric/biochemical activity assay", "Immune_System-Function_enhanced/numbers_increased": "Caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD95L", "Controlled_Terms_Unaffected": "Fas ligand / FasL / FASLG", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/101", "Drug": "Resveratrol", "Drug_category": "Polyphenolic phytoalexin", "Drugbank_ID": "DB02709", "Target/s_or_mechanism_of_action": "resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme", "KEGG_Drug__ID": "C03582", "Pubchem_ID": "445154", "STR_LINK_(SMILES)": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "11406544", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "RS4;11", "Dose": "50 mM resveratrol", "Technique": "RT-PCR, colorimetric\n assay using the caspase-9 activation kit", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay; Colorimetric/biochemical activity assay", "Immune_System-Function_enhanced/numbers_increased": "Caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD95L", "Controlled_Terms_Unaffected": "Fas ligand / FasL / FASLG", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/103", "Drug": "Resveratrol", "Drug_category": "Polyphenolic phytoalexin", "Drugbank_ID": "DB02709", "Target/s_or_mechanism_of_action": "resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme", "KEGG_Drug__ID": "C03582", "Pubchem_ID": "445154", "STR_LINK_(SMILES)": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "11406544", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "REH", "Dose": "50 mM resveratrol", "Technique": "RT-PCR, colorimetric\n assay using the caspase-9 activation kit", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay; Colorimetric/biochemical activity assay", "Immune_System-Function_enhanced/numbers_increased": "Caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD95L", "Controlled_Terms_Unaffected": "Fas ligand / FasL / FASLG", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/104", "Drug": "Resveratrol", "Drug_category": "Polyphenolic phytoalexin", "Drugbank_ID": "DB02709", "Target/s_or_mechanism_of_action": "resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme", "KEGG_Drug__ID": "C03582", "Pubchem_ID": "445154", "STR_LINK_(SMILES)": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "11406544", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "Nalm-6", "Dose": "50 mM resveratrol", "Technique": "RT-PCR, colorimetric\n assay using the caspase-9 activation kit", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay; Colorimetric/biochemical activity assay", "Immune_System-Function_enhanced/numbers_increased": "Caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD95L", "Controlled_Terms_Unaffected": "Fas ligand / FasL / FASLG", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/105", "Drug": "Resveratrol", "Drug_category": "Polyphenolic phytoalexin", "Drugbank_ID": "DB02709", "Target/s_or_mechanism_of_action": "resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme", "KEGG_Drug__ID": "C03582", "Pubchem_ID": "445154", "STR_LINK_(SMILES)": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "11406544", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "MV4;11", "Dose": "50 mM resveratrol", "Technique": "RT-PCR, colorimetric\n assay using the caspase-9 activation kit", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay; Colorimetric/biochemical activity assay", "Immune_System-Function_enhanced/numbers_increased": "CD95L Caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Fas ligand / FasL / FASLG; Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/106", "Drug": "Resveratrol", "Drug_category": "Polyphenolic phytoalexin", "Drugbank_ID": "DB02709", "Target/s_or_mechanism_of_action": "resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme", "KEGG_Drug__ID": "C03582", "Pubchem_ID": "445154", "STR_LINK_(SMILES)": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "11406544", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "Jurkat", "Dose": "50 mM resveratrol", "Technique": "RT-PCR, colorimetric\n assay using the caspase-9 activation kit", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay; Colorimetric/biochemical activity assay", "Immune_System-Function_enhanced/numbers_increased": "CD95L Caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Fas ligand / FasL / FASLG; Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/107", "Drug": "Resveratrol", "Drug_category": "Polyphenolic phytoalexin", "Drugbank_ID": "DB02709", "Target/s_or_mechanism_of_action": "resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme", "KEGG_Drug__ID": "C03582", "Pubchem_ID": "445154", "STR_LINK_(SMILES)": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "11406544", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "CEM", "Dose": "50 mM resveratrol", "Technique": "RT-PCR, colorimetric\n assay using the caspase-9 activation kit", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay; Colorimetric/biochemical activity assay", "Immune_System-Function_enhanced/numbers_increased": "CD95L Caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Fas ligand / FasL / FASLG; Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/99", "Drug": "Resveratrol", "Drug_category": "Polyphenolic phytoalexin", "Drugbank_ID": "DB02709", "Target/s_or_mechanism_of_action": "resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme", "KEGG_Drug__ID": "C03582", "Pubchem_ID": "445154", "STR_LINK_(SMILES)": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "11406544", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Lymphoblastic Leukemias (ALLs)", "System": "HL60", "Dose": "50 mM resveratrol", "Technique": "RT-PCR, colorimetric\n assay using the caspase-9 activation kit", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay; Colorimetric/biochemical activity assay", "Immune_System-Function_enhanced/numbers_increased": "Caspase-9", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-9; Caspase activation", "Immune_System-Function_inhibited/numbers_decreased": "CD95L", "Controlled_Terms_Function_inhibited_Number_decreased": "Fas ligand / FasL / FASLG", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/904", "Drug": "AST 487", "Drug_category": "RET kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Medullary Carcinoma", "System": "TT cells", "Dose": "AST487(0-1000nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/971", "Drug": "AST 487", "Drug_category": "RET kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung - Human Lung Adenocarcinoma", "System": "LC-2/ad", "Dose": "AST487(0-100nM)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C, HLA-A*02:01", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1481", "Drug": "AST 487", "Drug_category": "RET kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "RET kinase inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid - Human Papillary Thyroid Carcinoma", "System": "TPC1 cells", "Dose": "AST487(0-100nM)", "Technique": "Western BLot and Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C, HLA-A*02:01", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": "pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": "IFNα, IFNγ, IL4, IL6 or TNFα secretion", "Controlled_Terms_Unaffected": "IL-4; IL-6; TNF-α / TNF; IFN-α; IFN-γ", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1073", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug__ID": "D00094", "Pubchem_ID": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "28515123", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "RAW264.7 cells treated with the supernatant of K7M2 WT cells", "Dose": "1 μmol/L ATRA for 48 hours", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "M1 polarization of macrophages CD86+ cells,(CCL3 and CCL5)", "Controlled_Terms_Function_enhanced_Number_increased": "CD86; CCL3 / MIP-1α; CCL5 / RANTES; Macrophages", "Immune_System-Function_inhibited/numbers_decreased": "M2 polarization CD206+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD206 / MRC1; M2 macrophage polarization", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1336", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug__ID": "D00094", "Pubchem_ID": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "31296953", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "System": "K7M2 WT cells", "Dose": null, "Technique": "Colony formation assay, tumor sphere-formation assay, Flow cytometry, real-time PCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "M2 polarization CD117+Stro-1+ cells ( M2 polarization-induced stemness of osteosarcoma cells), CD133, CXCR4 Nanog, and Oct4", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCR4; M2 macrophage polarization; CD117 / KIT; STRO-1; CD133 / PROM1; NANOG; Stemness-associated phenotype; M2 polarization-associated stemness", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1430", "Drug": "ATRA (all-trans\n retinoic acid)", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug__ID": "D00094", "Pubchem_ID": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "16957513", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "Colon cancer (SW480) cells", "Dose": "ATRA (all-trans\n retinoic acid) Range : 10–5, 10–6, 10–7 and 10–8mol/l,", "Technique": "Immunocytochemistry\n and Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunocytochemistry (ICC)", "Immune_System-Function_enhanced/numbers_increased": "Fas", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/744", "Drug": "Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug__ID": "D00094", "Pubchem_ID": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "12115542", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCC‐4", "Dose": "10^6 M RA for 7 days", "Technique": "Cell migration assays, sandwich ELISA technique", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "monocyte migration, macrophages for secretion of angiogenic factors,IL-8 and VEGF-Pro angiogenic factors MCP-1 and TGF-β1-inducer of monocyte chemotaxis", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8; VEGF; Macrophages; Monocytes; T-cell migration / chemotaxis", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/746", "Drug": "Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug__ID": "D00094", "Pubchem_ID": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "12115542", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCC‐9", "Dose": "10^6 M RA for 7 days", "Technique": "Cell migration assays, sandwich ELISA technique", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "monocyte migration, macrophages for secretion of angiogenic factors,IL-8 and VEGF-Pro angiogenic factors MCP-1 and TGF-β1-inducer of monocyte chemotaxis", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8; VEGF; Macrophages; Monocytes; T-cell migration / chemotaxis", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/747", "Drug": "Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug__ID": "D00094", "Pubchem_ID": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "12115542", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCC‐15", "Dose": "10^6 M RA for 7 days", "Technique": "Cell migration assays, sandwich ELISA technique", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "monocyte migration, macrophages for secretion of angiogenic factors,IL-8 and VEGF-Pro angiogenic factors MCP-1 and TGF-β1-inducer of monocyte chemotaxis", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8; VEGF; Macrophages; Monocytes; T-cell migration / chemotaxis", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/748", "Drug": "Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug__ID": "D00094", "Pubchem_ID": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "12115542", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCC‐25", "Dose": "10^6 M RA for 7 days", "Technique": "Cell migration assays, sandwich ELISA technique", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "monocyte migration, macrophages for secretion of angiogenic factors,IL-8 and VEGF-Pro angiogenic factors MCP-1 and TGF-β1-inducer of monocyte chemotaxis", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8; VEGF; Macrophages; Monocytes; T-cell migration / chemotaxis", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/749", "Drug": "Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug__ID": "D00094", "Pubchem_ID": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "12115542", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "OSCC‐3", "Dose": "10^6 M RA for 7 days", "Technique": "Cell migration assays, sandwich ELISA technique", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "monocyte migration, macrophages for secretion of angiogenic factors,IL-8 and VEGF-Pro angiogenic factors MCP-1 and TGF-β1-inducer of monocyte chemotaxis", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL2 / MCP-1; IL-8/CXCL8; VEGF; Macrophages; Monocytes; T-cell migration / chemotaxis", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/209", "Drug": "RK20449", "Drug_category": "Src family kinase Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28399411", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "primary CLL cells", "Dose": "trichostatin A-0.25 µM/L, TRAIL (100 ng/mL)", "Technique": "Western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "TRAIL-induced apoptosis-phosphatidylserine externalization, processing of caspase-3 to its catalytically active large subunits (p19/p17) and cleavage of PARP", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Caspase-3; Caspase activation; Apoptosis; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/756", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0", "Single/Combination": "Single Drug", "PMID": "29500278", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-231 +serum from mice treated with dtx", "Dose": null, "Technique": "ALDEFLUOR assay", "Controlled_Technique": "ALDEFLUOR assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "ALDEFLUORbright BC cells-stem cell marker", "Controlled_Terms_Negative_Regulation": "Stemness-associated phenotype"}, {"ID": "CANIMM/1423", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "20702612", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Mammary Tumor", "System": "4T1 tumor cells + T cells from tumor bearers", "Dose": null, "Technique": "24-h 51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "CTL from T cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/591", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C5", "Single/Combination": "Single Drug", "PMID": "12085250", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "PBMC + NK-sensitive K562 tumour targets For NK cell activity and PBMCs +NK-resistant Daudi tumour targets", "Dose": null, "Technique": "(3)H-thymidine proliferation assays, chromium release assay", "Controlled_Technique": "Cytotoxicity/release assay; Cell viability/proliferation assay; Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "NK and LAK cell cytotoxicity IL-6, GM-CSF, IFN-γ levels,", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; IFN-γ; GM-CSF / CSF2; Cytotoxicity / cytolysis; LAK cells; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "IL-1, TNF, and PGE2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; TNF-α / TNF; PGE2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/777", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "9499461", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma Cells", "System": "HT-29 cells +Unstimulated and IL-2 stimulated lymphocytes", "Dose": "3x10^-9 M", "Technique": "MTT-method + ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "lymphocyte mediated cytotoxicity TNF-alpha and IFN-gamma", "Controlled_Terms_Function_enhanced_Number_increased": "TNF-α / TNF; IFN-γ; Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/862", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0", "Single/Combination": "Single Drug", "PMID": "9499461", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma Cells", "System": "HT-29 cells", "Dose": "1-3x10^-9 M", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "LFA-3, ICAM-1, CD44s, CD44v6, CD15, CD13 and VLA-4/5/6 on the tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD13 / ANPEP; CD15; CD44; LFA-3 / CD58; ICAM-1 / CD54; VLA integrins", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD11a on tumor cells CD18, , MHC-II, VCAM-1, ELAM-1 and PECAM-1", "Controlled_Terms_Unaffected": "MHC class II; CD11a / ITGAL; CD18 / ITGB2; CD31 / PECAM-1; VCAM-1 / CD106; ELAM-1 / E-selectin; PECAM-1;", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/972", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0", "Single/Combination": "Single Drug", "PMID": "26439264", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC(Lung)", "System": "PC–9", "Dose": "1 or 10 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MICB and ULBP–2/5/6 on tumor cells- NKG2D ligands", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; MICB; NKG2D ligand;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/973", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0", "Single/Combination": "Single Drug", "PMID": "26439264", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC(Lung)", "System": "RERF-LC-AI", "Dose": "1 or 10 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ULBP–2/5/6- NKG2D ligands", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP2; ULBP2/5/6 family; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/974", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0", "Single/Combination": "Single Drug", "PMID": "26439264", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC(Lung)", "System": "A549", "Dose": "1 or 10 nM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC class I on tumor cells- NKG2D ligands", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; NKG2D / KLRK1; NKG2D ligand;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/499", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0", "Single/Combination": "Single Drug", "PMID": "9499461", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma Cells", "System": "HT-29 cells", "Dose": "1-3x10^-9 M", "Technique": "Flow cytometry", "Controlled_Technique": "LFA-3, ICAM-1, CD44s, CD44v6, CD15, CD13 and VLA-4/5/6 on the tumor cells", "Immune_System-Function_enhanced/numbers_increased": "ICAM-1 / CD54", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "CD11a on tumor cells CD18, , MHC-II, VCAM-1, ELAM-1 and PECAM-1", "Immune_System_function_unaffected": "CD31 / PECAM-1; MHC class II; VCAM-1 / CD106; CD11a / ITGAL; CD18 / ITGB2", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/498", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "9499461", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma Cells", "System": "HT-29 cells +Unstimulated and IL-2 stimulated lymphocytes", "Dose": "3x10^-9 M", "Technique": "MTT-method + ELISA", "Controlled_Technique": "lymphocyte mediated cytotoxicity TNF-alpha and IFN-gamma", "Immune_System-Function_enhanced/numbers_increased": "TNF-α / TNF; Cytotoxicity / cytolysis", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/92", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D07866", "Pubchem_ID": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C7", "Single/Combination": "Single Drug", "PMID": "19866475", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "LNCaP and LAPC4 prostate cancer cell lines", "Dose": "0, 1, 5, and 25 nM", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CCL2, CXCL10, IL-1β, IL-6 and IL-8", "Controlled_Terms_Negative_Regulation": "IL-1 family; IL-6; IL-8 / CXCL8; CCL2 / MCP-1; CXCL10 / IP-10; IL-8/CXCL8"}, {"ID": "CANIMM/1074", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "18074150", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Metastasizing Epithelioid Sarcoma (ES)", "System": "GRU", "Dose": "10 μg/ml", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD95 receptor expression CD95 activation resulted in apoptosis and cell death", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; Apoptosis; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1254", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-231", "Dose": "paclitaxel (0.1-1 µM)", "Technique": "Flow cytometry + ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1255", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7,", "Dose": "paclitaxel (0.1-1 µM)", "Technique": "Flow cytometry + ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1257", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "29138861", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SK-BR-3", "Dose": "paclitaxel (0.1-1 µM)", "Technique": "Flow cytometry + ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1 and calreticulin in tumor microenvironment", "Controlled_Terms_Function_enhanced_Number_increased": "Calreticulin / CRT; HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1273", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "21223350", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "T cells derived from tumour-bearing C57BL ⁄ 6 mice", "Dose": "0.1 micromole", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "T reg IL-10 and TGF-b by Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; Regulatory T cells / Tregs", "Immune_System_function_unaffected": "T-eff IL-2 and IFN-γ of Teff", "Controlled_Terms_Unaffected": "IL-2; IFN-γ", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1532", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "7847557", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "22396773", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "ZR-75-1", "Dose": "3 µM", "Technique": "immunoblotting, Flow cytometry, ELISA assay", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-β MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; IFN-β;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/581", "Drug": "paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single", "PMID": "32078695", "Cancer_Type": "Esophageal Cancer", "Cancer_Type_Description": "esophageal cancer cells (OE33 cells", "System": "OE33", "Dose": "0, 10 and 100 μM cisplatin", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": "No significant differences were observed in CD1d expression in OE33 cells", "Immune_System_function_unaffected": "Expression / abundance phenotype; CD1d", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/704", "Drug": "paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single", "PMID": "32078695", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "upper gastrointestinal cancer", "System": "Invariant natural killer T (iNKT) cells+CD1d-transfected HeLa cells", "Dose": "10 or 50 μM", "Technique": "Flow cytometry", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": "reduced CD107a expression", "Immune_System-Function_inhibited/numbers_decreased": "Expression / abundance phenotype; CD107a / LAMP1", "Controlled_Terms_Function_inhibited_Number_decreased": "No significant decrease in IFN-γ expression by viable iNKT cells, No significant difference in granzyme B or perforin production by activated iNKT cells", "Immune_System_function_unaffected": "Expression / abundance phenotype; Granzyme B / GZMB; IFN-γ", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/10", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": null, "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "22039576", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "BT474", "Dose": "10-25nm", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CSF1", "Controlled_Terms_Negative_Regulation": "CSF1 / M-CSF"}, {"ID": "CANIMM/11", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": null, "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "22039576", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-435", "Dose": "10-25nm", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CSF1", "Controlled_Terms_Negative_Regulation": "CSF1 / M-CSF"}, {"ID": "CANIMM/12", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": null, "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "22039576", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "SKBR3", "Dose": "10-25nm", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CSF1", "Controlled_Terms_Negative_Regulation": "CSF1 / M-CSF"}, {"ID": "CANIMM/13", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": null, "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "22039576", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "T47D", "Dose": "10-25nm", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CSF1", "Controlled_Terms_Negative_Regulation": "CSF1 / M-CSF"}, {"ID": "CANIMM/15", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": null, "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "22039576", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF7", "Dose": "10-25nm", "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CSF1", "Controlled_Terms_Negative_Regulation": "CSF1 / M-CSF"}, {"ID": "CANIMM/554", "Drug": "Irinotecan", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Single", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "SW620", "Dose": "25 µg/mL", "Technique": "Flow cytometry; immunoblotting and fluorescent staining", "Controlled_Technique": "Increased PD-L1 and MHC-I; NF-κB inhibition consistently enhanced MHC-I induction", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274; NF-κB", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/88", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "20683396", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "MA-148", "Dose": "43 pg/mL", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Macrophage chemoattractant protein-1 (MCP-1)", "Controlled_Terms_Negative_Regulation": "CCL2 / MCP-1; Macrophages"}, {"ID": "CANIMM/89", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "20683396", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "System": "SKOV-3", "Dose": "43 pg/mL", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Macrophage chemoattractant protein-1 (MCP-1)", "Controlled_Terms_Negative_Regulation": "CCL2 / MCP-1; Macrophages"}, {"ID": "CANIMM/9", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": null, "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "22039576", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MMTV-pMECs–derived MECs treated with PTXfor 24 hours ex vivo", "Dose": null, "Technique": "qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CSF1, CCL8/MCP2, and IL34", "Controlled_Terms_Negative_Regulation": "IL-34; CSF1 / M-CSF; CCL8 / MCP-2"}, {"ID": "CANIMM/167", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "20693278", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-468", "Dose": "7 Micromole", "Technique": "immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tyrosine-phosphorylated STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/168", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "20693278", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "BT549 cells", "Dose": null, "Technique": "immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tyrosine-phosphorylated STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/170", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": "D00491", "Pubchem_ID": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "20693278", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7 cells,", "Dose": null, "Technique": "immunoblot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "STAT3 phosphorylation induction-inhibition", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/843", "Drug": "Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a)", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug__ID": "D03257", "Pubchem_ID": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29703841", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "bone marrow–derived dendritic cells (DC) isolated from naive mice", "Dose": "DXd (0, 0.0625, 0.125, 0.25, 0.5, and 1.0 μmol/L)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD86, MHCII expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; CD86; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "PD-L1 expression", "Controlled_Terms_Unaffected": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1191", "Drug": "Camptothecin", "Drug_category": "Topoisomerase I Inhibitor", "Drugbank_ID": "DB04690", "Target/s_or_mechanism_of_action": "Camptothecin is an alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.", "KEGG_Drug__ID": "C01897", "Pubchem_ID": "24360", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "29267866", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Melanoma cell line 2549, along with its autologous tumor-infiltrating lymphocytes (TILs)", "Dose": "1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cell activated caspase 3-apoptosis marker", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/549", "Drug": "Camptothecin", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": "DB04690", "Target/s_or_mechanism_of_action": "Stabilizes the DNA–topoisomerase I cleavage complex, inhibiting DNA religation and causing DNA damage", "KEGG_Drug__ID": "C01897", "Pubchem_ID": "24360", "STR_LINK_(SMILES)": "CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O", "Single/Combination": "Single", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "SW620", "Dose": "0.5–1 µM", "Technique": "Flow cytometry; immunoblotting and fluorescent staining", "Controlled_Technique": "Increased PD-L1 and MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/548", "Drug": "Camptothecin", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": "DB04690", "Target/s_or_mechanism_of_action": "Stabilizes the DNA–topoisomerase I cleavage complex, inhibiting DNA religation and causing DNA damage", "KEGG_Drug__ID": "C01897", "Pubchem_ID": "24360", "STR_LINK_(SMILES)": "CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O", "Single/Combination": "Single", "PMID": "40051755", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "microsatellite instable (MSI) cell line", "System": "RKO", "Dose": "0.5 µM, 24 h", "Technique": "MHC-I immunoprecipitation and mass spectrometry", "Controlled_Technique": "MHC-I-associated peptide numbers increased by 5%; increased diversity of presented peptides", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "Reduced representation of cytosolic proteins in the MHC-I peptide repertoire", "Immune_System-Function_inhibited/numbers_decreased": "MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/547", "Drug": "Camptothecin", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": "DB04690", "Target/s_or_mechanism_of_action": "Stabilizes the DNA–topoisomerase I cleavage complex, inhibiting DNA religation and causing DNA damage", "KEGG_Drug__ID": "C01897", "Pubchem_ID": "24360", "STR_LINK_(SMILES)": "CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O", "Single/Combination": "Single", "PMID": "40051755", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "microsatellite stable (MSS) cell line", "System": "SW620", "Dose": "0.5 µM, 24 h", "Technique": "MHC-I immunoprecipitation and mass spectrometry", "Controlled_Technique": "MHC-I-associated peptide numbers increased by 83%; increased diversity of presented peptides", "Immune_System-Function_enhanced/numbers_increased": "MHC class I", "Controlled_Terms_Function_enhanced_Number_increased": "Reduced representation of cytosolic proteins in the MHC-I peptide repertoire", "Immune_System-Function_inhibited/numbers_decreased": "MHC class I", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/550", "Drug": "Camptothecin", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": "DB04690", "Target/s_or_mechanism_of_action": "Stabilizes the DNA–topoisomerase I cleavage complex, inhibiting DNA religation and causing DNA damage", "KEGG_Drug__ID": "C01897", "Pubchem_ID": "24360", "STR_LINK_(SMILES)": "CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O", "Single/Combination": "Single", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "HCT116", "Dose": "0.5–1 µM", "Technique": "Flow cytometry; immunoblotting and fluorescent staining", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Increased PD-L1 and MHC-I expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; PD-L1 / CD274; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/555", "Drug": "Etoposide (VP-16)", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "TOP2 inhibition; DNA damage", "KEGG_Drug__ID": null, "Pubchem_ID": "92209272", "STR_LINK_(SMILES)": "C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O", "Single/Combination": "Single", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "SW620", "Dose": "25 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Increased PD-L1 and MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; PD-L1 / CD274; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/552", "Drug": "Irinotecan", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Single", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "HT-29", "Dose": "25 µg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Increased PD-L1", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/553", "Drug": "Irinotecan", "Drug_category": "topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Inhibits TOP1", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Single", "PMID": "36589674", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "System": "RKO", "Dose": "25 µg/mL", "Technique": "Flow cytometry", "Controlled_Technique": "Increased PD-L1", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 / CD274", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1476", "Drug": "Irinotecan (CPT-11)", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Irinotecan inhibits the action of topoisomerase I", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "SW480", "Dose": "5 mM", "Technique": "immunoblotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/194", "Drug": "Irinotecan (CPT-11)", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Irinotecan inhibits the action of topoisomerase I", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "HCT116", "Dose": "5 mM", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/195", "Drug": "Irinotecan (CPT-11)", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Irinotecan inhibits the action of topoisomerase I", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "System": "LoVo", "Dose": "5 mM", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/437", "Drug": "Irinotecan (IRIN)+Radiotherapy", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "DNA damage; cGAS–STING pathway activation", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "combination", "PMID": "37779919", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "HCT8 human cell line", "System": "HCT8", "Dose": "3 μM IRIN + 4 Gy X-rays in mechanistic experiments", "Technique": "qRT-PCR, Western blot,flow cytometry", "Controlled_Technique": "cGAS/STING signaling; type I IFN pathway (IFN-α and IFN-β); enhanced DNA damage and apoptosis, protein expression levels of cGAS, p-IRF3, and p-TBK1, MHC-I , PD-L1, ISG15,  transporter associated with antigen processing 1 (TAP1), higher expression level of β2 microglobulin (β2M)", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis; MHC class I; IFN-α; IFN-β; PD-L1 / CD274; TAP1; Antigen presentation; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/438", "Drug": "Irinotecan (IRIN)+Radiotherapy", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "DNA damage; cGAS–STING pathway activation", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "combination", "PMID": "37779919", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "HT29 human cell line", "System": "HT29", "Dose": "3 μM IRIN + 4 Gy X-rays in mechanistic experiments", "Technique": "qRT-PCR, Western blot,flow cytometry", "Controlled_Technique": "Increased DNA damage and cytoplasmic dsDNA; combination-associated cGAS–STING/type I IFN activation, increased the protein expression levels of STING, p-IRF3, and p-TBK1", "Immune_System-Function_enhanced/numbers_increased": "Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": "PD-L1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 / CD274", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1192", "Drug": "Irinotecan Hydrochloride Trihydrate", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Irinotecan inhibits the action of topoisomerase I", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "Single/Combination": "Single Drug", "PMID": "29267866", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Melanoma cell line 2549, along with its autologous tumor-infiltrating lymphocytes (TILs)", "Dose": "1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cell activated caspase 3-apoptosis marker", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1193", "Drug": "SN38 (the active metabolite of irinotecan)", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Irinotecan inhibits the action of topoisomerase I", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "Single/Combination": "Single Drug", "PMID": "29267866", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "melanoma cell lines 2338", "Dose": "0 to 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cell activated caspase 3-apoptosis marker", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1194", "Drug": "SN38 (the active metabolite of irinotecan)", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Irinotecan inhibits the action of topoisomerase I", "KEGG_Drug__ID": "D08086", "Pubchem_ID": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "Single/Combination": "Single Drug", "PMID": "29267866", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "melanoma cell lines 2400", "Dose": "0 to 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cell activated caspase 3-apoptosis marker", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/740", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "28069806", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Human Breast Adenocarcinoma", "System": "MCF7", "Dose": "5 µg/ml TPT for 3 days", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/741", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "28069806", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical - Human Cervix Adenocarcinoma", "System": "HeLa", "Dose": "5 µg/ml TPT for 3 days", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/753", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "28069806", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung - Human Lung Epithelial Cells", "System": "A549", "Dose": "5 µg/ml TPT for 3 days", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/754", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "28069806", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung - Murine Lewis Lung Carcinoma", "System": "LLC", "Dose": "5 µg/ml TPT for 3 days", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/762", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "28069806", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Murine Lymphoma", "System": "EL4", "Dose": "5 µg/ml TPT for 3 days", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/773", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "28069806", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "System": "B16-F10", "Dose": "5 µg/ml TPT for 3 days", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1195", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "29267866", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "melanoma cell lines 2338", "Dose": "0 to 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cell activated caspase 3-apoptosis marker", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1196", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "29267866", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "melanoma cell lines 2400", "Dose": "0 to 1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cell activated caspase 3-apoptosis marker", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1454", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "22396773", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "ZR-75-1", "Dose": "TPT (40, 200, 20, and 40 nM, respectively) for 4 days", "Technique": "immunoblotting, Flow cytometry, real-time RT-PCR, ELISA assay", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-β level, IFN-α1, IFN-α2, TNF-α, IL-1β, IL-4, IL-6, and IL-8 MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; IL-1 family; IL-4; IL-6; IL-8 / CXCL8; TNF-α / TNF; IFN-β; IL-8/CXCL8; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1537", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "28069806", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "E0771", "Dose": "10 µM", "Technique": "ELISA, MTT assay,Flow cytometry, Microarray,Immunoblotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA); Cell viability/proliferation assay; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "DAMPs that induce IL-6 production by DCs,, innate immune cells,\n including Flt3 ligand–induced DCs, peritoneal macrophages, and\n M-CSF–induced macrophages, also produced IL-6 (secreted by GM-DCs in the presence of CM\n from E0771 cells treated with TPT) IL-6,IFN-β and CXCL10, Genes encoding cytokines\n (Il6 and Ifnb1), chemokines (Cxcl9) mRNA for chemokines (Cxcl9, Cxcl11, and Cxcl10) and T cell–costimulatory molecules (4-1bbl, Light, Cd30l, Cd80, and Cd86), T cell–costimulatory\n molecules (Tnfsf10 and Tnfsf9) , surface expression of the activation markers CD86 and\n I-A/I-E apoptosis, NF-kB, IRF3, and MAPKs.", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; CD86; 4-1BB ligand / TNFSF9; IL-6; IFN-β; CSF1 / M-CSF; CXCL10 / IP-10; CXCL9 / MIG; Apoptosis; CD80/CD86 costimulation; T cells; Dendritic cells; Macrophages; Expression / abundance phenotype; NF-κB activation; IRF3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "IL-1b, IL-18, TNF-a, or IL-33", "Controlled_Terms_Unaffected": "IL-18; TNF-α / TNF", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/171", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "22396773", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF-7", "Dose": "TPT (40, 200, 20, and 40 nM, respectively) for 4 days", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/172", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "22396773", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "T47D", "Dose": "TPT (40, 200, 20, and 40 nM, respectively) for 4 days", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/173", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "22396773", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MDA-MB-231", "Dose": "TPT (40, 200, 20, and 40 nM, respectively) for 4 days", "Technique": "immunoblotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1197", "Drug": "Topotecan Hydrochloride,", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug__ID": "D08618", "Pubchem_ID": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "29267866", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "Melanoma cell line 2549, along with its autologous tumor-infiltrating lymphocytes (TILs)", "Dose": "1 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cell activated caspase 3-apoptosis marker", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/574", "Drug": "Doxorubicin (DOX)+ indocyanine green +Ultrasound", "Drug_category": "topoisomerase inhibitor", "Drugbank_ID": "DB00997+DB09374", "Target/s_or_mechanism_of_action": "DOX inhibits topoisomerase II and intercalates DNA. ICG acts as a sonosensitizer under ultrasound exposure, promoting reactive oxygen species (ROS) generation and mitochondrial DNA oxidation/release, activating the cGAS–STING–TBK1–IRF3 pathway and type I interferon responses", "KEGG_Drug__ID": "D03899+D01342", "Pubchem_ID": "31703+11967809", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2= and CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS([O-])(=O)=O)C3=CC=C4=CC=CC=C4C=C3C2(C)C)N(CCCCS(O)(=O)=O)C2=CC=C3C=CC=CC3=C12", "Single/Combination": "Combination", "PMID": "37391428", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal/colon cancer", "System": "CT26", "Dose": "CG: 3 μM; DOX: 0.5 μM; US: 5 min; BMDC co-culture for 24 h", "Technique": "IFN-β ELISA", "Controlled_Technique": "IFNβ (mainly from BMDCS) in the supernatant as a readout for STING activation; ICD markers such as CRT and HMGB1, with levels similar (for CRT) or higher (for HMGB1)", "Immune_System-Function_enhanced/numbers_increased": "HMGB1; Calreticulin / CRT; Immunogenic cell death; IFN-β", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1361", "Drug": "Acalabrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB11703", "Target/s_or_mechanism_of_action": "Acalabrutinib is a small molecule inhibitor of BTK. Both acalabrutinib and its active metabolite, ACP-5862, act to form a covalent bond with a cysteine residue (Cys481) in the BTK active site, leading to inhibition of BTK enzymatic activity.", "KEGG_Drug__ID": null, "Pubchem_ID": "71226662", "STR_LINK_(SMILES)": "CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1", "Single/Combination": "Single Drug", "PMID": "28714866", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Natural Killer (NK) Large Granular Lymphocyte (LGL) Leukemia", "System": "NKL", "Dose": "SAHA (1, 2, 5 and 10 µM) and cladribine (0.125 µM)", "Technique": "MTS assay, Flow cytometry, PCR microarray and Western blot analyses", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Cell viability/proliferation assay; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "cytotoxicity, apoptotic cell death,activation of both intrinsic mitochondrial and extrinsic death receptor pathways -AIFM1 (apoptosis inducing factor), CYCS (cytochrome complex) and APAF1 (apoptotic protease activating factor-1),pro-apoptotic regulators including BBC2, BAX, BAK1 and BCL2L11 ,FAS, FASLG, FADD, TNFSF10, TNFRSF1A, TNFRSF10B, initiator and effector CASP (caspases) ,CYCS, ABL1, BCL2L11, CASP4, CASP8, CD40L, CD70, FAS, FASLG, TNFSF10, NOL3 and RIPK2", "Controlled_Terms_Function_enhanced_Number_increased": "CD95 / Fas / FAS; Fas ligand / FasL / FASLG; TRAIL-R2 / DR5 / TNFRSF10B; Caspase-8; Apoptosis; Cytotoxicity / cytolysis; BAX; BAK; BIM / BCL2L11", "Immune_System-Function_inhibited/numbers_decreased": "anti-apoptotic genes- BCL2 and BCL2L1, ERK and STAT3 signaling pathways", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; ERK / MAPK; BCL-2; BCL-xL / BCL2L1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/755", "Drug": "AG1478", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "AG1478 tyrosine kinase inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "2051", "STR_LINK_(SMILES)": "COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC", "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "D122-reactive CD8+ T cells were incubated with D122", "Dose": "(5 μM, 96 h)", "Technique": "ELISA,vitro lactate dehydrogenase assay", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells-mediated lysis. IFN-γ production by D122-specific CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; IFN-γ; Cytotoxicity / cytolysis; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1316", "Drug": "AG1478", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "AG1478 tyrosine kinase inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "2051", "STR_LINK_(SMILES)": "COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC", "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Mama", "System": "F3II", "Dose": "AG1478 (5 μM)", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "H-2K and H-2D β2-m, LMP subunits, PA28α, BLH, TAPs, ERAAP1, tapasin, calnexin, calreticulin, PDI, as well as ERp57", "Controlled_Terms_Function_enhanced_Number_increased": "Tapasin; Calnexin; Calreticulin / CRT; ERp57 / PDIA3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1322", "Drug": "AG1478", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "AG1478 tyrosine kinase inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "2051", "STR_LINK_(SMILES)": "COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC", "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Epidermoid Carcinoma", "Cancer_Type_Description": "Epidermoid Carcinoma", "System": "A431", "Dose": "AG1478 (5 μM)", "Technique": "Flow cytometry, real-time quantitative PCR (qPCR)", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-ABC membrane expression, HLA-A, HLA-B, and HLA-C β2-m, LMP subunits, TAPs, as well as tapasin", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A; HLA-B; HLA-C; Tapasin; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1329", "Drug": "AG1478", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "AG1478 tyrosine kinase inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "2051", "STR_LINK_(SMILES)": "COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC", "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "System": "D122", "Dose": "AG1478 (5 μM)", "Technique": "Flow cytometry, qPCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "H-2K and H-2D β2-m, LMP subunits, PA28α, BLH, TAPs, ERAAP1, tapasin, calnexin, calreticulin, PDI, as well as ERp57", "Controlled_Terms_Function_enhanced_Number_increased": "Tapasin; Calnexin; Calreticulin / CRT; ERp57 / PDIA3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1330", "Drug": "AG1478", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "AG1478 tyrosine kinase inhibitor", "KEGG_Drug__ID": null, "Pubchem_ID": "2051", "STR_LINK_(SMILES)": "COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC", "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Adenocarcinoma", "System": "H125", "Dose": "AG1478 (5 μM)", "Technique": "Flow cytometry, real-time quantitative PCR (qPCR)", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "HLA-ABC membrane expression, HLA-A, HLA-B, and HLA-C β2-m, LMP subunits, TAPs, as well as tapasin", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A; HLA-B; HLA-C; Tapasin; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/351", "Drug": "Alectinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB11363", "Target/s_or_mechanism_of_action": "Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase.", "KEGG_Drug__ID": "D10542", "Pubchem_ID": "49806720", "STR_LINK_(SMILES)": "CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O", "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Anaplastic Large Cell Lymphoma (ALCL)", "System": "Karpas 299", "Dose": "alectinib (0-100nM)", "Technique": "Western BLot and Flow cytometery", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": "IL6 and TNFα pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; TNF-α / TNF; ERK / MAPK", "Immune_System_function_unaffected": "IFNα, IFNγ, IL4", "Controlled_Terms_Unaffected": "IL-4; IFN-α; IFN-γ", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/352", "Drug": "Alectinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB11363", "Target/s_or_mechanism_of_action": "Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase.", "KEGG_Drug__ID": "D10542", "Pubchem_ID": "49806720", "STR_LINK_(SMILES)": "CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O", "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Anaplastic Large Cell Lymphoma (ALCL)", "System": "SUDHL-1", "Dose": "alectinib (0-100nM)", "Technique": "Western BLot and Flow cytometery", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": "pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1300", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug__ID": "D03218", "Pubchem_ID": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": "24135499", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "B16F1 cells", "Dose": "(0, 1, 10, 100, 1000, 10 000 nmol/l) for 72 h", "Technique": "MTT assay, Annexin V/PI doublestaining assay", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "induced the apoptosis of B16F1 cells", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1231", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug__ID": "D03218", "Pubchem_ID": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": "24804814", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastric Cancer (GC)", "System": "BGC-823", "Dose": "4.27 µmol/L", "Technique": "Annexin V-FITC and PI staining by Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "cell apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "CD 34", "Controlled_Terms_Function_inhibited_Number_decreased": "CD34", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1232", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug__ID": "D03218", "Pubchem_ID": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": "24804814", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastric Cancer (GC)", "System": "HGC-27", "Dose": "12.5 µmol/L", "Technique": "Annexin V-FITC and PI staining by Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "cell apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": "CD 34", "Controlled_Terms_Function_inhibited_Number_decreased": "CD34", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1548", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug__ID": "D03218", "Pubchem_ID": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": "26137411", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Subcutaneous And Intracranial Mouse Melanoma", "System": "Ly6G- (moMDSCs) and CD11b+Ly6CintLy6G+ (grMDSC) cells were sorted from the spleens of subcutaneous MO4-bearing mice on the 7th day of treatment with axitinib at 25 mg/kg", "Dose": null, "Technique": "suppression assay", "Controlled_Technique": "Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "suppressive capacity of CD11b+Ly6ChighLy6G- cells on CD4+ and CD8+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; CD11b / ITGAM; T cells; CD8+ T cells; T-cell suppressive function", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/757", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "PC3 human prostate cancer cells- PC3 cells were treated with 5 μM cabozantinib for 24 hours, followed by addition of neutrophils in a transwell migration assay for 4 hours. The neutrophils were obtained from a single patient donor with each condition being performed in 3 separate migration transwells", "Dose": "5 μM cabozantinib for 24 hours", "Technique": "transwell migration assay", "Controlled_Technique": "Cell co-culture/transwell assay", "Immune_System-Function_enhanced/numbers_increased": "neutrophil migration", "Controlled_Terms_Function_enhanced_Number_increased": "Neutrophils; Neutrophil migration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1267", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "SC1", "Dose": "30 μM", "Technique": "apoptosis analysis with Annexin V staining", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "modest apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1278", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "AC1", "Dose": "30 μM", "Technique": "apoptosis analysis with Annexin V staining", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "modest apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1289", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "AC3", "Dose": "30 μM", "Technique": "apoptosis analysis with Annexin V staining", "Controlled_Technique": "Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "modest apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1384", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H23", "Dose": "10 μM", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligand-surface expression of ULBP1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; Expression / abundance phenotype; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/602", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "25388653", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "System": "MC38-CEA cells treated with cabozantinib for 24 h and labeled with 111In, then coincubated with CTLs", "Dose": "2.5 μg/mL cabozantinib", "Technique": "Cytotoxic T lymphocyte killing assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "T cell-mediated lysis by cytotoxic T lymphocytes (CTLs)", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1060", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "PC3 cells were treated with cabozantinib for 24 hours, and then co-cultured with neutrophils for 6 hours", "Dose": "5 μM cabozantinib for 24 hours", "Technique": "nitric oxide staining and Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "neutrophils with nitric oxide (NO) staining", "Controlled_Terms_Function_enhanced_Number_increased": "Neutrophils; Nitric oxide / NO", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1061", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "29152128", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "Peripheral blood monocytes isolatedfrom patients - cultured with M-CSF", "Dose": null, "Technique": "FACS", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "M1 macrophage differentiation", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": "M2 macrophage", "Controlled_Terms_Unaffected": "Macrophages", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1062", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "29152128", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "Thioglycollate-induced, activated macrophages- cultured with or without lipopolysaccharide (LPS) or interleukin-4 (IL-4) or tumor lysate", "Dose": null, "Technique": "FACS", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "M1 macrophage", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": "M2 macrophage", "Controlled_Terms_Unaffected": "Macrophages", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/863", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "25388653", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "System": "MC38-CEA cells", "Dose": "2.5 μg/mL cabozantinib", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-I molecules on both the population level (H-2Db) and a per-cell basis (H-2Kb), increasing the potential for antigen presentation and T cell recognition of the tumor cells, ICAM-1, Fas, and calreticulin", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; CD95 / Fas / FAS; ICAM-1 / CD54; Antigen presentation; Calreticulin / CRT; T cells; Antigen-specific recognition; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1276", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "tumor-derived SC1 cells", "Dose": "10 μM", "Technique": "ELISA, FACS analysis", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CXCL12,HMGB1", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; CXCL12 / SDF-1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1277", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "SC1", "Dose": "cabozantinib (10 μM)", "Technique": "ELISA, FACS analysis", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CXCL12,HMGB1 release", "Controlled_Terms_Function_enhanced_Number_increased": "HMGB1; CXCL12 / SDF-1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1482", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid - Human Papillary Thyroid Carcinoma", "System": "TPC1 cells", "Dose": "Cabozantinib (0-100nM)", "Technique": "Western BLot and Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C, HLA-A*02:01", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": "pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1553", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "SC1", "Dose": "30 μM cabozantinib", "Technique": "IHC", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "modest apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1554", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "AC1", "Dose": "30 μM cabozantinib", "Technique": "IHC", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "modest apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1555", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug__ID": "D10062", "Pubchem_ID": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "System": "AC3", "Dose": "30 μM cabozantinib", "Technique": "IHC", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "modest apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/353", "Drug": "Crizotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08865", "Target/s_or_mechanism_of_action": "Crizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d'Origine Nantais (RON). Abnormalities in the ALK gene caused by mutations or translocations may lead to expression of oncogenic fusion proteins. In patients with NSCLC, they have the EML4-ALK gene. Crizotinib inhibits ALK tyrosine kinase which ultimately results in decreased proliferation of cells that carry the genetic mutation and tumour survivability.", "KEGG_Drug__ID": "D09731", "Pubchem_ID": "11626560", "STR_LINK_(SMILES)": "C[C@@H]OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl", "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Anaplastic Large Cell Lymphoma (ALCL)", "System": "Karpas 299", "Dose": "Crizotinib(1-100nM)", "Technique": "Western BLot and Flow cytometery", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": "pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/354", "Drug": "Crizotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08865", "Target/s_or_mechanism_of_action": "Crizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d'Origine Nantais (RON). Abnormalities in the ALK gene caused by mutations or translocations may lead to expression of oncogenic fusion proteins. In patients with NSCLC, they have the EML4-ALK gene. Crizotinib inhibits ALK tyrosine kinase which ultimately results in decreased proliferation of cells that carry the genetic mutation and tumour survivability.", "KEGG_Drug__ID": "D09731", "Pubchem_ID": "11626560", "STR_LINK_(SMILES)": "C[C@@H]OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl", "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Anaplastic Large Cell Lymphoma (ALCL)", "System": "SUDHL-1", "Dose": "Crizotinib(1-100nM)", "Technique": "Western BLot and Flow cytometery", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; HLA-A", "Immune_System-Function_inhibited/numbers_decreased": "pERK", "Controlled_Terms_Function_inhibited_Number_decreased": "ERK / MAPK", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1220", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug__ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "19295545", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "PBMCs from CLL patients", "Dose": "1 μM lenalidomide", "Technique": "apoptosis was analyzed by staining with annexin V, Flow cytometry, CFSE Staining", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "NKT-like cells (CD3+CD8+CD56+), proliferation of NK cells, CD4 T cells IL-2 by CD4 T cells NKp30 on NK cells apoptosis of leukemia cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD3; CD4; CD8; CD56 / NCAM1; NKp30 / NCR3; IL-2; Apoptosis; Cell proliferation; T cells; CD8+ T cells; CD4+ T cells; NKT cells; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1571", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug__ID": "D03658", "Pubchem_ID": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "22419518", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "primary CLL cells", "Dose": "lenalidomide (0.5 μM)", "Technique": "Flow cytometery, real-time reverse-transcribed polymerase chain reaction,laser scanning confocal microscopy", "Controlled_Technique": "Microscopy; Confocal microscopy; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD23 and CD38 activation markers on CLL cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD23 / FCER2; CD38", "Immune_System-Function_inhibited/numbers_decreased": "CD20 expression on CLL cells (CD20 internalization)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD20 / MS4A1; Expression / abundance phenotype", "Immune_System_function_unaffected": "CD19, CD5, and CD52", "Controlled_Terms_Unaffected": "CD52; CD19", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1367", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "31291990", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "PMA/ionomycin stimulation of CD4 T cells and CD 8 cells from the lungs of tumor bearing CCSP-rtTA; TetO-EGFRL858R mice treated with erlotinib", "Dose": "25 mg/kg, 5 days a week", "Technique": "Bio-Plex Cytokine assay", "Controlled_Technique": "Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ, TNF-α and IL-2", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; TNF-α / TNF; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/125", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549+cocultured with NK-92 cells", "Dose": "10 μM", "Technique": "using the DELFIA EuTDA cytotoxicity Reagents.", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "cytolytic activity of NK cells,", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/136", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H23+cocultured with NK-92 cells", "Dose": "10 μM", "Technique": "using the DELFIA EuTDA cytotoxicity Reagents.", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "cytolytic activity of NK cells,", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/147", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "SW-900+cocultured with NK-92 cells", "Dose": "10 μM", "Technique": "using the DELFIA EuTDA cytotoxicity Reagents.", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "cytolytic activity of NK cells,", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1368", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21951556", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "Caco-2", "Dose": "10 µM for 18 h", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated lysis UL16-binding protein-1 (ULBP1)- NKG2D ligand", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; Cytotoxicity / cytolysis; NK cells; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1369", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21951556", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HT-29", "Dose": "10 µM for 18 h", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated lysis UL16-binding protein-1 (ULBP1)- NKG2D ligand", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; Cytotoxicity / cytolysis; NK cells; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1371", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21951556", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "KM12", "Dose": "10 µM for 18 h", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated lysis UL16-binding protein-1 (ULBP1),ULBP2- NKG2D ligand", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; ULBP2; Cytotoxicity / cytolysis; NK cells; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1374", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21951556", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT-15", "Dose": "10 µM for 18 h", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated lysis MICB UL16-binding protein-1 (ULBP1)- NKG2D ligand", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; MICB; Cytotoxicity / cytolysis; NK cells; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1382", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "27467256", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H441-treated with IFNγ at a concentration of 1000 pg/ml", "Dose": "10 μM for 24 hours", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "Cytotoxic T cell", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; T cells", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1383", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549", "Dose": "10 μM", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligand-surface expression of ULBP1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; Expression / abundance phenotype; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/180", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "SW-900+cocultured with NK-92 cells", "Dose": "10 μM", "Technique": "using the DELFIA EuTDA cytotoxicity Reagents.", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "cytolytic activity of NK cells,", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1385", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "SW-900", "Dose": "10 μM", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligand-surface expression of ULBP1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; Expression / abundance phenotype; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1390", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "27467256", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "HCC2935--treated with IFNγ at a concentration of 1000 pg/ml", "Dose": "10 μM for 24 hours", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC-I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1391", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "27467256", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H1975--treated with IFNγ at a concentration of 1000 pg/ml", "Dose": "10 μM for 24 hours", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC-I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1392", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "27467256", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H1650--treated with IFNγ at a concentration of 1000 pg/ml", "Dose": "10 μM for 24 hours", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC-I,MHC-II expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; MHC class II; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1393", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "27467256", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "HCC827-treated with IFNγ at a concentration of 1000 pg/ml", "Dose": "10 μM for 24 hours", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHC-II expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; Expression / abundance phenotype;", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1394", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "27467256", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H3255-treated with IFNγ at a concentration of 1000 pg/ml", "Dose": "10 μM for 24 hours", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1395", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "27467256", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "HCC4006--treated with IFNγ at a concentration of 1000 pg/ml", "Dose": "10 μM for 24 hours", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1396", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "27467256", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549-treated with IFNγ at a concentration of 1000 pg/ml", "Dose": "10 μM for 24 hours", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1397", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "27467256", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H2023--treated with IFNγ at a concentration of 1000 pg/ml", "Dose": "10 μM for 24 hours", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/271", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug__ID": "D07907", "Pubchem_ID": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "28880013", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "HCC827", "Dose": "(200 nmol/L)", "Technique": "Western blot assay", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/812", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D02375", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "19997099", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF7 (breast)+T cells were isolated from pathologically healthy donor buffy coats", "Dose": null, "Technique": "MTT assay.", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic T cells", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/158", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549+cocultured with NK-92 cells", "Dose": "10 μM", "Technique": "using the DELFIA EuTDA cytotoxicity Reagents.", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "cytolytic activity of NK cells,", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/169", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H23+cocultured with NK-92 cells", "Dose": "10 μM", "Technique": "using the DELFIA EuTDA cytotoxicity Reagents.", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "cytolytic activity of NK cells,", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/844", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D02370", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "26156960", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF7 cells", "Dose": "1 μm", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA1 expression in tumour cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Expression / abundance phenotype; HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/846", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D02370", "Pubchem_ID": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "19997099", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "MCF7 (breast", "Dose": "GEM (1 μm)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Human leucocyte antigen class 1 on tumors", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/975", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "25998384", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "System": "PC-9 cell", "Dose": "(0, 2.5, 5, 10, 100 nM) for 48 h,", "Technique": "Flow cytometry,Immuofluorescence staining", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression and NF-κB in tumor cells,", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; NF-κB; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1370", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21951556", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HT-29", "Dose": "10 µM for 18 h", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated lysis UL16-binding protein-1 (ULBP1)- NKG2D ligand", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; Cytotoxicity / cytolysis; NK cells; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1372", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21951556", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "KM12", "Dose": "10 µM for 18 h", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated lysis UL16-binding protein-1 (ULBP1),ULBP2- NKG2D ligand", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; ULBP2; Cytotoxicity / cytolysis; NK cells; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1373", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21951556", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "Caco-2", "Dose": "10 µM for 18 h", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated lysis MICA UL16-binding protein-1 (ULBP1)- NKG2D ligand", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; MICA; Cytotoxicity / cytolysis; NK cells; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1375", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21951556", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "System": "HCT-15", "Dose": "10 µM for 18 h", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NK cell-mediated lysis MICB UL16-binding protein-1 (ULBP1)- NKG2D ligand", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; MICB; Cytotoxicity / cytolysis; NK cells; NKG2D ligand; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1386", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549", "Dose": "10 μM", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligand-surface expression of ULBP1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; Expression / abundance phenotype; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1387", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H23", "Dose": "10 μM", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligand-surface expression of ULBP1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; Expression / abundance phenotype; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1388", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "21499124", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "SW-900", "Dose": "10 μM", "Technique": "RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NKG2D ligand-surface expression of ULBP1", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; ULBP1; Expression / abundance phenotype; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1494", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "27698894", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "PC-9 cells", "Dose": "0.1 μM", "Technique": "Flow cytometry, western blot,", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression, pEGFR and its downstream pathway - in the pAKT, pERK and pSTAT3 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; ERK / MAPK; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1528", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "23937717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "H1975 + Human NK cells co-cultured", "Dose": "add dose", "Technique": "⁵¹Cr release assay, CD107a assay, and IFN-γ secretion assay,Flow cytometry,western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cytotoxicity/release assay; Degranulation assay", "Immune_System-Function_enhanced/numbers_increased": "NKG2D, NKp44 and NKp46 on NK cells IFN-γ NKG2D ligands- ULBP1, ULBP2, MICA, on tumor cells,autophagy and MPR expression", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D / KLRK1; NKp44 / NCR2; NKp46 / NCR1; ULBP1; ULBP2; MICA; IFN-γ; Autophagy / macroautophagy; NK cells; Expression / abundance phenotype; NKG2D ligand", "Immune_System-Function_inhibited/numbers_decreased": "stat3 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1529", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "23937717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "A549 + Human NK cells co-cultured", "Dose": "add dose", "Technique": "⁵¹Cr release assay, CD107a assay, and IFN-γ secretion assay,Flow cytometry,western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cytotoxicity/release assay; Degranulation assay", "Immune_System-Function_enhanced/numbers_increased": "NKG2D, NKp44 and NKp46 on NK cells IFN-γ MHC-I on tumor cells NKG2D ligands- ULBP1, ULBP2, MICA, on tumor cells,autophagy", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; NKG2D / KLRK1; NKp44 / NCR2; NKp46 / NCR1; ULBP1; ULBP2; MICA; IFN-γ; Autophagy / macroautophagy; NK cells; NKG2D ligand; ; MICA/MICB", "Immune_System-Function_inhibited/numbers_decreased": "stat3 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/266", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "27499357", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "HCC827", "Dose": "0.1 and 0.8 µM", "Technique": "western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression p-STAT3 and STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; IL-6/JAK/STAT3 signaling; STAT3; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/267", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "27499357", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "PC-9 cells", "Dose": "0.1 and 0.8 µM", "Technique": "western blot", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression p-STAT3 and STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; IL-6/JAK/STAT3 signaling; STAT3; PD-L1 immune checkpoint pathway; Expression / abundance phenotype; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/268", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "28880013", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "HCC827", "Dose": "(200 nmol/L)", "Technique": "Western blot assay", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/333", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "32195020", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "CAL-27", "Dose": "gefitinib and stimulated with 1 μg/mL LPS for 24 h", "Technique": "ELISA,western blotting", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "TNF-α, PGE2 and NO-suggest TLR4 induced tumor-associated inflammation was increased after EGFR inhibition, COX2 (PGE2 synthetase) and iNOS (NO synthetase), MyD88 proteins", "Controlled_Terms_Negative_Regulation": "TNF-α / TNF; NOS2 / iNOS; COX-2 / PTGS2; PGE2; EGFR; TLR4"}, {"ID": "CANIMM/381", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "26876213", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "PCI-13", "Dose": "12.5μM gefitinib for 5hrs", "Technique": "DB00317", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme. D01977 123631 COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Controlled_Terms_Function_enhanced_Number_increased": "EGFR; Adenosine signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "autophagy", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/382", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "26876213", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UDSCC2", "Dose": "12.5μM gefitinib for 5hrs", "Technique": "DB00317", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme. D01977 123631 COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Controlled_Terms_Function_enhanced_Number_increased": "EGFR; Adenosine signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "autophagy", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/383", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "26876213", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "SCC90", "Dose": "12.5μM gefitinib for 5hrs", "Technique": "DB00317", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme. D01977 123631 COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Controlled_Terms_Function_enhanced_Number_increased": "EGFR; Adenosine signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "autophagy", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/384", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug__ID": "D01977", "Pubchem_ID": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "26876213", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "System": "UMSCC22b", "Dose": "12.5μM gefitinib for 5hrs", "Technique": "DB00317", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme. D01977 123631 COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Controlled_Terms_Function_enhanced_Number_increased": "EGFR; Adenosine signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "autophagy", "Controlled_Terms_Negative_Regulation": "Autophagy / macroautophagy"}, {"ID": "CANIMM/763", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28424405", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "PBMCs (1 × 106)", "Dose": "ibrutinib (0.2, 0.5, 1, 2, 5 μM) for 1 hour", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CXCL12, CXCL13, CCL19, VEGF", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL13; VEGF; CXCL12 / SDF-1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/781", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "26660519", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Raji cells followed by γ-irradiation (to prevent further cell proliferation) + purified T lymphocytes from healthy donors", "Dose": "(2.5 µM)", "Technique": "ELISA , [3H]-thymidine uptake assay for T cell proliferation", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Cell viability/proliferation assay; Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "T cell proliferation IFNγ secretion", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Cell proliferation; T cells; T-cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1214", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31921116", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Natural Killer (NK) Large Granular Lymphocyte (LGL) Leukemia", "System": "Leukaemic NK cells from six chronic NK-LGL patients (CD3−CD56+ NK cells > 80%)", "Dose": "SAHA (1, 2, 5 and 10 µM) and cladribine (0.125 µM)", "Technique": "MTS assay, Flow cytometry", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "cytotoxicity, apoptotic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1381", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "27602755", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Raji cells", "Dose": "(1 µM)", "Technique": "Time course RT-PCR,Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "TNF-related costimulatory molecules - 4-1BB ligand (4-1BBL/TNFSF9),4-1BBL", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; 4-1BB ligand / TNFSF9; TNF-α / TNF; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/466", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Irreversible covalent BTK inhibition at Cys481", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/672", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Irreversible covalent BTK inhibition at Cys481", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "melanoma", "System": "B16F10", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1604", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28424405", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "THP-1 differentiated macrophages (2.5 × 105))", "Dose": "ibrutinib (0.2, 0.5, 1, 2, 5 μM) for 1 hour", "Technique": "ELISA, real time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CXCL12, CXCL13, CCL19, VEGF NF-κB, STAT3, and AP-1", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL13; VEGF; IL-6/JAK/STAT3 signaling; STAT3; NF-κB; CXCL12 / SDF-1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/50", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "27602755", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "U937", "Dose": "(1 µM)", "Technique": "Time course RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "TNF-related costimulatory molecules - 4-1BB ligand (4-1BBL/TNFSF9)", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; 4-1BB ligand / TNFSF9; TNF-α / TNF; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/118", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28416773", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Jurkat T cells (JA16 clone)", "Dose": "(2,5 µM)", "Technique": "Transcription Low Density Array,RT-PCR analysis,quantitative real time RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "TNF-related costimulatory molecules - 4-1BB ligand (4-1BBL/TNFSF9) p21/WAF/CDKN1A cell cycle inhibitor", "Controlled_Terms_Function_enhanced_Number_increased": "4-1BB / CD137; 4-1BB ligand / TNFSF9; TNF-α / TNF; p21 / CDKN1A; CD80/CD86 costimulation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/210", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28714866", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "Jurkat", "Dose": "CHAP31-100 nmol/L, (20 and 100 ng/mL, respectively)", "Technique": "Western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "TRAIL-induced apoptosis-phosphatidylserine externalization, processing of caspase-3 to its catalytically active large subunits (p19/p17) and cleavage of PARP", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Caspase-3; Caspase activation; Apoptosis; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/211", "Drug": "Ibrutinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09053", "Target/s_or_mechanism_of_action": "Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK).", "KEGG_Drug__ID": "D10223", "Pubchem_ID": "24821094", "STR_LINK_(SMILES)": "NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "28714866", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "System": "K562 cells", "Dose": "CHAP31- (25 nmol/L), (20 and 100 ng/mL, respectively)", "Technique": "Western blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "TRAIL-induced apoptosis-phosphatidylserine externalization, processing of caspase-3 to its catalytically active large subunits (p19/p17) and cleavage of PARP", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL; Caspase-3; Caspase activation; Apoptosis; PARP cleavage / PARP", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/365", "Drug": "Icotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB11737", "Target/s_or_mechanism_of_action": "Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)", "KEGG_Drug__ID": "D11251", "Pubchem_ID": "22024915", "STR_LINK_(SMILES)": "C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1", "Single/Combination": "Single Drug", "PMID": "30538492", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "SMMC7721", "Dose": "0.5 and 5 µM", "Technique": "western blot,fluorescence microscopy,situ TUNEL assay.", "Controlled_Technique": "Western blot/immunoblot analysis; Microscopy; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression BCL2, p-EGFR,apoptosis", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Apoptosis; BCL-2; EGFR; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/366", "Drug": "Icotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB11737", "Target/s_or_mechanism_of_action": "Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)", "KEGG_Drug__ID": "D11251", "Pubchem_ID": "22024915", "STR_LINK_(SMILES)": "C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1", "Single/Combination": "Single Drug", "PMID": "30538492", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "Huh7", "Dose": "0.5 and 5 µM", "Technique": "western blot,fluorescence microscopy,situ TUNEL assay.", "Controlled_Technique": "Western blot/immunoblot analysis; Microscopy; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression BCL2, p-EGFR,apoptosis", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Apoptosis; BCL-2; EGFR; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/580", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug__ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "15286804", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "System": "CD3–/CD56+ NK cells from GIST patients treated with drug + NK cell-–sensitive K562 targets and against a GIST cell line", "Dose": "(400 mg/day)", "Technique": "51Cr release assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell lysis", "Controlled_Terms_Function_enhanced_Number_increased": "Cytotoxicity / cytolysis; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/722", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug__ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "15286804", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "System": "Blood NK cells purified from GIST patients treated with drug + MD-DCs in the presence of LPS", "Dose": "(400 mg/day)", "Technique": "Cytotoxicity assays", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell IFN-γ production IFN-gamma production", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1424", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug__ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "27470968", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "System": "GIST-T1", "Dose": "(Im; 100 nM)", "Technique": "Flow cytometry + RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression in human GIST cell lines", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/946", "Drug": "Imatinib + DC vaccination (bone marrow-derived DC pulsed with A20 tumor lysate)", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug__ID": "D01441", "Pubchem_ID": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "18981115", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "System": "Normal B cells + CD154+ CLL cell", "Dose": "0.5 to 1μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "BID, DR5 IgG and IgM", "Controlled_Terms_Function_enhanced_Number_increased": "TRAIL-R2 / DR5 / TNFRSF10B; BID; Antibody / IgG / IgM", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/465", "Drug": "Lenvatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09078", "Target/s_or_mechanism_of_action": "Inhibits VEGFR1/2/3, FGFR1–4, PDGFRα, KIT and RET; associated with ↑MHC-I through IFNγ/STAT1 pathway", "KEGG_Drug__ID": "D09919", "Pubchem_ID": "9823820", "STR_LINK_(SMILES)": "COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/671", "Drug": "Lenvatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09078", "Target/s_or_mechanism_of_action": "Inhibits VEGFR1/2/3, FGFR1–4, PDGFRα, KIT and RET; associated with ↑MHC-I through IFNγ/STAT1 pathway", "KEGG_Drug__ID": "D09919", "Pubchem_ID": "9823820", "STR_LINK_(SMILES)": "COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "melanoma", "System": "B16F10", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1462", "Drug": "Osimertinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09330", "Target/s_or_mechanism_of_action": "Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumours following treatment with first-line EGFR-TKIs.", "KEGG_Drug__ID": "D10766", "Pubchem_ID": "71496458", "STR_LINK_(SMILES)": "COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C", "Single/Combination": "Single Drug", "PMID": "28880013", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "NCI-H1975 cells", "Dose": "125 nmol/L osimertinib for 3, 6, 12 and 24 h", "Technique": "Western blot assays, immunofluorescence,Flow cytometry, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression in NCI-H1975 cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/74", "Drug": "Osimertinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09330", "Target/s_or_mechanism_of_action": "Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumours following treatment with first-line EGFR-TKIs.", "KEGG_Drug__ID": "D10766", "Pubchem_ID": "71496458", "STR_LINK_(SMILES)": "COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C", "Single/Combination": "Single Drug", "PMID": "28880013", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "HCC827", "Dose": "(125 nmol/L)", "Technique": "RT-qPCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/764", "Drug": "PLS-123", "Drug_category": "Tyrosine Kinase Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28424405", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "PBMCs (1 × 106)", "Dose": "PLS-123 (0.2, 0.5, 1, 2, 5 μM) for 1 hour", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CXCL12, CXCL13, CCL19, VEGF", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL13; VEGF; CXCL12 / SDF-1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1605", "Drug": "PLS-123", "Drug_category": "Tyrosine Kinase Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28424405", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "THP-1 differentiated macrophages (2.5 × 105)", "Dose": "PLS-123 (0.2, 0.5, 1, 2, 5 μM) for 1 hour", "Technique": "ELISA, real time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CXCL12, CXCL13, CCL19, VEGF NF-κB, STAT3, and AP-1", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL13; VEGF; IL-6/JAK/STAT3 signaling; STAT3; NF-κB; CXCL12 / SDF-1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1198", "Drug": "Regorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08896", "Target/s_or_mechanism_of_action": "Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.", "KEGG_Drug__ID": "D10138", "Pubchem_ID": "11167602", "STR_LINK_(SMILES)": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1", "Single/Combination": "Single Drug", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "C8161, a human melanoma cell line which lacks BRAFV600 or NRAS mutations", "Dose": "1 μM Reg", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-I", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1199", "Drug": "Regorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08896", "Target/s_or_mechanism_of_action": "Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.", "KEGG_Drug__ID": "D10138", "Pubchem_ID": "11167602", "STR_LINK_(SMILES)": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1", "Single/Combination": "Single Drug", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "624-Mel", "Dose": "4 μM Reg", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-I", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1202", "Drug": "Regorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08896", "Target/s_or_mechanism_of_action": "Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.", "KEGG_Drug__ID": "D10138", "Pubchem_ID": "11167602", "STR_LINK_(SMILES)": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1", "Single/Combination": "Single Drug", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "MM-415", "Dose": "4 μM Reg", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-I", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/270", "Drug": "Rociletinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB11907", "Target/s_or_mechanism_of_action": "Rociletinib has been used in trials studying the treatment and prevention of Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer.", "KEGG_Drug__ID": null, "Pubchem_ID": null, "STR_LINK_(SMILES)": "COC1=CC(=CC=C1NC1=NC=C(C(NC2=CC=CC(NC(=O)C=C)=C2)=N1)C(F)(F)F)N1CCN(CC1)C(C)=O", "Single/Combination": "Single Drug", "PMID": "28880013", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "System": "HCC827", "Dose": "(200 nmol/L)", "Technique": "Western blot assay", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L1 immune checkpoint pathway; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1527", "Drug": "Ruxolitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08877", "Target/s_or_mechanism_of_action": "Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK Inhibitors). It is an inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2", "KEGG_Drug__ID": "D09959", "Pubchem_ID": "25126798", "STR_LINK_(SMILES)": "N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1", "Single/Combination": "Single Drug", "PMID": "25149535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "System": "1087-mel melanoma cells", "Dose": "(0.5 μM, 1 μM, 5 μM and 10 μM) and 48 hours", "Technique": "Flow cytometry using Annexin-V/7-AAD staining, western blotting", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay; Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "inhibits P-STAT3 expression but does not induce apoptosis", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; Apoptosis; Expression / abundance phenotype; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/867", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "30123861", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "HepG2", "Dose": "7.5-60 μM", "Technique": "Apo-one Homogeneous Caspase-3/7 Assay (Promega)", "Controlled_Technique": "Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/978", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "30123861", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatoma", "System": "SkHep1", "Dose": "7.5-60 μM", "Technique": "Apo-one Homogeneous Caspase-3/7 Assay (Promega)", "Controlled_Technique": "Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1005", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "25333973", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "pGBeLT-transduced CD8+ T cells were co-cultured with E.G7 cells", "Dose": "5 µM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ- producing CD8+ T cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; IFN-γ; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/907", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "31078430", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "human peripheral blood mononuclear cell (PBMC)-derived CAR (huCAR) T cells", "Dose": "10 μM sorafenib", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IL-2, IFN-γ, TNF-α", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; TNF-α / TNF; IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD107a", "Controlled_Terms_Unaffected": "CD107a / LAMP1; Degranulation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/908", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "31078430", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "coculture of mCAR T cells with LPS-activated Bone marrow-derived macrophages (BMDMs)", "Dose": "1–5 μM) sorafenib", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "ncreased the IFN-γ production of mCAR T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/909", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "27540594", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "Pretreatment samples of PBMCs from HCC patients were stimulated with anti-CD3/CD28", "Dose": "10 μM", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ and CD8+ T cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; IFN-γ; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "Foxp3+ Tregs and CTLA-4+ Tregs VEGFR2 expression on both CD4+PD-1+ and CD8+PD-1+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1; CTLA-4; CD4; CD8; T cells; Regulatory T cells / Tregs; Expression / abundance phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/910", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "31391334", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "PBMCs from patients with HCC were stimulated with anti–CD3/CD28", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+Ki67+IFN-γ+ T cells,CD8+Ki67+ T cells IFN-γ granzyme B", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; IFN-γ; Granzyme B / GZMB; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/911", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "31078430", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "mouse CAR T cells", "Dose": "10 μM sorafenib", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL-2, IFN-γ, TNF-α CD107a", "Controlled_Terms_Function_inhibited_Number_decreased": "CD107a / LAMP1; IL-2; TNF-α / TNF; IFN-γ; Degranulation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/913", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23409093", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "freshly isolated NK cells +K562", "Dose": "0-10 μM", "Technique": "LDH assay, Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK-mediated cytotoxicity IFN-γ production CD107a-degranulation marker NK cells NKG2D,Raf/MEK/ERK", "Controlled_Terms_Negative_Regulation": "CD107a / LAMP1; NKG2D / KLRK1; IFN-γ; ERK / MAPK; Cytotoxicity / cytolysis; NK cells; Degranulation"}, {"ID": "CANIMM/914", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23424039", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "HepG2 cells+macrophages +natural killer cells", "Dose": "(1.2 lg/mL, 3 hours)", "Technique": "Flow cytometry and killing assays", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cell", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1263", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23223899", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "CD4+CD25− Teff and CD4+CD25+ Tregs from patients with HCC", "Dose": "0.1-25 µM-", "Technique": "1:1 Teff/Treg suppression assays,ELISA, Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL-2 , IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; IL-6", "Immune_System-Function_inhibited/numbers_decreased": "Treg-mediated suppression", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; T-cell suppressive function", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1264", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23424039", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "K562 +macrophages +natural killer cells", "Dose": "(1.2 lg/mL, 3 hours)", "Technique": "Flow cytometry and killing assays,ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "NK cell IL12 , IL18,IFN-γ (NF-κB)", "Controlled_Terms_Function_enhanced_Number_increased": "IL-12; IL-18; IFN-γ; NF-κB; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1265", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23424039", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "Raji+macrophages +natural killer cells", "Dose": "(1.2 lg/mL, 3 hours)", "Technique": "Flow cytometry and killing assays,ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "NK cell IL12 , IL18,IFN-γ (NF-κB)", "Controlled_Terms_Function_enhanced_Number_increased": "IL-12; IL-18; IFN-γ; NF-κB; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/21", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "27926489", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "System": "769-p", "Dose": null, "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "granulocyte-macrophage colony stimulating factor (GM-CSF)", "Controlled_Terms_Function_inhibited_Number_decreased": "GM-CSF / CSF2; Macrophages; Granulocytes", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1282", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23223899", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "PBMC from patients with HCC(n = 20) +polyclonal stimulant PHA", "Dose": "0.1,1 and 3 µM concentrations, 12 µM", "Technique": "thymidine incorporation, ELISA and Flow cytometry", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "T cell proliferation IL-2 CD25 on HCC Teff", "Controlled_Terms_Function_enhanced_Number_increased": "CD25 / IL2RA; IL-2; Cell proliferation; T cells; T-cell proliferation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1504", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "25333973", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "System": "E.G7 mouse lymphoma cell line", "Dose": "5–15 µM", "Technique": "Western blotting, Flow cytometry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "TGF-β IDO expressions", "Controlled_Terms_Function_inhibited_Number_decreased": "TGF-β; IDO1/IDO; TGF-β / TGF-beta", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1513", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "28282575", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Breast Tumor", "System": "NT2.5 cells", "Dose": "0 to 10 μM", "Technique": "MTT assay, Flow cytometry,Western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "apoptotic markers Annexin V and 7-AAD", "Controlled_Terms_Function_enhanced_Number_increased": "Annexin V; 7-AAD", "Immune_System-Function_inhibited/numbers_decreased": "phosphorylation of ERK/MAPK, p38 MAPK, and STAT3,G1/S cyclins D1, D2, and D3", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; ERK / MAPK", "Immune_System_function_unaffected": "Bcl2 and BclXL, HER-2 or AKT signaling", "Controlled_Terms_Unaffected": "AKT; BCL-2; BCL-xL / BCL2L1; HER2 / ERBB2", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/463", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Inhibits RAF kinases and RTKs including VEGFR1/2/3, PDGFRβ, KIT, FLT3 and RET; in this study activates IFNγ/STAT1 → ↑MHC-I", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/667", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Inhibits RAF kinases and RTKs including VEGFR1/2/3, PDGFRβ, KIT, FLT3 and RET; in this study activates IFNγ/STAT1 → ↑MHC-I", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "melanoma", "System": "B16F10", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/385", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug__ID": "D08524", "Pubchem_ID": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "31078430", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "LPS-activated Bone marrow-derived macrophages (BMDMs)", "Dose": "1–5 μM sorafenib", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IL-12", "Controlled_Terms_Function_enhanced_Number_increased": "IL-12", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1089", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "30123861", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "System": "HepG2", "Dose": "7.5-60 μM", "Technique": "Apo-one Homogeneous Caspase-3/7 Assay (Promega)", "Controlled_Technique": "Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1200", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "30123861", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatoma", "System": "SkHep1", "Dose": "7.5-60 μM", "Technique": "Apo-one Homogeneous Caspase-3/7 Assay (Promega)", "Controlled_Technique": "Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1355", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "20053726", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Medulloblastoma Tumor Cells", "System": "VC312 cells", "Dose": "0-7.5 μM", "Technique": "Flow cytometry,,immunoblotting analyses,real-time PCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "apoptosis- cleaved caspase-3 (active form of caspase-3) and cleaved PARP (inactive form of PARP) levels, Bak and Bim , p21Cip1", "Controlled_Terms_Function_enhanced_Number_increased": "Caspase-3; Caspase activation; Apoptosis; PARP cleavage / PARP; BAK; BIM / BCL2L11; p21 / CDKN1A; Expression / abundance phenotype", "Immune_System-Function_inhibited/numbers_decreased": "survivin,cyclin E, cyclin D2 and cyclin D3, STAT3 and AKT phosphorylation ,phosphorylation of downstream proteins glycogen synthase kinase-3beta", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; AKT; Survivin / BIRC5; Cyclin E; Cyclin D2; Cyclin D3", "Immune_System_function_unaffected": "Mcl-1, Bcl-2, Bcl-xL, Bax, Puma and Noxa", "Controlled_Terms_Unaffected": "BCL-2; BCL-xL / BCL2L1; MCL-1; BAX; PUMA / BBC3; NOXA / PMAIP1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1514", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "19244102", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "System": "786-O", "Dose": "0-10 μM", "Technique": "Flow Cytometry,MTS assay,Western blot analyses", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "p-Stat3 inhibition,cleaved PARP, Cyclin E, Cyclin D1 and Survivin", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; PARP cleavage / PARP; Survivin / BIRC5; Cyclin D1 / CCND1; Cyclin E; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1515", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "19244102", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "System": "RCC4", "Dose": "0-10 μM", "Technique": "Flow Cytometry,MTS assay,Western blot analyses", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "p-Stat3 inhibition,cleaved PARP, Cyclin E, Cyclin D1 and Survivin", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6/JAK/STAT3 signaling; STAT3; PARP cleavage / PARP; Survivin / BIRC5; Cyclin D1 / CCND1; Cyclin E; STAT3 phosphorylation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1516", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug__ID": "D06402", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "19244102", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "System": "murine Renca", "Dose": "0-10 μM", "Technique": "Flow Cytometry,MTS assay,Western blot analyses", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "cleaved PARP, Cyclin E, Cyclin D1 and Survivin", "Controlled_Terms_Function_inhibited_Number_decreased": "PARP cleavage / PARP; Survivin / BIRC5; Cyclin D1 / CCND1; Cyclin E", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/464", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits VEGFR1/2/3, PDGFRα/β, KIT, FLT3, CSF1R, RET; activates IFNγ/STAT1 → ↑MHC-I", "KEGG_Drug__ID": "D08591", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "System": "4T1", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/670", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits VEGFR1/2/3, PDGFRα/β, KIT, FLT3, CSF1R, RET; activates IFNγ/STAT1 → ↑MHC-I", "KEGG_Drug__ID": "D08591", "Pubchem_ID": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "single", "PMID": "41019037", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "melanoma", "System": "B16F10", "Dose": "0–10 μM, 24 h in vitro", "Technique": "Flow cytometry", "Controlled_Technique": "MHC-I expression", "Immune_System-Function_enhanced/numbers_increased": "MHC class I; Expression / abundance phenotype", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1535", "Drug": "Vinblastine", "Drug_category": "Vinca alkaloids", "Drugbank_ID": "DB00570", "Target/s_or_mechanism_of_action": "inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.", "KEGG_Drug__ID": "D08675", "Pubchem_ID": "13342", "STR_LINK_(SMILES)": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC", "Single/Combination": "Single Drug", "PMID": "22396773", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "System": "ZR-75-1", "Dose": "6 nM", "Technique": "immunoblotting, Flow cytometry, ELISA assay", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-β MHC I", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; IFN-β;", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/609", "Drug": "vinorelbine", "Drug_category": "Vinca alkaloids", "Drugbank_ID": "DB00361", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": "D08680", "Pubchem_ID": "5311497", "STR_LINK_(SMILES)": "CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC", "Single/Combination": "single", "PMID": "40076874", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-small-cell lung cancer (NSCLC)", "System": "Monocytes, M1 macrophages and M2 macrophages", "Dose": "50 nM and 100 nM vinorelbine for 48 h", "Technique": "Flow cytometry;", "Controlled_Technique": "CD80", "Immune_System-Function_enhanced/numbers_increased": "CD80", "Controlled_Terms_Function_enhanced_Number_increased": "CD206 and CD163", "Immune_System-Function_inhibited/numbers_decreased": "CD206 / MRC1; CD163", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/610", "Drug": "vinorelbine", "Drug_category": "Vinca alkaloids", "Drugbank_ID": "DB00361", "Target/s_or_mechanism_of_action": null, "KEGG_Drug__ID": "D08680", "Pubchem_ID": "5311497", "STR_LINK_(SMILES)": "CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC", "Single/Combination": "single", "PMID": "40076874", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-small-cell lung cancer (NSCLC)", "System": "A549 cells+M2 macrophages coculture", "Dose": "50mM for 24 h", "Technique": "RT-qPCR; Western blotting", "Controlled_Technique": "EGF, EGFR, TGF-b1, TGFBR1, FGF2, MMP9, and CCL22", "Immune_System-Function_enhanced/numbers_increased": "EGFR", "Controlled_Terms_Function_enhanced_Number_increased": "TGFBR2, STAT3, and CCL17", "Immune_System-Function_inhibited/numbers_decreased": "STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}]